{"title": "PDF", "author": "PDF", "url": "http://geb.uni-giessen.de/geb/volltexte/2012/8753/pdf/KnocheAngela_2012_04_27.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Angela Knoche    Exp. Immunmodulation durch synth. TLR7- u. 7/8-Liganden\nVVB9 7 8 3 8 3 5 9 5 8 8 9 0VVB LAUFERSWEILER VERLAG\nSTAUFENBERGRING 15\nD-35396 GIESSEN\nTel: 0641-5599888 Fax: -5599890\nredaktion@doktorverlag.de\nwww.doktorverlag.deVVB LAUFERSWEILER VERLAG\u00e9dition scientifique\nISBN: 978-3-8359-5889-0Angela KnocheExperimentelle Immunmodulation durch den \nEinsatz synthetischer Toll-like Rezeptor7- und \n7/8-Liganden\nVVB LAUFERSWEILER VERLAG\u00e9dition scientifiqueINAUGURAL-DISSERTATION \nzur Erlangung des Grades eines Dr. med. vet. \nbeim Fachbereich Veterin\u00e4rmedizin \nder Justus-Liebig-Universit\u00e4t Gie\u00dfen\n \nDas Werk ist in allen seinen Teilen urheberrechtlich gesch\u00fctzt. \nJede Verwertung ist ohne schriftliche Zustimmung des Autors \noder des Verlages unzul\u00e4ssig. Das gilt insbesondere f\u00fcr \nVervielf\u00e4ltigungen, \u00dcbersetzungen, Mikroverfilmungen\n und die Einspeicherung in und Verarbeitung durch \nelektronische Systeme.\n1. Auflage 201 2\nAll rights reserv\ned. No part of this publication may be\n reproduced, stored in a retrieval system, or transmitted, \nin any form or by any means, electronic, mechanical, \nphotocopying, recording, or otherwise, without the prior \nwritten permission of the Author or the Publishers.\nst1  Edition 201 2\n\u00a9  201 2 by VVB LAUFERSWEILER VERLAG, Giessen\nPrinted in Germany \nVVB L\nAUFERSWEILER VERLAG\nSTAUFENBERGRING 15, D-35396 GIESSEN\nTel: 0641-5599888 Fax: 0641-5599890 \nemail: redaktion@doktorverlag.de\nwww.doktorverlag.de\u00e9dition  scientifique\n                                                                                                                                                                                          \n\u00a0\nAus\u00a0dem\u00a0 Institut\u00a0f\u00fcr\u00a0\nVirologie\u00a0\nder\u00a0Justus\u2010 Liebig\u2010 Universit\u00e4t\u00a0 Gie\u00dfen\u00a0\n\u00a0\nBetreuer: \u00a0Prof.\u00a0Dr.\u00a0Tillmann\u00a0R\u00fcmenapf \u00a0\n\u00a0\n\u00a0\nund\u00a0\n\u00a0\u00a0\naus\u00a0dem\u00a0 Zentrum\u00a0f\u00fcr\u00a0\nTransfusionsmedizin \u00a0und\u00a0H\u00e4motherapie, \u00a0\ndes\u00a0Universit\u00e4tsklinikums\u00a0 Gie\u00dfen\u00a0und\u00a0Marburg\u00a0GmbH,\u00a0\u00a0\nStandort\u00a0Gie\u00dfen\u00a0\n\u00a0\nBetreuer: \u00a0Prof.\u00a0Dr.\u00a0Holger\u00a0Hackstein \u00a0\n\u00a0\n\u00a0\u00a0\n\t\nExperimentelle \u00a0Immunmodulation\u00a0\u00a0\ndurch\u00a0den\u00a0 Einsatz\u00a0synthetischer \u00a0Toll\u2010like\u00a0\u00a0\nRezeptor7 \u2010\u00a0und\u00a07/8\u2010Liganden \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nINAUGURAL \u2010DISSERTATION \u00a0\nzur\u00a0Erlangung \u00a0des\u00a0Grades\u00a0eines\u00a0\nDr.\u00a0med.\u00a0vet.\u00a0\nbeim\u00a0Fachbereich\u00a0 Veterin\u00e4rmedizin \u00a0\nder\u00a0Justus\u2010 Liebig\u2010 Universit\u00e4t\u00a0 Gie\u00dfen\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\neingereicht \u00a0von\u00a0\n\u00a0\nAngela\u00a0 Knoche\u00a0\n\u00a0\nTier\u00e4rztin\u00a0 aus\u00a0Marburg\u00a0\n\u00a0\n\u00a0\nGie\u00dfen\u00a02012\u00a0                                                                                                                                                                                          \n\u00a0\nMit\u00a0Genehmigung\u00a0 des\u00a0Fachbereichs \u00a0Veterin\u00e4rmedizin \u00a0\nder\u00a0Justus\u2010 Liebig\u2010 Universit\u00e4t\u00a0 Gie\u00dfen\u00a0\n \n         \nDekan:\u00a0 Prof.\u00a0Dr.\u00a0Dr.\u00a0h.c.\u00a0M.\u00a0Kramer\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0Gutachter:\u00a0 Prof.\u00a0Dr.\u00a0H.\u00a0Hackstein \u00a0\n\u00a0 Prof.\u00a0Dr.\u00a0T.\u00a0R\u00fcmenapf \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0Tag\u00a0der\u00a0Disputation: \u00a0 27.04.2012 \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n \u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\"May\u00a0the\u00a0road\u00a0rise\u00a0to\u00a0meet\u00a0you\u00a0 on\u00a0your\u00a0journey,\u00a0\nmay\u00a0the\u00a0wind\u00a0 be\u00a0at\u00a0your\u00a0back\u00a0\nand\u00a0 the\u00a0sun\u00a0be\u00a0on\u00a0your\u00a0face,\u00a0\nand\u00a0 may\u00a0you\u00a0hold\u00a0yourself\u00a0in\u00a0the\u00a0palm\u00a0of\u00a0your\u00a0hand\u00a0\nand\u00a0 allow\u00a0others\u00a0 to\u00a0see\u00a0you\u00a0 as\u00a0you\u00a0 really\u00a0are...\"  \n\u00a0\n\u00a0. \u00a0Inhaltsverzeichnis\n1 Einleitung \u00a0 1\u00a0\n1.1 Das\u00a0Immunsystem \u00a0 1\u00a0\n1.2 Toll\u2010like\u00a0Rezeptoren \u00a0 3\u00a0\n1.2.1 Die\u00a0Familie\u00a0der\u00a0Toll\u2010like\u00a0Rezeptoren \u00a0 3\u00a0\n1.2.2 Lokalisation \u00a0der\u00a0TLR\u00b4s\u00a0 4\u00a0\n1.2.3 TLR\u2010Liganden\u00a0 4\u00a0\n1.2.3.1  Resiquimod \u00a0(R848)\u00a0 6\u00a0\n1.2.3.2  Gardiquimod \u00a0 6\u00a0\n1.2.3.3  Loxoribine \u00a0 7\u00a0\n1.2.3.4  Lipopolysaccharid \u00a0(LPS)\u00a0 7\u00a0\n1.2.3.5  CpG\u00a0ODN\u00b4s\u00a0 8\u00a0\n1.2.3.6  iODN\u00b4s\u00a0 9\u00a0\n1.2.4 Die\u00a0Signalkaskade \u00a0der\u00a0TLR\u00b4s\u00a0 10\u00a0\n1.3 Die\u00a0dendritischen \u00a0Zellen\u00a0 12\u00a0\n1.3.1 DC\u2010Subpopulationen \u00a0 13\u00a0\n1.3.2 DC\u2010Migration \u00a0und\u00a0\u2013Reifung\u00a0 14\u00a0\n1.3.3 Aufnahme \u00a0von\u00a0Antigenen \u00a0 15\u00a0\n1.3.4 DC\u2010Aktivierung \u00a0und\u00a0\u2013Reifung\u00a0 16\u00a0\n1.3.5 Antigen\u2010Aufarbeitung \u00a0und\u00a0\u2013Pr\u00e4sentation \u00a0 17\u00a0\u00a0Inhaltsverzeichnis\n1.3.5.1  MHC\u2010Klasse\u00a0II\u00a0 17\u00a0\n1.3.5.2  MHC\u2010Klasse\u00a0I\u00a0 18\u00a0\n1.3.6 T\u2010Zell\u2010Aktivierung \u00a0 18\u00a0\n1.3.7 Plastizit\u00e4t \u00a0der\u00a0dendritischen \u00a0Zellen\u00a0 19\u00a0\n1.4 T\u2010Zellen\u00a0 19\u00a0\n1.4.1 T\u2010Zell\u2010Subpopulationen \u00a0 20\u00a0\n1.4.2 T\u2010Zell\u2010Aktivierung \u00a0 21\u00a0\n1.5 Verschiedene \u00a0Marker\u2010Molek\u00fcle \u00a0 23\u00a0\n1.5.1 HLA\u2010DR\u00a0 23\u00a0\n1.5.2 CD40,\u00a0CD83,\u00a0CD86\u00a0 23\u00a0\n1.5.3 BDCA\u20102,\u00a0BDCA\u20104,\u00a0BDCA\u20101\u00a0 23\u00a0\n1.5.4 CD25\u00a0 24\u00a0\n1.5.5 CD123\u00a0 24\u00a0\n1.5.6 CD122\u00a0 25\u00a0\n1.5.7 FOXP3\u00a0 25\u00a0\n1.6 Verschiedene \u00a0inflammatorische \u00a0und\u00a0antiinflammatorische \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nZytokine\u00a0 25\u00a0\n1.6.1 IL\u20101\u03b2\u00a0 25\u00a0\n1.6.2 IL\u20106\u00a0 26\u00a0\n1.6.3 IL\u20108\u00a0 27\u00a0\u00a0Inhaltsverzeichnis\n1.6.4 IL\u201010\u00a0 27\u00a0\n1.6.5 IL\u201012p70\u00a0 28\u00a0\n1.6.6 TNF\u00a0 28\u00a0\n1.7 Zielsetzung \u00a0 29\u00a0\n2 Material\u00a0und\u00a0Methoden \u00a0 31\u00a0\n2.1 Material\u00a0 31\u00a0\n2.1.1 Ger\u00e4te\u00a0 31\u00a0\n2.1.2 Verbrauchsmaterialien \u00a0 32\u00a0\n2.1.3 Chemikalien \u00a0 33\u00a0\n2.1.4 Fertige\u00a0Reagenziens\u00e4tze \u00a0 34\u00a0\n2.1.5 Immunmodulatoren \u00a0 35\u00a0\n2.1.6 Zytokine\u00a0 35\u00a0\n2.1.7 Antik\u00f6rper \u00a0 35\u00a0\n2.1.8 Computersoftware \u00a0 37\u00a0\n2.1.9 Humanes \u00a0Probenmaterial \u00a0 38\u00a0\n2.1.10  Statistik\u00a0 38\u00a0\n2.2 Methoden \u00a0 39\u00a0\n2.2.1 Isolierung \u00a0von\u00a0peripheren \u00a0mononukle\u00e4ren \u00a0Blutzellen \u00a0(PBMC\u00b4s)\u00a0aus\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\ndem\u00a0buffy\u00a0coat\u00a0 39\u00a0\u00a0Inhaltsverzeichnis\n2.2.2 Separation \u00a0von\u00a0CD14+\u2010Zellen\u00a0mit\u00a0Hilfe\u00a0des\u00a0automated \u00a0magnetic \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nactivating \u00a0cell\u00a0sorting\u00a0(AutoMACS\u00ae)\u00a0 40\u00a0\n2.2.3 Bestimmung \u00a0der\u00a0Leukozytenzahl \u00a0mit\u00a0dem\u00a0Automatischen \u00a0\u00a0\nH\u00e4matologieanalysator \u00a0KX\u201021N\u00a0(Sysmex)\u00a0 42\u00a0\n2.2.4 Kultivierung \u00a0und\u00a0Stimulation \u00a0der\u00a0Monozyten \u00a0f\u00fcr\u00a0die\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\ndurchflusszytometrische \u00a0Untersuchung \u00a0 42\u00a0\n2.2.5 Durchflusszytometrie \u00a0(FACS:\u00a0fluorescent \u00a0activating \u00a0cell\u00a0sorting )\u00a0 43\u00a0\n2.2.6 T\u2010Zell\u2010Proliferationstest \u00a0 48\u00a0\n2.2.7 Kultivierung \u00a0und\u00a0Stimulation \u00a0der\u00a0Monozyten \u00a0f\u00fcr\u00a0den\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nCytometric \u00a0Bead\u00a0Array\u00a0(CBA)\u00a0 52\u00a0\n2.2.8 Human\u00a0Inflammatory \u00a0Cytokines \u00a0Cytometric \u00a0Bead\u00a0Array\u00a0(CBA)\u00a0 53\u00a0\n3 Ergebnisse \u00a0 56\u00a0\n3.1 Der\u00a0TLR7/8\u2010Ligand\u00a0R848\u00a0modifiziert \u00a0dosisabh\u00e4ngig \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\ndie\u00a0Differenzierung \u00a0konventioneller \u00a0MoDC\u00b4s\u00a0 56\u00a0\n3.2 Die\u00a0Wirkung\u00a0von\u00a0R848\u00a0auf\u00a0die\u00a0DC\u2010Differenzierung \u00a0ist\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nTLR8\u00a0vermittelt \u00a0 61\u00a0\n3.2.1 Der\u00a0Einfluss\u00a0des\u00a0spezifischen \u00a0TLR7\u2010Liganden\u00a0Gardiquimod \u00a0auf\u00a0die\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nDC\u2010Differenzierung \u00a0 61\u00a0\n3.2.2 Der\u00a0Einfluss\u00a0von\u00a0Loxoribine, \u00a0eines\u00a0weiteren\u00a0TLR7\u2010Liganden, \u00a0auf\u00a0die\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nDC\u2010Differenzierung \u00a0 67\u00a0\n3.2.3 Die\u00a0Verwendung \u00a0verschiedener \u00a0inhibitorischer \u00a0Oligonukleotide \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n(iODN\u00b4s)\u00a0zur\u00a0Verifizierung \u00a0der\u00a0TLR8\u2010Wirkung\u00a0 69\u00a0\u00a0Inhaltsverzeichnis\n3.3 R848\u2010DC\u00b4s\u00a0exprimieren \u00a0gr\u00f6\u00dfere\u00a0Mengen\u00a0an\u00a0T\u2010Zell\u00a0\u00a0\u00a0\u00a0\u00a0\nkostimulatorischen \u00a0Molek\u00fclen \u00a0und\u00a0HLA\u2010DR\u00a0\u00a0 72\u00a0\n3.3.1 R848\u2010DC\u00b4s\u00a0exprimieren \u00a0gr\u00f6\u00dfere\u00a0Mengen\u00a0an\u00a0T\u2010Zell\u00a0kostimulatorischen \u00a0\u00a0\u00a0\u00a0\nMolek\u00fclen \u00a0und\u00a0HLA\u2010DR\u00a0im\u00a0Vergleich \u00a0zu\u00a0konventionellen \u00a0MoDC\u00b4s\u00a0 72\u00a0\n3.3.2 R848\u2010DC\u00b4s\u00a0exprimieren \u00a0CD123\u00a0 78\u00a0\n3.4 Die\u00a0Expression \u00a0von\u00a0FOXP3\u00a0und\u00a0CD122\u00a0 80\u00a0\n3.4.1 Expression \u00a0von\u00a0FOXP3\u00a0 80\u00a0\n3.4.2 Expression \u00a0von\u00a0CD122\u00a0 81\u00a0\n3.5 R848\u2010DC\u00b4s\u00a0zeigen\u00a0auch\u00a0nach\u00a0dem\u00a0Entfernen \u00a0des\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nStimulators \u00a0R848\u00a0einen\u00a0stabilen\u00a0Ph\u00e4notyp \u00a0 82\u00a0\n3.6 R848\u2010DC\u00b4s\u00a0induzieren \u00a0eine\u00a0bessere\u00a0T\u2010Zell\u2010Proliferation \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nals\u00a0konventionelle \u00a0MoDC\u00b4s\u00a0 84\u00a0\n3.7 R848\u2010DC\u00b4s\u00a0produzieren \u00a0verschiedene \u00a0Zytokine\u00a0mit\u00a0\nimmunregulatorischen \u00a0Funktionen \u00a0 88\u00a0\n4 Diskussion \u00a0 93\u00a0\n4.1 Expression \u00a0der\u00a0T\u2010Zell\u00a0kostimulatorischen \u00a0Molek\u00fcle \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nCD40,\u00a0CD83,\u00a0CD86,\u00a0HLA\u2010DR\u00a0und\u00a0CD123\u00a0 94\u00a0\n4.2 TLR8\u00a0als\u00a0Vermittler \u00a0der\u00a0immunmodulatorischen \u00a0Wirkung\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nvon\u00a0R848\u00a0auf\u00a0MoDC\u00b4s\u00a0 96\u00a0\u00a0Inhaltsverzeichnis\n4.3 Induktion \u00a0der\u00a0allogenen \u00a0T\u2010Zell\u2010Proliferation \u00a0durch\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nR848\u2010DC\u00b4s\u00a0\u00a0 97\u00a0\n4.4 Zytokinproduktion \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0 98\u00a0\n5. Zusammenfassung \u00a0 100\u00a0\n6. Summary \u00a0 102\u00a0\n7. Literaturverzeichnis \u00a0 104\u00a0\n8. Abbildungsverzeichnis \u00a0 116\u00a0\n9. Abk\u00fcrzungsverzeichnis \u00a0 124\u00a0\n10. Danksagung \u00a0 130\u00a0\n11. Publikationen \u00a0 131\u00a0\n\u00a0\u00a01 Einleitung\n1 Einleitung \t\n\u00a0\n1.1 Das\tImmunsystem \t\n\u00a0\nVielzellige \u00a0Organismen \u00a0sind\u00a0in\u00a0ihrer\u00a0Umwelt\u00a0st\u00e4ndig\u00a0Fremdstoffen \u00a0bzw.\u00a0mikrobiellen \u00a0\nStoffwechselprodukten \u00a0sowie\u00a0pflanzlichen \u00a0und\u00a0tierischen \u00a0Giften\u00a0ausgesetzt. \u00a0Im\u00a0Laufe\u00a0der\u00a0\nEvolution \u00a0haben\u00a0sie\u00a0verschiedenste \u00a0Verteidigungsmechanismen \u00a0entwickelt, \u00a0um\u00a0sich\u00a0vor\u00a0\ndiesen\u00a0Einfl\u00fcssen \u00a0zu\u00a0sch\u00fctzen\u00a0(1).\u00a0\n\u00a0Vertebraten \u00a0besitzen\u00a0dazu\u00a0das\u00a0sog.\u00a0Immunsystem, \u00a0bei\u00a0dem\u00a0man\u00a0einen\u00a0angeborenen \u00a0und\u00a0\neinen\u00a0erworbenen \u00a0Teil\u00a0unterscheidet. \u00a0\n\u00a0\nAngeborenes \u00a0\nImmunsystem \u00a0Erworbenes \u00a0\u00a0\u00a0\nImmunsystem \u00a0\n\u00a0 physikalische \u00a0Barrieren\nHaut,\u00a0Mikrovilli, \u00a0Cilien\u00a0im\u00a0\nRespirationstrakt, \u00a0...\u00a0keine\u00a0\n\u00a0 humorale Komponenten\nKomplementsystem, \u00a0Akute\u00a0\nPhase\u00a0Proteine,\u00a0\nInterferone, \u00a0Enzyme\u00a0Immunglobuline \u00a0\n(Antik\u00f6rper) \u00a0\n\u00a0 zellul\u00e4re\u00a0Komponenten\nPhagozyten, \u00a0NK\u2010Zellen,\u00a0\nGranulozyten \u00a0T\u2010und\u00a0B\u2010Lymphozyten \u00a0\n\u00a0\nAbb.\u00a01.1.1:\u00a0Mechanismen \u00a0des\u00a0angeborenen \u00a0und\u00a0erworbenen \u00a0\nImmunsystems. \u00a0\u00a02 Einleitung\nBei\u00a0der\u00a0erworbenen \u00a0Immunit\u00e4t, \u00a0kommt\u00a0es\u00a0beispielsweise \u00a0zu\u00a0einer\u00a0Reaktion\u00a0zwischen\u00a0\nspezifischen \u00a0Antik\u00f6rpern \u00a0mit\u00a0dem\u00a0entsprechenden \u00a0Antigen\u00a0bzw.\u00a0wird\u00a0diese\u00a0hervorgerufen \u00a0\ndurch\u00a0spezifisch \u00a0sensibilisierte \u00a0T\u2010Lymphozyten, \u00a0Makrophagen \u00a0oder\u00a0andere\u00a0\nimmunkompetente \u00a0Zellen.\u00a0Hierbei\u00a0spielen\u00a0bei\u00a0der\u00a0Vermittlung \u00a0komplexer \u00a0Vorg\u00e4nge \u00a0\nbestimmte \u00a0\u00dcbertragungssubstanzen, \u00a0die\u00a0Zytokine,\u00a0eine\u00a0wichtige\u00a0Rolle.\u00a0Au\u00dferdem \u00a0ist\u00a0das\u00a0\nangeborene \u00a0Immunsystem \u00a0entscheidend \u00a0an\u00a0der\u00a0Stimulation \u00a0des\u00a0erworbenen \u00a0Immunsystems \u00a0\nbeteiligt.\u00a0\nIm\u00a0Gegensatz \u00a0zum\u00a0angeborenen \u00a0Immunsystem \u00a0reagiert\u00a0das\u00a0erworbene \u00a0Immunsystem \u00a0nicht\u00a0\nunmittelbar. \u00a0\nDas\u00a0angeborene \u00a0Immunsystem \u00a0ist\u00a0der\u00a0phylogenetisch \u00a0\u00e4ltere\u00a0Teil\u00a0und\u00a0in\u00a0allen\u00a0multizellul\u00e4ren \u00a0\nOrganismen \u00a0vorhanden. \u00a0Es\u00a0stellt\u00a0die\u00a0erste\u00a0Verteidigungslinie \u00a0gegen\u00a0eingedrungene \u00a0\nMikroorganismen \u00a0dar.\u00a0Die\u00a0Haut\u2010Schleimhaut \u2010Barriere,\u00a0humorale \u00a0Faktoren\u00a0(z.B.\u00a0\nantimikrobielle \u00a0Enzyme\u00a0und\u00a0das\u00a0Komplementsystem), \u00a0sowie\u00a0eine\u00a0Vielzahl\u00a0verschiedener \u00a0\nZellen\u00a0garantieren \u00a0die\u00a0erste\u00a0und\u00a0unmittelbare \u00a0Verteidigungslinie \u00a0gegen\u00a0pathogene \u00a0\nMikroorganismen. \u00a0\nIm\u00a0Wesentlichen \u00a0verwendet \u00a0das\u00a0angeborene \u00a0Immunsystem \u00a03\u00a0Strategien. \u00a0\nZum\u00a0einen\u00a0erkennt\u00a0es\u00a0k\u00f6rpereigene \u00a0Zellen,\u00a0die\u00a0ein\u00a0ver\u00e4ndertes \u00a0Muster\u00a0von\u00a0Markern\u00a0\naufweisen. \u00a0Die\u00a0Zellen\u00a0werden\u00a0apoptotisch \u00a0und\u00a0dann\u00a0von\u00a0Makrophagen \u00a0phagozytiert \u00a0(altered\u00a0\nself).\u00a0\u00a0\nWeiterhin \u00a0f\u00fchrt\u00a0eine\u00a0fehlende\u00a0Expression \u00a0von\u00a0Oberfl\u00e4chenmarkern \u00a0(z.B.\u00a0werden\u00a0MHC\u2010\nKlasse\u2010I\u2010Molek\u00fcle \u00a0bei\u00a0infizierten \u00a0kernhaltigen \u00a0K\u00f6rperzellen \u00a0nicht\u00a0mehr\u00a0exprimiert) \u00a0zum\u00a0T\u00f6ten\u00a0\nderselben \u00a0durch\u00a0nat\u00fcrliche \u00a0Killerzellen \u00a0(NK\u2010Zellen)\u00a0(missing\u00a0self).\u00a0Als\u00a0dritte\u00a0Strategie\u00a0werden\u00a0\ninvariante \u00a0Strukturen \u00a0von\u00a0Mikroorganismen \u00a0(gram\u2010positiven\u00a0und\u00a0gram\u2010negativen \u00a0Bakterien, \u00a0\nPilzen\u00a0und\u00a0Protozoen) \u00a0und\u00a0Viren,\u00a0die\u00a0sogenannten \u00a0pathogen \u2010associated \u00a0molecular \u00a0patterns\u00a0\n(PAMP\u00b4s), \u00a0erkannt.\u00a0Diese\u00a0werden\u00a0vom\u00a0Wirt\u00a0selbst\u00a0nicht\u00a0gebildet\u00a0und\u00a0stellen\u00a0mikrobielle \u00a0\nProdukte, \u00a0wie\u00a0LPS,\u00a0hypomethylierte \u00a0DNA\u00a0(CpG\u2010Motive),\u00a0Flagellin,\u00a0Peptide\u00a0und\u00a0\nNukleins\u00e4urestrukturen \u00a0dar\u00a0(nonself)\u00a0(2\u20105).\u00a0\n\u00a0\u00a0\u00a03 Einleitung\n1.2 Toll\u2010like\tRezeptoren \t\n\u00a0\n1.2.1  Die\tFamilie\tder\tToll\u2010like\tRezeptoren \t\n\u00a0\nImmunzellen, \u00a0die\u00a0dem\u00a0angeborenen \u00a0Immunsystem \u00a0angeh\u00f6ren, \u00a0besitzen\u00a0eine\u00a0festgelegte \u00a0\nAnzahl\u00a0an\u00a0Keimbahn \u2010kodierten \u00a0Rezeptoren, \u00a0sogenannte \u00a0pattern\u00a0recognition \u00a0receptors \u00a0\n(PRR\u00b4s).\u00a0\nZu\u00a0den\u00a0PRR\u00b4s\u00a0z\u00e4hlen\u00a0drei\u00a0gro\u00dfe\u00a0Proteinklassen: \u00a0Toll\u2010like\u00a0receptors \u00a0(TLR\u00b4s),\u00a0NOD\u2010like\u00a0receptors \u00a0\n(NLR\u00b4s)\u00a0und\u00a0RIG\u2010like\u00a0helicases\u00a0(RLH\u00b4s).\u00a0TLR\u00b4s\u00a0sind\u00a0entweder \u00a0an\u00a0der\u00a0Plasmamembran \u00a0oder\u00a0an\u00a0\nvesikul\u00e4ren \u00a0Membranen \u00a0lokalisiert, \u00a0wo\u00a0sie\u00a0diverse\u00a0PAMP\u00b4s\u00a0von\u00a0Bakterien, \u00a0Viren,\u00a0Pilzen\u00a0und\u00a0\nProtozoen \u00a0detektieren. \u00a0NLR\u00b4s\u00a0stellen\u00a0eine\u00a0neu\u00a0entstehende \u00a0Familie\u00a0dar,\u00a0von\u00a0denen\u00a0einige\u00a0\nRezeptoren \u00a0haupts\u00e4chlich \u00a0PAMP\u00b4s\u00a0von\u00a0Bakterien \u00a0erkennen, \u00a0die\u00a0sich\u00a0im\u00a0Zytosol\u00a0befinden. \u00a0\nMDA5/Helicard \u00a0und\u00a0RIG\u2010I\u00a0geh\u00f6ren\u00a0zu\u00a0den\u00a0RLH\u00b4s\u00a0und\u00a0sind\u00a0auch\u00a0Zytosolrezeptoren, \u00a0die\u00a0\nallerdings \u00a0virale\u00a0ssRNA\u00a0und\u00a0dsRNA\u00a0detektieren. \u00a0\n\u00a0\nHaben\u00a0PRR\u00b4s\u00a0Mikroorganismen \u00a0und\u00a0Viren\u00a0an\u00a0ihren\u00a0evolution\u00e4r \u00a0konservierten \u00a0Strukturen \u00a0\n(PAMP\u00b4s) \u00a0erkannt,\u00a0f\u00fchren\u00a0zellul\u00e4re\u00a0Signalkaskaden \u00a0zu\u00a0einer\u00a0entsprechenden \u00a0Zellantwort. \u00a0\n\u00a0\nDie\u00a0am\u00a0besten\u00a0charakterisierte \u00a0Klasse\u00a0der\u00a0PRR\u00b4s\u00a0stellt\u00a0die\u00a0Familie\u00a0der\u00a0Toll\u2010like\u2010receptors \u00a0\n(TLR\u00b4s)\u00a0dar\u00a0(6\u20109).\u00a0\u00a0\nUrspr\u00fcnglich \u00a0wurde\u00a0das\u00a0Protein\u00a0Toll\u00a0in\u00a0Drosophila \u00a0melanogaster \u00a0entdeckt, \u00a0wo\u00a0es\u00a0in\u00a0der\u00a0\nEmbryogenese \u00a0f\u00fcr\u00a0die\u00a0dorsoventrale \u00a0Polarit\u00e4t\u00a0verantwortlich \u00a0ist.\u00a01996\u00a0fand\u00a0man\u00a0heraus,\u00a0dass\u00a0\nToll\u00a0zus\u00e4tzlich \u00a0wichtig\u00a0f\u00fcr\u00a0die\u00a0Immunabwehr \u00a0von\u00a0Drosophila \u00a0gegen\u00a0Befall\u00a0mit\u00a0Pilzen\u00a0ist.\u00a0Ein\u00a0\nJahr\u00a0sp\u00e4ter\u00a0konnten\u00a0\"Toll\u2010like\"\u2010Sequenzen \u00a0auch\u00a0in\u00a0Vertebraten \u00a0identifiziert \u00a0werden\u00a0(8,\u00a010\u2010\n12).\u00a0\u00a0\nBis\u00a0heute\u00a0sind\u00a0bei\u00a0M\u00e4usen\u00a013\u00a0und\u00a0beim\u00a0Menschen \u00a011\u00a0verschiedene \u00a0Toll\u2010like\u00a0Rezeptoren \u00a0\n(TLR1\u201010)\u00a0identifiziert \u00a0worden,\u00a0die\u00a0alle\u00a0unterschiedliche \u00a0Strukturen, \u00a0spezifische \u00a0\nStrukturgruppen \u00a0oder\u00a0einzelne\u00a0Molek\u00fcle \u00a0erkennen. \u00a0TLR1\u20109\u00a0sind\u00a0zwischen\u00a0Mensch\u00a0und\u00a0Maus\u00a0\nkonserviert. \u00a0Durch\u00a0Rezeptor/Ligand \u2010Bindung\u00a0induzieren \u00a0TLR\u00b4s\u00a0verschiedene \u00a0Signalkaskaden, \u00a0\u00a04 Einleitung\ndie\u00a0wiederum \u00a0eine\u00a0Reihe\u00a0von\u00a0Zellantworten, \u00a0wie\u00a0die\u00a0Produktion \u00a0von\u00a0Interferonen \u00a0(IFN\u00b4s)\u00a0und\u00a0\nanderen\u00a0Zytokinen \u00a0(z.\u00a0B.\u00a0Tumornekrosefaktor \u00a0(TNF)\u2010\u03b1,\u00a0Interleukin \u00a0(IL)\u20106\u00a0und\u00a0IL\u201012)\u00a0ausl\u00f6sen\u00a0\nund\u00a0so\u00a0\u00fcber\u00a0verschiedene \u00a0Signalkaskaden \u00a0zu\u00a0einer\u00a0entsprechenden \u00a0Entz\u00fcndungsreaktion \u00a0\nf\u00fchren\u00a0(8).\u00a0\u00a0\n\u00a0\u00a0\n1.2.2  Lokalisation \tder\tTLR\u00b4s\t\n\u00a0\nTLRs\u00a0liegen\u00a0entweder \u00a0als\u00a0Monomer \u00a0(TLR3,\u00a0TLR4,\u00a0TLR5,\n\u00a0TLR7,\u00a0TLR8,\u00a0TLR9\u00a0und\u00a0TLR10),\u00a0als\u00a0\nHeterodimer \u00a0(TLR1/2\u00a0oder\u00a0TLR2/6,\u00a0eventuell \u00a0TLR4/5)\u00a0oder\u00a0vermutlich \u00a0auch\u00a0als\u00a0homologes \u00a0\nDimer\u00a0(TLR2/2)\u00a0vor.\u00a0Sechs\u00a0der\u00a0Rezeptoren \u00a0sind\u00a0an\u00a0der\u00a0Plasmamembran \u00a0lokalisiert \u00a0(TLR1,\u00a0\nTLR2,\u00a0TLR4,\u00a0TLR5,\u00a0TLR6\u00a0und\u00a0TLR10),\u00a0die\u00a0\u00fcbrigen\u00a0vier\u00a0befinden\u00a0sich\u00a0an\u00a0der\u00a0\nEndosomenmembran \u00a0(TLR3,\u00a0TLR7,\u00a0TLR8\u00a0und\u00a0TLR9)\u00a0(6,\u00a013,\u00a014).\u00a0\n\u00a0\n\u00a0\n1.2.3  TLR\u2010Liganden \t\n\u00a0\nNeben\u00a0einigen\u00a0endogenen \u00a0Liganden, \u00a0die\u00a0bei\u00a0verschiedenen \u00a0Autoimmunerkrankungen \u00a0eine\u00a0\nRolle\u00a0spielen\u00a0k\u00f6nnen,\u00a0existieren \u00a0eine\u00a0ganze\u00a0Reihe\u00a0exogener \u00a0Liganden\u00a0bakteriellen, \u00a0viralen,\u00a0\nfungalen\u00a0bzw.\u00a0parasit\u00e4ren \u00a0Ursprungs, \u00a0die\u00a0bis\u00a0heute\u00a0identifiziert \u00a0worden\u00a0sind.\u00a0Mittels\u00a0TLR\u2010\ndefizienter \u00a0M\u00e4use\u00a0und\u00a0\u00dcberexpressionsexperimenten \u00a0mit\u00a0einzelnen \u00a0TLR\u2010Genen\u00a0in\u00a0einfachen \u00a0\nZellkulturmodellen \u00a0k\u00f6nnen\u00a0die\u00a0verschiedenen \u00a0Liganden\u00a0ihren\u00a0jeweiligen \u00a0Rezeptoren \u00a0\nzugeordnet \u00a0werden\u00a0(15\u201019).\u00a0Abb.\u00a01.2.3.1\u00a0gibt\u00a0eine\u00a0\u00dcbersicht \u00a0bekannter \u00a0pathogen \u2010\nassoziierter, \u00a0exogener \u00a0Liganden\u00a0wieder,\u00a0die\u00a0f\u00fcr\u00a0TLR\u00b4s\u00a0spezifisch \u00a0sind.\u00a0\n\u00a0\n\u00a0\u00a0\u00a05 Einleitung\n\u00a0\nTLR\u00b4s\u00a0 Exogene\u00a0Liganden\u00a0\nTLR1/2\u00a0 (TLR1\u00a0ist\u00a0funktionell \u00a0assoziiert \u00a0mit\u00a0TLR2)\u00a0\ntriacetylierte \u00a0Lipopeptide \u00a0(verschiedene \u00a0Bakterien \u00a0und\u00a0Mykobakterien), \u00a0\nPam3Cys\u00a0(synthetisches \u00a0tripalmitoyliertes \u00a0Lipopeptid), \u00a019kDa\u2010\nLipopeptid \u00a0(Mykobakterien) \u00a0\nTLR2\u00a0 Lipoarabinomannan, \u00a0Lipoproteine, \u00a0Zymosan, \u00a0Glykolipid, \u00a0\u00e4u\u00dferes\u00a0\nMembranprotein \u00a0A\u00a0(K.pneumoniae )\u00a0\nTLR3\u00a0 Poly\u00a0(I:C),\u00a0mRNA/tRNA, \u00a0doppelstr\u00e4ngige \u00a0RNA\u00a0(dsRNA)\u00a0\nTLR4\u00a0 LPS\u00a0(Lipid\u00a0A),\u00a0LTA,\u00a0Protein\u00a0F\u00a0\nTLR5\u00a0 Flagellin\u00a0(verschiedene \u00a0bewegliche \u00a0Bakterien) \u00a0\nTLR2/6\u00a0 (TLR6\u00a0ist\u00a0funktionell \u00a0assoziiert \u00a0mit\u00a0TLR2)\u00a0\nZymosan, \u00a0diacetylierte \u00a0Lipopeptide \u00a0(verschiedene \u00a0Bakterien \u00a0und\u00a0\nMykobakterien) \u00a0\nTLR7\u00a0 synthetische \u00a0 Guanosin \u2010Analoga,\u00a0 Imidazoquinolin \u00a0 Pr\u00e4parate, \u00a0\neinzelstr\u00e4ngige \u00a0RNA\u00a0(ssRNA)\u00a0aus\u00a0Viren\u00a0(z.\u00a0B.\u00a0Influenzavirus, \u00a0HIV\u20101),\u00a0\u00a0\nTLR8\u00a0 (TLR8\u00a0nicht\u00a0funktionell \u00a0in\u00a0der\u00a0Maus)\u00a0\nsynthetische \u00a0 Guanosin \u2010Analoga,\u00a0 Imidazoquinolin \u00a0 Pr\u00e4parate, \u00a0\neinzelstr\u00e4ngige \u00a0RNA\u00a0(ssRNA)\u00a0aus\u00a0Viren\u00a0(z.\u00a0B\u00a0HIV\u20101),\u00a0\u00a0\nTLR9\u00a0 unmethylierte \u00a0CpG\u2010DNA\u00a0aus\u00a0Viren\u00a0und\u00a0Bakterien \u00a0\nTLR10\u00a0 bis\u00a0heute\u00a0kein\u00a0Ligand\u00a0identifiziert \u00a0\nTLR11\u00a0 Profilin\u00a0\nTLR12\u00a0 (TLR12\u00a0nur\u00a0in\u00a0der\u00a0Maus)\u00a0\u00a0\nbis\u00a0heute\u00a0kein\u00a0Ligand\u00a0identifiziert \u00a0\nTLR13\u00a0 (TLR13\u00a0nur\u00a0in\u00a0der\u00a0Maus)\u00a0\u00a0\nbis\u00a0heute\u00a0kein\u00a0Ligand\u00a0identifiziert \u00a0\n\u00a0\nAbb.\u00a01.2.3.1:\u00a0\u00dcbersicht \u00a0exogener \u00a0TLR\u2010Liganden\u00a0im\u00a0humanen \u00a0und\u00a0\nmurinen\u00a0System.\u00a0Dargestellt \u00a0sind\u00a0zur\u00a0Verdeutlichung \u00a0der\u00a0Vielfalt\u00a0der\u00a0\nPathogenerkennung \u00a0verschiedene \u00a0exogene\u00a0TLR\u2010Liganden\u00a0(6,\u00a020\u201021).\u00a0\u00a06 Einleitung\n1.2.3.1  Resiquimod \t(R848)\t\n\u00a0\n\u00a0\nAbb.\u00a01.2.3.1.1: \u00a0Strukturformel \u00a0von\u00a0R848.\u00a0\n\u00a0\nR848\u00a0ist\u00a0ein\u00a0Imidazoquinolin \u2010Bestandteil \u00a0mit\u00a0hoher\u00a0anti\u2010viraler\u00a0Aktivit\u00e4t.\u00a0Als\u00a0synthetisches \u00a0\nMolek\u00fcl\u00a0mit\u00a0niedrigem \u00a0Molekulargewicht \u00a0aktiviert\u00a0es\u00a0Immunzellen \u00a0auf\u00a0dem\u00a0TLR7/8\u00a0MyD88\u2010\nabh\u00e4ngigen \u00a0Signalweg \u00a0(22\u201023).\u00a0Eine\u00a0Stimulation \u00a0von\u00a0TLR7\u00a0kann\u00a0mit\u00a0einer\u00a0Konzentration \u00a0von\u00a0\n50\u00a0ng/ml\u00a0\u2010\u00a05\u00a0\u00b5g/ml\u00a0und\u00a0eine\u00a0Stimulation \u00a0von\u00a0TLR8\u00a0mit\u00a00,5\u00a0\u2010\u00a05\u00a0\u00b5g/ml\u00a0erreicht\u00a0werden.\u00a0So\u00a0\nmoduliert \u00a0es\u00a0neben\u00a0der\u00a0Antik\u00f6rpersekretion \u00a0die\u00a0Zytokinproduktion, \u00a0sch\u00fctzt\u00a0vor\u00a0Apoptose \u00a0\nund\u00a0f\u00fchrt\u00a0zu\u00a0einer\u00a0Hochregulation \u00a0von\u00a0CD80\u00a0(24).\u00a0\n\u00a0\n\u00a0\n1.2.3.2  Gardiquimod \t\n\u00a0\n\u00a0\nAbb.\u00a01.2.3.2.1: \u00a0Strukturformel \u00a0vom\u00a0Gardiquimod. \u00a0\n\u00a0\nGardiquimod \u00a0ist\u00a0wie\u00a0R848\u00a0ein\u00a0Imidazoquinolin \u2010Bestandteil, \u00a0jedoch\u00a010\u00a0x\u00a0aktiver\u00a0als\u00a0z.B.\u00a0\nImiquimod, \u00a0so\u00a0dass\u00a0eine\u00a0Konzentration \u00a0von\u00a00,1\u00a0\u00b5g/ml\u00a0ausreicht, \u00a0um\u00a0eine\u00a0NF\u2010\u03baB\u00a0Aktivierung \u00a0\n\u00fcber\u00a0TLR7\u00a0zu\u00a0erzielen.\u00a0Erst\u00a0bei\u00a0hohen\u00a0Konzentrationen \u00a0(3\u00a0\u00b5g/ml)\u00a0aktiviert\u00a0Gardiquimod \u00a0auch\u00a0\ngeringf\u00fcgig \u00a0TLR8.\u00a0\n\u00a07 Einleitung\n1.2.3.3  Loxoribine \t\n\u00a0\n\u00a0\nAbb.\u00a01.2.3.3.1: \u00a0Strukturformel \u00a0von\u00a0Loxoribine. \u00a0\n\u00a0\nLoxoribine \u00a0ist\u00a0ein\u00a0Guanosin \u00a0Analogon. \u00a0\u00c4hnlich\u00a0wie\u00a0Imidazoquinoline \u00a0aktiviert\u00a0Loxoribine \u00a0das\u00a0\nangeborene \u00a0Immunsystem \u00a0\u00fcber\u00a0TLR7.\u00a0Die\u00a0Aktivierung \u00a0beruht\u00a0auf\u00a0einer\u00a0Ans\u00e4uerung \u00a0und\u00a0\nReifung\u00a0der\u00a0Endosomen \u00a0(25).\u00a0\n\u00a0\u00a0\n1.2.3.4  Lipopolysaccharid \t(LPS)\t\n\u00a0\nDie\u00a0Zellwand\u00a0der\u00a0meisten\u00a0gram\u2010negativen \u00a0Bakterien \u00a0enth\u00e4lt\u00a0im\u00a0Gegensatz \u00a0zu\u00a0der\u00a0\ngram\u2010\npositiver\u00a0Bakterien \u00a0eine\u00a0aus\u00a0Lipopolysacchariden \u00a0(LPS)\u00a0aufgebaute \u00a0Schicht.\u00a0Solange\u00a0diese\u00a0\nMolek\u00fcle \u00a0in\u00a0der\u00a0Zellwand\u00a0eingebaut \u00a0sind,\u00a0sind\u00a0sie\u00a0f\u00fcr\u00a0das\u00a0Immunsystem \u00a0nicht\u00a0zug\u00e4nglich. \u00a0\nErst\u00a0bei\u00a0der\u00a0Vermehrung, \u00a0dem\u00a0Absterben \u00a0oder\u00a0der\u00a0Lyse\u00a0des\u00a0Bakteriums \u00a0werden\u00a0diese\u00a0\nMolek\u00fcle \u00a0frei.\u00a0Als\u00a0exogener \u00a0TLR4\u2010Ligand\u00a0stellt\u00a0LPS\u00a0das\u00a0st\u00e4rkste\u00a0PAMP\u00a0gram\u2010negativer \u00a0\nBakterien \u00a0dar,\u00a0welches\u00a0neben\u00a0dem\u00a0Beschleunigen \u00a0von\u00a0Immunantworten \u00a0auf\u00a0l\u00f6sliche\u00a0\nAntigene\u00a0(26\u201027)\u00a0auch\u00a0pyrogene \u00a0Eigenschaften \u00a0besitzt.\u00a0\nAufgebaut \u00a0ist\u00a0das\u00a0LPS\u2010Molek\u00fcl\u00a0aus\u00a0zwei\u00a0Untereinheiten. \u00a0Das\u00a0Lipid\u00a0A,\u00a0das\u00a0aus\u00a0sechs\u00a0oder\u00a0\nmehr,\u00a0an\u00a0zwei\u00a0phosphorylierte \u00a0Glucosamine \u00a0gebundenen \u00a0Fetts\u00e4uren \u00a0besteht\u00a0und\u00a0den\u00a0\nimmunologisch \u00a0relevanten \u00a0Teil\u00a0des\u00a0LPS\u2010Molek\u00fcls\u00a0darstellt,\u00a0und\u00a0der\u00a0Polysaccharidkette, \u00a0die\u00a0\nsich\u00a0wiederum \u00a0aus\u00a0zwei\u00a0Teilen\u00a0zusammensetzt, \u00a0n\u00e4mlich\u00a0aus\u00a0einem\u00a0Kernteil\u00a0(core)\u00a0und\u00a0einer\u00a0\nOligosaccharidkette \u00a0(O\u2010Antigen).\u00a0Der\u00a0Kernteil\u00a0ist\u00a0spezifisch \u00a0f\u00fcr\u00a0ganze\u00a0Gruppen\u00a0von\u00a0Bakterien, \u00a0\nw\u00e4hrend\u00a0das\u00a0O\u2010Antigen\u00a0von\u00a0Spezies\u00a0zu\u00a0Spezies\u00a0und\u00a0von\u00a0Stamm\u00a0zu\u00a0Stamm\u00a0stark\u00a0variiert.\u00a0\n\u00a08 Einleitung\n1.2.3.5  CpG\tODN\u00b4s\t\n\u00a0\nTLR9\u00a0wird\u00a0durch\u00a0spezifische \u00a0unmethylierte \u00a0CpG\u00a0(Cytosin\u2010phosphatidyl \u2010Guanosin) \u2010reiche\u00a0\nSequenzen \u00a0in\u00a0bakterieller \u00a0DNA\u00a0oder\u00a0durch\u00a0synthethische \u00a0Oligonukleotide \u00a0(ODN\u00b4s)\u00a0aktiviert.\u00a0\nDiese\u00a0spezifischen \u00a0CpG\u2010Sequenzen \u00a0sind\u00a0h\u00e4ufig\u00a0in\u00a0bakterieller \u00a0DNA,\u00a0aber\u00a0sehr\u00a0selten\u00a0in\u00a0\nS\u00e4ugetier \u2010DNA\u00a0anzutreffen. \u00a0Der\u00a0Methylierungsgrad \u00a0stellt\u00a0ein\u00a0wesentliches \u00a0\nUnterscheidungskriterium \u00a0zwischen\u00a0bakterieller \u00a0und\u00a0S\u00e4ugetier \u2010DNA\u00a0dar.\u00a0Unmethylierte \u00a0DNA\u00a0\nmit\u00a0eingeschlossenen \u00a0CpG\u00a0Sequenzen \u00a0kann\u00a0die\u00a0Effekte\u00a0von\u00a0bakterieller \u00a0DNA\u00a0imitieren, \u00a0wie\u00a0\nz.B.\u00a0die\u00a0B\u2010Zell\u00a0Proliferation. \u00a0\nEs\u00a0gibt\u00a03\u00a0Typen\u00a0von\u00a0stimulatorischen \u00a0CpG\u00a0ODN\u00b4s:\u00a0A\u2010,\u00a0B\u2010\u00a0und\u00a0C\u2010Typ,\u00a0die\u00a0sich\u00a0in\u00a0ihren\u00a0\nimmunstimulatorischen \u00a0Aktivit\u00e4ten \u00a0unterscheiden. \u00a0\n\u00a0\nA\u2010Typ\nB\u2010Typ\nC\u2010TypPlasmazytoide dendritische \u00a0\nZellen\n(pDC\u00b4s)B\u2010Zellen\nDifferenzierung \u00a0\u00a0\nvon\u00a0PlasmazellenAK\u2010Produktion\nAktivierung \u00a0von\u00a0T\u2010Zellen,\u00a0\nNK\u2010Zellen,\u00a0Monozyten \u00a0und\u00a0neutrophilen GranulozytenIFNIF\nNIFN\u2010\u03b1\nIIF\nN\u2010IFN\u2010\u03b3\nIl\u20102IL\u20102\nIL\u201012IL\n\u2010\n6IL\u20106\nIL\u201010\n\u00a0\nAbb.\u00a01.2.3.5.1: \u00a0Haupts\u00e4chliche \u00a0Angriffspunkte \u00a0und\u00a0deren\u00a0\nAuswirkungen \u00a0hervorgerufen \u00a0durch\u00a0die\u00a0verschiedenen \u00a0CpG\u00a0ODN\u00b4s.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a09 Einleitung\n\u00a0\nODN\u00a0 Sequenz\u00a0(5\u00b4\u00a0\u20103\u00b4)\n2216\u00a0(A\u00a0\u2013\u00a0Typ)\u00a0 ggG\u00a0GGA\u00a0CGA\u00a0TCG\u00a0TCg\u00a0ggg\u00a0gg\u00a0\u00a0\n2006\u00a0(B\u00a0\u2013\u00a0Typ)\u00a0 tcg\u00a0tcg\u00a0ttt\u00a0tgt\u00a0cgt\u00a0ttt\u00a0gtc\u00a0gtt\u00a0\u00a0\n2395\u00a0(C\u00a0\u2013\u00a0Typ)\u00a0 tcgtcgttttcggcgc:gcgccg\n\u00a0\nAbb.\u00a01.2.3.5.2: \u00a0Die\u00a0unterschiedlichen \u00a0Basensequenzen \u00a0der\u00a0drei\u00a0CpG\u00a0\nODN\u00a0Klassen.\u00a0Basen\u00a0in\u00a0Gro\u00dfbuchstaben \u00a0dargestellt \u00a0bezeichnen \u00a0\nPhosphodiester \u00a0und\u00a0Basen\u00a0in\u00a0Kleinbuchstaben \u00a0sind\u00a0Phosphorothioate \u00a0\n(Nuklease \u00a0resistent). \u00a0\n\u00a0\n\u00a0\n1.2.3.6  iODN\u00b4s\t\n\u00a0\nNeben\u00a0den\u00a0synthetischen \u00a0CpG\u00a0ODN\u00b4s,\u00a0die\u00a0stimulatorische \u00a0Eigenschaften \u00a0besitzen,\u00a0existieren \u00a0\nsogenannte \u00a0inhibitorische \u00a0ODN\u00b4s,\u00a0die\u00a0mehr\u00a0oder\u00a0weniger\u00a0spezifisch \u00a0inhibitorisch \u00a0auf\u00a0\nverschiedene \u00a0TLR\u00b4s\u00a0wirken.\u00a0\n\u00a0\niODN\u00a0 Sequenz\u00a0(5\u00b4\u00a0\u20103\u00b4)\n2088\u00a0(TLR7/8/9 \u00a0inh.)\u00a0 TCC\u00a0TGG\u00a0CGG\u00a0GGA\u00a0AGT\n20958\u00a0(TLR7\u00a0inh.)\u00a0 TCC\u00a0TAA\u00a0CAA\u00a0AAA\u00a0AAT\n20959\u00a0(TLR7/8\u00a0inh.)\u00a0 TAA\u00a0TGG\u00a0CGG\u00a0GGA\u00a0AGT\n\u00a0\nAbb.\u00a01.2.3.6.1: \u00a0Die\u00a0unterschiedlichen \u00a0Basensequenzen \u00a0der\u00a0\nverwendeten \u00a0iODN\u00b4s.\u00a0\u00a010 Einleitung\n1.2.4  Die\tSignalkaskade \tder\tTLR\u00b4s\t\n\u00a0\nJe\u00a0nachdem \u00a0welcher\u00a0der\u00a0zehn\u00a0TLR\u00b4s\u00a0durch\u00a0seinen\u00a0Liganden\u00a0angesprochen \u00a0wird,\u00a0\nunterscheiden \u00a0sich\u00a0die\u00a0nachfolgenden \u00a0unterschiedlichen \u00a0Adapterproteine \u00a0in\u00a0der\u00a0\nSignalkaskade. \u00a0Es\u00a0wird\u00a0zwischen\u00a0einem\u00a0MyD88\u2010abh\u00e4ngigen \u00a0und\u00a0MyD88\u2010unabh\u00e4ngigen \u00a0Weg\u00a0\nunterschieden \u00a0(8,\u00a028).\u00a0\nBeim\u00a0MyD88\u2010abh\u00e4ngigen \u00a0Weg\u00a0l\u00f6st\u00a0die\u00a0Assoziation \u00a0der\u00a0TLR\u00b4s\u00a0mit\u00a0MyD88\u00a0\u2010\u00a0direkt\u00a0oder\u00a0indirekt\u00a0\n\u00fcber\u00a0das\u00a0Adapterprotein \u00a0TIRAP\u00a0\u2010\u00a0die\u00a0Rekrutierung \u00a0der\u00a0Molek\u00fcle \u00a0der\u00a0IRAK\u2010Familie\u00a0aus.\u00a0IRAK\u20101\u00a0\nwird\u00a0hyperphosphoryliert \u00a0und\u00a0induziert\u00a0die\u00a0Interaktion \u00a0mit\u00a0TRAF6.\u00a0Der\u00a0Komplex\u00a0aus\u00a0MyD88,\u00a0\nIRAK4,\u00a0IRAK1\u00a0und\u00a0TRAF6\u00a0f\u00fchrt\u00a0zur\u00a0Aktivierung \u00a0von\u00a0Transkriptionsfaktoren, \u00a0wie\u00a0Interferon \u2010\naktivierenden \u00a0Faktoren\u00a0(IRF3,\u00a0IRF5\u00a0und\u00a0IRF7)\u00a0und\u00a0NF\u2010\u03baB.\u00a0Dadurch\u00a0kommt\u00a0es\u00a0zur\u00a0Freisetzung \u00a0\nproinflammatorischer \u00a0Zytokine.\u00a0\nBeim\u00a0MyD88\u2010unabh\u00e4ngigen \u00a0Weg\u00a0wird\u00a0anstelle\u00a0des\u00a0Adapterproteins \u00a0MyD88\u00a0das\u00a0\nAdapterprotein \u00a0TRIF\u00a0rekrutiert, \u00a0beim\u00a0TRIF\u2010abh\u00e4ngigen \u00a0TLR4\u2010Signalweg \u00a0wird\u00a0zus\u00e4tzlich \u00a0das\u00a0\nAdapterprotein \u00a0TRAM\u00a0ben\u00f6tigt.\u00a0Die\u00a0Aktivierung \u00a0von\u00a0TRIF\u00a0f\u00fchrt\u00a0zur\u00a0Rekrutierung \u00a0der\u00a0Kinase\u00a0\nTBK1,\u00a0die\u00a0wiederum \u00a0IRF3\u00a0induziert. \u00a0Die\u00a0Assoziation \u00a0von\u00a0TRAF6\u00a0an\u00a0das\u00a0Adapterprotein \u00a0TRIF\u00a0\u2010\u00a0\nbei\u00a0TLR3\u00a0in\u00a0Verbindung \u00a0mit\u00a0RIP1\u00a0\u2010\u00a0f\u00fchrt\u00a0zur\u00a0Aktivierung \u00a0von\u00a0NF\u2010\u03baB.\u00a0Dabei\u00a0kommt\u00a0es\u00a0zur\u00a0\nBildung\u00a0von\u00a0Typ\u00a0I\u2010IFN.\u00a0Die\u00a0Besonderheit \u00a0des\u00a0TLR3\u2010Signalweges \u00a0liegt\u00a0au\u00dferdem \u00a0in\u00a0der\u00a0\nInduktion \u00a0zur\u00a0Expression \u00a0des\u00a0Adh\u00e4sionsmolek\u00fcls \u00a0ICAM1,\u00a0welches\u00a0durch\u00a0den\u00a0TRIF\u2010RIP1\u2010\nTRAF6\u2010Komplex\u00a0induziert\u00a0wird\u00a0(Abb.\u00a01.2.4.1)\u00a0(6,\u00a028\u201029).\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a011 Einleitung\n\u00a0\n\u00a0\nTLR3\nTLR4\nTLR7/8/9\nTLR5\nTLR1/2/6TRAM\nTIRAP\nTIRAPMyD88\nMyD88\nMyD88\nMyD88TRIF\nTRIF\nIRAK4IRAK4\nIRAK4\nIRAK4TRAF6\nTRAF6RIP1\nIRAK1IRAK1\nIRAK1\nIRAK1TBK1\nTBK1\nTRAF6TRAF6TRAF6TRAF6IRF3\nIRF3\nIRF5IRF5\nIRF5IRF5IRF5IRF5\nIRF5IRF7IRF3IRF3\nNF\u2010\u03baBNF\u2010\u03baBNF\u2010\u03baBNF\u2010\u03baB\nNF\u2010\u03baB\nNF\u2010\u03baBIRF5\nIRF7\ninflammatorische\nZytokineIFN\u2010\u03b1IFN\u2010\u03b2\nICAM1\nIFN\u2010\u03b2\ninflammatorische\nZytokine\ninflammatorische\nZytokine\ninflammatorische\nZytokine\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a01.2.4.1:\u00a0Schematische \u00a0Darstellung \u00a0der\u00a0TLR\u2010Signalwege. \u00a0Es\u00a0\nwerden\u00a0der\u00a0MyD88\u2010abh\u00e4ngige \u00a0und\u00a0der\u00a0MyD88\u2010unabh\u00e4ngige \u00a0\nSignalweg \u00a0unterschieden. \u00a0Beide\u00a0aktivieren \u00a0die\u00a0Transkriptionsfaktoren \u00a0\nNF\u2010\u03baB\u00a0sowie\u00a0verschiedene \u00a0Interferon \u2010regulierende \u00a0Faktoren\u00a0(IRF3,\u00a0\nIRF5,\u00a0IRF7)\u00a0und\u00a0induzieren \u00a0so\u00a0die\u00a0Freisetzung \u00a0verschiedener \u00a0Zytokine,\u00a0\nsowie\u00a0die\u00a0Bildung\u00a0von\u00a0Adh\u00e4sionsmolek\u00fclen. \u00a0Die\u00a0Abbildung \u00a0ist\u00a0\nmodifiziert \u00a0von\u00a0(28).\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a012 Einleitung\n1.3 Die\tdendritischen \tZellen\t\n\u00a0\nBei\u00a0diesen\u00a0Zellen\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0heterogene \u00a0Zellpopulation, \u00a0die\u00a0ihren\u00a0Namen\u00a0den\u00a0\ntypischen \u00a0zellul\u00e4ren \u00a0Ausl\u00e4ufern \u00a0zu\u00a0verdanken \u00a0haben.\u00a0\n\u00a0\n\u00a0\nAbb.\u00a01.3.1:\u00a0Dendritische \u00a0Zellen.\u00a0\n\u00a0\nDie\u00a0dendritische \u00a0Zelle\u00a0(DC)\u00a0wurde\u00a0erstmals\u00a01868\u00a0in\u00a0der\u00a0Epidermis \u00a0beschrieben \u00a0und\u00a0nach\u00a0\nihrem\u00a0Entdecker \u00a0als\u00a0Langerhans \u2010Zelle\u00a0benannt.\u00a0Fast\u00a0hundert\u00a0Jahre\u00a0sp\u00e4ter\u00a0wurden\u00a0DC\u00b4s\u00a0auch\u00a0\nin\u00a0anderen\u00a0Geweben \u00a0entdeckt\u00a0und\u00a0als\u00a0wichtige\u00a0Zellen\u00a0des\u00a0Immunsystems \u00a0erkannt\u00a0(30).\u00a0\nDC\u00b4s\u00a0sind\u00a0professionelle \u00a0antigenpr\u00e4sentierende \u00a0Zellen\u00a0(APC)\u00a0mit\u00a0einer\u00a0au\u00dfergew\u00f6hnlichen \u00a0\nF\u00e4higkeit, \u00a0prim\u00e4re\u00a0Immunantworten \u00a0auszul\u00f6sen. \u00a0Au\u00dferdem \u00a0nehmen\u00a0DC\u00b4s\u00a0einen\u00a0hohen\u00a0\nStellenwert \u00a0in\u00a0der\u00a0Induktion \u00a0der\u00a0immunologischen \u00a0Toleranz\u00a0ein\u00a0und\u00a0sind\u00a0verantwortlich \u00a0f\u00fcr\u00a0\ndie\u00a0Regulation \u00a0der\u00a0T\u2010Zell\u2010vermittelten \u00a0Immunantworten. \u00a0\nDC\u00b4s\u00a0sind\u00a0also\u00a0eine\u00a0besondere \u00a0Form\u00a0der\u00a0APC\u00b4s,\u00a0die\u00a0besonders \u00a0in\u00a0der\u00a0Lage\u00a0sind\u00a0prim\u00e4re\u00a0\nImmunantworten \u00a0und\u00a0ein\u00a0immunologisches \u00a0Ged\u00e4chtnis \u00a0zu\u00a0initiieren. \u00a0\u00a0\nStammzellen \u00a0aus\u00a0dem\u00a0Knochenmark \u00a0teilen\u00a0sich\u00a0zu\u00a0zirkulierenden \u00a0Vorl\u00e4uferzellen, \u00a0die\u00a0in\u00a0den\u00a0\nverschiedenen \u00a0Geweben \u00a0als\u00a0unreife\u00a0DC\u00b4s\u00a0mit\u00a0gro\u00dfer\u00a0Phagozytoseaktivit\u00e4t \u00a0sesshaft\u00a0werden.\u00a0\nSie\u00a0finden\u00a0sich\u00a0in\u00a0den\u00a0meisten\u00a0peripheren \u00a0Geweben, \u00a0wie\u00a0auch\u00a0der\u00a0Lunge\u00a0und\u00a0besonders \u00a0an\u00a0\nden\u00a0Grenzschichten \u00a0zur\u00a0Au\u00dfenwelt \u00a0(Haut,\u00a0Mucosa). \u00a0\nErst\u00a0nach\u00a0Antigenaufnahme \u00a0oder\u00a0Stimulation \u00a0durch\u00a0das\u00a0umliegende \u00a0Zytokinmilieu \u00a0des\u00a0\njeweiligen \u00a0infizierten \u00a0Gewebes \u00a0oder\u00a0Organs\u00a0reifen\u00a0sie\u00a0aus\u00a0und\u00a0sind\u00a0in\u00a0der\u00a0Lage\u00a0T\u2010Zellen\u00a0zur\u00a0\n\u00a013 Einleitung\nAktivierung \u00a0und\u00a0Proliferation \u00a0anzuregen, \u00a0wobei\u00a0eine\u00a0einzige\u00a0dendritische \u00a0Zelle\u00a0hunderte \u00a0von\u00a0\nnaiven\u00a0T\u2010Zellen\u00a0stimulieren \u00a0kann.\u00a0Nach\u00a0der\u00a0Migration \u00a0zu\u00a0den\u00a0lymphatischen \u00a0Organen\u00a0\npr\u00e4sentieren \u00a0sie\u00a0T\u2010Zellen\u00a0die\u00a0prozessierten \u00a0Antigene\u00a0und\u00a0l\u00f6sen\u00a0so\u00a0eine\u00a0Immunantwort \u00a0aus.\u00a0\u00a0\n\u00a0\u00a0\n1.3.1  DC\u2010Subpopulationen \t\n\u00a0\nEs\u00a0sind\u00a0mindestens \u00a0vier\u00a0Entwicklungsstufen \u00a0der\u00a0DC\u00b4s\u00a0bekannt:\u00a0a)\u00a0Progenitor \u2010DC\u00b4s\n\u00a0aus\u00a0dem\u00a0\nKnochenmark; \u00a0b)\u00a0Vorl\u00e4ufer \u2010DC\u00b4s,\u00a0die\u00a0sich\u00a0im\u00a0Blut,\u00a0in\u00a0der\u00a0Lymphe\u00a0und\u00a0in\u00a0den\u00a0lymphatischen \u00a0\nGeweben \u00a0aufhalten \u00a0und\u00a0die,\u00a0wenn\u00a0sie\u00a0Pathogene \u00a0erkannt\u00a0haben,\u00a0hohe\u00a0Mengen\u00a0an\u00a0Zytokinen \u00a0\nfreisetzen \u00a0(z.B.\u00a0IFN\u2010\u03b1);\u00a0c)\u00a0gewebsst\u00e4ndige \u00a0unreife\u00a0DC\u00b4s\u00a0(iDC\u00b4s),\u00a0die\u00a0eine\u00a0gro\u00dfe\u00a0\nPhagozytoseaktivit\u00e4t \u00a0aufweisen \u00a0und\u00a0d)\u00a0reife\u00a0DC\u00b4s,\u00a0die\u00a0sich\u00a0in\u00a0den\u00a0sekund\u00e4ren \u00a0lymphatischen \u00a0\nOrganen\u00a0befinden\u00a0und\u00a0gro\u00dfe\u00a0Mengen\u00a0an\u00a0kostimulatorischen \u00a0Molek\u00fclen \u00a0exprimieren \u00a0(31\u201034).\u00a0\nMindestens \u00a0zwei\u00a0Subpopulationen \u00a0der\u00a0Vorl\u00e4ufer \u2010DC\u00b4s\u00a0zirkulieren \u00a0im\u00a0Blut,\u00a0n\u00e4mlich\u00a0die\u00a0CD14\u2010/+\u00a0\nCD11c+\u00a0CD1c+\u00a0Vorl\u00e4uferzellen \u00a0und\u00a0die\u00a0CD14\u2010\u00a0CD11c\u2010\u00a0CD123+\u00a0Vorl\u00e4uferzellen \u00a0(35\u201038).\u00a0\nmyeloide CD34+ lymphoide \u00a0CD34+Vorl\u00e4uferzellen\nreife\u00a0ZellenBlut\u2010Vorl\u00e4uferzellen\nCD11c+\nCD13+CD\u00a033+\nCD14+CD11c+\nCD13+CD\u00a033+\nCD14\u2010CD11c\u2010\nCD13\u2010\nCD\u00a033\u2010\nCD14\u2010\nCD123+Granulozyten T \u2010Zellen\nB\u2010Zellen\nNK\u2010Zellen\nMonozyten\nGM\u2010CSF\nIL\u20104M\u2010CSF\ninterstitielle \u00a0DCMakrophageGM\u2010CSF\nIL\u20104\nLangerhans \u2010DCLangerhans \u2010DCIL\u20103\nplasmazytoide DC\n\u00a0\nAbb.\u00a01.3.1.1:\u00a0Verschiedene \u00a0Urspr\u00fcnge \u00a0der\u00a0dendritischen \u00a0Zellen\u00a0\n(DC\u00b4s).\u00a0Die\u00a0Abbildung \u00a0ist\u00a0modifiziert \u00a0von\u00a0(39).\u00a0\u00a014 Einleitung\nAnhand\u00a0der\u00a0Lokalisation \u00a0der\u00a0DC\u00b4s\u00a0kann\u00a0man\u00a0u.a.\u00a0epidermale \u00a0Langerhans \u2010DC\u00b4s\u00a0(LC\u00b4s),\u00a0dermale\u00a0\n(intestinale) \u00a0DC\u00b4s,\u00a0marginale \u00a0Milz\u2010DC\u00b4s,\u00a0germinale \u00a0Zentren\u2010DC\u00b4s,\u00a0Thymus\u2010DC\u00b4s,\u00a0Leber\u2010DC\u00b4s,\u00a0\nLungen\u2010DC\u00b4s\u00a0und\u00a0Blut\u2010DC\u00b4s\u00a0unterscheiden. \u00a0Alle\u00a0diese\u00a0Zellen\u00a0weisen\u00a0einige\u00a0ph\u00e4notypische \u00a0\nUnterschiede \u00a0zueinander \u00a0auf;\u00a0ihre\u00a0Herkunft, \u00a0ihre\u00a0Reifestadien \u00a0und\u00a0ihre\u00a0funktionellen \u00a0\nUnterschiede \u00a0sind\u00a0bis\u00a0dato\u00a0noch\u00a0nicht\u00a0komplett\u00a0erforscht. \u00a0\nZum\u00a0anderen\u00a0k\u00f6nnen\u00a0DC\u00b4s\u00a0auch\u00a0anhand\u00a0ihrer\u00a0verschiedenen \u00a0Funktionen \u00a0unterschieden \u00a0\nwerden.\u00a0Einige\u00a0regulieren \u00a0die\u00a0B\u2010Zell\u2010Proliferation, \u00a0andere\u00a0die\u00a0Aktivierung \u00a0naiver\u00a0T\u2010Zellen,\u00a0\nwieder\u00a0andere\u00a0aktivieren \u00a0NK\u2010Zellen\u00a0(CD11c\u2010\u2010Vorl\u00e4uferzellen \u00a0aktivieren \u00a0NK\u2010Zellen\u00a0durch\u00a0IFN\u2010\u03b1\u00a0\nProduktion \u00a0und\u00a0f\u00fchren\u00a0so\u00a0zu\u00a0einer\u00a0gesteigerten \u00a0antiviralen \u00a0und\u00a0antitumoralen \u00a0Aktivit\u00e4t\u00a0der\u00a0\nNK\u2010Zellen)\u00a0(40\u201042).\u00a0In\u00a0sp\u00e4teren\u00a0Stadien\u00a0der\u00a0Differenzierung \u00a0regulieren \u00a0DC\u00b4s\u00a0die\u00a0Aktivit\u00e4t\u00a0der\u00a0\nNK\u2010Zellen\u00a0\u00fcber\u00a0IL\u201012\u2010\u00a0,\u00a0IL\u201015\u2010\u00a0und\u00a0IL\u201018\u2010Produktion \u00a0(43\u201044)\u00a0und\u00a0einige\u00a0induzieren \u00a0\nantigenspezifische \u00a0Unempf\u00e4nglichkeit \u00a0auf\u00a0Seiten\u00a0der\u00a0Lymphozyten \u00a0in\u00a0den\u00a0prim\u00e4ren \u00a0und\u00a0\nsekund\u00e4ren \u00a0lymphatischen \u00a0Organen\u00a0\u00fcber\u00a0Deletion\u00a0bzw.\u00a0Induktion \u00a0von\u00a0regulatorischen \u00a0Zellen\u00a0\n(39).\u00a0\nCD14+\u00a0CD11c+\u00a0\u2010DC\u00b4s\u00a0lassen\u00a0naive\u00a0T\u2010Zellen\u00a0vornehmlich \u00a0zu\u00a0TH1\u2010Zellen\u00a0differenzieren, \u00a0w\u00e4hrend\u00a0\nCD11c\u2010\u00a0\u2010DC\u00b4s\u00a0die\u00a0T\u2010Zellen\u00a0dazu\u00a0veranlassen \u00a0das\u00a0Zytokinprofil \u00a0der\u00a0TH2\u2010Zellen\u00a0zu\u00a0sezernieren. \u00a0\nNeben\u00a0der\u00a0Aktivierung \u00a0naiver\u00a0T\u2010Zellen\u00a0k\u00f6nnen\u00a0DC\u00b4s\u00a0auch\u00a0direkt\u00a0naive\u00a0und\u00a0Ged\u00e4chtnis \u2010B\u2010\nZellen\u00a0aktivieren. \u00a0DC\u00b4s\u00a0unterst\u00fctzen \u00a0die\u00a0Differenzierung \u00a0aktivierter \u00a0naiver\u00a0B\u2010Zellen\u00a0zu\u00a0\nPlasmazellen \u00a0durch\u00a0IL\u201012\u2010\u00a0und\u00a0IL\u20106\u2010Sekretion. \u00a0\n\u00a0\u00a0\n1.3.2  DC\u2010Migration \tund\t\u2010Reifung\t\n\u00a0\nDC\u00b4s\u00a0stammen \u00a0von\u00a0CD34\n+\u00a0Progenitorzellen \u00a0aus\u00a0dem\u00a0Knochenmark \u00a0oder\u00a0von\u00a0CD14+\u00a0\nMonozyten \u00a0ab.\u00a0Die\u00a0Progenitorzellen \u00a0teilen\u00a0sich\u00a0zu\u00a0Vorl\u00e4ufer \u2010DC\u00b4s.\u00a0Daraus\u00a0gehen\u00a0unreife\u00a0DC\u00b4s\u00a0\n(iDC\u00b4s)\u00a0und\u00a0Langerhanszellen \u00a0(LC\u00b4s)\u00a0hervor,\u00a0die\u00a0CCR6\u00a0(CC\u00a0motif\u00a0receptor\u00a06)\u00a0exprimieren. \u00a0Der\u00a0\nLigand\u00a0des\u00a0CCR6\u00a0ist\u00a0MIP\u20103\u03b1,\u00a0der\u00a0als\u00a0st\u00e4rkstes\u00a0Chemokin \u00a0der\u00a0DC\u2010Migration \u00a0bekannt\u00a0ist\u00a0(45\u2010\n46).\u00a0MIP\u20103\u03b1\u00a0hat\u00a0keinen\u00a0Effekt\u00a0auf\u00a0unreife\u00a0MoDC\u00b4s\u00a0(45\u201047).\u00a0MIP\u20103\u03b1\u00a0wird\u00a0haupts\u00e4chlich \u00a0von\u00a0\nEpithelzellen \u00a0exprimiert \u00a0(wie\u00a0z.B.\u00a0in\u00a0Tonsille\u00a0oder\u00a0Magen\u2010Darm\u2010Trakt)\u00a0und\u00a0dessen\u00a0Expression \u00a0\u00a015 Einleitung\nwird\u00a0durch\u00a0entz\u00fcndliche \u00a0Prozesse\u00a0vermehrt \u00a0ausgel\u00f6st. \u00a0Nach\u00a0Antigenkontakt \u00a0der\u00a0DC\u00b4s\u00a0wird\u00a0\ndie\u00a0CCR6\u2010Expression \u00a0durch\u00a0die\u00a0Expression \u00a0von\u00a0CCR7\u00a0ersetzt,\u00a0dessen\u00a0Liganden\u00a06Ckine\u00a0(CCL21)\u00a0\n(wird\u00a0von\u00a0Lymphgef\u00e4\u00dfw\u00e4nden \u00a0exprimiert) \u00a0und\u00a0MIP\u20103\u03b2\u00a0(CCL19)\u00a0(wird\u00a0in\u00a0T\u2010\u00a0und\u00a0B\u2010Zellregionen \u00a0\nexprimiert) \u00a0sind.\u00a0Dieser\u00a0Rezeptor\u00a0f\u00fchrt\u00a0die\u00a0reifenden \u00a0DC\u00b4s\u00a0zu\u00a0den\u00a0T\u2010\u00a0und\u00a0B\u2010Zell\u2010Regionen, \u00a0wo\u00a0\nsie\u00a0dann\u00a0mit\u00a0der\u00a0Produktion \u00a0von\u00a0Chemokinen \u00a0und\u00a0Zytokinen \u00a0beginnen \u00a0und\u00a0so\u00a0Lymphozyten \u00a0\nanlocken. \u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Stimulation \u00a0naiver\u00a0T\u2010Zellen\u00a0(sog.\u00a0priming )\u00a0ist\u00a0die\u00a0verst\u00e4rkte \u00a0Expression \u00a0von\u00a0\nAdh\u00e4sions \u2010\u00a0und\u00a0kostimulatorischen \u00a0Molek\u00fclen \u00a0auf\u00a0den\u00a0reifen\u00a0DC\u00b4s\u00a0wie\u00a0z.B.\u00a0CD80,\u00a0CD86\u00a0und\u00a0\nMHC\u2010Klasse\u2010II\u2010Molek\u00fcl\u00a0notwendig. \u00a0\nDas\u00a0priming\u00a0geschieht \u00a0in\u00a0den\u00a0T\u2010Zell\u2010Regionen \u00a0der\u00a0Lymphknoten, \u00a0wohin\u00a0die\u00a0dendritischen \u00a0\nZellen\u00a0nach\u00a0ihrer\u00a0Stimulation \u00a0\u00fcber\u00a0das\u00a0afferente \u00a0Lymphsystem \u00a0wandern. \u00a0So\u00a0wird\u00a0das\u00a0Muster\u00a0\nder\u00a0Expression \u00a0von\u00a0Chemokin \u2010Rezeptoren \u00a0und\u00a0Adh\u00e4sionsmolek\u00fclen \u00a0ver\u00e4ndert, \u00a0um\u00a0die\u00a0\nMigration \u00a0der\u00a0reifen\u00a0Zellen\u00a0zu\u00a0den\u00a0lymphatischen \u00a0Geweben \u00a0zu\u00a0erm\u00f6glichen \u00a0(z.B.\u00a0wird\u00a0CCR7\u00a0\n((CC\u00a0motif\u00a0receptor\u00a07),\u00a0der\u00a0den\u00a0Rezeptor\u00a0f\u00fcr\u00a0CCL19\u00a0und\u00a0CCL21\u00a0darstellt)\u00a0vermehrt \u00a0\nexprimiert). \u00a0\nAu\u00dferdem \u00a0sezernieren \u00a0DC\u00b4s\u00a0weitere\u00a0Zytokine\u00a0und\u00a0Chemokine \u00a0(Molek\u00fcle, \u00a0die\u00a0z.B.\u00a0f\u00fcr\u00a0die\u00a0\nAktivierung \u00a0und\u00a0Migration \u00a0von\u00a0Leukozyten \u00a0entlang\u00a0eines\u00a0chemischen \u00a0Gradienten \u00a0\nverantwortlich \u00a0sind),\u00a0welche\u00a0die\u00a0Zellen\u00a0des\u00a0angeborenen \u00a0Immunsystems \u00a0an\u00a0den\u00a0Ort\u00a0der\u00a0\nEntz\u00fcndung \u00a0locken\u00a0und\u00a0aktivieren. \u00a0\n\u00a0\u00a0\n1.3.3  Aufnahme \t\nvon\tAntigenen \t\n\u00a0\nUnreife\u00a0DC\u00b4s\u00a0sind\u00a0sehr\u00a0effizient\u00a0in\u00a0der\u00a0Aufnahme \u00a0von\u00a0Antigenen. \u00a0Dazu\u00a0nutzen\u00a0sie\u00a0\nverschiedene \u00a0Mechanismen \u00a0wie\u00a0Makropinozytose, \u00a0Rezeptor\u2010vermittelte \u00a0Endozytose \u00a0\u00fcber\u00a0\nden\u00a0Mannose \u2010Rezeptor\u00a0(48\u201053)\u00a0oder\u00a0Fcy\u2010Rezeptor\u00a0I\u00a0(CD64)\u00a0und\u00a0II\u00a0(CD32)\u00a0(f\u00fcr\u00a0die\u00a0Aufnahme \u00a0\nvon\u00a0Immunkomplexen \u00a0oder\u00a0opsonierten \u00a0Partikeln\u00a0(54))\u00a0sowie\u00a0die\u00a0Phagozytose \u00a0von\u00a0Bakterien \u00a0\n(55\u201056),\u00a0Viren,\u00a0intrazellul\u00e4ren \u00a0Parasiten \u00a0oder\u00a0apoptotischen \u00a0und\u00a0nekrotischen \u00a0\nZellfragmenten \u00a0(57\u201059).\u00a0\u00a016 Einleitung\n1.3.4  DC\u2010Aktivierung \tund\t\u2010Reifung\t\n\u00a0\nDie\u00a0DC\u2010Reifung\u00a0ist\u00a0ein\u00a0kontinuierlicher \u00a0Prozess,\u00a0der\u00a0in\u00a0der\u00a0Peripherie \u00a0durch\u00a0die\u00a0Aufnahme \u00a0\nvon\u00a0Antigenen \u00a0und/oder \u00a0inflammatorischen \u00a0Zytokinen \u00a0ausgel\u00f6st \u00a0wird,\u00a0und\u00a0ihren\u00a0Abschluss \u00a0\nz.B.\u00a0in\u00a0der\u00a0DC\u2010T\u2010Zell\u2010Interaktion \u00a0findet.\u00a0Zahlreiche \u00a0Faktoren\u00a0induzieren \u00a0und/oder \u00a0regulieren \u00a0\ndie\u00a0DC\u2010Reifung.\u00a0\n\u00a0\nVorl\u00e4ufer \u2010DC\nunreife DC\nreife DCZytokine wie \u00a0z.B.\u00a0GM\u2010CSF,\u00a0IL\u20103,\u00a0IL4\nPathogene \u00a0wie\u00a0z.B.\u00a0LPS,\u00a0bakterielle \u00a0DNA,\u00a0CpG\nZytokine wie \u00a0z.B.\u00a0TNF,\u00a0GM\u2010CSF\nT\u00a0\u2013Z e l l e n\u00a0\u2010>\u00a0CD40Lproduzierte \u00a0Zytokine\nIFN\u2010\u03b1,\u00a0TNF,\u00a0IL\u20101ausl\u00f6sende \u00a0Faktoren\nAntigenbindung\nMIIC\u00b4s,\u00a0Endozytose, \u00a0Phagozytose\nCCR6\u00a0high,\u00a0CCR7\u00a0low\nCD40,\u00a0CD80,\u00a0CD83,\u00a0CD86\u00a0low\nAntigenpr\u00e4sentation\nMHC\u2010II\u00a0highgeringe\u00a0Endozytose, \u00a0Phagozytose\nCCR6\u00a0low,\u00a0CCR7\u00a0high\nCD40,\u00a0CD80,\u00a0CD83,\u00a0CD86\u00a0high\n\u00a0\n\u00a0\nAbb.\u00a01.3.4.1:\u00a0Reifung\u00a0der\u00a0dendritischen \u00a0Zellen.\u00a0Die\u00a0Abbildung \u00a0ist\u00a0\nmodifiziert \u00a0von\u00a0(39).\u00a0\n\u00a0\n\u00a0\nDer\u00a0Reifungsprozess \u00a0beinhaltet \u00a0mehrere\u00a0Ver\u00e4nderungen, \u00a0die\u00a0z.B.\u00a0Morphologiever\u00e4ndungen, \u00a0\nVer\u00e4nderungen \u00a0von\u00a0Adh\u00e4sionsmolek\u00fclen, \u00a0Reorganisation \u00a0des\u00a0Zytoskeletts \u00a0und\u00a0gr\u00f6\u00dfere\u00a0\nzellul\u00e4re\u00a0Motilit\u00e4t\u00a0beinhalten \u00a0(60).\u00a0Au\u00dferdem \u00a0beobachtet \u00a0man\u00a0bei\u00a0reifen\u00a0DC\u00b4s\u00a0einen\u00a0Verlust\u00a0\nder\u00a0Phagozytoserezeptoren \u00a0und\u00a0die\u00a0Hochregulation \u00a0von\u00a0kostimulatorischen \u00a0\nOberfl\u00e4chenmolek\u00fclen, \u00a0die\u00a0f\u00fcr\u00a0die\u00a0T\u2010Zell\u2010Aktivierung \u00a0notwendig \u00a0sind.\u00a0Dazu\u00a0geh\u00f6ren\u00a0u.a.\u00a0\u00a017 Einleitung\nCD80\u00a0und\u00a0CD86,\u00a0die\u00a0zum\u00a0sog.\u00a0B7\u2010Komplex\u00a0geh\u00f6ren\u00a0und\u00a0mit\u00a0CD28\u00a0auf\u00a0den\u00a0T\u2010Zellen\u00a0\ninteragieren. \u00a0Wichtig\u00a0f\u00fcr\u00a0die\u00a0T\u2010Zellstimulierung \u00a0ist\u00a0die\u00a0Pr\u00e4sentation \u00a0von\u00a0Antigenen \u00a0auf\u00a0MHC\u2010\nKlasse\u2010I\u2010\u00a0und\u00a0MHC\u2010Klasse\u2010II\u2010Molek\u00fclen, \u00a0\u00fcber\u00a0die\u00a0die\u00a0Erkennung \u00a0durch\u00a0den\u00a0spezifischen \u00a0T\u2010\nZellrezeptor \u00a0verl\u00e4uft.\u00a0Deshalb\u00a0exprimieren \u00a0stimulierte \u00a0und\u00a0ausgereifte \u00a0DC\u00b4s\u00a0vermehrt \u00a0diese\u00a0\nMolek\u00fcle \u00a0auf\u00a0ihren\u00a0Oberfl\u00e4chen. \u00a0Weitere\u00a0Oberfl\u00e4chenmolek\u00fcle, \u00a0die\u00a0hochreguliert \u00a0werden,\u00a0\nsind\u00a0das\u00a0CD83,\u00a0ein\u00a0relativ\u00a0spezifischer \u00a0Marker\u00a0f\u00fcr\u00a0reife\u00a0dendritische \u00a0Zellen\u00a0(61),\u00a0CD1a,\u00a0das\u00a0\nstrukturelle \u00a0\u00c4hnlichkeiten \u00a0zu\u00a0MHC\u2010Proteinen \u00a0hat\u00a0mit\u00a0ebenfalls\u00a0antigenpr\u00e4sentierender \u00a0\nFunktion, \u00a0und\u00a0CD40,\u00a0das\u00a0mit\u00a0dem\u00a0CD40\u2010Liganden\u00a0auf\u00a0T\u2010Zellen\u00a0interagiert. \u00a0Reife\u00a0dendritische \u00a0\nZellen\u00a0exprimieren \u00a0auch\u00a0den\u00a0Oberfl\u00e4chenmarker \u00a0CD54\u00a0(ICAM\u00a0I)\u00a0(32).\u00a0\n\u00a0\u00a0\n1.3.5  Antigen\u2010Aufarbeitung \tund\t\u2010Pr\u00e4sentation \t\n\u00a0\n1.3.5.1  MHC\u2010Klasse\tII\t\n\u00a0\nL\u00f6sliche\u00a0und\u00a0kleine\u00a0partikul\u00e4re \u00a0Antigene\u00a0werden\u00a0von\u00a0unreifen\u00a0DC\u00b4s\u00a0entweder \u00a0durch\u00a0\nPhagozytose, \u00a0Makropinozytose \u00a0oder\u00a0durch\u00a0rezeptorvermittelte \u00a0Endozytose \u00a0effizient\u00a0\naufgenommen \u00a0und\u00a0in\u00a0Endosomen \u00a0zu\u00a0intrazellul\u00e4ren \u00a0MHC\u2010II\u2010Kompartimente \u00a0verbracht \u00a0(39,\u00a0\n49,\u00a052,\u00a062\u201064).\u00a0Unreife\u00a0DC\u00b4s\u00a0akkumulieren \u00a0MHC\u2010Klasse\u2010II\u2010Molek\u00fcle \u00a0in\u00a0Lysosomen \u2010\u00e4hnlichen \u00a0\nintrazell\u00fcl\u00e4ren \u00a0Kompartimenten \u00a0(sog.\u00a0MIIC\u00b4s\u00a0=\u00a0MHC\u2010II\u2010rich\u2010compartiments )\u00a0(65\u201066).\u00a0Die\u00a0\nMHC\u2010Klasse\u2010II\u2010Molek\u00fcle \u00a0der\u00a0unreifen\u00a0DC\u00b4s\u00a0werden\u00a0schnell\u00a0wieder\u00a0ins\u00a0Zellinnere \u00a0\naufgenommen \u00a0und\u00a0haben\u00a0nur\u00a0eine\u00a0kurze\u00a0Halbwertszeit. \u00a0Reifungs\u2010\u00a0und\u00a0\nEntz\u00fcndungsstimulationen \u00a0f\u00fchren\u00a0jedoch\u00a0zu\u00a0einer\u00a0hochgradig \u00a0gesteigerten \u00a0MHC\u2010Klasse\u2010II\u2010\nSynthese\u00a0und\u00a0Translokation \u00a0der\u00a0MHC\u2010Klasse\u2010II\u2010Peptid\u2010Komplexe \u00a0auf\u00a0die\u00a0Zelloberfl\u00e4che, \u00a0wo\u00a0\nsie\u00a0f\u00fcr\u00a0mehrere\u00a0Tage\u00a0verbleiben \u00a0und\u00a0von\u00a0CD4+\u00a0T\u2010Zellen\u00a0erkannt\u00a0werden\u00a0k\u00f6nnen\u00a0(42,\u00a060,\u00a064,\u00a0\n67).\u00a0\n\u00a0\u00a0\n\u00a0\u00a018 Einleitung\n1.3.5.2  MHC\u2010Klasse\tI\t\n\u00a0\nUm\u00a0CD8+\u00a0zytotoxische \u00a0T\u2010Zellen\u00a0zu\u00a0aktivieren \u00a0m\u00fcssen\u00a0DC\u00b4s\u00a0die\u00a0Peptide\u00a0auf\u00a0MHC\u2010Klasse\u2010I\u2010\nMolek\u00fclen \u00a0pr\u00e4sentieren. \u00a0\nDie\u00a0phagozytierten \u00a0Partikel\u00a0oder\u00a0Immunkomplexe \u00a0werden\u00a0im\u00a0Zytosol\u00a0gespalten \u00a0und\u00a0dann\u00a0in\u00a0\nProteasomen \u00a0zum\u00a0Endoplasmatischen \u00a0Retikulum \u00a0(ER)\u00a0transportiert. \u00a0Auch\u00a0das\u00a0\nZusammensetzen \u00a0des\u00a0MHC\u2010I\u2010Molek\u00fcls\u00a0findet\u00a0im\u00a0ER\u00a0statt.\u00a0Die\u00a0Peptide\u00a0lagern\u00a0sich\u00a0an\u00a0das\u00a0\nMHC\u2010I\u2010Molek\u00fcl\u00a0an\u00a0und\u00a0wenn\u00a0die\u00a0Verbindung \u00a0stabil\u00a0genug\u00a0ist\u00a0wird\u00a0der\u00a0neu\u00a0entstandene \u00a0\nMHC\u2010I\u2010Peptid\u2010Komplex\u00a0in\u00a0Vesikeln\u00a0des\u00a0ER\u00a0zur\u00a0Zelloberfl\u00e4che \u00a0transportiert \u00a0(68).\u00a0\n\u00a0\n\u00a0\n1.3.6  T\u2010Zell\u2010Aktivierung \t\n\u00a0\nDie\u00a0wichtige\u00a0Funktion\u00a0der\u00a0DC\u00b4s\u00a0ist\u00a0die\u00a0Stimulation \u00a0von\u00a0naiven\u00a0CD4+\u00a0T\u2010Zellen\u00a0in\u00a0vitro\u00a0und\u00a0in\u00a0\nvivo.\u00a0\u00a0\nIn\u00a0Gegenwart \u00a0freier\u00a0Antigene\u00a0k\u00f6nnen\u00a0von\u00a0DC\u00b4s\u00a0aktivierte \u00a0TH\u2010Zellen\u00a0mit\u00a0B\u2010Zellen\u00a0interagieren \u00a0\nund\u00a0so\u00a0eine\u00a0antigenspezifische \u00a0Antik\u00f6rperproduktion \u00a0stimulieren \u00a0(69).\u00a0\nDC\u00b4s\u00a0stimulieren \u00a0auch\u00a0naive\u00a0CD8+\u00a0zytotoxische \u00a0T\u2010Zellen\u00a0(CTL)\u00a0und\u00a0somit\u00a0ihre\u00a0Proliferation \u00a0\n(70).\u00a0Desweiteren \u00a0k\u00f6nnen\u00a0DC\u00b4s\u00a0direkt\u00a0antigenspezifische \u00a0CTL\u00a0von\u00a0Vorl\u00e4uferzellen \u00a0generieren \u00a0\n(71\u201073).\u00a0\nMHC\u2010Molek\u00fcle \u00a0und\u00a0MHC\u2010Peptid\u2010Komplexe \u00a0kommen\u00a0auf\u00a0DC\u00b4s\u00a0in\u00a010\u00a0\u2010 \u00a0100\u00a0fach\u00a0gr\u00f6\u00dferer\u00a0\nMenge\u00a0vor\u00a0als\u00a0auf\u00a0anderen\u00a0APC\u00b4s\u00a0(wie\u00a0z.B.\u00a0B\u2010Zellen\u00a0oder\u00a0Monozyten). \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a019 Einleitung\n1.3.7  Plastizit\u00e4t \tder\tdendritischen \tZellen\t\n\u00a0\nVorl\u00e4ufer \u2010\nDCunreife\u00a0DC\nMakrophageAG\u2010tragende\u00a0\nDCproinflammatorisches Umfeld\nanti\u2010inflammatorisches Umfeld``immunstimulatorische`` \u00a0DC\nTH1\u2010Antwort\n``tolerante`` \u00a0DC\nTH2\u2010Antwort\nRegulatorische \u00a0T\u2010Zellen\n\u00a0\nAbb.\u00a01.3.7.1:\u00a0Die\u00a0Plastizit\u00e4t \u00a0der\u00a0dendritischen \u00a0Zellen.\u00a0Die\u00a0Abbildung \u00a0\nist\u00a0modifiziert \u00a0von\u00a0(39).\u00a0\n\u00a0\n\u00a0\nDie\u00a0Funktionen \u00a0der\u00a0DC\u00b4s\u00a0k\u00f6nnen\u00a0sich\u00a0\u00e4ndern.\u00a0So\u00a0k\u00f6nnen\u00a0sich\u00a0DC\u00b4s\u00a0z.B.\u00a0nach\u00a0einer\u00a0Stimulation \u00a0\nmit\u00a0M\u2010CSF\u00a0zu\u00a0Makrophagen \u00a0mit\u00a0gro\u00dfer\u00a0Phagozytoseaktivit\u00e4t \u00a0differenzieren. \u00a0Au\u00dferdem \u00a0\nk\u00f6nnen\u00a0IL\u201012\u00a0sezernierende \u00a0DC\u00b4s,\u00a0die\u00a0so\u00a0die\u00a0TH1\u2010Zelldifferenzierung \u00a0induzieren, \u00a0durch\u00a0IL\u201010\u2010\u00a0\nund\u00a0PGE 2\u2010Stimulation \u00a0eine\u00a0T\u2010Zell\u2010Anergie\u00a0oder\u00a0eine\u00a0T\u2010Zell\u2010Differenzierung \u00a0in\u00a0Richtung\u00a0TH2\u2010\nZellen\u00a0oder\u00a0regulatorischen \u00a0T\u2010Zellen\u00a0ausl\u00f6sen. \u00a0\n\u00a0\n\u00a0\n1.4 T\u2010Zellen\t\n\u00a0\nDie\u00a0T\u2010Lymphozyten \u00a0stammen \u00a0wie\u00a0alle\u00a0Blutzellen \u00a0aus\u00a0dem\u00a0Knochenmark. \u00a0Nach\u00a0der\u00a0\nWanderung \u00a0der\u00a0T\u2010Zellen\u00a0zum\u00a0Thymus\u00a0reifen\u00a0sie\u00a0dort\u00a0aus.\u00a0Es\u00a0werden\u00a0MHC\u2010Molek\u00fcle \u00a0auf\u00a0ihrer\u00a0\u00a020 Einleitung\nOberfl\u00e4che \u00a0ausgebildet \u00a0und\u00a0die\u00a0Zellen\u00a0selektiert, \u00a0die\u00a0die\u00a0k\u00f6rperfremden \u00a0Antigene\u00a0mit\u00a0hoher\u00a0\nAffinit\u00e4t\u00a0erkennen \u00a0(74).\u00a0\nDie\u00a0T\u2010Zellen\u00a0erkennen \u00a0mit\u00a0ihrem\u00a0T\u2010Zell\u2010Rezeptor\u00a0(TCR)\u00a0k\u00f6rperfremde \u00a0Antigene\u00a0jedoch\u00a0nur,\u00a0\nwenn\u00a0sie\u00a0auf\u00a0der\u00a0Oberfl\u00e4che \u00a0von\u00a0APC\u00b4s\u00a0an\u00a0deren\u00a0MHC\u00a0gebunden \u00a0sind.\u00a0\n\u00a0\u00a0\n1.4.1  T\u2010Zell\u2010Subpopulationen \t\n\u00a0\nEs\u00a0existieren \u00a0CD4\n+\u00a0T\u2010Zellen,\u00a0die,\u00a0wegen\u00a0ihrer\u00a0wichtigen \u00a0Funktion\u00a0bei\u00a0der\u00a0T\u2010B\u2010Stimulation, \u00a0\nauch\u00a0T\u2010Helferzellen \u00a0(TH\u2010Zellen)\u00a0genannt\u00a0werden.\u00a0Sie\u00a0produzieren \u00a0selbst\u00a0oder\u00a0induzieren \u00a0die\u00a0\nProduktion \u00a0von\u00a0Interleukinen, \u00a0dadurch\u00a0aktivieren \u00a0sie\u00a0unter\u00a0anderem\u00a0Makrophagen \u00a0und\u00a0\nhaben\u00a0regulierende \u00a0Wirkung\u00a0auf\u00a0andere\u00a0Lymphozyten. \u00a0\n\u00a0\nCD8+ CD4+\nCTL TH1 TH2IL\u20102I L \u20102\nIL\u201012\nIFN\u2010\u03b3IL\u20102\nIL\u20104\nIL\u20106\nIL\u201010IL\u20104\nIL\u201010\nIFN\u2010\u03b3\nBildung\u00a0von\nIFN\u2010\u03b3Bildung\u00a0von\nIL\u20102,\u00a0IL\u201012,\u00a0\nIFN\u2010\u03b3und\u00a0\nTNF\u2010\u03b1Bildung\u00a0von\nIL\u20102,\u00a0IL\u20104,\u00a0IL\u20106\u00a0\nund\u00a0IL\u201010\nAktivierung \u00a0\nvon\u00a0\nMakrophagenAktivierung \u00a0\nvon\u00a0B\u2010Zellen\nZelllyse AK \u2010Produktion PhagozytoseDC\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a01.4.1.1:\u00a0T\u2010Zell\u2010Differenzierung. \u00a0\u00a021 Einleitung\nAu\u00dferdem \u00a0kommen\u00a0CD8+\u00a0T\u2010Zellen\u00a0vor,\u00a0die\u00a0auch\u00a0oft\u00a0als\u00a0zytotoxische \u00a0T\u2010Zellen\u00a0(CTL)\u00a0bezeichnet \u00a0\nwerden,\u00a0da\u00a0sie\u00a0virusinfizierte, \u00a0histoinkompatible \u00a0oder\u00a0sonst\u00a0ver\u00e4nderte \u00a0Zellen\u00a0zerst\u00f6ren \u00a0\nk\u00f6nnen.\u00a0Sie\u00a0haben\u00a0aber\u00a0auch\u00a0viele\u00a0\u00fcber\u00a0Interleukinfreisetzung \u00a0und\u00a0\u2010induktion \u00a0vermittelte \u00a0\nnichtlytische \u00a0Funktionen. \u00a0\nAls\u00a0dritte\u00a0bekannte \u00a0Gruppe\u00a0der\u00a0T\u2010Zellen\u00a0sind\u00a0die\u00a0\u03b3\u03b4\u2010T\u2010Zellen\u00a0zu\u00a0nennen.\u00a0\n\u00a0\n\u00a0\n1.4.2  T\u2010Zell\u2010Aktivierung \t\n\u00a0\nT\u2010Zellen\u00a0werden\u00a0erst\u00a0durch\u00a0APC\u00b4s\u00a0aktiviert\u00a0(75).\u00a0Bei\u00a0Virusinfektionen \u00a0spielt\u00a0vor\u00a0allem\u00a0die\u00a0\ndendritische \u00a0Zelle\u00a0als\u00a0professionelle \u00a0APC\u00a0neben\u00a0B\u2010Zellen\u00a0und\u00a0Makrophagen \u00a0die\u00a0Hauptrolle. \u00a0\n\u00a0\nDie\u00a0Interaktion \u00a0zwischen\u00a0CD8+\u00a0CTL\u00a0und\u00a0ihren\u00a0Zielzellen \u00a0erfolgt\u00a0\u00fcber\u00a0MHC\u2010Klasse\u2010I\u2010Molek\u00fcle. \u00a0\u00a0\nDie\u00a0Interaktion \u00a0zwischen\u00a0APC\u00b4s\u00a0und\u00a0CD4+\u00a0T\u2010Zellen\u00a0erfolgt\u00a0\u00fcber\u00a0MHC\u2010Klasse\u2010II\u2010Molek\u00fcle. \u00a0Dazu\u00a0\nmigrieren \u00a0die\u00a0reifen\u00a0DC\u00b4s\u00a0in\u00a0die\u00a0paracortikale \u00a0Zone\u00a0der\u00a0Lymphknoten \u00a0und\u00a0pr\u00e4sentieren \u00a0den\u00a0\nCD4+\u00a0T\u2010Zellen\u00a0die\u00a0prozessierten \u00a0Antigene. \u00a0Die\u00a0naiven\u00a0T\u2010Zellen,\u00a0deren\u00a0TCR\u00a0spezifisch \u00a0an\u00a0die\u00a0\nvon\u00a0der\u00a0reifen\u00a0DC\u00a0pr\u00e4sentierten \u00a0MHC\u2010Klasse\u2010II\u2010Peptid\u2010Komplexe \u00a0bindet,\u00a0werden\u00a0\ndeterminiert. \u00a0Dieses\u00a0erste\u00a0Signal\u00a0allein\u00a0gen\u00fcgt\u00a0aber\u00a0noch\u00a0nicht,\u00a0um\u00a0eine\u00a0ausreichende \u00a0\nAktivierung \u00a0und\u00a0klonale\u00a0Expansion \u00a0der\u00a0T\u2010Zellen\u00a0auszul\u00f6sen. \u00a0Es\u00a0bedarf\u00a0eines\u00a0zweiten\u00a0Signals\u00a0\n\u00fcber\u00a0kostimulatorische \u00a0Molek\u00fcle \u00a0wie\u00a0z.B.\u00a0CD80/86\u00a0(B7\u2010Komplex), \u00a0die\u00a0mit\u00a0dem\u00a0CD28\u2010Molek\u00fcl\u00a0\nder\u00a0T\u2010Zellen\u00a0interagieren. \u00a0CD86\u00a0wird\u00a0als\u00a0wichtigstes \u00a0Molek\u00fcl\u00a0f\u00fcr\u00a0die\u00a0Ausl\u00f6sung \u00a0von\u00a0T\u2010Zell\u2010\nAntworten \u00a0angesehen \u00a0(76\u201077).\u00a0Als\u00a0drittes\u00a0Signal\u00a0dient\u00a0das\u00a0von\u00a0reifen\u00a0DC\u00b4s\u00a0freigesetzte \u00a0\nZytokinprofil, \u00a0das\u00a0die\u00a0funktionelle \u00a0Ausrichtung \u00a0der\u00a0CD4+\u00a0T\u2010Zellen\u00a0bestimmt \u00a0und\u00a0die\u00a0\nAusbildung \u00a0einer\u00a0TH1\u2010bzw.\u00a0TH2\u2010dominierten \u00a0Immunantwort \u00a0steuern\u00a0kann.\u00a0\nT\u2010Zellen\u00a0k\u00f6nnen\u00a0DC\u00b4s\u00a0\u00fcber\u00a0CD40\u2010L\u2010CD40\u00a0aktivieren, \u00a0was\u00a0auf\u00a0Seiten\u00a0der\u00a0DC\u00b4s\u00a0zu\u00a0einer\u00a0\nerh\u00f6hten \u00a0Expression \u00a0von\u00a0CD80/86\u00a0und\u00a0Zytokinproduktion \u00a0(IL\u20101,\u00a0TNF,\u00a0IL\u201012,\u00a0Chemokine) \u00a0f\u00fchrt\u00a0\n(62,\u00a078\u201081).\u00a0Au\u00dferdem \u00a0k\u00f6nnen\u00a0aktivierte \u00a0T\u2010Zellen\u00a0die\u00a0Sekretion \u00a0von\u00a0IL\u201012,\u00a0IL\u20106\u00a0und\u00a0IL\u20101\u00a0bei\u00a0\nDC\u00b4s\u00a0stimulieren, \u00a0was\u00a0zu\u00a0einer\u00a0erh\u00f6hten \u00a0DC\u2010\u00dcberlebenszeit, \u00a0einer\u00a0Inhibition \u00a0der\u00a0DC\u2010\nApoptose \u00a0und\u00a0somit\u00a0zu\u00a0einer\u00a0erh\u00f6hten \u00a0T\u2010Zell\u2010Proliferation \u00a0f\u00fchrt.\u00a0\u00a022 Einleitung\nDCCD4 +\nT\u2010ZelleB7 CD28\nTCR\nMHC\u2010IIPeptidIL\u201012\u00a0RezeptorIL\u20101\nIL\u20106IL\u201012\nPathogene\nTLR4Signal\u00a01:\u00a0Spezifit\u00e4t\nSignal\u00a03:\u00a0DifferenzierungSignal\u00a02:\u00a0Aktivierung\nSignal\u00a01Signal\u00a03\nSignal\u00a02\n\u00a0\nAbb.\u00a01.4.2.1:\u00a0T\u2010Zell\u2010Aktivierung \u00a0durch\u00a0reife\u00a0DC\u00b4s.\u00a0\n\u00a0\n\u00a0\nBiochemisch \u00a0findet\u00a0die\u00a0erste\u00a0Signalweiterleitung \u00a0\u00fcber\u00a0den\u00a0TCR\u2010assoziierten \u00a0CD3\u2010Komplex\u00a0\nstatt,\u00a0indem\u00a0eine\u00a0Tyrosinkinase \u00a0aktiviert\u00a0wird,\u00a0die\u00a0ihrerseits \u00a0die\u00a0Phospholipase \u00a0C\u00a0(PLC)\u00a0\naktiviert.\u00a0PLC\u00a0spaltet\u00a0dann\u00a0Phosphatidylinositoldiphosphat \u00a0(PIP 2)\u00a0in\u00a0Inositoltriphosphat \u00a0(IP3)\u00a0\nund\u00a0Diacylglycerol \u00a0(DAG).\u00a0IP3\u00a0setzt\u00a0Ca2+\u00a0aus\u00a0intrazellul\u00e4ren \u00a0Speichern \u00a0frei,\u00a0DAG\u00a0aktiviert\u00a0die\u00a0\nProteinkinase \u00a0C\u00a0(PKC).\u00a0Die\u00a0PKC\u00a0wie\u00a0auch\u00a0Ca2+\u00a0induzieren \u00a0und\u00a0aktivieren \u00a0Phosphoproteine, \u00a0die\u00a0\nim\u00a0Zellkern\u00a0f\u00fcr\u00a0die\u00a0IL\u20102\u00a0Gentranskription \u00a0notwendig \u00a0sind.\u00a0Durch\u00a0die\u00a0CD28\u2010Stimulation \u00a0\nwerden\u00a0Tyrosinkinasen \u00a0aktiviert,\u00a0die\u00a0sowohl\u00a0die\u00a0Transkription \u00a0unterst\u00fctzen, \u00a0sowie\u00a0die\u00a0mRNA\u00a0\nf\u00fcr\u00a0die\u00a0IL\u20102\u2010Produktion \u00a0posttranskriptionell \u00a0stabilisieren \u00a0(74).\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a023 Einleitung\n1.5 Verschiedene \tMarker\u2010Molek\u00fcle \t\n\u00a0\n1.5.1  HLA\u2010DR\t\n\u00a0\nDas\u00a0Oberfl\u00e4chenmolek\u00fcl \u00a0HLA\u2013DR,\u00a0das\u00a0humane\u00a0MHC\u2010Klasse\u2010II\u2010Molek\u00fcl,\u00a0stellt\u00a0ein\u00a0\nTransmembran \u2010Glykoprotein, \u00a0bestehend \u00a0aus\u00a0einer\u00a0\u03b1 \u2010und\u00a0einer\u00a0\u03b2 \u2010Untereinheit, \u00a0dar.\u00a0Es\u00a0\nkommt\u00a0prim\u00e4r\u00a0auf\u00a0allen\u00a0antigenpr\u00e4sentierenden \u00a0Zellen\u00a0vor,\u00a0wie\u00a0z.\u00a0B.\u00a0Monozyten, \u00a0\nMakrophagen, \u00a0B\u2010Zellen\u00a0und\u00a0aktivierten \u00a0T\u2010Zellen.\u00a0Anhand\u00a0dieses\u00a0Molek\u00fcls\u00a0kann\u00a0man\u00a0den\u00a0\nReifungsstatus \u00a0der\u00a0Zelle\u00a0erkennen \u00a0(82).\u00a0\n\u00a0\n\u00a0\n1.5.2  CD40,\tCD83,\tCD86\t\n\u00a0\nDiese\u00a0Oberfl\u00e4chenmolek\u00fcle \u00a0stellen\u00a0Reifungsmarker \u00a0dar.\u00a0CD40\u00a0befindet\u00a0sich\u00a0vor\u00a0allem\u00a0auf\u00a0B\u2010\nZellen,\u00a0die\u00a0im\u00a0peripheren \u00a0Blut\u00a0und\u00a0in\u00a0den\u00a0Tonsillen\u00a0vorkommen, \u00a0aber\u00a0es\u00a0wird\u00a0nicht\u00a0auf\u00a0\nletztendlich \u00a0differenzierten \u00a0B\u2010Zellen\u00a0exprimiert. \u00a0Au\u00dferdem \u00a0kommt\u00a0es\u00a0auf\u00a0einigen\u00a0DC\u00b4s\u00a0und\u00a0\nMakrophagen \u00a0vor.\u00a0CD40\u00a0dient\u00a0als\u00a0Rezeptor\u00a0f\u00fcr\u00a0den\u00a0CD40\u2010Liganden\u00a0und\u00a0f\u00f6rdert\u00a0so\u00a0das\u00a0\nWachstum \u00a0und\u00a0die\u00a0Differenzierung \u00a0von\u00a0B\u2010Zellen\u00a0und\u00a0die\u00a0Zytokinproduktion \u00a0bei\u00a0\nMakrophagen \u00a0und\u00a0dendritischen \u00a0Zellen.\u00a0CD83\u00a0wird\u00a0von\u00a0DC\u00b4s\u00a0und\u00a0einigen\u00a0B\u2010Zellen\u00a0exprimiert \u00a0\nund\u00a0dient\u00a0als\u00a0Aktivierungsmarker \u00a0f\u00fcr\u00a0DC\u00b4s.\u00a0CD86\u00a0findet\u00a0man\u00a0prim\u00e4r\u00a0auf\u00a0der\u00a0Oberfl\u00e4che \u00a0von\u00a0\nMonozyten, \u00a0aktivierten \u00a0APC\u00b4s,\u00a0insbesondere \u00a0auf\u00a0DC\u00b4s\u00a0(83\u201084).\u00a0\n\u00a0\n\u00a0\n1.5.3  BDCA\u20102,\tBDCA\u20104,\tBDCA\u20101\t\n\u00a0\nBDCA\u20102\u00a0(CD303)\u00a0ist\u00a0auf\u00a0der\u00a0Oberfl\u00e4che \u00a0von\u00a0frisch\u00a0isolierten \u00a0plasmazytoiden \u00a0DC\u00b4s\u00a0(pDC\u00b4s)\u00a0zu\u00a0\nfinden\u00a0und\u00a0ist\u00a0auch\u00a0an\u00a0der\u00a0Antigenbindung \u00a0und\u2010prozessierung \u00a0beteiligt.\u00a0\u00a024 Einleitung\nNeben\u00a0pDC\u00b4s\u00a0exprimieren \u00a0auch\u00a0in\u00a0vitro\u00a0generierte \u00a0MoDC\u00b4s\u00a0und\u00a0h\u00e4matopoetische \u00a0\nStammzellen \u00a0BDCA\u20104\u00a0(CD304/Neuropilin \u20101).\u00a0\u00a0\nDas\u00a0Oberfl\u00e4chenmolek\u00fcl \u00a0BDCA\u20101\u00a0(CD1c)\u00a0geh\u00f6rt\u00a0zu\u00a0der\u00a0CD1\u00a0Familie,\u00a0deren\u00a0Proteine\u00a0\nstrukturell \u00a0verwandt \u00a0sind\u00a0mit\u00a0denen\u00a0der\u00a0MHC\u2010Klasse\u2010I.\u00a0BDCA\u20101\u00a0findet\u00a0sich\u00a0haupts\u00e4chlich \u00a0auf\u00a0\nmyeloiden \u00a0dendritischen \u00a0Zellen\u00a0(mDC\u00b4s),\u00a0in\u00a0vitro\u00a0generierten \u00a0MoDC\u00b4s,\u00a0kortikalen \u00a0\nThymozyten, \u00a0Langhans \u00a0Zellen\u00a0und\u00a0h\u00e4matopoetischen \u00a0Stammzellen. \u00a0Es\u00a0\u00e4hnelt,\u00a0wie\u00a0auch\u00a0\nCD1a,\u00a0dem\u00a0MHC\u2010Klasse\u2010I\u2010Molek\u00fcl\u00a0und\u00a0dient\u00a0der\u00a0nicht\u2010Peptid\u2010Antigen\u2010Pr\u00e4sentation \u00a0und\u00a0der\u00a0\nLymphozyten \u2010Aktivierung \u00a0und\u00a0Entwicklung \u00a0(85\u201086).\u00a0\n\u00a0\u00a0\n1.5.4  CD25\n\t\n\u00a0\nCD25\u00a0ist\u00a0auch\u00a0als\u00a0die\u00a0\u03b1\u2010Kette\u00a0des\u00a0IL\u20102\u2010Rezeptors \u00a0bekannt.\u00a0Sie\u00a0wird\u00a0auf\u00a0aktivierten \u00a0T\u2010\u00a0und\u00a0B\u2010\nZellen,\u00a0Makrophagen, \u00a0aktivierten \u00a0Monozyten \u00a0und\u00a0einem\u00a0Teil\u00a0der\u00a0regulatorischen \u00a0T\u2010Zellen\u00a0\nsowie\u00a0auf\u00a0einigen\u00a0regulatorischen \u00a0DC\u00b4s\u00a0exprimiert \u00a0(87).\u00a0\n\u00a0\u00a0\n1.5.5  CD123\n\t\n\u00a0\nCD123\u00a0ist\u00a0die\u00a0\u03b1\u2010Kette\u00a0des\u00a0IL\u20103\u2010Rezeptors \u00a0und\u00a0wird\u00a0in\u00a0hohem\u00a0Ma\u00dfe\u00a0nur\u00a0auf\u00a0pDC\u00b4s\u00a0und\u00a0\nbasophilen \u00a0Granulozyten \u00a0exprimiert. \u00a0Auf\u00a0myeloiden \u00a0Stammzellen, \u00a0Mastzellen, \u00a0\nMakrophagen, \u00a0Monozyten, \u00a0Lymphozyten, \u00a0mDC\u00b4s,\u00a0eosinophilen \u00a0Granulozyten \u00a0findet\u00a0man\u00a0sie\u00a0\nnur\u00a0in\u00a0geringen\u00a0Konzentrationen \u00a0(88).\u00a0\n\u00a0\u00a0\u00a0\u00a025 Einleitung\n1.5.6  CD122\t\n\u00a0\nCD122\u00a0stellt\u00a0die\u00a0\u03b2\u2010Kette\u00a0des\u00a0IL\u20102\u2010Rezeptors \u00a0dar\u00a0und\u00a0wird\u00a0vor\u00a0allem\u00a0von\u00a0reifen\u00a0T\u2010\u00a0und\u00a0pr\u00e4\u2010B\u2010\nZellen,\u00a0Thymozyten, \u00a0Monozyten \u00a0und\u00a0h\u00e4matopoetischen \u00a0Stammzellen \u00a0exprimiert. \u00a0Es\u00a0ist\u00a0an\u00a0\nder\u00a0IL\u20102\u2010\u00a0und\u00a0IL\u201015\u2010vermittelten \u00a0Signal\u00fcbertragung \u00a0beteiligt\u00a0(83).\u00a0\n\u00a0\n\u00a0\n1.5.7  FOXP3\t\n\u00a0\nFOXP3\u00a0(Forkhead \u00a0box\u00a0protein\u00a0P3)\u00a0ist\u00a0ein\u00a0Transkriptionsfaktor, \u00a0der\u00a0ein\u00a0regulatorisches \u00a0\nSchl\u00fcssel\u2010Gen\u00a0bei\u00a0den\u00a0regulatorischen \u00a0T\u2010Zellen\u00a0darstellt\u00a0und\u00a0somit\u00a0ein\u00a0spezifischerer \u00a0Marker\u00a0\nf\u00fcr\u00a0diese\u00a0Zellen\u00a0ist\u00a0als\u00a0die\u00a0Oberfl\u00e4chenmolek\u00fcle \u00a0CD4\u00a0und\u00a0CD25\u00a0(89).\u00a0\n\u00a0\n\u00a0\n1.6 Verschiedene \tinflammatorische \tund\tantiinflammatorische \t\nZytokine \t\n\u00a0\n1.6.1  IL\u20101\u03b2\t\n\u00a0\nInterleukin \u20101\u03b2\u00a0geh\u00f6rt\u00a0zu\u00a0der\u00a0IL\u20101\u00a0Familie.\u00a0Es\u00a0wird\u00a0haupts\u00e4chlich \u00a0von\u00a0Makrophagen \u00a0und\u00a0zum\u00a0\nTeil\u00a0auch\u00a0von\u00a0Epithelzellen \u00a0produziert. \u00a0IL\u20101\u03b2\u00a0ist\u00a0ein\u00a0hochwirksames \u00a0Zytokin.\u00a0Es\u00a0f\u00fchrt\u00a0schon\u00a0in\u00a0\ngeringen\u00a0Konzentrationen \u00a0zu\u00a0Fieber,\u00a0einem\u00a0Anstieg\u00a0der\u00a0neutrophilen \u00a0Granulozyten, \u00a0\nThrombozyten, \u00a0der\u00a0Akute\u2010Phase\u2010Proteine\u00a0und\u00a0IL\u20106.\u00a0Au\u00dferdem \u00a0unterst\u00fctzt \u00a0es\u00a0die\u00a0Aktivierung \u00a0\nvon\u00a0T\u2010Zellen\u00a0und\u00a0Makrophagen \u00a0(90).\u00a0\nIL\u20101\u03b2\u00a0induziert\u00a0\u00fcber\u00a0den\u00a0aktivierten \u00a0IL\u20101\u2010Rezeptor\u00a0Typ\u00a01\u00a0(vorhanden \u00a0in\u00a0Endothelzellen) \u00a0\u00fcber\u00a0\nNF\u2010\u03baB\u00a0die\u00a0Transduktion \u00a0der\u00a0Cyclooxygenase \u00a02\u00a0(COX2)\u00a0und\u00a0f\u00fchrt\u00a0dar\u00fcber\u00a0zu\u00a0einer\u00a0vermehrten \u00a0\nBildung\u00a0von\u00a0PGE 2\u00a0(91).\u00a0\u00a026 Einleitung\nSo\u00a0f\u00fchrt\u00a0IL\u20101\u03b2\u00a0zu\u00a0einer\u00a0vermehrten \u00a0Bildung\u00a0von\u00a0CD14,\u00a0einer\u00a0vermehrten \u00a0IL\u20106\u2010Freisetzung \u00a0und\u00a0\neiner\u00a0vermehrten \u00a0Freisetzung \u00a0an\u00a0neutrophilen \u00a0Granulozyten \u00a0aus\u00a0dem\u00a0Knochenmark \u00a0(91,\u00a068).\u00a0\n\u00a0\n\u00a0\n1.6.2  IL\u20106\t\n\u00a0\nAuch\u00a0Interleukin \u20106\u00a0reguliert\u00a0verschiedene \u00a0Entz\u00fcndungsreaktionen \u00a0im\u00a0Organismus \u00a0und\u00a0ist\u00a0in\u00a0\nder\u00a0Abfolge\u00a0der\u00a0Entz\u00fcndungskaskade \u00a0u.a.\u00a0TNF\u2010\u03b1\u00a0untergeordnet. \u00a0\nEs\u00a0regelt\u00a0komplex\u00a0die\u00a0Funktionen \u00a0anderer\u00a0Zellen\u00a0und\u00a0Zytokine.\u00a0Somit\u00a0nimmt\u00a0es\u00a0eine\u00a0\nSchl\u00fcsselstellung \u00a0im\u00a0\u00dcbergang \u00a0der\u00a0Mechanismen \u00a0des\u00a0angeborenen \u00a0Immunsystems \u00a0zu\u00a0den\u00a0\nMechanismen \u00a0des\u00a0erworbenen \u00a0Immunsystems \u00a0ein\u00a0(92).\u00a0\nIL\u20106\u00a0wird\u00a0vor\u00a0allem\u00a0von\u00a0T\u2010Zellen,\u00a0Makrophagen \u00a0und\u00a0Endothelzellen \u00a0produziert \u00a0und\u00a0induziert\u00a0\ndas\u00a0Wachstum \u00a0und\u00a0die\u00a0Differenzierung \u00a0von\u00a0T\u2010\u00a0und\u00a0B\u2010Zellen.\u00a0Au\u00dferdem \u00a0l\u00f6st\u00a0es\u00a0Fieber\u00a0und\u00a0die\u00a0\nTranskription \u00a0von\u00a0Akute\u2010Phase\u2010Proteinen \u00a0aus.\u00a0Es\u00a0ist\u00a0involviert \u00a0in\u00a0der\u00a0Regulation \u00a0der\u00a0\nApoptose \u00a0von\u00a0Leukozyten \u00a0und\u00a0in\u00a0seiner\u00a0Anwesenheit \u00a0differenzieren \u00a0sich\u00a0Monozyten \u00a0\nvermehrt \u00a0zu\u00a0Makrophagen. \u00a0\nDurch\u00a0die\u00a0Aktivierung \u00a0des\u00a0IL\u20106\u2010Rezeptors \u00a0wird\u00a0im\u00a0Zellinneren \u00a0eine\u00a0Janus\u2010aktivierte \u00a0Kinase\u00a0\n(JAK)\u00a0an\u00a0einem\u00a0Tyrosin\u00a0phosphoryliert, \u00a0wodurch\u00a0der\u00a0JAK\u2010STAT\u2010Signalweg \u00a0und\u00a0der\u00a0MAP\u2010\nKinase\u2010Weg\u00a0aktiviert\u00a0werden,\u00a0welcher\u00a0dann\u00a0zu\u00a0der\u00a0Transkription \u00a0verschiedener \u00a0Zielgene\u00a0im\u00a0\nZellkern\u00a0f\u00fchrt\u00a0(93\u201094).\u00a0\nBei\u00a0einer\u00a0akuten\u00a0lokalen\u00a0Entz\u00fcndung \u00a0werden\u00a0zun\u00e4chst\u00a0neutrophile \u00a0Granulozyten \u00a0rekrutiert, \u00a0\ndie\u00a0den\u00a0Entz\u00fcndungsherd \u00a0infiltrieren, \u00a0dann\u00a0aber\u00a0rasch\u00a0absterben \u00a0und\u00a0durch\u00a0Lymphozyten \u00a0\nund\u00a0mononukle\u00e4re \u00a0Zellen\u00a0ersetzt\u00a0werden.\u00a0Mit\u00a0dem\u00a0Grad\u00a0der\u00a0Infiltration \u00a0der\u00a0neutrophilen \u00a0\nGranulozyten \u00a0steigt\u00a0die\u00a0Konzentration \u00a0des\u00a0l\u00f6slichen\u00a0IL\u20106\u2010Rezeptors \u00a0(sIL\u20106R),\u00a0was\u00a0auf\u00a0\nverschiedenen \u00a0Wegen\u00a0zu\u00a0einer\u00a0Begrenzung \u00a0der\u00a0neutrophilen \u00a0Granulozyten \u00a0im\u00a0entz\u00fcndeten \u00a0\nGewebe\u00a0f\u00fchrt.\u00a0Dadurch\u00a0werden\u00a0gleichzeitig \u00a0CD3+\u00a0T\u2010Zellen\u00a0angelockt, \u00a0was\u00a0den\u00a0\u00dcbergang \u00a0von\u00a0\nder\u00a0angeborenen \u00a0Immunantwort \u00a0zu\u00a0der\u00a0erworbenen \u00a0Immunantwort \u00a0markiert\u00a0(92,\u00a068).\u00a0\u00a027 Einleitung\n1.6.3  IL\u20108\t\n\u00a0\nInterleukin \u20108\u00a0wird\u00a0vor\u00a0allem\u00a0von\u00a0Makrophagen, \u00a0Epithelzellen \u00a0und\u00a0Endothelzellen \u00a0produziert. \u00a0\nEs\u00a0stellt\u00a0einen\u00a0der\u00a0Hauptvermittler \u00a0der\u00a0Entz\u00fcndungsreaktionen \u00a0dar.\u00a0Neben\u00a0der\u00a0Funktion\u00a0\neines\u00a0Lockstoffes \u00a0ist\u00a0es\u00a0ein\u00a0potenter\u00a0Angiogenese \u2010Faktor\u00a0(95).\u00a0\nDie\u00a0Hauptfunktion \u00a0des\u00a0IL\u20108\u00a0ist\u00a0die\u00a0Induktion \u00a0von\u00a0Chemotaxis \u00a0bei\u00a0seinen\u00a0Zielzellen \u00a0\n(neutrophile \u00a0Granulozyten) \u00a0und\u00a0deren\u00a0\u00a0Aktivierung \u00a0zur\u00a0Phagozytose. \u00a0\nAuch\u00a0nachdem \u00a0Makrophagen \u00a0Antigene\u00a0phagozytiert \u00a0haben,\u00a0sezernieren \u00a0sie\u00a0IL\u20108\u00a0und\u00a0locken\u00a0\nso\u00a0andere\u00a0Immunzellen \u00a0an\u00a0den\u00a0Ort\u00a0der\u00a0Entz\u00fcndung \u00a0(68).\u00a0\n\u00a0\u00a0\n1.6.4  IL\u201010\t\n\u00a0\nInterleukin \u201010\u00a0stellt\u00a0ein\u00a0antiinflammatorisches \u00a0Zytokin\u00a0dar,\u00a0welches\u00a0zahlreiche \u00a0Funktionen \u00a0in\u00a0\nder\u00a0Regulation \u00a0des\u00a0Immunsytems \u00a0aus\u00fcbt.\u00a0Es\u00a0wird\u00a0haupts\u00e4chlich \u00a0von\u00a0Makrophagen \u00a0und\n\u00a0T\u2010\nZell\u2010Subpopulationen \u00a0produziert. \u00a0\nEs\u00a0wirkt\u00a0u.a.\u00a0hemmend \u00a0auf\u00a0Abwehrvorg\u00e4nge \u00a0und\u00a0sch\u00fctzt\u00a0so\u00a0den\u00a0Organismus \u00a0vor\u00a0einer\u00a0\n\u00fcbersteigerten \u00a0Entz\u00fcndungsreaktion \u00a0(96).\u00a0Desweitern \u00a0hemmt\u00a0es\u00a0die\u00a0Bildung\u00a0von\u00a0Zytokinen \u00a0\nder\u00a0TH1\u2010Antwort\u00a0(IL\u20102,\u00a0IL\u20103,\u00a0IL\u20106,\u00a0IFN\u2010\u03b3,\u00a0TNF\u2010\u03b2)\u00a0und\u00a0wirkt\u00a0verl\u00e4ngernd \u00a0auf\u00a0das\u00a0\u00dcberleben, \u00a0die\u00a0\nVermehrung \u00a0und\u00a0die\u00a0Antik\u00f6rperproduktion \u00a0von\u00a0B\u2010Zellen.\u00a0IL\u201010\u00a0blockiert\u00a0au\u00dferdem \u00a0NF\u2010\u03baB\u00a0\nund\u00a0ist\u00a0in\u00a0die\u00a0Regulation \u00a0des\u00a0JAK\u2010STAT\u2010Signalweges \u00a0miteinbezogen. \u00a0\nSo\u00a0hemmt\u00a0es\u00a0die\u00a0Bildung\u00a0von\u00a0TNF\u00a0und\u00a0IL\u20106\u00a0in\u00a0antigenpr\u00e4sentierenden \u00a0Zellen\u00a0wie\u00a0Monozyten \u00a0\nund\u00a0DC\u00b4s\u00a0und\u00a0damit\u00a0direkt\u00a0die\u00a0Aktivierung \u00a0von\u00a0T\u2010Zellen.\u00a0Au\u00dferdem \u00a0lenkt\u00a0es\u00a0die\u00a0CD4+\u00a0T\u2010\nZellantwort \u00a0mehr\u00a0von\u00a0der\u00a0TH1\u2010\u00a0auf\u00a0TH2\u2010Differenzierung \u00a0und\u00a0es\u00a0f\u00f6rdert\u00a0die\u00a0Proliferation \u00a0von\u00a0B\u2010\nZellen\u00a0und\u00a0ihre\u00a0Differenzierung \u00a0zu\u00a0Plasmazellen. \u00a0Desweiteren \u00a0blockiert\u00a0es\u00a0die\u00a0Translokation \u00a0\nvon\u00a0MHC\u2010Klasse\u2010II\u2010Peptid\u2010Komplexen \u00a0auf\u00a0die\u00a0Zelloberfl\u00e4che \u00a0und\u00a0somit\u00a0auch\u00a0die\u00a0DC\u2010Reifung\u00a0\n(68).\u00a0\n\u00a0\u00a028 Einleitung\n1.6.5  IL\u201012p70\t\n\u00a0\nIL\u201012\u00a0besteht\u00a0aus\u00a0den\u00a0Untereinheiten \u00a0IL\u201012p35\u00a0und\u00a0IL\u201012p40.\u00a0Die\u00a0biologisch \u00a0aktive\u00a0Form\u00a0des\u00a0\nIL\u201012\u00a0wird\u00a0IL\u201012p70\u00a0bezeichnet. \u00a0\nIL\u201012\u00a0wird\u00a0von\u00a0DC\u00b4s,\u00a0Makrophagen \u00a0und\u00a0B\u2010Zellen\u00a0produziert. \u00a0Es\u00a0ist\u00a0bei\u00a0der\u00a0Differenzierung \u00a0von\u00a0\nnaiven\u00a0CD4+\u00a0T\u2010Zellen\u00a0zu\u00a0TH1\u2010Zellen\u00a0behilflich. \u00a0Weiterhin \u00a0stimuliert \u00a0IL\u201012p70\u00a0das\u00a0Wachstum \u00a0\nund\u00a0die\u00a0Funktion\u00a0der\u00a0T\u2010Zellen.\u00a0So\u00a0induziert\u00a0es\u00a0bei\u00a0T\u2010Zellen\u00a0und\u00a0NK\u2010Zellen\u00a0die\u00a0Produktion \u00a0von\u00a0\nIFN\u2010\u03b1\u00a0und\u00a0TNF\u2010\u03b1.\u00a0\nIL\u201012p70\u00a0vermittelt \u00a0die\u00a0Steigerung \u00a0der\u00a0zytotoxischen \u00a0Aktivit\u00e4t\u00a0von\u00a0NK\u2010Zellen\u00a0und\u00a0CD8+\u00a0CTL\u00a0\n(97).\u00a0Des\u00a0Weiteren \u00a0\u00fcbt\u00a0es\u00a0indirekt\u00a0eine\u00a0anti\u2010angiogenetische \u00a0Funktion\u00a0aus,\u00a0die\u00a0\u00fcber\u00a0eine\u00a0\nInduktion \u00a0von\u00a0IFN\u2010\u03b3\u00a0f\u00fchrt\u00a0(68).\u00a0\n\u00a0\n\u00a0\n1.6.6  TNF\t\n\u00a0\nTumornekrosefaktor \u00a0(TNF)\u00a0stellt\u00a0ein\u00a0multifaktorielles \u00a0Zytokin\u00a0des\u00a0Immunsystems \u00a0dar,\u00a0\nwelches\u00a0an\u00a0Entz\u00fcndungsreaktionen \u00a0beteiligt\u00a0ist.\u00a0\u00a0\nTNF\u2010\u03b1\u00a0wird\u00a0haupts\u00e4chlich \u00a0von\u00a0Makrophagen, \u00a0NK\u2010Zellen\u00a0und\u00a0T\u2010Zellen\u00a0produziert \u00a0und\u00a0ist\u00a0f\u00fcr\u00a0\ndie\u00a0Entstehung \u00a0einer\u00a0Entz\u00fcndungsreaktion \u00a0und\u00a0Endothelaktivierung \u00a0verantwortlich. \u00a0\nTNF\u2010\u03b2\u00a0wird\u00a0haupts\u00e4chlich \u00a0von\u00a0T\u2010und\u00a0B\u2010Zellen\u00a0produziert \u00a0und\u00a0regelt\u00a0vor\u00a0allem\u00a0Apoptose \u00a0und\u00a0\nEndothelaktivierung. \u00a0\u00a0\nBeide\u00a0sind\u00a0also\u00a0f\u00fcr\u00a0die\u00a0Regulation \u00a0der\u00a0Aktivit\u00e4t\u00a0der\u00a0verschiedenen \u00a0Immunzellen, \u00a0wie\u00a0z.B.\u00a0die\u00a0\nZellproliferation, \u00a0Zelldifferenzierung \u00a0und\u00a0Zytokinproduktion, \u00a0unerl\u00e4sslich \u00a0(98,\u00a068).\u00a0\n\u00a0\u00a0\u00a029 Einleitung\n1.7 Zielsetzung \t\n\u00a0\nSeit\u00a01959\u00a0Schwartz\u00a0et\u00a0al.\u00a0(99\u2010100)\u00a0belegten, \u00a0dass\u00a06\u2010Mercaptopurin \u00a0effektiv\u00a0die\u00a0\nLymphozytenproliferation \u00a0hemmt\u00a0und\u00a0somit\u00a0eine\u00a0l\u00e4ngere\u00a0Transplantat \u2010Halbwertszeit \u00a0\nerreicht\u00a0werden\u00a0konnte,\u00a0wurden\u00a0immunsuppressive \u00a0Medikamente \u00a0in\u00a0der\u00a0experimentellen \u00a0\nund\u00a0klinischen \u00a0Therapie\u00a0verst\u00e4rkt\u00a0angewendet. \u00a0\nZu\u00a0dieser\u00a0Zeit\u00a0konzentrierte \u00a0man\u00a0sich\u00a0auf\u00a0die\u00a0Beeinflussung \u00a0der\u00a0Lymphozytenproliferation, \u00a0\nals\u00a0Hauptangriffspunkt, \u00a0zur\u00a0Ver\u00e4nderung \u00a0der\u00a0Immunantwort. \u00a0\nDeshalb\u00a0waren\u00a0viele\u00a0traditionelle \u00a0immunsuppressive \u00a0Medikamente \u00a0solche,\u00a0von\u00a0denen\u00a0man\u00a0\nglaubte,\u00a0dass\u00a0sie\u00a0als\u00a0Hauptwirkungsmechanismus \u00a0in\u00a0die\u00a0Lymphozytenproliferation \u00a0\neingreifen. \u00a0\nEs\u00a0gibt\u00a0heute\u00a0aber\u00a0viele\u00a0Beweise\u00a0daf\u00fcr,\u00a0dass\u00a0viele\u00a0lang\u00a0etablierte \u00a0immunsuppressive \u00a0\nMedikamente \u00a0schon\u00a0in\u00a0fr\u00fcheren\u00a0Stufen\u00a0der\u00a0Immunantwort \u00a0eingreifen, \u00a0n\u00e4mlich\u00a0bei\u00a0der\u00a0\nAktivierung \u00a0der\u00a0DC\u00b4s.\u00a0\nDC\u00b4s\u00a0sind\u00a0eine\u00a0heterogene \u00a0Zellpopulation \u00a0von\u00a0APC\u00b4s,\u00a0die\u00a0Immunantworten \u00a0ausl\u00f6sen\u00a0und\u00a0\nregulieren \u00a0(39).\u00a0So\u00a0l\u00f6sen\u00a0sie\u00a0Immunantworten \u00a0entweder \u00a0\u00fcber\u00a0das\u00a0angeborene \u00a0Immunsystem \u00a0\naus,\u00a0indem\u00a0sie\u00a0NK\u2010Zellen\u00a0aktivieren. \u00a0Oder\u00a0sie\u00a0vermitteln \u00a0Immunantworten \u00a0\u00fcber\u00a0das\u00a0\nerworbene \u00a0Immunsystem, \u00a0indem\u00a0sie\u00a0naive\u00a0T\u2010und\u00a0B\u2010Zellen\u00a0aktivieren. \u00a0Au\u00dferdem \u00a0k\u00f6nnen\u00a0\nDC\u00b4s\u00a0die\u00a0Bildung\u00a0von\u00a0regulatorischen \u00a0T\u2010Zellen\u00a0induzieren \u00a0(39).\u00a0So\u00a0existieren \u00a0einige\u00a0\nImmunsuppressiva, \u00a0wie\u00a0Rapamycin \u00a0(101\u2010103)\u00a0oder\u00a0Acetylsalicyls\u00e4ure \u00a0(104\u2010105),\u00a0die\u00a0in\u00a0der\u00a0\nklinischen \u00a0Therapie\u00a0bereits\u00a0eingesetzt \u00a0werden\u00a0und\u00a0auch\u00a0Schl\u00fcsselfunktionen \u00a0der\u00a0DC\u00b4s\u00a0\nbeeinflussen \u00a0(106\u2010107).\u00a0\u00a0\nImidazoquinoline \u00a0geh\u00f6ren\u00a0zu\u00a0den\u00a0wenigen\u00a0klinisch\u00a0verf\u00fcgbaren \u00a0immunstimulatorischen \u00a0\nMedikamenten, \u00a0die\u00a0verschiedene \u00a0Zellen\u00a0des\u00a0angeborenen \u00a0Immunsystems \u00a0entweder \u00a0\u00fcber\u00a0\nToll\u2010like\u00a0Rezeptor\u00a07\u00a0(TLR7)\u00a0oder\u00a0\u00fcber\u00a0TLR7/8\u00a0aktivieren \u00a0(108\u2010109).\u00a0\nDer\u00a0synthetische \u00a0Imidazoquinolin \u2010Bestandteil \u00a0Resiquimod \u00a0(R848),\u00a0der\u00a0seine\u00a0Zielzellen \u00a0\u00fcber\u00a0\nTLR7\u00a0und\u00a0TLR8\u00a0moduliert, \u00a0befindet\u00a0sich\u00a0zur\u00a0Zeit\u00a0in\u00a0klinischen \u00a0Studien\u00a0\u00fcber\u00a0seine\u00a0Wirkung\u00a0bei\u00a0\naktinischer \u00a0Keratose\u00a0(110\u2010111).\u00a0\u00a030 Einleitung\nVon\u00a0einigen\u00a0Autoren\u00a0wird\u00a0eine\u00a0durch\u00a0R848\u00a0ausgel\u00f6ste \u00a0Beeintr\u00e4chtigung \u00a0der\u00a0Differenzierung \u00a0\nund\u00a0Reifung\u00a0der\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0DC\u00b4s\u00a0(MoDC\u00b4s) \u00a0beschrieben \u00a0(112).\u00a0Andere\u00a0\nUntersuchungen \u00a0belegen,\u00a0dass\u00a0eine\u00a0TLR7\u00a0und/oder \u00a08\u00a0Stimulation \u00a0der\u00a0DC\u00b4s\u00a0\nimmunstimulatorische \u00a0Auswirkungen \u00a0hat\u00a0und\u00a0verschiedene \u00a0Signalwege \u00a0der\u00a0DC\u2010Reifung\u00a0in\u00a0\nGang\u00a0setzt\u00a0(113\u2010115).\u00a0\n\u00a0\n\u00a0Zielsetzung: \u00a0\nUm\u00a0die\u00a0Wirkung\u00a0des\u00a0R848\u00a0auf\u00a0in\u00a0vitro\u00a0generierte \u00a0humane\u00a0MoDC\u00b4s\u00a0besser\u00a0zu\u00a0verstehen, \u00a0\nm\u00fcssen\u00a0systematische \u00a0Untersuchungen \u00a0des\u00a0TLR7/8\u00a0Liganden\u00a0R848\u00a0auf\u00a0die\u00a0MoDC\u2010\nDifferenzierung \u00a0und\u00a0\u2010Reifung\u00a0vorgenommen \u00a0werden.\u00a0Au\u00dferdem \u00a0soll\u00a0die\u00a0funktionelle \u00a0Rolle\u00a0\nvon\u00a0R848\u00a0auf\u00a0TLR7\u00a0und\u00a08\u00a0analysiert \u00a0werden\u00a0und\u00a0weitergehend \u00a0die\u00a0Auswirkung \u00a0der\u00a0mit\u00a0R848\u00a0\nstimulierten \u00a0MoDC\u00b4s\u00a0auf\u00a0die\u00a0allogene\u00a0T\u2010Zell\u00a0Stimulation \u00a0untersucht \u00a0werden.\u00a0\nSo\u00a0k\u00f6nnen\u00a0R\u00fcckschl\u00fcsse \u00a0auf\u00a0eine\u00a0durch\u00a0R848\u00a0ausgel\u00f6ste \u00a0Modulation \u00a0der\u00a0Immunantwort \u00a0\ngezogen\u00a0werden,\u00a0um\u00a0den\u00a0Wirkstoff \u00a0in\u00a0Zukunft\u00a0effektiv\u00a0in\u00a0der\u00a0klinischen \u00a0Therapie\u00a0einsetzen \u00a0\nzu\u00a0k\u00f6nnen.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a031 Material\u00a0und\u00a0Methoden\n2 Material \tund\tMethoden \t\n\u00a0\n2.1 Material \t\n\u00a0\n2.1.1  Ger\u00e4te\t\n\u00a0\nAutoMACS\u2122 \u00a0Separator \u00a0 Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\nAutomatischer \u00a0H\u00e4matologie \u2010Analysator \u00a0\nKX\u201021N\u00a0Sysmex\u00a0Deutschland \u00a0GmbH,\u00a0Norderstedt, \u00a0\nD\u00a0\nSystec\u00ae\u00a02540\u00a0EL\u00a0Autoklav\u00a0 Systec\u00a0GmbH,\u00a0Wettenberg, \u00a0D\u00a0\nDurchflusszytometer \u00a0FACSCalibur\u2122 \u00a0 Becton\u00a0Dickinson, \u00a0Heidelberg, \u00a0D\u00a0\nDurchflusszytometer \u00a0FACSCanto \u00a0II\u2122\u00a0 Becton\u00a0Dickinson, \u00a0Heidelberg, \u00a0D\u00a0\nHanddispenser \u00a0Handy\u00a0Step\u00ae\u00a0 BRAND\u00a0GmbH\u00a0+\u00a0CO\u00a0KG,\u00a0Wertheim, \u00a0D\u00a0\nInkubator \u00a0HERAcell240 \u00a0 Heraeus,\u00a0Kendro\u00a0Laboratory \u00a0Products, \u00a0\nHanau,\u00a0D\u00a0\nInolab\u00a0pH\u2010Meter\u00a0 Inolab\u00a0WTW,\u00a0Weilheim, \u00a0D\u00a0\nLaborzentrifuge \u00a0Heraeus\u00a0Biofuge\u00a0primo\u00a0 Heraeus,\u00a0Kendro\u00a0Laboratory \u00a0Products, \u00a0\nHanau,\u00a0D\u00a0\nLaborzentrifuge \u00a0ROTANTA/TRC \u00a0 Hettich,\u00a0Tuttlingen, \u00a0D\u00a0\nLaborzentrifuge \u00a0ROTIXA/A \u00a0 Hettich,\u00a0Tuttlingen, \u00a0D\u00a0\nLaborzentrifuge \u00a0ROTIXA/AP \u00a0 Hettich,\u00a0Tuttlingen, \u00a0D\u00a0\nMikropipetten \u00a0 Eppendorf, \u00a0Hamburg, \u00a0D\u00a0\nMillipore\u2122 \u00a0Elix5\u00a0aqua\u00a0dest\u00a0Anlage\u00a0 Millipore\u00a0GmbH,\u00a0Eschborn, \u00a0D\u00a0\nMultikanalpipette \u00a0 Eppendorf, \u00a0Hamburg, \u00a0D\u00a0\nMultipipette \u00a0plus\u00a0 Eppendorf, \u00a0Hamburg, \u00a0D\u00a0\nPipette\u00a0Research ,\u00a00,5\u201010\u00a0\u00b5l\u00a0 Eppendorf, \u00a0Hamburg, \u00a0D\u00a0\nPipette\u00a0Research ,\u00a010\u2010100\u00a0\u00b5l\u00a0 Eppendorf, \u00a0Hamburg, \u00a0D\u00a0\u00a032 Material\u00a0und\u00a0Methoden\nPipette\u00a0Research ,\u00a0100\u20101000\u00a0\u00b5l\u00a0 Eppendorf, \u00a0Hamburg, \u00a0D\u00a0\nPlattenzentrifuge \u00a0Heraeus\u00a0Christ\u00a0\nLabofugeGL\u00a0Heraeus,\u00a0Kendro\u00a0Laboratory \u00a0Products, \u00a0\nHanau,\u00a0D\u00a0\nRotationssch\u00fcttler \u00a0CAT\u00a0RM5\u00a0 Kobe,\u00a0Marburg, \u00a0D\u00a0\nSicherheitswerkbank \u00a0HERAsafe \u00a0 Heraeus,\u00a0Kendro\u00a0Laboratory \u00a0Products, \u00a0\nHanau,\u00a0D\u00a0\nSTARLAB\u00ae \u00a0Pipettor\u00a0 STARLAB\u00a0GmbH,\u00a0Ahrensburg, \u00a0D\u00a0\nWaage\u00a0Mettler\u00ae\u00a0AE\u00a0100S\u00a0 Mettler\u00a0Toledo\u00a0GmbH,\u00a0Gie\u00dfen,\u00a0D\u00a0\nWaage\u00a0Mettler\u00ae\u00a0PJ\u00a06000\u00a0 Mettler\u00a0Toledo\u00a0GmbH,\u00a0Gie\u00dfen,\u00a0D\u00a0\nWasserbad \u00a0Julabo\u00ae\u00a0ED\u20105M\u00a0 Julabo,\u00a0Seelbach, \u00a0D\u00a0\n\u00a0\n\u00a0\n2.1.2  Verbrauchsmaterialien \t\n\u00a0\n24\u00a0well\u00a0cell\u00a0culture\u00a0plate,\u00a0flat\u00a0bottom\u00a0with\u00a0\nlid,\u00a0Cellstar\u00ae\u00a0Greiner\u00a0Bio\u2010One,\u00a0Frickenhausen, \u00a0D\u00a0\n96\u00a0well\u00a0cell\u00a0culture\u00a0plate,\u00a0flat\u00a0bottom\u00a0with\u00a0\nlid,\u00a0Cellstar\u00ae\u00a0Greiner Bio\u2010One,\u00a0Frickenhausen, \u00a0D\u00a0\n96\u00a0well\u00a0cell\u00a0culture\u00a0plate,\u00a0U\u2010bottom\u00a0with\u00a0\nlid,\u00a0Cellstar\u00ae\u00a0Greiner\u00a0Bio\u2010One,\u00a0Frickenhausen, \u00a0D\u00a0\nBlue\u00a0MAX\u2122\u00a0Polypropylene \u00a0Conical\u00a0Tube ,\u00a0\n50\u00a0ml\u00a0Becton\u00a0Dickinson \u00a0Labware,\u00a0Heidelberg, \u00a0D\u00a0\nBlue\u00a0MAX\u2122\u00a0Polypropylene \u00a0Conical\u00a0Tube ,\u00a0\n15\u00a0ml\u00a0Becton\u00a0Dickinson \u00a0Labware,\u00a0Heidelberg, \u00a0D\u00a0\nCorning\u00ae\u00a0Cell\u00a0Culture\u00a0Dish,\u00a060\u00a0x\u00a015mm\u00a0\nstyle\u00a0Corning\u00a0Incorporated, \u00a0NY,\u00a0USA\u00a0\nDispenser \u2010Tips,\u00a0MTB,\u00a01,25\u00a0ml,\u00a02,5\u00a0ml,\u00a05\u00a0ml MTB,\u00a0Gie\u00dfen,\u00a0D\nDisposable \u00a0Scalpel,\u00a0Feather \u00ae\u00a0 PFM,\u00a0K\u00f6ln,\u00a0D\nEinmalspritzen, \u00a05\u00a0ml,\u00a010\u00a0ml,\u00a020\u00a0ml,\u00a0Inject\u00ae B.\u00a0Braun,\u00a0Melsungen, \u00a0D\nFilterspitze \u00a0PP\u00a0natur\u00a00,5\u201310\u00a0\u00b5l\u00a0 Nerbe\u00a0plus\u00a0GmbH,\u00a0Winsen/Luhe, \u00a0D\u00a0\u00a033 Material\u00a0und\u00a0Methoden\nFilterspitze \u00a0PP\u00a0natur\u00a01\u2013100\u00a0\u00b5l\u00a0 Nerbe\u00a0plus\u00a0GmbH,\u00a0Winsen/Luhe, \u00a0D\u00a0\nFilterspitze \u00a0PP\u00a0natur\u00a0100\u20131000\u00a0\u00b5l\u00a0 Nerbe\u00a0plus\u00a0GmbH,\u00a0Winsen/Luhe, \u00a0D\u00a0\nBD\u00a0Microlance\u2122 \u00a020G\u00a01\u00bd,\u00a00,9\u00a0x\u00a040\u00a0mm Becton\u00a0Dickinson \u00a0Labware,\u00a0Heidelberg, \u00a0D\u00a0\nMaxisorp, \u00a0Nunc\u2010Immuno\u00a0Platte\u00a0 Nunc,\u00a0Roskilde,\u00a0DK\nPlastibrand\u00ae \u00a0Pr\u00e4zisions \u00a0Dispenser \u2010Tips\u00a0\n12,5\u00a0ml\u00a0BRAND\u00a0GmbH\u00a0+\u00a0CO\u00a0KG,\u00a0Wertheim, \u00a0D\u00a0\nSarstedt\u00ae \u00a0R\u00f6hrchen, \u00a05ml,\u00a075\u00a0x\u00a012\u00a0mm,\u00a0PS\u00a0\nf\u00fcr\u00a0Flow\u00a0Cytometry \u00a0Sarstedt,\u00a0N\u00fcmbrecht, \u00a0D\nTranswel l\u00ae\u00a05\u00a0\u00b5m\u00a0Polycarbonat \u00a0 Corning\u00a0Costar,\u00a0NY,\u00a0USA\n\u00a0\n\u00a0\n2.1.3  Chemikalien \t\n\u00a0\nAqua\u00a0ad\u00a0iniectabilia \u00a0 Baxter\u00a0S.A.,\u00a0Lessines,\u00a0B\nAqua\u00a0B.\u00a0Braun,\u00a0Ecotainer\u00ae \u00a0 Braun,\u00a0Melsungen, \u00a0D\nBovine\u00a0Serum\u00a0Albumin (BSA)\u00a0 SERVA,\u00a0Heidelberg, \u00a0D\nCellfix \u2122\u00a0(10x)\u00a0 BD\u00a0Biosciences, \u00a0Erembodegem, \u00a0B\u00a0\nDimethylsulfoxid \u00a0(DMSO)\u00a0 Roth,\u00a0Karlsruhe, \u00a0D\nDulbecco`s \u00a0PBS\u00a0(DPBS\u00a010x)\u00a0ohne\u00a0Ca2+&\u00a0\nMg2+\u00a0PAA\u00a0Laboratories \u00a0GmbH,\u00a0Pasching, \u00a0A\u00a0\nEthanol\u00a070%\u00a0 Otto\u00a0Fischar\u00a0GmbH\u00a0&\u00a0Co\u00a0KG,\u00a0Saarbr\u00fccken, \u00a0\nD\u00a0\nEthanol\u00a0absolut\u00a0puriss.\u00a0p.a.,\u00a0steril\u00a0 Sigma\u2010Aldrich,\u00a0Steinheim, \u00a0D\u00a0\nEthylendiamintetraacetat \u00a0(EDTA,\u00a0Titriplex) Merck,\u00a0Darmstadt, \u00a0D\nFACS\u00a0Clean \u2122\u00a0 BD\u00a0Biosciences, \u00a0Heidelberg, \u00a0D\u00a0\nFACS\u00a0Flow \u2122\u00a0 BD\u00a0Biosciences, \u00a0Heidelberg, \u00a0D\u00a0\nFACS\u00a0Rinse \u2122\u00a0 BD\u00a0Biosciences, \u00a0Heidelberg, \u00a0D\u00a0\u00a034 Material\u00a0und\u00a0Methoden\nFicoll\u2010Paque\u2122\u00a0PLUS\u00a0 Amersham \u00a0Biosciences, \u00a0Uppsala,\u00a0S\u00a0\nFOXP3\u00a0Fix/Perm\u00a0Buffer (4x)\u00a0 BioLegend,San \u00a0Diego,\u00a0USA\nFOXP3\u00a0Perm\u00a0Buffer\u00a0(10x)\u00a0 BioLegend,San \u00a0Diego,\u00a0USA\nHEPES\u00a0 Gibco,\u00a0Invitrogen, \u00a0Carlsbad, \u00a0USA\u00a0\nHitze\u2010inaktiviertes \u00a0Fetal\u00a0Calf\u00a0Serum\u00a0Gold\n(FCS)\u00a0PAA\u00a0Laboratories \u00a0GmbH,\u00a0Pasching, \u00a0A\u00a0\nNatriumazid \u00a0 Merck,\u00a0Darmstadt, \u00a0D\nNatriumpyruvat \u00a0(100\u00a0mM)\u00a0 Gibco,\u00a0Invitrogen, \u00a0Carlsbad, \u00a0USA\u00a0\nNicht\u2010essentielle \u00a0Aminos\u00e4uren \u00a0(100x) Sigma\u2010Aldrich,\u00a0Taufkirchen, \u00a0D\u00a0\nPenicillin/Streptomycin \u00a0 PAN\u00a0Biotech\u00a0GmbH,\u00a0Aidenbach, \u00a0D\u00a0\nPhosphat \u2010gepufferte \u00a0physiologische \u00a0\nKochsalzl\u00f6sung \u00a0(PBS\u00a01x)\u00a0PAN\u00a0Biotech\u00a0GmbH,\u00a0Aidenbach, \u00a0D\u00a0\nRPMI\u00a01640\u00a0mit\u00a0Glutamin\u00a0 PAA\u00a0Laboratories \u00a0GmbH,\u00a0Pasching, \u00a0A\u00a0\n\u00a0\n\u00a0\n2.1.4  Fertige\tReagenziens\u00e4tze \t\n\u00a0\nAnti\u2010Mouse\u00a0Ig,\u00a0\u03ba/Negative \u00a0Control\u00a0(FBS)\u00a0\nCompensation \u00a0Particles\u00a0Set\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nAnti\u2010Rat\u00a0and\u00a0Anti\u2010Hamster\u00a0Ig,\u00a0\u03ba/Negative \u00a0\nControl\u00a0Compensation \u00a0Particles\u00a0Set\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nBD\u2122\u00a0Cytometric \u00a0Bead\u00a0Array\u00a0(CBA),\u00a0\nHuman\u00a0Inflammatory \u00a0Cytokines \u00a0Kit\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nCD14+\u00a0MicroBeads ,\u00a0human\u00a0 Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\nVybrant\u00ae\u00a0CFDA\u00a0SE\u00a0Cell\u00a0Tracer\u00a0Kit\u00a0 Molecular \u00a0Probes,\u00a0Eugene,\u00a0USA\u00a0\n\u00a0\n\u00a0\u00a035 Material\u00a0und\u00a0Methoden\n2.1.5  Immunmodulatoren \t\n\u00a0\nResiquimod \u00a0(R848)\u00a0 InvivoGen, \u00a0San\u00a0Diego,\u00a0USA\u00a0\nGardiquimod \u00a0 InvivoGen, \u00a0San\u00a0Diego,\u00a0USA\nLoxoribine \u00a0 AXXORA,\u00a0L\u00f6rrach,\u00a0D\niODN\u00a02088\u00a0 AXXORA,\u00a0L\u00f6rrach,\u00a0D\u00a0\niODN\u00a020958\u00a0 zur\u00a0Verf\u00fcgung \u00a0gestellt\u00a0von\u00a0Dr.\u00a0J.\u00a0Vollmer,\u00a0\nColey\u00a0Pharmaceutical \u00a0GmbH,\u00a0D\u00fcsseldorf, \u00a0\nD\u00a0\niODN\u00a020959\u00a0 zur\u00a0Verf\u00fcgung \u00a0gestellt\u00a0von\u00a0Dr.\u00a0J.\u00a0Vollmer,\u00a0\nColey\u00a0Pharmaceutical \u00a0GmbH,\u00a0D\u00fcsseldorf, \u00a0\nD\u00a0\nCpG\u00a02006\u00a0 InvivoGen, \u00a0San\u00a0Diego,\u00a0USA\u00a0\nLipopolysaccharid \u00a0(LPS\u00a0O:6\u00a0B:26)\u00a0 Sigma\u00a0\u2010Aldrich,\u00a0Saint\u00a0Louis,\u00a0USA\u00a0\n\u00a0\n\u00a0\n2.1.6  Zytokine \t\n\u00a0\nrh\u00a0GM\u2010CSF\u00a0 Promocell \u00a0GmbH,\u00a0Heidelberg, \u00a0D\u00a0\nrh\u00a0Interleukin \u20104\u00a0 Strathmann \u00a0Biotec\u00a0GmbH\u00a0Co.\u00a0KG,\u00a0\nHamburg, \u00a0D\u00a0\n\u00a0\n\u00a0\n2.1.7  Antik\u00f6rper \t\n\u00a0\nAlexaFluor\u00ae647 \u00a0anti\u2010human\u00a0FOXP3\u00a0mouse\nIgG1\u00a0\u03ba,\u00a0Klon:\u00a0259D\u00a0BioLegend,San \u00a0Diego,\u00a0USA\u00a036 Material\u00a0und\u00a0Methoden\nAlexaFluor\u00ae647 \u00a0mouse IgG1\u00a0\u03ba\u00a0Isotype\u00a0\nControl ,\u00a0Klon:\u00a0MOPC\u201021\u00a0BioLegend,San \u00a0Diego,\u00a0USA\nAPC\u00a0anti\u2010human\u00a0CD1a\u00a0mouse\u00a0IgG1\u00a0\u03ba,\u00a0\nKlon:\u00a0HI149\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nAPC\u00a0anti\u2010human\u00a0CD11b/Mac \u20101\u00a0mouse\nIgG1\u00a0\u03ba,\u00a0Klon:\u00a0ICRF44\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nAPC\u00a0anti\u2010human\u00a0CD25\u00a0mouse\u00a0IgG1\u00a0\u03ba,\u00a0\nKlon:\u00a0M\u2010A251\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nAPC\u00a0mouse\u00a0IgG1\u00a0\u03ba\u00a0Isotype\u00a0Contro l,\u00a0Klon:\u00a0\nMOPC\u201021\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nAPC\u2010H7\u00a0anti\u2010human\u00a0CD4\u00a0mouse\u00a0IgG1\u00a0\u03ba,\u00a0\nKlon:\u00a0RPA\u2010T8\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nAPC\u2010H7\u00a0mouse\u00a0IgG1\u00a0\u03ba\u00a0Isotype\u00a0Contro l BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nFITC\u00a0anti\u2010human\u00a0CD14\u00a0mouse\u00a0IgG2\u00a0\u03ba,\u00a0\nKlon:\u00a0M5E2\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nFITC\u00a0anti\u2010human\u00a0CD123\u00a0mouse\u00a0IgG2a,\u00a0\nKlon:\u00a0AC145\u00a0Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\nFITC\u00a0mouse\u00a0IgG2a\u00a0\u03ba\u00a0Isotype\u00a0Contro l,\u00a0Klon:\u00a0\nG155\u2010178\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nFITC\u00a0mouse\u00a0IgG2a\u00a0Isotype\u00a0Contro l\u00a0 Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\nPacific\u00a0Blue\u2122\u00a0anti\u2010human\u00a0CD3\u00a0mouse IgG\u00a0\n1\u00a0\u03ba,\u00a0Klon:\u00a0UCHT1\u00a0BioLegend,San \u00a0Diego,\u00a0USA\nPacific\u00a0Blue\u2122\u00a0mouse\u00a0IgG1\u00a0\u03ba\u00a0Isotype\u00a0\nControl ,\u00a0Klon:\u00a0MOPC\u201021\u00a0BioLegend,San \u00a0Diego,\u00a0USA\nPE\u00a0anti\u2010human\u00a0BDCA\u20101\u00a0(CD1c)\u00a0mouse\nIgG2a,\u00a0Klon:\u00a0AD5\u20108E7\u00a0Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\nPE\u00a0anti\u2010human\u00a0BDCA\u20102\u00a0(CD303)\u00a0mouse\nIgG1,\u00a0Klon:AC144 \u00a0Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\nPE\u00a0anti\u2010human\u00a0BDCA\u20104\u00a0(CD304)\u00a0mouse\nIgG1,\u00a0Klon:\u00a0ADS\u201017F6\u00a0Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\nPE\u00a0anti\u2010human\u00a0CD25\u00a0mouse\u00a0IgG2b,\u00a0Klon:\u00a0\n4E3\u00a0Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\u00a037 Material\u00a0und\u00a0Methoden\nPE\u00a0anti\u2010human\u00a0CD40\u00a0mouse\u00a0IgG1\u00a0\u03ba,\u00a0Klon:\u00a0\n5C3\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nPE\u00a0anti\u2010human\u00a0CD83\u00a0mouse\u00a0IgG1\u00a0\u03ba,\u00a0Klon:\u00a0\nHB15e\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nPE\u00a0anti\u2010human\u00a0CD86\u00a0mouse\u00a0IgG2b\u00a0\u03ba,\u00a0Klon:\u00a0\nIT2.2\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nPE\u00a0anti\u2010human\u00a0CD122\u00a0mouse\u00a0IgG1\u00a0\u03ba,\u00a0Klon:\u00a0\nMik\u2010\u03b23\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nPE\u00a0anti\u2010human\u00a0CD123\u00a0mouse\u00a0IgG1\u00a0\u03ba,\u00a0Klon:\u00a0\n9F5\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nPE\u00a0anti\u2010human\u00a0HLA\u2010DR\u00a0mouse\u00a0IgG2a\u00a0\u03ba,\u00a0\nKlon:\u00a0G46\u20106\u00a0BDPharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nPE\u00a0mouse\u00a0IgG1\u00a0Isotype\u00a0Contro l\u00a0 Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\nPE\u00a0mouse\u00a0IgG1\u00a0\u03ba\u00a0Isotype\u00a0Contro l,\u00a0Klon:\u00a0\nMOPC\u201021\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nPE\u00a0mouse\u00a0IgG2a\u00a0Isotype\u00a0Contro l\u00a0 Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\nPE\u00a0mouse\u00a0IgG2a\u00a0\u03ba\u00a0Isotype\u00a0Contro l,\u00a0Klon:\u00a0\nG155\u2010178\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nPE\u00a0mouse\u00a0IgG2b\u00a0\u03ba\u00a0Isotype\u00a0Contro l,\u00a0Klon:\u00a0\n27\u201035\u00a0BD\u00a0Pharmingen\u2122, \u00a0Heidelberg, \u00a0D\u00a0\nPE\u00a0mouse\u00a0IgG2b\u00a0Isotype\u00a0Contro l\u00a0 Miltenyi\u00a0Biotec,\u00a0Bergisch\u00a0Gladbach, \u00a0D\u00a0\n\u00a0\n\u00a0\n2.1.8  Computersoftware \t\n\u00a0\nCellQues t\u2122,\u00a0Version\u00a03.2.1f1\u00a0 Becton\u00a0Dickinson, \u00a0Heidelberg, \u00a0D\u00a0\nDIVA6.1\u2122 \u00a0 Becton\u00a0Dickinson, \u00a0Heidelberg, \u00a0D\u00a0\nFCAP\u00a0Array \u2122\u00a0V\u00a01.0.1\u00a0 Becton\u00a0Dickinson, \u00a0Heidelberg, \u00a0D\u00a0\n\u00a0\u00a038 Material\u00a0und\u00a0Methoden\nSPSS\u00ae\u00a0Software\u00a0Version\u00a016.0\u00a0 SPSS\u00a0Inc.,\u00a0Chicago,\u00a0USA\nWinMDI,\u00a0Version\u00a02.8\u00a0 Joe\u00a0Trotter,\u00a0Scribbs\u00a0Research\u00a0Institute,\u00a0La\u00a0\nJolla,\u00a0USA\u00a0\n\u00a0\n\u00a0\n2.1.9  Humanes \tProbenmaterial \t\n\u00a0\nDie\u00a0Isolation\u00a0humaner\u00a0Monozyten \u00a0und\u00a0PBMC\u00b4s\u00a0erfolgte\u00a0aus\u00a0Restmaterialien \u00a0(buffy\u00a0coats)\u00a0\ngesunder \u00a0Blutspender \u00a0des\u00a0Zentrums \u00a0f\u00fcr\u00a0Transfusionsmedizin \u00a0und\u00a0H\u00e4motherapie, \u00a0des\u00a0\nUniversit\u00e4tsklinikums \u00a0Gie\u00dfen\u00a0und\u00a0Marburg\u00a0GmbH,\u00a0am\u00a0Standort\u00a0Gie\u00dfen.\u00a0Alle\u00a0Blutspender \u00a0\nstimmten \u00a0einer\u00a0Verwendung \u00a0\u00fcbersch\u00fcssigen \u00a0Materiales \u00a0ihrer\u00a0Blutspende \u00a0zu\u00a0\nwissenschaftlichen \u00a0Zwecken\u00a0zu.\u00a0\n\u00a0\n\u00a0\n2.1.10  Statistik \t\n\u00a0\nF\u00fcr\u00a0die\u00a0statistischen \u00a0Analysen\u00a0der\u00a0Daten\u00a0wurde\u00a0der\u00a0two\u2010tailed\u00a0t\u2010test\u00a0und\u00a0der\u00a0friedman\u00a0test\u00a0\nverwendet. \u00a0Eine\u00a0Wahrscheinlichkeit \u00a0von\u00a0p<\u00a00,05\u00a0wurde\u00a0als\u00a0signifikant \u00a0erachtet.\u00a0\nAlle\u00a0Analysen\u00a0wurden\u00a0mit\u00a0Hilfe\u00a0der\u00a0SPSS\u00ae\u00a0Software\u00a0Version\u00a016.0\u00a0(SPSS\u00a0Inc.,\u00a0Chicago,\u00a0USA)\u00a0\nerhoben.\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\u00a039 Material\u00a0und\u00a0Methoden\n2.2 Methoden \t\n\u00a0\n2.2.1  Isolierung \tvon\tperipheren \tmononukle\u00e4ren \tBlutzellen \t(PBMC\u00b4s) \taus\tdem\t\nbuffy\tcoat\t\n\u00a0\nUnter\u00a0einem\u00a0buffy\u00a0coat\u00a0versteht\u00a0man\u00a0die\u00a0Grenzschicht \u00a0zwischen\u00a0Erythrozyten \u00a0und\u00a0dem\u00a0\nBlutplasma, \u00a0die\u00a0entsteht,\u00a0wenn\u00a0man\u00a0Vollblut\u00a0mit\u00a0einem\u00a0Gerinnungshemmer \u00a0versetzt\u00a0und\u00a0\ndieses\u00a0dann\u00a0anschlie\u00dfend \u00a0zentrifugiert. \u00a0Die\u00a0Schicht\u00a0besteht\u00a0haupts\u00e4chlich \u00a0aus\u00a0Leukozyten \u00a0\nund\u00a0Thrombozyten, \u00a0aber\u00a0zu\u00a0einem\u00a0kleinen\u00a0Teil\u00a0befinden\u00a0sich\u00a0auch\u00a0Erythrozyten \u00a0darin.\u00a0\n\u00a0\nDie\u00a0peripheren \u00a0mononukle\u00e4ren \u00a0Zellen\u00a0(PBMC\u00b4s)\u00a0wurden\u00a0aus\u00a0frischen\u00a0buffy\u00a0coats\u00a0aus\u00a0dem\u00a0\nVollblut\u00a0gesunder \u00a0Blutspender \u00a0des\u00a0Zentrums \u00a0f\u00fcr\u00a0Transfusionsmedizin \u00a0und\u00a0H\u00e4motherapie, \u00a0\ndes\u00a0Universit\u00e4tsklinikums \u00a0Gie\u00dfen\u00a0und\u00a0Marburg\u00a0GmbH,\u00a0am\u00a0Standort\u00a0Gie\u00dfen\u00a0isoliert.\u00a0Die\u00a0\nGewinnung \u00a0der\u00a0PBMC\u00b4s\u00a0erfolgte\u00a0anhand\u00a0der\u00a0Ficoll\u2010Dichtegradientenzentrifugation. \u00a0\nFicoll\u00a0ist\u00a0ein\u00a0wasserl\u00f6sliches, \u00a0synthetisches \u00a0Polymer\u00a0aus\u00a0Sucrose\u00a0und\u00a0Epichlorhydrin \u00a0mit\u00a0einer\u00a0\nDichte\u00a0von\u00a01,007\u00a0g/ml.\u00a0W\u00e4hrend \u00a0der\u00a0Zentrifugation \u00a0sedimentieren \u00a0die\u00a0Blutzellen \u00a0in\u00a0Richtung\u00a0\nder\u00a0Grenzschicht \u00a0zwischen\u00a0Blut\u00a0und\u00a0Ficoll.\u00a0Erythrozyten \u00a0aggregieren \u00a0durch\u00a0das\u00a0Reagenz\u00a0und\u00a0\nsedimentieren \u00a0somit\u00a0schnell\u00a0zum\u00a0Boden\u00a0des\u00a0R\u00f6hrchens. \u00a0Auch\u00a0tote\u00a0Zellen\u00a0h\u00f6herer\u00a0Dichte\u00a0und\u00a0\nGranulozyten \u00a0passieren \u00a0die\u00a0Ficollphase. \u00a0Lymphozyten, \u00a0Monozyten \u00a0und\u00a0Thrombozyten \u00a0haben\u00a0\neine\u00a0geringere \u00a0Dichte\u00a0und\u00a0k\u00f6nnen\u00a0die\u00a0Ficollschicht \u00a0nicht\u00a0penetrieren, \u00a0sie\u00a0sammeln\u00a0sich\u00a0in\u00a0der\u00a0\nInterphase \u00a0an.\u00a0\n\u00a0Das\u00a0unter\u00a0sterilen\u00a0Bedingungen \u00a0entnommene \u00a0Blut\u00a0aus\u00a0einen\u00a0buffy\u00a0coat\u00a0(Volumen \u00a0ca.\u00a080\u00a0ml)\u00a0\nwurde\u00a0gleichm\u00e4\u00dfig \u00a0auf\u00a0drei\u00a0sterile\u00a050\u00a0ml\u2010Gef\u00e4\u00dfe\u00a0aufgeteilt \u00a0und\u00a0mit\u00a0jeweils\u00a030\u00a0ml\u00a0Phosphat \u2010\ngepufferter \u00a0physiologischer\n\u00a0Kochsalzl\u00f6sung \u00a0(PBS)\u00a0gemischt. \u00a0Anschlie\u00dfend \u00a0wurden\u00a015\u00a0ml\u00a0\nFicoll\u2010Paque\u2122\u00a0PLUS\u00a0in\u00a0vier\u00a0sterile\u00a050\u00a0ml\u2010Gef\u00e4\u00dfe\u00a0vorgelegt \u00a0und\u00a0vorsichtig \u00a0mit\u00a0dem\u00a0Blut/PBS\u2010\nGemisch\u00a0bis\u00a0auf\u00a0ein\u00a0Gesamtvolumen \u00a0von\u00a050\u00a0ml\u00a0geschichtet. \u00a0Danach\u00a0erfolgte\u00a0eine\u00a0\nZentrifugation \u00a0von\u00a030\u00a0min\u00a0bei\u00a0300\u00a0x\u00a0g\u00a0bei\u00a0RT\u00a0ohne\u00a0Bremse.\u00a0Der\u00a0Interphasenring \u00a0wurde\u00a0mit\u00a0\u00a0\u00a040 Material\u00a0und\u00a0Methoden\neiner\u00a0Pasteurpipette \u00a0abgenommen \u00a0und\u00a0in\u00a0zwei\u00a050\u00a0ml\u2010Gef\u00e4\u00dfe\u00a0\u00fcberf\u00fchrt \u00a0und\u00a0jeweils\u00a0mit\u00a0PBS\u00a0\nauf\u00a050\u00a0ml\u00a0aufgef\u00fcllt. \u00a0Nach\u00a0einer\u00a0Zentrifugationsdauer \u00a0von\u00a010\u00a0min\u00a0bei\u00a0340\u00a0x\u00a0g\u00a0wurde\u00a0der\u00a0\nInhalt\u00a0dekantiert. \u00a0Das\u00a0Zellpellet\u00a0wurde\u00a0aufger\u00fcttelt \u00a0und\u00a0in\u00a050\u00a0ml\u00a0PBS\u00a0aufgenommen. \u00a0Es\u00a0\nschloss\u00a0sich\u00a0eine\u00a0Zentrifugation \u00a0von\u00a010\u00a0min\u00a0bei\u00a0210\u00a0x\u00a0g\u00a0an.\u00a0Dieser\u00a0Waschschritt \u00a0wurde\u00a0noch\u00a0\neinmal\u00a0wiederholt. \u00a0Die\u00a0Zellpellets \u00a0wurden\u00a0vereinigt\u00a0und\u00a0in\u00a05\u00a0ml\u00a0eiskaltem \u00a0PBS/EDTA/BSA \u2010\nPuffer\u00a0aufgenommen \u00a0und\u00a0auf\u00a0Eis\u00a0gestellt.\u00a0F\u00fcr\u00a0die\u00a0Zellzahlbestimmung \u00a0am\u00a0Automatischen \u00a0\nH\u00e4matologie \u2010Analysator \u00a0KX\u201021N\u00a0wurde\u00a0ein\u00a0Aliquot\u00a0aus\u00a0der\u00a0Zellsuspension \u00a0entnommen \u00a0und\u00a0\n1:10\u00a0mit\u00a0PBS\u00a0verd\u00fcnnt. \u00a0\n\u00a0\u00a0\nPBS/EDTA/BSA \u2010Puffer\u00a0PBS\n\u00a0(1x)\u00a0\n\u00a0 2\u00a0mM\u00a0EDTA\u00a0\n\u00a0 0,5\u00a0%\u00a0(w/v)\u00a0BSA\u00a0\n\u00a0 0,22\u00a0\u00b5m\u00a0filtriert\u00a0\n\u00a0\n\u00a0\n2.2.2  Separation \tvon\tCD14+\u2010Zellen\tmit\tHilfe\tdes\tautomated \tmagnetic \tactivating \t\ncell\tsorting\t(AutoMACS\u00ae)\t\n\u00a0\nDurch\u00a0die\u00a0magnetische \u00a0Zellseparation \u00a0(engl.:\u00a0magnetic \u00a0activating \u00a0cell\u00a0sorting ,\u00a0MACS\u00ae)\u00a0\nk\u00f6nnen\u00a0Zellen\u00a0aus\u00a0komplexen \u00a0Zellgemischen \u00a0mit\u00a0hoher\u00a0Reinheit\u00a0f\u00fcr\u00a0weitere\u00a0Untersuchungen \u00a0\nisoliert\u00a0werden.\u00a0Bei\u00a0diesem\u00a0System\u00a0werden\u00a0mit\u00a0superparamagnetischen \u00a0Mikropartikeln \u00a0(ca.\u00a0\n50\u00a0nm\u00a0Durchmesser) \u00a0konjugierte \u00a0Antik\u00f6rper \u00a0(MicroBeads )\u00a0verwendet. \u00a0Die\u00a0gew\u00fcnschten \u00a0\nZellen\u00a0werden\u00a0durch\u00a0spezifische \u00a0Antik\u00f6rperbindung \u00a0an\u00a0MicroBeads \u00a0markiert\u00a0und\u00a0durch\u00a0eine\u00a0\nTrenns\u00e4ule, \u00a0die\u00a0aus\u00a0Eisenk\u00fcgelchen \u00a0besteht,\u00a0gef\u00fchrt.\u00a0Die\u00a0Trenns\u00e4ule \u00a0befindet\u00a0sich\u00a0zwischen\u00a0\nMagnetpolen \u00a0eines\u00a0Hochleistungsmagneten. \u00a0Durch\u00a0das\u00a0Anlegen\u00a0eines\u00a0elektromagnetischen \u00a0\nFeldes\u00a0werden\u00a0die\u00a0markierten \u00a0Zellen\u00a0in\u00a0der\u00a0S\u00e4ule\u00a0zur\u00fcckgehalten, \u00a0w\u00e4hrend\u00a0die\u00a0unmarkierten \u00a0\nZellen\u00a0die\u00a0S\u00e4ule\u00a0passieren \u00a0k\u00f6nnen\u00a0(negative \u00a0Fraktion). \u00a0Die\u00a0markierten \u00a0Zellen\u00a0lassen\u00a0sich\u00a0\ndurch\u00a0Aussp\u00fclen \u00a0der\u00a0S\u00e4ule\u00a0au\u00dferhalb \u00a0des\u00a0Magnetfeldes \u00a0gewinnen \u00a0(positive\u00a0Fraktion). \u00a0Das\u00a0\u00a041 Material\u00a0und\u00a0Methoden\nMACS\u2010System\u00a0kann\u00a0zur\u00a0Anreicherung \u00a0(positive\u00a0Selektion) \u00a0oder\u00a0zur\u00a0Depletion \u00a0(negative \u00a0\nSelektion) \u00a0von\u00a0Zellpopulationen \u00a0verwendet \u00a0werden.\u00a0\n1,0\u00a0\u2013\u00a04,0\u00a0x\u00a0108\u00a0PBMC\u00b4s\u00a0(400\u00a0\u00b5l\u00a0PBS\u00a0/\u00a01,0\u00a0x\u00a0108\u00a0PBMC)\u00a0wurden\u00a0mit\u00a0100\u00a0\u00b5l\u00a0bis\u00a0400\u00a0\u00b5l\u00a0CD14+\u2010\nMicroBeads \u00a0(Miltenyi\u00a0Biotec)\u00a0in\u00a0einem\u00a0sterilen\u00a050\u00a0ml\u2010Gef\u00e4\u00df\u00a0versetzt\u00a0und\u00a0f\u00fcr\u00a015\u00a0min\u00a0bei\u00a04\u00b0C\u00a0\ninkubiert.  Nach\u00a015\u00a0min\u00a0wurde\u00a0das\u00a010\u2010fache\u00a0Volumen\u00a0an\u00a0PBS\u00a0auf\u00a0das\u00a0Zell/ MicroBead \u2010\nGemisch\u00a0gegeben\u00a0und\u00a05\u00a0min\u00a0bei\u00a0300\u00a0x\u00a0g\u00a0gewaschen. \u00a0Der\u00a0\u00dcberstand \u00a0wurde\u00a0abgenommen \u00a0\nund\u00a0das\u00a0Pellet\u00a0in\u00a00,5\u00a0\u2013\u00a02,0\u00a0ml\u00a0PBS/EDTA/BSA \u2010Puffer\u00a0aufgenommen. \u00a0Danach\u00a0wurde\u00a0die\u00a0\nZellsuspension \u00a0mit\u00a0dem\u00a0Programm \u00a0,,posseld\u2018\u2018 \u00a0(positive\u00a0Selektion) \u00a0im\u00a0AutoMACS\u00ae\u00a0\naufgereinigt. \u00a0Aus\u00a0der\u00a0positiven\u00a0Fraktion\u00a0wurde\u00a0ein\u00a0Aliquot\u00a0entnommen \u00a0und\u00a0mit\u00a0PBS\u00a01:10\u00a0\nverd\u00fcnnt. \u00a0Damit\u00a0erfolgte\u00a0die\u00a0Bestimmung \u00a0der\u00a0Monozytenzahl \u00a0am\u00a0Automatischen \u00a0\nH\u00e4matologieanalysator \u00a0KX\u201021N.\u00a0\n\u00a0\u00a0\nPBS/EDTA \u2010Puffer\u00a0 PBS\u00a0(1x)\u00a0\n\u00a0 2\u00a0mM\u00a0EDTA\u00a0\n\u00a0 0,22\u00a0\u00b5m\u00a0filtriert\u00a0\n\u00a0\nPBS/EDTA/BSA \u2010Puffer\u00a0PBS\u00a0(1x)\u00a0\n\u00a0 2\u00a0mM\u00a0EDTA\u00a0\n\u00a0 0,5\u00a0%\u00a0(w/v)\u00a0BSA\u00a0\n\u00a0 0,22\n\u00a0\u00b5m\u00a0filtriert\u00a0\n\u00a0\nEthanol\u00a070%\u00a0 Ethanol\u00a0absolut\u00a0puriss.\u00a0p.\u00a0a.\u00a0\n\u00a0 Aqua\u00a0B.\u00a0Braun\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a042 Material\u00a0und\u00a0Methoden\n2.2.3  Bestimmung \tder\tLeukozytenzahl \tmit\tdem\tAutomatischen \t\nH\u00e4matologieanalysator \tKX\u201021N\t(Sysmex) \t\n\u00a0\nDie\u00a0Leukozytenzahl \u00a0wurde\u00a0am\u00a0Automatischen \u00a0H\u00e4matologieanalysator \u00a0KX\u201021N\u00a0(Sysmex)\u00a0\nbestimmt. \u00a0Das\u00a0Ger\u00e4t\u00a0arbeitet\u00a0mit\u00a0dem\u00a0Impedanzme\u00dfprinzip. \u00a0Zwei\u00a0ineinanderstehende \u00a0\nGef\u00e4\u00dfe\u00a0enthalten \u00a0eine\u00a0Elektrolytl\u00f6sung. \u00a0Im\u00a0\u00e4u\u00dferen\u00a0Gef\u00e4\u00df\u00a0befinden\u00a0sich\u00a0die\u00a0Zellen,\u00a0die\u00a0\ndurch\u00a0eine\u00a0Me\u00df\u00f6ffnung \u00a0in\u00a0das\u00a0innere\u00a0Gef\u00e4\u00df\u00a0gesaugt\u00a0werden.\u00a0Es\u00a0flie\u00dft\u00a0ein\u00a0schwacher \u00a0\nGleichstrom \u00a0und\u00a0die\u00a0inneren\u00a0und\u00a0\u00e4u\u00dferen\u00a0Elektroden \u00a0registrieren \u00a0dabei\u00a0\nSpannungs\u00e4nderungen. \u00a0Zellen\u00a0sind\u00a0nur\u00a0sehr\u00a0gering\u00a0leitf\u00e4hig\u00a0und\u00a0setzen\u00a0beim\u00a0Passieren \u00a0der\u00a0\nElektrolytl\u00f6sung \u00a0ein\u00a0Signal\u00a0ab,\u00a0das\u00a0proportional \u00a0zur\u00a0Zellgr\u00f6\u00dfe \u00a0ist.\u00a0\n\u00a0\u00a0\n2.2.4  Kultivierung \tund\tStimulation \tder\tMonozyten \tf\u00fcr\tdie\t\ndurchflusszytometrische \tUntersuchung \t\n\u00a0\nCD14\n+\u2010Zellen\u00a0wurden\u00a0nach\u00a0der\u00a0Aufreinigung \u00a0am\u00a0AutoMACS\u00ae \u00a0auf\u00a0eine\u00a0Zellzahl\u00a0von\u00a01\u00a0x\u00a0106\u00a0\nZellen/ml \u00a0mit\u00a0DC\u2010Medium\u00a0eingestellt. \u00a0Es\u00a0wurden\u00a01\u00a0ml\u00a0Zellsuspension \u00a0in\u00a0eine\u00a0Vertiefung \u00a0einer\u00a0\n24\u00a0well\u2010Platte\u00a0pipettiert \u00a0und\u00a0verschiedene \u00a0Stimulationsvariationen \u00a0durchgef\u00fchrt. \u00a0Die\u00a0Zellen\u00a0\nwurden\u00a0bei\u00a037\u00b0C\u00a0und\u00a05%\u00a0CO2\u00a0f\u00fcr\u00a0bis\u00a0zu\u00a06\u00a0Tage\u00a0inkubiert. \u00a0\nF\u00fcr\u00a0die\u00a0Kultivierung \u00a0der\u00a0Zellen\u00a0\u00fcber\u00a05\u00a0Tage\u00a0wurden\u00a0die\u00a0Zellen\u00a0entweder \u00a0nur\u00a0mit\u00a0DC\u2010Medium\u00a0\ninkubiert\u00a0oder\u00a0das\u00a0DC\u2010Medium\u00a0wurde\u00a0mit\u00a01000\u00a0IU/ml\u00a0IL\u20104\u00a0und\u00a01000\u00a0IU/ml\u00a0GM\u2010CSF\u00a0\nkomplettiert \u00a0und\u00a0die\u00a0Zellen\u00a0dann\u00a0jeweils\u00a0mit\u00a03\u00a0\u00b5M\u00a0\u2013\u00a0300\u00a0nM\u00a0R848,\u00a01\u00a0mM\u00a0\u2013\u00a0100\u00a0\u00b5M\u00a0\nLoxoribine, \u00a01\u00a0\u00b5g/ml\u00a0\u2013\u00a00,1\u00a0\u00b5g/ml\u00a0Gardiquimod, \u00a01\u00a0\u00b5M\u00a0iODN\u00a02088,\u00a02,5\u00a0\u00b5M\u00a0iODN\u00a020958\u00a0und\u00a0\u00a0\u00a0\n2,5\u00a0\u00b5M\u00a0iODN\u00a020959\u00a0stimuliert. \u00a0Am\u00a0dritten\u00a0Tag\u00a0der\u00a0Kultivierung \u00a0wurde\u00a0die\u00a0H\u00e4lfte\u00a0des\u00a0DC\u2010\nMediums \u00a0durch\u00a0frisches\u00a0ersetzt\u00a0und\u00a0wieder\u00a0mit\u00a0der\u00a0entsprechenden \u00a0Stimuli\u2010Konzentration \u00a0\nangereichert. \u00a0\nDie\u00a0Kultivierung \u00a0der\u00a0Zellen\u00a0\u00fcber\u00a06\u00a0Tage\u00a0erfolgte\u00a0mit\u00a0komplettiertem \u00a0DC\u2010Medium\u00a0mit\u00a0und\u00a0\nohne\u00a03\u00a0\u00b5M\u00a0R848.\u00a0Am\u00a0dritten\u00a0Tag\u00a0wurden\u00a0die\u00a0Zellen\u00a03\u00a0x\u00a0mit\u00a0DC\u2010Medium\u00a0gewaschen \u00a0und\u00a0dann\u00a0\nf\u00fcr\u00a0weitere\u00a03\u00a0Tage\u00a0mit\u00a0DC\u2010Medium\u00a0oder\u00a0mit\u00a0komplettiertem \u00a0DC\u2010Medium\u00a0inkubiert. \u00a0\u00a043 Material\u00a0und\u00a0Methoden\nF\u00fcr\u00a0den\u00a0T\u2010Zell\u2010Proliferationstest \u00a0wurden\u00a0die\u00a0Zellen\u00a03\u00a0Tage\u00a0mit\u00a0komplettiertem \u00a0DC\u2010Medium\u00a0\nmit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0kultiviert. \u00a0\n\u00a0\u00a0\nDC\u2010Medium\u00a0 RPMI\u00a01640\u00a0mit\u00a0Glutamin\u00a0\n\u00a0 10\u00a0%\u00a0FCS\u00a0\n\u00a0 1\u00a0%\u00a0(v/v)\u00a0Penicillin/Streptomycin \u00a0\n\u00a0 1\u00a0%\u00a0HEPES\u00a0\n\u00a0 1\u00a0%\u00a0nicht\u2010essentielle \u00a0Aminos\u00e4uren \u00a0\n\u00a0 1\u00a0%\u00a0Natriumpyruvat \u00a0\n\u00a0\nKomplettiertes \u00a0\nDC\u2010\nMedium\u00a0DC\u2010Medium\u00a0\n\u00a0 1000\u00a0IU/ml\u00a0IL\u20104\u00a0\n\u00a0 1000\u00a0IU/ml\u00a0GM\u2010CSF\u00a0\n\u00a0\n\u00a0\n2.2.5  Durchflusszytometrie \t(FACS:\tfluorescent \tactivating \tcell\tsorting )\t\n\u00a0\nMit\u00a0Hilfe\u00a0der\u00a0Durchflusszytometrie \u00a0wurden\u00a0die\u00a0ph\u00e4notypischen \u00a0Eigenschaften \u00a0der,\u00a0mit\u00a0dem\u00a0\nAutoMACS\u00ae \u00a0aufgereinigten, \u00a0Monozyten \u00a0nach\u00a0den\u00a0verschiedenen \u00a0Stimulationsvarianten \u00a0\nbestimmt. \u00a0Die\u00a0Messungen \u00a0wurden\u00a0am\u00a0FACSCalibur\u2122 \u00a0und\u00a0FACSCanto \u00a0II\u2122\u00a0durchgef\u00fchrt. \u00a0Die\u00a0\nAufnahme \u00a0und\u00a0Auswertung \u00a0der\u00a0Zellparameter \u00a0erfolgten\u00a0mit\u00a0Hilfe\u00a0der\u00a0Software\u00a0CellQuest\u2122, \u00a0\nWinMDI\u00a0(Version\u00a02.8)\u00a0und\u00a0DIVA6.1.\u2122. \u00a0\nDie\u00a0fluoreszenzaktivierte \u00a0Zellanalyse \u00a0ist\u00a0ein\u00a0Verfahren \u00a0zur\u00a0quantitativen \u00a0Bestimmung \u00a0der\u00a0\nOberfl\u00e4chenmolek\u00fcle \u00a0und\u00a0intrazellul\u00e4ren \u00a0Proteine.\u00a0Grundlage \u00a0der\u00a0FACS\u2010Analyse\u00a0ist\u00a0eine\u00a0\nAntigen\u2010Antik\u00f6rper \u2010Reaktion, \u00a0die\u00a0mit\u00a0Fluoreszenzfarbstoff \u2010markierten \u00a0Antik\u00f6rpern \u00a0\ndurchgef\u00fchrt \u00a0wird. Das\u00a0Messprinzip \u00a0beruht\u00a0auf\u00a0der\u00a0Methode \u00a0der\u00a0hydrodynamischen \u00a0\nFokussierung \u00a0(siehe\u00a0Abb.\u00a02.2.5.1).\u00a0\u00a044 Material\u00a0und\u00a0Methoden\nEine\u00a0Zellsuspension \u00a0wird\u00a0durch\u00a0einen\u00a0H\u00fcllstom\u00a0verd\u00fcnnt\u00a0und\u00a0die\u00a0Zellen\u00a0passieren \u00a0\nanschlie\u00dfend \u00a0einen\u00a0rechtwinklig \u00a0zum\u00a0Probenflu\u00df \u00a0angeordneten \u00a0monochromatischen \u00a0\nLaserstrahl. \u00a0Zellen\u00a0in\u00a0Gr\u00f6\u00dfen\u00a0von\u00a00,2\u00a0bis\u00a020\u00a0\u00b5m\u00a0werden\u00a0mit\u00a0Geschwindigkeiten \u00a0zwischen\u00a02\u00a0\nund\u00a0200\u00a0Ereignissen \u00a0pro\u00a0Sekunde\u00a0am\u00a0Laserstrahl \u00a0vorbeigef\u00fchrt. \u00a0Die\u00a0Zuf\u00fchrung \u00a0des\u00a0\nProbenstroms \u00a0liegt\u00a0typischerweise \u00a0zwischen\u00a010\u00a0und\u00a060\u00a0\u00b5l/min.\u00a0\u00a0\nAm\u00a0Messpunkt \u00a0werden\u00a0Lichtstreuung \u00a0und\u00a0Fluoreszenzen \u00a0der\u00a0einzelnen \u00a0Zellen\u00a0gemessen. \u00a0Als\u00a0\nphysikalische \u00a0Messgr\u00f6\u00dfen \u00a0werden\u00a0die\u00a0Lichtsteuung \u00a0der\u00a0Zellen\u00a0in\u00a0einem\u00a0engen\u00a0Winkel\u00a0zum\u00a0\nLaserlicht \u00a0als\u00a0Vorw\u00e4rtsstreulicht \u00a0(forward\u00a0scatter ;\u00a0FCS)\u00a0und\u00a0die\u00a0Lichtstreuung \u00a0der\u00a0Zellen\u00a0im\u00a0\nWinkel\u00a0von\u00a090\u00b0\u00a0als\u00a0Seitw\u00e4rtsstreulicht \u00a0(side\u00a0scatter ;\u00a0SSC)\u00a0erfasst.\u00a0FSC\u00a0ist\u00a0grob\u00a0betrachtet \u00a0ein\u00a0\nMa\u00df\u00a0f\u00fcr\u00a0die\u00a0Gr\u00f6\u00dfe\u00a0der\u00a0Zellen\u00a0und\u00a0SSC\u00a0h\u00e4ngt\u00a0haupts\u00e4chlich \u00a0von\u00a0der\u00a0Granul\u00e4rit\u00e4t \u00a0und\u00a0der\u00a0\nBinnenstruktur \u00a0der\u00a0Zellen\u00a0ab.\u00a0Die\u00a0Lichtstreuung \u00a0wird\u00a0mit\u00a0zunehmendem \u00a0Winkel\u00a0zum\u00a0\nLaserstrahl \u00a0schw\u00e4cher, \u00a0deshalb\u00a0werden\u00a0die\u00a0in\u00a0alle\u00a0Richtungen \u00a0ausgesandten \u00a0\nFluoreszenzsignale \u00a0ebenfalls\u00a0in\u00a0einem\u00a0Winkel\u00a0von\u00a090\u00b0\u00a0detektiert. \u00a0Hierzu\u00a0werden\u00a0\nBandpassfilter \u00a0und\u00a0Farbteilerspiegel \u00a0f\u00fcr\u00a0die\u00a0optische\u00a0Trennung \u00a0der\u00a0Emissionsspektren \u00a0der\u00a0\nverschiedenen \u00a0Fluorochrome \u00a0eingesetzt. \u00a0Die\u00a0unterschiedlichen \u00a0Lichtsignale \u00a0der\u00a0\nFluorochrome \u00a0werden\u00a0dann\u00a0\u00fcber\u00a0den\u00a0Photomultiplier \u00a0detektiert \u00a0und\u00a0in\u00a0elektrische \u00a0Signale\u00a0\numgewandelt. \u00a0So\u00a0erkennt\u00a0der\u00a0FL1\u2010Detektor\u00a0nach\u00a0Anregung \u00a0mit\u00a0dem\u00a0blau\u2010gr\u00fcnen\u00a0Licht\u00a0eines\u00a0\n488\u2010nm\u2010Argon\u2010Lasers\u00a0gr\u00fcnes,\u00a0der\u00a0FL2\u2010Detektor\u00a0orangenes \u00a0und\u00a0der\u00a0FL3\u2010Detektor\u00a0rotes\u00a0Licht.\u00a0\n\u00a0\u00a045 Material\u00a0und\u00a0Methoden\n\u00a0\n\u00a0\nAbb.\u00a02.2.5.1:\u00a0Schematische \u00a0Darstellung \u00a0der\u00a0FACS\u2010Messung. \u00a0Die\u00a0\nAbbildung \u00a0wurde\u00a0mit\u00a0freundlicher \u00a0Genehmigung \u00a0\u00fcbernommen \u00a0von\u00a0\n(116).\u00a0\nDie\u00a0fluoreszenzmarkierten \u00a0Zellen\u00a0werden\u00a0mit\u00a0dem\u00a0Probenstrom \u00a0in\u00a0\ndie\u00a0Messzelle \u00a0geleitet.\u00a0Der\u00a0H\u00fcllstrom \u00a0beschleunigt \u00a0die\u00a0Zellen\u00a0und\u00a0\nf\u00fchrt\u00a0sie\u00a0einzeln\u00a0hintereinander \u00a0in\u00a0die\u00a0Mitte\u00a0des\u00a0Probenflusses \u00a0zur\u00a0\nMesskapillare \u00a0(hydrodynamische \u00a0Fokussierung). \u00a0Wenn\u00a0die\u00a0Zelle\u00a0die\u00a0\nLichtquelle \u00a0passiert,\u00a0wird\u00a0ein\u00a0Fluorochrom \u00a0angeregt\u00a0und\u00a0als\u00a0\nEmissionslicht \u00a0zum\u00a0Photomultiplier \u00a0geleitet.\u00a0Das\u00a0Lichtsignal \u00a0wird\u00a0\nverst\u00e4rkt\u00a0und\u00a0in\u00a0ein\u00a0elektrisches \u00a0Signal\u00a0umgewandelt. \u00a0Der\u00a0Computer \u00a0\nberechnet \u00a0angehende \u00a0Signale\u00a0und\u00a0zeigt\u00a0diese\u00a0digital\u00a0an\u00a0(Histogramm, \u00a0\nDot\u00a0Plot).\u00a0\n\u00a0\n\u00a0\nProbenstrom \u00a0\nLichtquelleElektronische Umwandlung Compute r Dot Plot, \nHistogamm \nFL1\u00a0 FL2 SSC\u00a0 FL4 FL3 FL1\u00a0 FL2 SSC\u00a0 FL4 FL3\nH\u00fcllstrom\nZellenEmissionslicht\nFSC\u00a0\nAnregungslicht\n\u00a046 Material\u00a0und\u00a0Methoden\nVor\u00a0der\u00a0eigentlichen \u00a0Messung\u00a0am\u00a0Durchflusszytometer \u00a0muss\u00a0eine\u00a0Korrektur \u00a0der\u00a0Messdaten \u00a0\nf\u00fcr\u00a0Fluoreszenzsignale \u00a0entsprechend \u00a0der\u00a0spektralen \u00a0\u00dcberlappung \u00a0der\u00a0Farbstoffe \u00a0erfolgen,\u00a0\ndie\u00a0sogenannte \u00a0Kompensation. \u00a0Die\u00a0eingesetzten \u00a0Farbstoffe \u00a0\u00fcberlappen \u00a0sich\u00a0in\u00a0ihren\u00a0\nEmissionsspektren, \u00a0so\u00a0dass\u00a0jeweils\u00a0Mischungen \u00a0mit\u00a0verschiedenen \u00a0Anteilen\u00a0von\u00a0Farbstoffen \u00a0\ndetektiert \u00a0werden.\u00a0Eine\u00a0nicht\u00a0kompensierte \u00a0Messung\u00a0f\u00fcr\u00a0nur\u00a0einfach\u00a0gef\u00e4rbte\u00a0Zellen\u00a0zeigt\u00a0\nz.B.\u00a0Mischsignale \u00a0auf\u00a0zwei\u00a0Detektoren. \u00a0\n\u00a0Dazu\u00a0wurden\u00a0FACS\u2010R\u00f6hrchen \u00a0mit\u00a0100\u00a0\u00b5l\u00a0Staining\u00a0buffer\u00a0gef\u00fcllt\u00a0und\u00a0je\u00a01\u00a0Tropfen\u00a0BD\u2122\u00a0\nCompBeads \u00a0Negative\u00a0Control\u00a0bzw.\u00a0BD\u2122 CompBeads \u00a0Anti\u2010Mouse\u00a0Ig,\u00a0\u03ba \u00a0zugegeben. \u00a0Dann\u00a0\nwurden\u00a02,5\u00a0\u2013\u00a010\u00a0\u00b5l\u00a0der\u00a0entsprechenden \u00a0prim\u00e4ren \u00a0Antik\u00f6rper \u00a0als\u00a0Einzelf\u00e4rbung \u00a0in\u00a0die\u00a0\nR\u00f6hrchen \u00a0gegeben\u00a0und\u00a020\u00a0min\u00a0bei\n\u00a0RT\u00a0im\u00a0Dunkeln\u00a0inkubiert. \u00a0Anschlie\u00dfend \u00a0wurden\u00a0die\u00a0Beads\u00a0\nmit\u00a0je\u00a02\u00a0ml\u00a0Staining\u00a0buffer\u00a0bei\u00a0200\u00a0x\u00a0g\u00a0f\u00fcr\u00a010\u00a0min\u00a0gewaschen. \u00a0Der\u00a0\u00dcberstand \u00a0wurde\u00a0\nabgenommen \u00a0und\u00a0das\u00a0Pellet\u00a0mit\u00a0500\u00a0\u00b5l\u00a0Staining\u00a0buffer\u00a0gel\u00f6st.\u00a0\n\u00a0\nZur\u00a0Messung\u00a0der\u00a0Reinheit\u00a0der\u00a0Zellen\u00a0wurden\u00a0jeweils\u00a01\u00a0x\u00a0106\u00a0Zellen\u00a0in\u00a0ein\u00a0FACS\u2010R\u00f6rchen\u00a0\ngegeben\u00a0und\u00a0mit\u00a02,5\u00a0\u00b5l\u00a0CD14\u00a0FITC\u00a0bzw.\u00a0der\u00a0entsprechenden \u00a0Isotypkontrolle \u00a0markiert.\u00a0Die\u00a0\nInkubation \u00a0der\u00a0Zellen\u00a0mit\u00a0den\u00a0Fluoreszenzfarbstoffen \u00a0erfolgte\u00a015\u00a0min\u00a0bei\u00a04\u00b0C\u00a0im\u00a0Dunkeln.\u00a0\nAnschlie\u00dfend \u00a0wurde\u00a0zu\u00a0den\u00a0Zellen\u00a02\u00a0ml\u00a0PBS\u2010Azid\u00a0gegeben\u00a0und\u00a05\u00a0min\u00a0bei\u00a0300\u00a0x\u00a0g\u00a0\nzentrifugiert. \u00a0Der\u00a0\u00dcberstand \u00a0wurde\u00a0verworfen \u00a0und\u00a0das\u00a0Pellet\u00a0wurde\u00a0mit\u00a0300\u00a0\u00b5l\u00a0Cellfix \u2122\u00a0(1x)\u00a0\ngel\u00f6st.\u00a0Die\u00a0Zellsuspension \u00a0wurde\u00a0bis\u00a0zur\u00a0Analyse\u00a0am\u00a0FACSCalibur\u2122 \u00a0bzw.\u00a0FACSCanto \u00a0II\u2122\u00a0bei\u00a0\n4\u00b0C\u00a0im\u00a0Dunkeln\u00a0aufbewahrt. \u00a0\n\u00a0\nZur\u00a0Ph\u00e4notypisierung \u00a0der\u00a0unterschiedlich \u00a0stimulierten \u00a0Monozyten \u00a0wurde\u00a0die\u00a0Zellsuspension \u00a0\nauf\u00a02\u00a0x\u00a0106\u00a0Zellen/ml \u00a0mit\u00a0PBS\u00a0eingestellt \u00a0und\u00a0pro\u00a0FACS\u2010R\u00f6hrchen \u00a0je\u00a0100\u00a0\u00b5l\u00a0Zellsuspension \u00a0mit\u00a0\n2,5\u00a0\u2013\u00a010\u00a0\u00b5l\u00a0prim\u00e4ren \u00a0Antik\u00f6rpern \u00a0(CD1a\u00a0APC,\u00a0CD14\u00a0FITC,\u00a0CD25\u00a0APC,\u00a0CD25\u00a0PE,\u00a0CD40\u00a0PE,\u00a0CD83\u00a0\nPE,\u00a0CD86\u00a0PE,\u00a0CD122\u00a0PE,\u00a0CD123\u00a0FITC,\u00a0BDCA\u20101\u00a0PE,\u00a0BDCA\u20102\u00a0PE,\u00a0BDCA\u20104\u00a0PE,\u00a0HLA\u2010DR\u00a0PE)\u00a0bzw.\u00a0den\u00a0\nentsprechenden \u00a0Isotypkontrollen \u00a0versetzt.\u00a0Nach\u00a0einer\u00a0Inkubationszeit \u00a0von\u00a015\u00a0min\u00a0bei\u00a04\u00b0C\u00a0im\u00a0\nDunkeln\u00a0wurden\u00a02\u00a0ml\u00a0PBS\u2010Azid\u00a0zugegeben \u00a0und\u00a05\u00a0min\u00a0bei\u00a0300\u00a0x\u00a0g\u00a0zentrifugiert. \u00a0Anschlie\u00dfend \u00a0\nwurde\u00a0der\u00a0\u00dcberstand \u00a0verworfen, \u00a0das\u00a0Pellet\u00a0mit\u00a0300\u00a0\u00b5l\u00a0Cellfix \u2122\u00a0(1x)\u00a0resuspendiert \u00a0und\u00a0die\u00a0\u00a047 Material\u00a0und\u00a0Methoden\nZellsuspension \u00a0bis\u00a0zur\u00a0Analyse\u00a0am\u00a0FACSCalibur\u2122 \u00a0bzw.\u00a0FACSCanto \u00a0II\u2122\u00a0bei\u00a04\u00b0C\u00a0im\u00a0Dunkeln\u00a0\naufbewahrt. \u00a0\nNeben\u00a0der\u00a0Oberfl\u00e4chenf\u00e4rbung \u00a0der\u00a0Zellen\u00a0wurde\u00a0auch\u00a0eine\u00a0Intrazellul\u00e4rf\u00e4rbung \u00a0\ndurchgef\u00fchrt. \u00a0Dazu\u00a0wurden\u00a0die\u00a0Oberfl\u00e4chenmolek\u00fcle \u00a0der\u00a0Zellen\u00a0zun\u00e4chst\u00a0wie\u00a0schon\u00a0\nbeschrieben \u00a0markiert\u00a0(CD1a\u00a0APC,\u00a0CD14\u00a0FITC,\u00a0CD25\u00a0PE,\u00a0CD123\u00a0FITC,\u00a0HLA\u2010DR\u00a0PE\u00a0bzw.\u00a0den\u00a0\nentprechenden \u00a0Isotypkontrollen). \u00a0Nach\u00a0einer\u00a0Inkubation \u00a0von\u00a0diesmal\u00a020\u00a0min\u00a0bei\u00a04\u00b0C\u00a0im\u00a0\nDunkeln\u00a0wurden\u00a0je\u00a01\u00a0ml\u00a0Staining\u00a0buffer\u00a0in\u00a0die\u00a0R\u00f6hrchen \u00a0gegeben.\u00a0Es\u00a0folgte\u00a0eine\u00a0\nZentrifugation \u00a0bei\u00a0250\u00a0x\u00a0g\u00a0f\u00fcr\u00a05\u00a0min.\u00a0Anschlie\u00dfend \u00a0wurden\u00a0die\u00a0\u00dcberst\u00e4nde \u00a0abgenommen \u00a0und\u00a0\nje\u00a01\u00a0ml\u00a0FOXP3\u00a0Fix/Perm\u00a0Solution\u00a0zugegeben. \u00a0An\u00a0eine\u00a0Inkubationszeit \u00a0von\u00a020\u00a0min\u00a0bei\u00a0RT\u00a0im\u00a0\nDunkeln\u00a0schloss\u00a0sich\u00a0ein\u00a0Zentrifugationsschritt \u00a0von\u00a05\u00a0min\u00a0bei\u00a0250\u00a0x\u00a0g\u00a0an.\u00a0Nun\u00a0wurde\u00a0das\u00a0\nZellpellet\u00a0dekantiert \u00a0und\u00a0je\u00a01\u00a0ml\u00a0Staining\u00a0buffer\u00a0pro\u00a0R\u00f6hrchen \u00a0hinzugegeben. \u00a0Nach\u00a0einer\u00a0\nZentrifugation \u00a0von\u00a05\u00a0min\u00a0bei\u00a0250\u00a0x\u00a0g\u00a0wurden\u00a0die\u00a0Zellpellets \u00a0mit\u00a0je\u00a01\u00a0ml\u00a0FOXP3\u00a0Perm\u00a0Solution\u00a0\nresuspendiert \u00a0und\u00a0wiederum \u00a05\u00a0min\u00a0bei\u00a0250\u00a0x\u00a0g\u00a0gewaschen. \u00a0Die\u00a0\u00dcberst\u00e4nde \u00a0wurden\u00a0\nabgenommen \u00a0und\u00a0die\u00a0Pellets\u00a0mit\u00a0je\u00a01\u00a0ml\u00a0FOXP3\u00a0Perm\u00a0Solution\u00a0gel\u00f6st.\u00a0Nach\u00a0einer\u00a0\nInkubationszeit \u00a0von\u00a010\u00a0min\u00a0bei\u00a0RT\u00a0im\u00a0Dunkeln\u00a0wurden\u00a0die\u00a0Zellen\u00a0erneut\u00a05\u00a0min\u00a0bei\u00a0250\u00a0x\u00a0g\u00a0\nzentrifugiert \u00a0und\u00a0anschlie\u00dfend \u00a0dekantiert. \u00a0Die\u00a0Zellpellets \u00a0wurde\u00a0mit\u00a0je\u00a0100\u00a0\u00b5l\u00a0FOXP3\u00a0Solution\u00a0\nresuspendiert \u00a0und\u00a0mit\u00a0je\u00a03\u00a0\u00b5l\u00a0prim\u00e4rem \u00a0Antik\u00f6rper \u00a0(FOXP3\u00a0AlexaFluor647) \u00a0markiert.\u00a0Nach\u00a0\neiner\u00a0Inkubationszeit \u00a0von\u00a030\u00a0min\u00a0bei\u00a0RT\u00a0im\u00a0Dunkeln\u00a0wurden\u00a0die\u00a0Zellen\u00a0zweimal\u00a0mit\u00a0je\u00a02\u00a0ml\u00a0\nStaining\u00a0buffer\u00a0bei\u00a0250\u00a0x\u00a0g\u00a0f\u00fcr\u00a05\u00a0min\u00a0gewaschen. \u00a0Die\u00a0\u00dcberst\u00e4nde \u00a0wurden\u00a0abgenommen \u00a0und\u00a0\ndie\u00a0Zellpellets \u00a0mit\u00a0je\u00a0300\u00a0\u00b5l\u00a0Staining\u00a0buffer\u00a0gel\u00f6st.\u00a0Die\u00a0Zellsuspension \u00a0wurde\u00a0bis\u00a0zur\u00a0Analyse\u00a0\nam\u00a0FACSCanto \u00a0II\u2122\u00a0bei\u00a04\u00b0C\u00a0im\u00a0Dunkeln\u00a0aufbewahrt. \u00a0\n\u00a0\n\u00a0\nCellfix \u2122\u00a0(1x)\u00a0 Cellfix \u2122\u00a0(10x)\u00a0\n\u00a0 PBS\u00a0(1x)\u00a0\n\u00a0\nFOXP3\u00a0Fix/Perm\u00a0\nSolution\u00a0PBS\u00a01(x)\u00a0\n\u00a0 25\u00a0%\u00a0FOXP3\u00a0Fix/Perm\u00a0Buffer\u00a0(4x)\u00a0\n\u00a0\u00a048 Material\u00a0und\u00a0Methoden\nFOXP3\u00a0Perm\u00a0Solution\u00a0 PBS\u00a01(x)\u00a0\n\u00a0 10\u00a0%\u00a0FOXP3\u00a0Perm\u00a0Buffer\u00a0(10x)\u00a0\n\u00a0\nPBS\u2010Azid\u00a00,1%\u00a0 PBS\u00a0(1x)\u00a0\n\u00a0 0,1\u00a0%\u00a0Natriumazid \u00a0\n\u00a0\nStaining\u00a0buffer\u00a0 PBS\u2010Azid\u00a00,1\u00a0%\u00a0\n\u00a0 1\u00a0%\u00a0FCS\u00a0\n\u00a0\n\u00a0\n2.2.6  T\u2010Zell\u2010Proliferationstest \t\n\u00a0\nCarboxyfluoreszeindiazetat \u2010Succinimidylester \u00a0(CFDA\u2010SE)\u00a0ist\u00a0eine\u00a0membrang\u00e4ngige \u00a0Substanz, \u00a0\ndie\u00a0durch\u00a0Diffusion\u00a0in\u00a0die\u00a0Zellen\u00a0gelangt.\u00a0Intrazellul\u00e4r \u00a0verliert\u00a0die\u00a0Substanz, \u00a0nach\u00a0Abspaltung \u00a0\nder\u00a0Diazetatgruppe \u00a0(Carboxyfluoreszein \u2010Succinimidylester, \u00a0CFSE)\u00a0durch\u00a0Esterasen, \u00a0ihre\u00a0\nPermeabilit\u00e4t \u00a0und\u00a0beginnt\u00a0zu\u00a0fluoreszieren. \u00a0CFSE\u00a0wird\u00a0dabei\u00a0\u00fcber\u00a0die\u00a0Estergruppe \u00a0kovalent\u00a0\nan\u00a0zytoplasmatische \u00a0Proteine\u00a0gebunden, \u00a0ohne\u00a0dabei\u00a0Zellfunktionen \u00a0wesentlich \u00a0zu\u00a0\nbeeintr\u00e4chtigen, \u00a0wenn\u00a0eine\u00a0bestimmte \u00a0Konzentration \u00a0bei\u00a0der\u00a0F\u00e4rbung\u00a0nicht\u00a0\u00fcberschritten \u00a0\nwird .\u00a0Bei\u00a0einer\u00a0Zellteilung \u00a0verteilt\u00a0sich\u00a0das\u00a0vorhandene \u00a0CFSE\u00a0gleichm\u00e4\u00dfig \u00a0auf\u00a0beide\u00a0\nTochterzellen. \u00a0Aufgrund \u00a0des\u00a0geringeren \u00a0Fluoreszenzsignals \u00a0kann\u00a0am\u00a0Durchflusszytometer \u00a0\nnun\u00a0auf\u00a0die\u00a0zur\u00fcckliegenden \u00a0Teilungsschritte \u00a0der\u00a0einmal\u00a0markierten \u00a0(gelabelten) \u00a0Zellen\u00a0\ngeschlossen \u00a0werden\u00a0(siehe\u00a0Abb.\u00a02.2.6.1).\u00a0Die\u00a0CFSE\u2010Peaks\u00a0werden\u00a0in\u00a0der\u00a0FL1\u00a0am\u00a0\nDurchflusszytometer \u00a0gemessen. \u00a0\u00a049 Material\u00a0und\u00a0Methoden\nCFDA\u2010SE CFSEA\n\u00a0\nCFSEB\n\u00a0\nAbbildung \u00a02.2.6.1:\u00a0Schematische \u00a0Darstellung \u00a0des\u00a0CFDA\u2010SE\u2010Labeling\u00a0\nund\u00a0der\u00a0Verteilung \u00a0des\u00a0CFSE\u00a0auf\u00a0die\u00a0Tochterzellen. \u00a0\u00a0\nA\u00a0Im\u00a0ersten\u00a0Labelingschritt \u00a0diffundiert \u00a0CFDA\u2010SE\u00a0durch\u00a0die\u00a0\nZellmembran, \u00a0danach\u00a0wird\u00a0es\u00a0durch\u00a0Esterasen \u00a0gespalten \u00a0und\u00a0das\u00a0\nfluoreszierende \u00a0CFSE\u00a0kann\u00a0nicht\u00a0mehr\u00a0zur\u00fcckdiffundieren. \u00a0B\u00a0Bei\u00a0einer\u00a0\nZellteilung \u00a0wird\u00a0das\u00a0intrazellul\u00e4r \u00a0vorhandene \u00a0CFSE\u00a0gleichm\u00e4\u00dfig \u00a0auf\u00a0\u00a050 Material\u00a0und\u00a0Methoden\ndie\u00a0Tochterzellen \u00a0verteilt.\u00a0Die\u00a0dadurch\u00a0bedingte\u00a0niedrigere \u00a0\nFluoreszenz \u00a0der\u00a0proliferierten \u00a0Zellen\u00a0l\u00e4sst\u00a0sich\u00a0am\u00a0\nDurchflusszytometer \u00a0messen.\u00a0\n\u00a0\n\u00a0\nUm\u00a0die\u00a0F\u00e4higkeit\u00a0der\u00a0Proliferationsanregung \u00a0der\u00a0T\u2010Zellen\u00a0durch\u00a0die\u00a0verschieden \u00a0stimulierten \u00a0\nMonozyten \u00a0zu\u00a0erfassen,\u00a0wurde\u00a0eine\u00a0MLR\u00a0(engl.\u00a0Mixed\u00a0Lymphocyte \u2010Reaction )\u00a0durchgef\u00fchrt. \u00a0\nDie\u00a0MLR\u00a0dient\u00a0in\u00a0vitro\u00a0als\u00a0Modell\u00a0f\u00fcr\u00a0die\u00a0Aktivierung \u00a0von\u00a0T\u2010Zellen.\u00a0Bei\u00a0einer\u00a0einfachen \u00a0MLR\u00a0\nkultiviert\u00a0man\u00a0bestrahlte \u00a0PBMC\u00b4s\u00a0eines\u00a0Spenders \u00a0(Stimulatorzellen) \u00a0mit\u00a0z.B.\u00a0CFDA\u2010SE\u00a0\nmarkierten \u00a0PBMC\u00b4s\u00a0eines\u00a0anderen\u00a0(allogenen) \u00a0Spenders \u00a0(Responderzellen). \u00a0Die\u00a0Responder \u2010\nT\u2010Zellen\u00a0proliferieren \u00a0umso\u00a0st\u00e4rker,\u00a0je\u00a0verschiedener \u00a0die\u00a0HLA\u2010Typen\u00a0der\u00a0beiden\u00a0Spender\u00a0\nsind.\u00a0Als\u00a0Positiv\u2010Kontrolle\u00a0werden\u00a0die\u00a0Responderzellen \u00a0mit\u00a0l\u00f6slichen\u00a0Antik\u00f6rpern \u00a0gegen\u00a0die\u00a0\nOberfl\u00e4chenmolek\u00fcle \u00a0CD3\u00a0und\u00a0CD28\u00a0stimuliert. \u00a0\u00dcber\u00a0eine\u00a0Kreuzvernetzung \u00a0des\u00a0T\u2010Zell\u2010\nRezeptor\u2010Komplexes \u00a0durch\u00a0anti\u2010CD3\u00a0und\u00a0des\u00a0kostimulatorischen \u00a0Rezeptors \u00a0durch\u00a0anti\u2010CD28\u00a0\nwerden\u00a0verschiedene \u00a0Signalkaskaden, \u00a0die\u00a0zur\u00a0T\u2010Zell\u2010Aktivierung \u00a0f\u00fchren,\u00a0ausgel\u00f6st. \u00a0\nZur\u00a0Optimierung \u00a0der\u00a0Proliferationsbedingungen \u00a0wurden\u00a0zun\u00e4chst\u00a0viele\u00a0Vorversuche \u00a0\ndurchgef\u00fchrt, \u00a0in\u00a0denen\u00a0die\u00a0optimale\u00a0CFDA\u2010SE\u2010Konzentration, \u00a0die\u00a0CFDA\u2010SE\u2010Inkubationszeiten, \u00a0\ndas\u00a0Stimulator \u2010Responder \u2010Verh\u00e4ltnis \u00a0sowie\u00a0die\u00a0Kultivierungsdauer \u00a0ermittelt\u00a0wurden.\u00a0\n\u00a0\nF\u00fcr\u00a0die\u00a0Experimente \u00a0wurden\u00a0PBMC\u00b4s\u00a0aus\u00a0einem\u00a0buffy\u00a0coat\u00a0mittels\u00a0der\u00a0Dichtegradienten \u2010\nZentrifugation \u00a0gewonnen, \u00a0die\u00a0als\u00a0Responderzellen \u00a0fungierten. \u00a0Die\u00a0Zellzahl\u00a0wurde\u00a0mit\u00a0DC\u2010\nMedium\u00a0auf\u00a01\u00a0x\u00a0107\u00a0Zellen/ml \u00a0eingestellt \u00a0und\u00a0die\u00a0Zellen\u00a0anschlie\u00dfend \u00a0f\u00fcr\u00a05\u00a0min\u00a0mit\u00a01\u00a0\u00b5M\u00a0\nCFDA\u2010SE\u00a0(Vybrant\u00ae \u00a0CFDA\u2010SE\u00a0Cell\u00a0Tracer\u00a0Kit\u00a0von\u00a0Molecular \u00a0Probes)\u00a0im\u00a0Dunkeln\u00a0bei\u00a038\u00b0C\u00a0im\u00a0\nWasserbad \u00a0inkubiert. \u00a0Die\u00a0Lebendf\u00e4rbung \u00a0wurde\u00a0dann\u00a0durch\u00a0Zugabe\u00a0von\u00a05\u00a0ml\u00a0DC\u2010Medium\u00a0\nunterbrochen. \u00a0Es\u00a0folgten\u00a02\u00a0Waschschritte \u00a0mit\u00a0jeweils\u00a05\u00a0ml\u00a0DC\u2010Medium\u00a0und\u00a0einer\u00a0\nZentrifugation \u00a0der\u00a0Zellsuspension \u00a0bei\u00a0300\u00a0x\u00a0g\u00a0f\u00fcr\u00a05\u00a0min.\u00a0Die\u00a0Bestimmung \u00a0der\u00a0Leukozytenzahl \u00a0\nerfolgte\u00a0am\u00a0Automatischen \u00a0H\u00e4matologieanalysator \u00a0KX\u201021N.\u00a0Nach\u00a0Einstellen \u00a0der\u00a0Zellzahl\u00a0auf\u00a0\n1\u00a0x\u00a0106\u00a0Zellen/ml \u00a0mit\u00a0DC\u2010Medium\u00a0wurden\u00a0jeweils\u00a0100\u00a0\u00b5l\u00a0der\u00a0Zellsuspension \u00a0in\u00a0eine\u00a096\u00a0well\u2010\nRundboden \u2010Platte\u00a0ausges\u00e4at. \u00a0\u00a051 Material\u00a0und\u00a0Methoden\nDie\u00a03\u00a0Tage\u00a0zuvor\u00a0mit\u00a0komplettiertem \u00a0DC\u2010Medium\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0stimulierten \u00a0\nMonozyten \u00a0(Stimulatorzellen, \u00a0allogener \u00a0Spender)\u00a0wurden\u00a0aus\u00a0ihren\u00a0wells\u00a0gel\u00f6st,\u00a03\u00a0x\u00a0mit\u00a0DC\u2010\nMedium\u00a0gewaschen \u00a0und\u00a0nach\u00a0einer\u00a0letzten\u00a0Zentrifugation \u00a0von\u00a05\u00a0min\u00a0bei\u00a0300\u00a0x\u00a0g\u00a0auf\u00a0eine\u00a0\nZellzahl\u00a0von\u00a0je\u00a02,5\u00a0x\u00a0105/ml\u00a0mit\u00a0DC\u2010Medium\u00a0eingestellt. \u00a0Auch\u00a0von\u00a0diesen\u00a0Zellsuspensionen \u00a0\nwurden\u00a0je\u00a0100\u00a0\u00b5l\u00a0pro\u00a0well\u00a0in\u00a0die\u00a096\u00a0well\u2010Rundboden \u2010Platte\u00a0pipettiert, \u00a0so\u00a0dass\u00a0in\u00a0den\u00a0wells\u00a0ein\u00a0\nStimulator \u2010Responder \u2010Verh\u00e4ltnis \u00a0von\u00a01:5\u00a0herrschte. \u00a0Als\u00a0Positiv\u2010Kontrolle\u00a0dienten\u00a0markierte \u00a0\nResponderzellen, \u00a0die\u00a0mit\u00a00,5\u00a0\u00b5g/ml\u00a0anti\u2010CD3\u00a0und\u00a0anti\u2010CD28\u00a0behandelt \u00a0wurden.\u00a0Die\u00a0Negativ\u2010\nKontrollen \u00a0bestanden \u00a0einerseits \u00a0aus\u00a0unmarkierten \u00a0Responderzellen \u00a0und\u00a0andererseits \u00a0aus\u00a0\nden\u00a0verschiedenen \u00a0Stimulatorzellen. \u00a0Die\u00a0MLR\u00a0wurde\u00a0f\u00fcr\u00a05\u00a0\u2010\u00a07\u00a0Tage\u00a0bei\u00a037\u00b0C\u00a0und\u00a05%\u00a0CO2\u00a0\nkultiviert. \u00a0Bei\u00a0der\u00a07\u00a0Tage\u00a0Kultur\u00a0wurde\u00a0am\u00a0dritten\u00a0Tag\u00a0die\u00a0H\u00e4lfte\u00a0des\u00a0DC\u2010Mediums \u00a0durch\u00a0\nfrisches\u00a0ersetzt\u00a0und\u00a0wieder\u00a0mit\u00a0der\u00a0entsprechenden \u00a0Konzentration \u00a0an\u00a0anti\u2010CD3\u00a0und\u00a0anti\u2010\nCD28\u00a0angereichert. \u00a0\n\u00a0\nZur\u00a0Bestimmung \u00a0der\u00a0Zellproliferation \u00a0wurden\u00a0die\u00a0Zellen\u00a0der\u00a0MLR,\u00a0sowie\u00a0die\u00a0Kontrollen \u00a0aus\u00a0\nihren\u00a0wells\u00a0gel\u00f6st\u00a0und\u00a0die\u00a0Zellzahl\u00a0auf\u00a02\u00a0x\u00a0106/ml\u00a0mit\u00a0PBS\u00a0eingestellt \u00a0und\u00a0pro\u00a0FACS\u2010R\u00f6hrchen \u00a0\nje\u00a0100\u00a0\u00b5l\u00a0Zellsuspension \u00a0mit\u00a01,5\u00a0\u2010\u00a02,5\u00a0\u00b5l\u00a0prim\u00e4rem \u00a0Antik\u00f6rper \u00a0(CD3\u00a0Pacific\u00a0Blue,\u00a0CD4\u00a0APC/H7,\u00a0\nCD11b/Mac \u20101\u00a0APC)\u00a0bzw.\u00a0den\u00a0entsprechenden \u00a0Isotypkontrollen \u00a0versetzt.\u00a0Die\u00a0Inkubation \u00a0\nerfolgte\u00a015\u00a0min\u00a0im\u00a0K\u00fchlschrank. \u00a0Anschlie\u00dfend \u00a0wurde\u00a0zu\u00a0den\u00a0Zellen\u00a02\u00a0ml\u00a0PBS\u2010Azid\u00a0gegeben\u00a0\nund\u00a05\u00a0min\u00a0bei\u00a0300\u00a0x\u00a0g\u00a0zentrifugiert. \u00a0Der\u00a0\u00dcberstand \u00a0wurde\u00a0verworfen \u00a0und\u00a0das\u00a0Pellet\u00a0mit\u00a0\u00a0\u00a0\u00a0\u00a0\n300\u00a0\u00b5l\u00a0Cellfix \u2122\u00a0(1x)\u00a0gel\u00f6st.\u00a0Die\u00a0Zellsuspension \u00a0wurde\u00a0bis\u00a0zur\u00a0Analyse\u00a0am\u00a0FACSCanto \u00a0II\u2122\u00a0bei\u00a0\n4\u00b0C\u00a0im\u00a0Dunkeln\u00a0aufbewahrt. \u00a0\n\u00a0\u00a0\nDC\u2010Medium\u00a0 RPMI\u00a01640\u00a0mit\u00a0Glutamin\u00a0\n\u00a0 10\u00a0%\u00a0FCS\u00a0\n\u00a0 1\u00a0%\u00a0(v/v)\u00a0Penicillin/Streptomycin \u00a0\n\u00a0 1\u00a0%\u00a0HEPES\n\u00a0\n\u00a0 1\u00a0%\u00a0nicht\u2010essentielle \u00a0Aminos\u00e4uren \u00a0\n\u00a0 1\u00a0%\u00a0Natriumpyruvat \u00a0\n\u00a0\u00a052 Material\u00a0und\u00a0Methoden\nKomplettiertes \u00a0\nDC\u2010Medium\u00a0DC\u2010Medium\u00a0\n\u00a0 1000\u00a0IU/ml\u00a0Il\u20104\u00a0\n\u00a0 1000\u00a0IU/ml\u00a0GM\u2010CSF\u00a0\n\u00a0\nPBS\u2010Azid\u00a00,1%\u00a0 PBS\u00a0(1x)\u00a0\n\u00a0 0,1\u00a0%\u00a0Natriumazid \u00a0\n\u00a0\nStaining\u00a0buffer\u00a0 PBS\u2010Azid\u00a00,1%\u00a0\n\u00a0 1\u00a0%\u00a0FCS\u00a0\n\u00a0\n\u00a0\u00a0\n2.2.7  Kultivierung \tund\tStimulation \tder\tMonozyten \tf\u00fcr\tden\tCytometric \tBead\t\nArray\t(CBA)\t\n\u00a0\nEs\u00a0wurden\u00a01\u00a0x\u00a010\n6\u00a0Zellen/ml \u00a0in\u00a096\u00a0well\u2010Rundboden \u2010Platten\u00a0ausges\u00e4at. \u00a0Die\u00a0Kultivierung \u00a0der\u00a0\nZellen\u00a0erfolgte\u00a0\u00fcber\u00a06\u00a0Tage\u00a0mit\u00a0komplettiertem \u00a0DC\u2010Medium\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848.\u00a0Am\u00a0\ndritten\u00a0Tag\u00a0wurden\u00a0die\u00a0Zellen\u00a03\u00a0x\u00a0mit\u00a0DC\u2010Medium\u00a0gewaschen \u00a0und\u00a0wieder\u00a0mit\u00a0\nkomplettiertem \u00a0DC\u2010Medium\u00a0inkubiert. \u00a0Die\u00a0H\u00e4lfte\u00a0der\u00a0Zellen\u00a0wurde\u00a012\u00a0h\u00a0nach\u00a0dem\u00a0Waschen\u00a0\nf\u00fcr\u00a024\u00a0h\u00a0mit\u00a01\u00a0\u00b5g/ml\u00a0LPS\u00a0und\u00a03\u00a0\u00b5g/ml\u00a0CpG\u00a02006\u00a0stimuliert. \u00a0Die\u00a0zweite\u00a0H\u00e4lfte\u00a0der\u00a0Zellen\u00a0\nwurde\u00a072\u00a0h\u00a0nach\u00a0dem\u00a0Waschen\u00a0f\u00fcr\u00a024\u00a0h\u00a0mit\u00a01\u00a0\u00b5g/ml\u00a0LPS\u00a0und\u00a03\u00a0\u00b5g/ml\u00a0CpG\u00a02006\u00a0stimuliert. \u00a0\nNach\u00a0jeweils\u00a024\u00a0h\u00a0Stimulation \u00a0wurden\u00a0die\u00a0Platten\u00a010\u00a0min\u00a0bei\u00a0300\u00a0x\u00a0g\u00a0zentrifugiert, \u00a0die\u00a0\n\u00dcberst\u00e4nde \u00a0abgenommen \u00a0und\u00a0bei\u00a0\u201080\u00b0C\u00a0eingefroren. \u00a0\n\u00a0\u00a0\u00a0\u00a053 Material\u00a0und\u00a0Methoden\n2.2.8  Human\tInflammatory \tCytokines \tCytometric \tBead\tArray\t(CBA)\t\n\u00a0\nDer\u00a0Cytometric \u00a0Bead\u00a0Array\u00a0(CBA)\u00a0basiert\u00a0auf\u00a0einem\u00a0Partikel\u2010gebundenen \u00a0Immuntest, \u00a0ein\u00a0\nrelativ\u00a0neues\u00a0Analysenprinzip. \u00a0Der\u00a0hier\u00a0verwendete \u00a0CBA\u00a0beinhaltet \u00a0mehrere\u00a0verschiedene \u00a0\nPartikel\u00a0(Beads)\u00a0mit\u00a0unterschiedlichen \u00a0Fluoreszenz \u2010Intensit\u00e4ten. \u00a0Auf\u00a0den\u00a0unterschiedlichen \u00a0\nBead\u2010Populationen \u00a0werden\u00a0die\u00a0entsprechenden, \u00a0gegen\u00a0das\u00a0zu\u00a0bestimmende \u00a0Protein\u00a0\ngerichteten, \u00a0Antik\u00f6rper \u00a0fixiert\u00a0(Capture\u00a0Beads ).\u00a0Jeder\u00a0Capture\u00a0Bead\u00a0ist\u00a0somit\u00a0vergleichbar \u00a0mit\u00a0\neinem\u00a0gecoateten \u00a0well\u00a0einer\u00a0ELISA\u2010Platte.\u00a0Es\u00a0werden\u00a0mehrere\u00a0Capture\u00a0Bead\u2010Populationen \u00a0\nmiteinander \u00a0gemischt, \u00a0um\u00a0gleichzeitig \u00a0mehrere\u00a0l\u00f6sliche\u00a0Analyten, \u00a0im\u00a0sog.\u00a0\nMultiplexverfahren, \u00a0in\u00a0einer\u00a0einzigen\u00a0Probe\u00a0zu\u00a0detektieren. \u00a0Nachdem \u00a0die\u00a0Capture\u00a0Beads\u00a0mit\u00a0\nder\u00a0Probe\u00a0inkubiert\u00a0wurden,\u00a0werden\u00a0die,\u00a0gegen\u00a0die\u00a0zu\u00a0detektierenden \u00a0Proteine\u00a0gerichteten, \u00a0\nPE\u2010konjugierten \u00a0Antik\u00f6rper \u00a0(PE\u00a0Detection \u00a0Reagent )\u00a0zugegeben \u00a0und\u00a0die\u00a0Fluoreszenz \u00a0von\u00a0\neinem\u00a0FL3\u2010\u00a0oder\u00a0FL4\u2010Detektor\u00a0gemessen \u00a0(siehe\u00a0Abb.\u00a02.2.7.1).\u00a0Die\u00a0Proteinkonzentrationen \u00a0in\u00a0\nder\u00a0Probe\u00a0werden\u00a0mittels\u00a0Vergleich \u00a0der\u00a0Anzahl\u00a0der\u00a0detektierten \u00a0Beads\u00a0der\u00a0Standards \u00a0\nbekannter \u00a0Konzentrationen \u00a0anhand\u00a0von\u00a0Standardkurven \u00a0ermittelt. \u00a0Das\u00a0Prinzip\u00a0der\u00a0\nDurchflu\u00dfzytometrie \u00a0wurde\u00a0weiter\u00a0oben\u00a0schon\u00a0ausf\u00fchrlich \u00a0beschrieben. \u00a0\nMit\u00a0dem\u00a0Human\u00a0Inflammatory \u00a0Cytokines \u00a0CBA\u00a0k\u00f6nnen\u00a0Interleukin \u20108\u00a0(IL\u20108),\u00a0Interleukin \u20101\u03b2\u00a0(IL\u2010\n1\u03b2),\u00a0Interleukin \u20106\u00a0(IL\u20106),\u00a0Interleukin \u201010\u00a0(IL\u201010),\u00a0Tumor\u00a0Nekrose\u00a0Faktor\u00a0(TNF)\u00a0und\u00a0Interleukin \u2010\n12p70\u00a0(IL\u201012p70)\u00a0quantitativ \u00a0gemessen \u00a0werden.\u00a0Neben\u00a0\u00dcberst\u00e4nden \u00a0aus\u00a0Zellkulturen \u00a0kann\u00a0\nauch\u00a0EDTA\u2010Plasma\u00a0und\u00a0Serum\u00a0untersucht \u00a0werden.\u00a0\nIm\u00a0Vergleich \u00a0zu\u00a0den\u00a0g\u00e4ngigen\u00a0auf\u00a0dem\u00a0Markt\u00a0befindlichen \u00a0enzyme\u2010linked\u00a0immunosorbent \u00a0\nassays\u00a0(ELISAS\u00b4s) \u00a0k\u00f6nnen\u00a0mit\u00a0dem\u00a0gleichen\u00a0Probevolumen \u00a0wie\u00a0man\u00a0f\u00fcr\u00a0einen\u00a0Zytokin\u2010ELISA\u00a0\nbr\u00e4uchte\u00a0gleich\u00a0mehrere\u00a0Zytokine\u00a0bestimmt \u00a0werden\u00a0und\u00a0das\u00a0alles\u00a0in\u00a0einem\u00a0Bruchteil\u00a0der\u00a0\nZeit.\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a054 Material\u00a0und\u00a0Methoden\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a02.2.8.1:\u00a0Als\u00a0Beispiel\u00a0abgebildet \u00a0ist\u00a0eine\u00a0Probenmessung \u00a0mit\u00a0\nden\u00a06\u00a0im\u00a0Kit\u00a0enthaltenen \u00a0Beads .\u00a0\nGemessen \u00a0wurden\u00a0die\u00a0Fluoreszenz \u2010Intensit\u00e4ten \u00a0mit\u00a0dem\u00a0FL3\u2010\nDetektor\u00a0(Abszisse). \u00a0Die\u00a0quantitative \u00a0Konzentration \u00a0der\u00a0einzelnen \u00a0\nZytokine\u00a0ist\u00a0auf\u00a0der\u00a0Ordinate\u00a0dargestellt. \u00a0\n\u00a0\n\u00a0Vor\u00a0Beginn\u00a0des\u00a0eigentlichen \u00a0Tests\u00a0musste\u00a0ein\u00a0Cytometer \u00a0Setup\u00a0Bead\u00a0Procedure \u00a0durchgef\u00fchrt \u00a0\nwerden.\u00a0Daf\u00fcr\u00a0wurden\u00a050\u00a0\u00b5l\u00a0der\u00a0Cytometer \u00a0Setup\u00a0Beads\u00a0in\u00a03\u00a0R\u00f6hrchen \u00a0gegeben.\u00a0Zu\u00a0einem\u00a0\nR\u00f6hrchen \u00a0wurde\u00a050\u00a0\u00b5l\u00a0FITC\u00a0Positive\u00a0Control\u00a0und\u00a0zu\u00a0einem\u00a0anderen\u00a0R\u00f6hrchen \u00a0wurde\u00a050\u00a0\u00b5l\u00a0PE\u00a0\nPositive\u00a0Control\u00a0pipettiert. \u00a0Nach\u00a030\u00a0min\u00a0Inkubationszeit \u00a0bei\u00a0RT\u00a0im\u00a0Dunkeln\u00a0wurden\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n400\u00a0\u2013\u00a0450\u00a0\u00b5l\u00a0Waschpuffer \u00a0pro\u00a0R\u00f6hrchen \u00a0zugegeben \u00a0und\u00a0das\u00a0Cytometer \u00a0Setup\u00a0am\u00a0\nDurchflusszytometer \u00a0FACSCanto \u00a0II\u2122\u00a0durchgef\u00fchrt. \u00a0\nZu\u00a0Beginn\u00a0des\u00a0Tests\u00a0wurden\u00a0die\u00a06\u00a0verschiedenen \u00a0Standards \u00a0mit\u00a0je\u00a02\u00a0ml\u00a0Assay\u00a0Diluent\u00a0\nrekonstituiert \u00a0und\u00a0ca.\u00a015\u00a0min\u00a0bei\u00a0RT\u00a0stehen\u00a0gelassen.\u00a0Anschlie\u00dfend \u00a0wurden\u00a0serielle\u00a01:2\u00a0\nStandard\u00a0Verd\u00fcnnungen \u00a0hergestellt, \u00a0bei\u00a0denen\u00a0die\u00a0h\u00f6chste\u00a0Standard\u2010Konzentration \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n5000\u00a0pg/ml\u00a0und\u00a0die\u00a0niedrigste \u00a020\u00a0pg/ml\u00a0betrug.\u00a0Zus\u00e4tzlich \u00a0wurde\u00a0noch\u00a0ein\u00a0Leerwert\u00a0mit\u00a00\u00a0\npg/ml\u00a0ben\u00f6tigt.\u00a0Die\u00a06\u00a0verschiedenen \u00a0Capture\u00a0Beads\u00a0wurden\u00a0miteinander \u00a0vermischt \u00a0und\u00a0je\u00a050\u00a0\n\u00b5l\u00a0in\u00a0ein\u00a0Testr\u00f6hrchen \u00a0\u00fcberf\u00fchrt. \u00a0Danach\u00a0wurden\u00a0je\u00a050\u00a0\u00b5l\u00a0der\u00a0Standard\u2010Verd\u00fcnnungen, \u00a0der\u00a0\nLeerwerte \u00a0und\u00a0der\u00a01:2\u00a0mit\u00a0Assay\u00a0Diluent\u00a0verd\u00fcnnten \u00a0Proben\u00a0in\u00a0die\u00a0R\u00f6hrchen \u00a0pipettiert. \u00a0\n\u00a055 Material\u00a0und\u00a0Methoden\nAnschlie\u00dfend \u00a0wurden\u00a0noch\u00a0je\u00a050\u00a0\u00b5l\u00a0des\u00a0PE\u00a0Detection \u00a0Reagent\u00a0zugegeben. \u00a0Es\u00a0schloss\u00a0sich\u00a0eine\u00a0\nInkubationszeit \u00a0von\u00a03\u00a0Stunden\u00a0bei\u00a0RT\u00a0im\u00a0Dunkeln\u00a0an.\u00a0Um\u00a0nicht\u00a0gebundene \u00a0Zytokine\u00a0und\u00a0\nAntik\u00f6rper \u00a0zu\u00a0entfernen \u00a0wurden\u00a0die\u00a0R\u00f6hrchen \u00a0mit\u00a0je\u00a01\u00a0ml\u00a0Waschpuffer \u00a0gewaschen. \u00a0Das\u00a0\nBead\u2010Pellet\u00a0wurde\u00a0anschlie\u00dfend \u00a0mit\u00a0300\u00a0\u00b5l\u00a0Waschpuffer \u00a0gel\u00f6st\u00a0und\u00a0die\u00a0Proben\u00a0am\u00a0\nFACSCanto \u00a0II\u2122\u00a0analysiert. \u00a0\nMit\u00a0dem\u00a0Programm \u00a0FCAP\u00a0Array\u2122\u00a0V\u00a01.0.1\u00a0wurden\u00a0die\u00a0Standardkurven \u00a0erstellt,\u00a0die\u00a0das\u00a0\nBerechnen \u00a0der\u00a0Zytokinkonzentrationen \u00a0in\u00a0den\u00a0Proben\u00a0erm\u00f6glichten. \u00a0\n\u00a0\n\u00a0\u00a056 Ergebnisse\n3 Ergebnisse \t\n\u00a0\nResiquimod \u00a0(R848)\u00a0stellt\u00a0einen\u00a0neuartigen \u00a0Immunmodulator \u00a0dar,\u00a0der\u00a0seine\u00a0Wirkung\u00a0\u00fcber\u00a0\nden\u00a0TLR7\u00a0und\u00a0TLR8\u00a0entfaltet. \u00a0Um\u00a0R\u00fcckschl\u00fcsse \u00a0auf\u00a0eine\u00a0durch\u00a0R848\u00a0ausgel\u00f6ste \u00a0Modulation \u00a0\nder\u00a0Immunantwort \u00a0ziehen\u00a0zu\u00a0k\u00f6nnen\u00a0und\u00a0somit\u00a0den\u00a0Wirkstoff \u00a0in\u00a0Zukunft\u00a0effektiv\u00a0in\u00a0der\u00a0\nklinischen \u00a0Therapie\u00a0einzusetzen, \u00a0wurden\u00a0im\u00a0Rahmen\u00a0dieser\u00a0Dissertation \u00a0weitergehende \u00a0\nUntersuchungen \u00a0an\u00a0in\u00a0vitro\u00a0generierten \u00a0MoDC\u00b4s\u00a0durchgef\u00fchrt. \u00a0\u00a0\nSo\u00a0wurden\u00a0mittels\u00a0FACS\u2010Analysen\u00a0die\u00a0Wirkungen \u00a0verschiedener \u00a0TLR7\u2010\u00a0und\u00a0TLR7/8\u2010Liganden\u00a0\nauf\u00a0die\u00a0MoDC\u2010Differenzierung \u00a0und\u00a0\u2013Reifung\u00a0untersucht. \u00a0Nach\u00a0der\u00a0Stimulation \u00a0der\u00a0MoDC\u00b4s\u00a0\nmit\u00a0R848\u00a0enstand\u00a0eine\u00a0neue\u00a0Zellpopulation, \u00a0so\u00a0dass\u00a0verschiedene \u00a0inhibitorische \u00a0ODN\u00b4s\u00a0\neingesetzt \u00a0wurden,\u00a0um\u00a0den\u00a0Toll\u2010like\u00a0Rezeptor\u00a0zu\u00a0identifizieren, \u00a0durch\u00a0den\u00a0die\u00a0Modulation \u00a0\nder\u00a0in\u00a0vitro\u00a0generierten \u00a0MoDC\u00b4s\u00a0hervorgerufen \u00a0wurde.\u00a0Um\u00a0die\u00a0funktionelle \u00a0Rolle\u00a0von\u00a0R848\u00a0\nauf\u00a0MoDC\u00b4s\u00a0weiter\u00a0zu\u00a0charakterisieren \u00a0wurde\u00a0die\u00a0neu\u00a0entstandene \u00a0Zellpopulation \u00a0noch\u00a0auf\u00a0\nihre\u00a0F\u00e4higkeit\u00a0hin\u00a0untersucht \u00a0allogene\u00a0T\u2010Zellen\u00a0zur\u00a0Proliferation \u00a0anzuregen \u00a0und\u00a0nach\u00a0\nRestimulation \u00a0verschiedene \u00a0Zytokine\u00a0zu\u00a0produzieren. \u00a0\n\u00a0\n3.1 Der\tTLR7/8\u2010Ligand\tR848\tmodifiziert \tdosisabh\u00e4ngig \tdie\t\nDifferenzierung \tkonventioneller \tMoDC\u00b4s\t\n\u00a0\nMonozyten \u00a0wurden\u00a0aus\u00a0Restmaterialien \u00a0(buffy\u00a0coats)\u00a0gesunder \u00a0Blutspender \u00a0mit\u00a0Hilfe\u00a0der\u00a0\nFicolldichtegradientenzentrifugation \u00a0und\u00a0anschlie\u00dfender \u00a0Monozyten \u2010Separation \u00a0durch\u00a0den\u00a0\nAutoMACS\u2122 \u00a0Separator \u00a0isoliert\u00a0(siehe\u00a02.2.1\u00a0und\u00a02.2.2).\u00a0Die\u00a0Reinheit\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0\nbetrug\u00a0>\u00a095%.\u00a0Anschlie\u00dfend \u00a0wurden\u00a0die\u00a0Zellen\u00a0mit\u00a01000\u00a0IU/ml\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a0\nR848\u00a0f\u00fcr\u00a05\u00a0Tage\u00a0in\u00a0Kultur\u00a0genommen. \u00a0Der\u00a0TLR7/8\u2010Ligand\u00a0R848\u00a0wurde\u00a0dem\u00a0komplettierten \u00a0\nDC\u2010Medium\u00a0in\u00a0unterschiedlichen \u00a0Konzentrationen \u00a0zugesetzt, \u00a0so\u00a0dass\u00a0eine\u00a0Titrationsreihe \u00a0von\u00a0\n3\u00a0\u00b5M,\u00a02,25\u00a0\u00b5M,\u00a01,5\u00a0\u00b5M,\u00a0750\u00a0nM\u00a0und\u00a0300\u00a0nM\u00a0erreicht\u00a0wurde.\u00a0Danach\u00a0wurden\u00a0die\u00a0Zellen\u00a0\ngeerntet\u00a0und\u00a0mit\u00a0verschiedenen \u00a0Oberfl\u00e4chenantik\u00f6rpern \u00a0gef\u00e4rbt\u00a0(siehe\u00a0Abb.\u00a03.1.1).\u00a0\u00a057 Ergebnisse\nDie\u00a0aus\u00a0dem\u00a0Blut\u00a0isolierten \u00a0Monozyten \u00a0wurden\u00a0anhand\u00a0ihres,\u00a0auf\u00a0der\u00a0Oberfl\u00e4che \u00a0\nexprimierten, \u00a0Molek\u00fcls\u00a0CD14\u00a0identifiziert. \u00a0\u00a0\nAnhand\u00a0der\u00a0Oberfl\u00e4chenmolek\u00fcle \u00a0CD14\u00a0und\u00a0CD1a\u00a0konnten\u00a0die\u00a0aus\u00a0Monozyten, \u00a0mit\u00a0Hilfe\u00a0von\u00a0\nGM\u2010CSF/IL\u20104,\u00a0generierten \u00a0``monocyte \u2010derived\u00a0dendritic\u00a0cells`` ,\u00a0im\u00a0weiteren\u00a0MoDC\u00b4s\u00a0genannt,\u00a0\nidentifiziert \u00a0werden.\u00a0MoDC\u00b4s\u00a0exprimieren \u00a0CD1a,\u00a0aber\u00a0kein\u00a0CD14\u00a0mehr.\u00a0Das\u00a0\nOberfl\u00e4chenmolek\u00fcl \u00a0CD14\u00a0wird\u00a0vor\u00a0allem\u00a0in\u00a0gro\u00dfem\u00a0Ma\u00dfe\u00a0von\u00a0Monozyten \u00a0exprimiert, \u00a0man\u00a0\nfindet\u00a0es\u00a0aber\u00a0auch\u00a0auf\u00a0interfollikul\u00e4ren \u00a0Makrophagen, \u00a0retikul\u00e4ren \u00a0DC\u00b4s\u00a0und\u00a0einigen\u00a0\nLangerhans \u2010Zellen.\u00a0Es\u00a0fungiert\u00a0u.a.\u00a0als\u00a0LPS\u2010Rezeptor. \u00a0CD1a\u00a0findet\u00a0man\u00a0vor\u00a0allem\u00a0auf\u00a0DC\u00b4s,\u00a0\nkortikalen \u00a0Thymozyten \u00a0und\u00a0Langerhans \u2010Zellen.\u00a0Es\u00a0dient,\u00a0\u00e4hnlich\u00a0dem\u00a0MHC\u2010Klasse\u2010II\u2010Molek\u00fcl\u00a0\n(HLA\u2010DR),\u00a0der\u00a0Antigen\u2010Pr\u00e4sentation, \u00a0der\u00a0Lymphozyten \u2010Aktivierung \u00a0und\u00a0\u2010Entwicklung. \u00a0\n\u00a0\n\u00a0\nA\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0B\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a058 Ergebnisse\nC\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nD\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.1.1:\u00a0R848\u00a0ver\u00e4ndert \u00a0dosisabh\u00e4ngig \u00a0die\u00a0Differenzierung \u00a0der\u00a0\naus\u00a0Monozyten \u00a0expandierten \u00a0dendritischen \u00a0Zellen\u00a0(DC`s).\u00a0FACS\u2010\nAnalyse\u00a0eines\u00a0Spenders \u00a0nach\u00a0Monozyten \u2010Separation \u00a0durch\u00a0den\u00a0\nAutoMACS\u2122 \u00a0Separator \u00a0und\u00a0anschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0\nmit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0\u2013\u00a0300\u00a0nM\u00a0R848\u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nA\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s\u00a0mit\u00a0FITC\u00a0anti\u2010human\u00a0CD14\u00a0und\u00a0APC\u00a0anti\u2010\nhuman\u00a0CD1a;\u00a0B\u00a0F\u00e4rbung\u00a0der\u00a03\u00a0\u00b5M\u00a0R848\u2010DC\u00b4s\u00a0s.o.;\u00a0C\u00a0F\u00e4rbung\u00a0der\u00a0\u00a0\u00a0\u00a0\n750\u00a0nM\u00a0R848\u2010DC\u00b4s\u00a0s.o.;\u00a0D\u00a0F\u00e4rbung\u00a0der\u00a0300\u00a0nM\u00a0R848\u2010DC\u00b4s\u00a0s.o..\u00a0Die\u00a0\nentsprechenden \u00a0Isotypkontrollen \u00a0wurden\u00a0mitgef\u00fchrt. \u00a0\u00a0\n\u00a0\n\u00a059 Ergebnisse\nDie\u00a0unterschiedlichen \u00a0FACS\u2010Analysen\u00a0der\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0DC\u00b4s,\u00a0\ndie\u00a0mit\u00a0und\u00a0ohne\u00a0R848\u00a0f\u00fcr\u00a05\u00a0Tage\u00a0kultiviert\u00a0wurden,\u00a0ergaben\u00a0eine\u00a0signifikante \u00a0Ver\u00e4nderung \u00a0\nin\u00a0der\u00a0Differenzierung \u00a0der\u00a0DC\u00b4s.\u00a0\u00a0\nDie\u00a0nur\u00a0mit\u00a0GM\u2010CSF\u00a0und\u00a0IL\u20104\u00a0expandierten \u00a0Monozyten \u00a0(konventionelle \u00a0MoDC\u00b4s)\u00a0\nexprimierten \u00a0nach\u00a05\u00a0Tagen\u00a0Kultur\u00a0vor\u00a0allem\u00a0das\u00a0Oberfl\u00e4chenmolek\u00fcl \u00a0CD1a.\u00a0CD14\u00a0wurde\u00a0im\u00a0\nProzess\u00a0der\u00a0Differenzierung \u00a0von\u00a0Monozyten \u00a0zu\u00a0MoDC\u00b4s\u00a0deutlich\u00a0herunterreguliert \u00a0(Abb.\u00a0\n3.1.1.\u00a0A).\u00a0\nMit\u00a0steigender \u00a0Konzentration \u00a0von\u00a0R848\u00a0lie\u00df\u00a0sich\u00a0eine\u00a0Ver\u00e4nderung \u00a0der\u00a0Differenzierung \u00a0der\u00a0\nMoDC\u00b4s\u00a0erreichen. \u00a0Bei\u00a0einer\u00a0Stimulationskonzentration \u00a0von\u00a0300\u00a0nM\u00a0R848\u00a0stimmten \u00a0die\u00a0so\u00a0\nstimulierten \u00a0MoDC\u00b4s\u00a0in\u00a0ihrem\u00a0Ph\u00e4notyp \u00a0noch\u00a0mit\u00a0den\u00a0konventionellen \u00a0MoDC\u00b4s\u00a0\u00fcberein\u00a0(Abb.\u00a0\n3.1.1\u00a0D).\u00a0Ab\u00a0einer\u00a0Stimulationskonzentration \u00a0von\u00a01,5\u00a0\u00b5M\u00a0R848\u00a0konnten\u00a0deutliche \u00a0Effekte\u00a0\nerzielt\u00a0werden.\u00a0So\u00a0zeigten\u00a0die\u00a0mit\u00a03\u00a0\u00b5M\u00a0stimulierten \u00a0MoDC\u00b4s\u00a0deutliche \u00a0ph\u00e4notypische \u00a0\nUnterschiede. \u00a0Die\u00a0CD14\u2010Expression \u00a0blieb\u00a0weiterhin \u00a0erhalten\u00a0und\u00a0eine\u00a0CD1a\u2010Expression \u00a0\nwurde\u00a0zunehmend \u00a0unterdr\u00fcckt \u00a0(Abb.\u00a03.1.1\u00a0B).\u00a0Die\u00a0so\u00a0entstandenen \u00a0Zellen\u00a0werden\u00a0im\u00a0\nFolgenden \u00a0als\u00a0R848\u2010DC\u00b4s\u00a0bezeichnet. \u00a0\n\u00a0\nAnhand\u00a0der\u00a0graphischen \u00a0Darstellung \u00a0der\u00a0FACS\u2010Analysen\u00a0l\u00e4sst\u00a0sich\u00a0eine\u00a0signifikante, \u00a0\ndosisabh\u00e4ngige \u00a0Ver\u00e4nderung \u00a0der\u00a0Differenzierung \u00a0der\u00a0aus\u00a0Monozyten \u00a0expandierten \u00a0DC\u00b4s\u00a0\nzeigen.\u00a0Es\u00a0ist\u00a0deutlich\u00a0zu\u00a0erkennen, \u00a0dass\u00a0mit\u00a0zunehmender \u00a0Stimulationskonzentration \u00a0von\u00a0\nR848\u00a0eine\u00a0Hemmung \u00a0von\u00a0CD1a\u00a0und\u00a0eine\u00a0Persistenz \u00a0von\u00a0CD14\u00a0stattfindet. \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a060 Ergebnisse\nA\u00a0\n\u00a0\n\u00a0\nB\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.1.2:\u00a0R848\u00a0ver\u00e4ndert \u00a0dosisabh\u00e4ngig \u00a0die\u00a0Differenzierung \u00a0der\u00a0\naus\u00a0Monozyten \u00a0expandierten \u00a0dendritischen \u00a0Zellen\u00a0(DC`s).\u00a0\nGraphische \u00a0Darstellung \u00a0der\u00a0z.T.\u00a0beispielhaft \u00a0dargestellten \u00a0FACS\u2010\nAnalysen. \u00a0\nA\u00a0CD14\u2010Expression \u00a0(%)\u00a0und\u00a0B\u00a0CD1a\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0\nMonozyten \u00a0nach\u00a05\u00a0Tagen\u00a0Stimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a0\n3\u00a0\u00b5M\u00a0\u2013\u00a0300\u00a0nM\u00a0R848.\u00a0\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a04.\u00a0\n\u00a0\u00a0\u00a0p<\u00a00,05\u00a0versus\u00a0MoDC\u00b4s\u00a0(Kontroll\u2010DC\u00b4s)\u00a0(two\u2010tailed\u00a0t\u2010test).\u00a00102030405060\nMoDC\u00b4s 3 \u00a0\u00b5M\u00a0R848 2,25 \u00a0\u00b5M\nR8481,5\u00a0\u00b5M\nR848750\u00a0nM\nR848300\u00a0nM\nR848CD14\u00a0pos\u00a0(%)\u00a0\n0102030405060708090\nMoDC\u00b4s 3 \u00a0\u00b5M\u00a0R848 2,25 \u00a0\u00b5M\nR8481,5\u00a0\u00b5M\nR848750\u00a0nM\nR848300\u00a0nM\nR848CD1a\u00a0pos\u00a0(%)\u00a0\u00a0\u00a0\u00a061 Ergebnisse\n3.2 Die\tWirkung \tvon\tR848\tauf\tdie\tDC\u2010Differenzierung \tist\tTLR8\t\nvermittelt \t\n\u00a0\n3.2.1  Der\tEinfluss\tdes\tspezifischen \tTLR7\u2010Liganden \tGardiquimod \tauf\tdie\tDC\u2010\nDifferenzierung \t\n\u00a0\nUm\u00a0festzustellen \u00a0durch\u00a0welchen\u00a0TLR\u00a0die\u00a0ver\u00e4nderte \u00a0Differenzierung \u00a0der\u00a0Monozyten \u00a0\nhervorgerufen \u00a0wurde,\u00a0musste\u00a0der\u00a0Einfluss\u00a0eines\u00a0spezifischen \u00a0TLR7\u2010Liganden, \u00a0der\u00a0wie\u00a0R848\u00a0\nein\u00a0Imidazoquinolin \u2010Bestandteil \u00a0ist,\u00a0auf\u00a0die\u00a0Monozyten \u00a0untersucht \u00a0werden.\u00a0\nZun\u00e4chst\u00a0wurde\u00a0also\u00a0der\u00a0spezifische \u00a0TLR7\u2010Ligand\u00a0Gardiquimod \u00a0eingesetzt, \u00a0der\u00a0nur\u00a0in\u00a0hohen\u00a0\nStimulationskonzentrationen \u00a0(>\u00a03\u00a0\u00b5g/ml;\u00a0>\u00a09\u00a0\u00b5M)\u00a0eine\u00a0leichte\u00a0TLR8\u2010Wirkung\u00a0besitzt\u00a0und\u00a0\ndeshalb\u00a0in\u00a0den\u00a0folgenden \u00a0Versuchen \u00a0nur\u00a0in\u00a0niedrigeren \u00a0Stimulationskonzentrationen \u00a0\neingesetzt \u00a0wurde.\u00a0\nMonozyten \u00a0wurden\u00a0wieder\u00a0\u00fcber\u00a05\u00a0Tage\u00a0mit\u00a01000\u00a0IU/ml\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a01\u00a0\u2013\u00a00,1\u00a0\n\u00b5g/ml\u00a0(3,19\u00a0\u00b5M\u00a0\u2013\u00a00,319\u00a0\u00b5M)\u00a0Gardiquimod \u00a0oder\u00a03\u00a0\u00b5M\u00a0R848\u00a0f\u00fcr\u00a05\u00a0Tage\u00a0in\u00a0Kultur\u00a0genommen \u00a0\nund\u00a0anschlie\u00dfend \u00a0mit\u00a0verschiedenen \u00a0Oberfl\u00e4chenantik\u00f6rpern \u00a0angef\u00e4rbt \u00a0(Abb.\u00a03.2.1.1).\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a062 Ergebnisse\nA\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nB\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a063 Ergebnisse\nC\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nD\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a064 Ergebnisse\nE\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nF\u00a0\n\u00a0\u00a0\n\u00a0\nAbb.\u00a03.2.1.1:\u00a0Gardiquimod \u00a0und\u00a0R848\u00a0im\u00a0Vergleich. \u00a0Gardiquimod \u00a0als\u00a0\nspezifischer \u00a0TLR7\u2010Ligand\u00a0ver\u00e4ndert \u00a0im\u00a0Gegensatz \u00a0zu\u00a0R848\u00a0die\u00a0\nDifferenzierung \u00a0der\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0dendritischen \u00a0\nZellen\u00a0(MoDC`s) \u00a0nicht.\u00a0FACS\u2010Analyse\u00a0eines\u00a0Spenders \u00a0nach\u00a0\nMonozyten \u2010Separation \u00a0durch\u00a0den\u00a0AutoMACS\u2122 \u00a0Separator \u00a0und\u00a0\nanschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0\n\u00a065 Ergebnisse\nohne\u00a00,1\u00a0\u2013\u00a01\u00a0\u00b5g/ml\u00a0(0,319\u00a0\u2013\u00a03,19\u00a0\u00b5M)\u00a0Gardiquimod \u00a0bzw.\u00a03\u00a0\u00b5M\u00a0R848\u00a0\n\u00fcber\u00a05\u00a0Tage.\u00a0\nA\u00a0Isotypkontrolle \u00a0der\u00a0MoDC\u00b4s;\u00a0B\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s\u00a0mit\u00a0FITC\u00a0anti\u2010\nhuman\u00a0CD14\u00a0und\u00a0APC\u00a0anti\u2010human\u00a0CD1a;\u00a0C\u00a0F\u00e4rbung\u00a0der\u00a00,1\u00a0\u00b5g/ml\u00a0\n(0,319\u00a0\u00b5M)\u00a0Gardiquimod \u2010DC\u00b4s\u00a0s.o.;\u00a0Isotypkontrolle \u00a00,1\u00a0\u00b5g/ml\u00a0(0,319\u00a0\n\u00b5M)\u00a0Gardiquimod \u2010DC\u00b4s\u00a0siehe\u00a0MoDC\u00b4s;\u00a0D\u00a0F\u00e4rbung\u00a0der\u00a01\u00a0\u00b5g/ml\u00a0(3,19\u00a0\n\u00b5M)\u00a0Gardiquimod \u2010DC\u00b4s\u00a0s.o.;\u00a0Isotypkontrolle \u00a0der\u00a01\u00a0\u00b5g/ml\u00a0(3,19\u00a0\u00b5M)\u00a0\nGardiquimod \u2010DC\u00b4s\u00a0siehe\u00a0MoDC\u00b4s;\u00a0E\u00a0Isotypkontrolle \u00a0der\u00a03\u00a0\u00b5M\u00a0R848\u2010\nDC\u00b4s;\u00a0F\u00a0F\u00e4rbung\u00a0der\u00a03\u00a0\u00b5M\u00a0R848\u2010DC\u00b4s\u00a0s.o..\u00a0\u00a0\n\u00a0\nEs\u00a0ist\u00a0deutlich\u00a0zu\u00a0erkennen, \u00a0dass\u00a0die\u00a0MoDC\u00b4s\u00a0und\u00a0die\u00a0Gardiquimod \u2010DC\u00b4s\u00a0einen\u00a0\u00e4hnlichen \u00a0\nPh\u00e4notyp \u00a0aufweisen. \u00a0Man\u00a0kann\u00a0dieses\u00a0gut\u00a0auf\u00a0einen\u00a0Blick\u00a0an\u00a0den\u00a0FACS\u2010Analysen\u00a0erkennen, \u00a0\nbei\u00a0denen\u00a0CD14\u00a0auf\u00a0der\u00a0Abszisse\u00a0und\u00a0CD1a\u00a0auf\u00a0der\u00a0Ordinate\u00a0aufgetragen \u00a0sind\u00a0(Abb.\u00a03.2.1.1\u00a0\nA,\u00a0C,\u00a0D).\u00a0Es\u00a0sind\u00a0deutlich\u00a0die\u00a0unterschiedlichen \u00a0Ph\u00e4notypen \u00a0der\u00a0expandierten \u00a0MoDC\u00b4s\u00a0und\u00a0\nGardiquimod \u2010DC\u00b4s,\u00a0die\u00a0das\u00a0Oberfl\u00e4chenmolek\u00fcl \u00a0CD1a\u00a0exprimieren \u00a0und\u00a0zus\u00e4tzlich \u00a0CD14\u00a0\nherunterregulieren, \u00a0von\u00a0den\u00a0CD14\u00a0pos\u00a0und\u00a0CD1a\u00a0neg\u00a0R848\u2010DC\u00b4s\u00a0zu\u00a0unterscheiden \u00a0(Abb.\u00a0\n3.2.1.1\u00a0E).\u00a0\n\u00a0Die\u00a0FACS\u2010Analysen\u00a0dieser\u00a0Versuche \u00a0best\u00e4tigten \u00a0die\u00a0These,\u00a0dass\u00a0die\u00a0R848\u2010Wirkung\u00a0nicht\u00a0\u00fcber\u00a0\nden\u00a0TLR7,\u00a0sondern\u00a0\u00fcber\u00a0den\u00a0TLR8\u00a0vermittelt \u00a0wird,\u00a0da\u00a0R848\u00a0als\u00a0TLR7/8\u2010Ligand\u00a0eine\u00a0\nver\u00e4nderte \u00a0Differenzierung\n\u00a0der\u00a0Monozyten \u00a0hervorruft, \u00a0Gardiquimod, \u00a0als\u00a0TLR7\u2010Ligand\u00a0jedoch\u00a0\nnicht.\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a066 Ergebnisse\nA\u00a0\n\u00a0\n\u00a0\nB\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.2.1.2:\u00a0Gardiquimod \u00a0und\u00a0R848\u00a0im\u00a0Vergleich. \u00a0Gardiquimod \u00a0als\u00a0\nspezifischer \u00a0TLR7\u2010Ligand\u00a0ver\u00e4ndert \u00a0im\u00a0Gegensatz \u00a0zu\u00a0R848\u00a0die\u00a0\nDifferenzierung \u00a0der\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0dendritischen \u00a0\nZellen\u00a0(DC`s)\u00a0nicht.\u00a0Graphische \u00a0Darstellung \u00a0der\u00a0beispielhaft \u00a0\ndargestellten \u00a0FACS\u2010Analysen. \u00a0\nA\u00a0CD14\u2010Expression \u00a0(%),\u00a0B\u00a0CD1a\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0\nMonozyten \u00a0nach\u00a05\u00a0Tagen\u00a0Stimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0und\u00a00,1\u00a0\u2013\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n1\u00a0\u00b5g/ml\u00a0(0,319\u00a0\u2013\u00a03,19\u00a0\u00b5M)\u00a0Gardiquimod \u00a0oder\u00a03\u00b5M\u00a0R848.\u00a0\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a06.\u00a00,0010,0020,0030,0040,0050,0060,0070,0080,00\nMoDC\u00b4s 0,1\u00b5g/ml\nGardiquimod1\u00b5g/ml\nGardiquimod3\u00b5M\u00a0R848CD14\u00a0pos\u00a0(%)\n0,0010,0020,0030,0040,0050,0060,0070,0080,0090,00100,00\nMoDC\u00b4s 0,1\u00b5g/ml\nGardiquimod1\u00b5g/ml\nGardiquimod3\u00b5M\u00a0R848CD1a\u00a0pos\u00a0(%)\u00a067 Ergebnisse\n3.2.2  Der\tEinfluss\tvon\tLoxoribine, \teines\tweiteren \tTLR7\u2010Liganden, \tauf\tdie\tDC\u2010\nDifferenzierung \t\n\u00a0\nDa\u00a0Gardiquimod \u00a0in\u00a0sehr\u00a0hohen\u00a0Dosen\u00a0(>\u00a03\u00a0\u00b5g/ml;\u00a0>\u00a09\u00a0mM)\u00a0auch\u00a0eine\u00a0leichte\u00a0TLR8\u00a0Wirkung\u00a0\nbesitzt,\u00a0wurden\u00a0zus\u00e4tzliche \u00a0Experimente \u00a0mit\u00a0einem\u00a0weiteren\u00a0spezifischen \u00a0TLR7\u2010Liganden\u00a0\ndurchgef\u00fchrt. \u00a0Zum\u00a0Vergleich \u00a0wurde\u00a0Loxoribine \u00a0auf\u00a0seine\u00a0Wirkung\u00a0auf\u00a0die\u00a0Differenzierung \u00a0\nvon\u00a0Monozyten \u00a0hin\u00a0untersucht. \u00a0Die\u00a0Monozyten \u00a0wurden\u00a0wieder\u00a05\u00a0Tage\u00a0mit\u00a01000\u00a0IU/ml\u00a0GM\u2010\nCSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a0Loxoribine \u00a0kultiviert\u00a0und\u00a0anschlie\u00dfend \u00a0wie\u00a0in\u00a03.1\u00a0angef\u00e4rbt. \u00a0Hier\u00a0\nwurde\u00a0mit\u00a0dem\u00a0TLR7\u2010Liganden\u00a0Loxoribine \u00a0eine\u00a0Titrationsreihe \u00a0mit\u00a0den\u00a0entsprechenden \u00a0\nStimulationskonzentrationen \u00a0zu\u00a0denen\u00a0von\u00a0R848\u00a0in\u00a03.1.erstellt \u00a0(1\u00a0mM,\u00a0500\u00a0\u00b5M\u00a0und\u00a0100\u00a0\u00b5M).\u00a0\n\u00a0\u00a0A\u00a0\n\u00a0\u00a0 \u00a0\n\u00a0\nB\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a068 Ergebnisse\nAbb.\u00a03.2.2.1:\u00a0Loxoribine \u00a0hat\u00a0keinen\u00a0Effekt\u00a0auf\u00a0die\u00a0Differenzierung \u00a0\nder\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0dendritischen \u00a0Zellen\u00a0(MoDC`s). \u00a0Als\u00a0\nBeispiel\u00a0eine\u00a0FACS\u2010Analyse\u00a0eines\u00a0Spenders \u00a0nach\u00a0Monozyten \u2010\nSeparation \u00a0durch\u00a0den\u00a0AutoMACS\u2122 \u00a0Separator \u00a0und\u00a0anschlie\u00dfender \u00a0\nStimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a0500\u00a0\u00b5M\u00a0\nLoxoribine \u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nA\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s\u00a0mit\u00a0FITC\u00a0anti\u2010human\u00a0CD14\u00a0und\u00a0APC\u00a0anti\u2010\nhuman\u00a0CD1a;\u00a0B\u00a0F\u00e4rbung\u00a0der\u00a0mit\u00a0500\u00a0\u00b5M\u00a0Loxoribine \u00a0stimulierten \u00a0\nMoDC\u00b4s\u00a0s.o..\u00a0\u00a0\n\u00a0\n\u00a0\nBei\u00a0der\u00a0Konzentration \u00a0von\u00a01\u00a0mM\u00a0Loxoribine \u00a0waren\u00a0deutliche \u00a0zelltoxische \u00a0Wirkungen \u00a0zu\u00a0\nerkennen, \u00a0was\u00a0auf\u00a0die\u00a0hohe\u00a0Konzentration \u00a0des\u00a0L\u00f6sungsmittels \u00a0DMSO\u00a0zur\u00fcckzuf\u00fchren \u00a0war.\u00a0\nBei\u00a0den\u00a0zwei\u00a0n\u00e4chst\u00a0niedrigeren \u00a0Konzentration \u00a0(500\u00a0\u00b5M\u00a0und\u00a0100\u00a0\u00b5M)\u00a0traten\u00a0diese\u00a0toxischen \u00a0\nWirkungen \u00a0nicht\u00a0mehr\u00a0auf.\u00a0Die\u00a0FACS\u2010Analysen\u00a0ergaben\u00a0aber\u00a0keine\u00a0signifikante \u00a0Ver\u00e4nderung \u00a0\nder\u00a0Differenzierung \u00a0der\u00a0Monozyten \u00a0im\u00a0Vergleich \u00a0zu\u00a0der\u00a0Kontrolle\u00a0(MoDC\u00b4s). \u00a0\n\u00a0\u00a0A\u00a0\n\u00a0\n\u00a0\n\u00a005101520253035404550\nMoDC\u00b4s 14 \u00a0\u00b5l\nDMSO1\u00a0mM\nLoxo7\u00a0\u00b5l\nDMSO500\u00a0\u00b5M\nLoxo1,4\u00a0\u00b5l\nDMSO100\u00a0\u00b5M\nLoxoCD14\u00a0pos\u00a0(%)\u00a0\u00a069 Ergebnisse\nB\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.2.2.2:\u00a0Loxoribine \u00a0hat\u00a0keinen\u00a0Effekt\u00a0auf\u00a0die\u00a0Differenzierung \u00a0\nder\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0dendritischen \u00a0Zellen\u00a0(MoDC`s). \u00a0\nGraphische \u00a0Darstellung \u00a0der\u00a0z.T.\u00a0beispielhaft \u00a0dargestellten \u00a0FACS\u2010\nAnalysen. \u00a0\nA\u00a0CD14\u2010Expression \u00a0(%)\u00a0und\u00a0B\u00a0CD1a\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0\nMonozyten \u00a0nach\u00a05\u00a0Tagen\u00a0Stimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a0\n1\u00a0mM\u00a0\u2013\u00a0100\u00a0\u00b5M\u00a0Loxoribine \u00a0bzw.\u00a0der\u00a0entsprechenden, \u00a0als\u00a0neg.\u00a0\nKontrolle\u00a0dienenden, \u00a0Mengen\u00a0DMSO\u00a0(L\u00f6sungsmittel). \u00a0\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a03.\u00a0\n\u00a0\n\u00a0\n3.2.3  Die\tVerwendung \tverschiedener \tinhibitorischer \tOligonukleotide \t(iODN\u00b4s) \t\nzur\tVerifizierung \tder\tTLR8\u2010Wirkung \t\n\u00a0\nUm\u00a0die\u00a0These\u00a0letztendlich \u00a0zu\u00a0best\u00e4tigen, \u00a0wurden\u00a0Versuche \u00a0mit\u00a0spezifischen \u00a0iODN\u00b4s\u00a0\nangeschlossen. \u00a0Dazu\u00a0wurde\u00a0zu\u00a0den\u00a0kultivierten \u00a0Monozyten \u00a0(+/\u2010\u00a03\u00a0\u00b5M\u00a0R848)\u00a0zu\u00a0Beginn\u00a0der\u00a0\nKultur\u00a0entweder \u00a0iODN\u00a02088\u00a0(ein\u00a0TLR7/8/9\u2010Inhibitor), \u00a0iODN\u00a020958\u00a0(ein\u00a0TLR7\u2010Inhibitor) \u00a0oder\u00a0\niODN\u00a020959\u00a0(ein\u00a0TLR7/8\u2010Inhibitor) \u00a0zugegeben. \u00a0Die\u00a0Kulturdauer \u00a0betrug\u00a0wieder\u00a05\u00a0Tage\u00a0und\u00a0\ndanach\u00a0wurden\u00a0wieder\u00a0die\u00a0Oberfl\u00e4chenmolek\u00fcle \u00a0mit\u00a0Antik\u00f6rpern \u00a0angef\u00e4rbt. \u00a00102030405060708090\nMoDC\u00b4s 14 \u00a0\u00b5l\nDMSO1\u00a0mM\nLoxo7\u00a0\u00b5l\nDMSO500\u00a0\u00b5M\nLoxo1,4\u00a0\u00b5l\nDMSO100\u00a0\u00b5M\nLoxoCD1a\u00a0pos\u00a0(%)\u00a070 Ergebnisse\nNur\u00a0die\u00a0iODN\u00b4s,\u00a0die\u00a0auch\u00a0TLR8\u00a0inhibieren \u00a0(iODN\u00a02088\u00a0und\u00a0iODN\u00a020959)\u00a0waren\u00a0in\u00a0der\u00a0Lage\u00a0die\u00a0\nR848\u2010Effekte\u00a0auf\u00a0MoDC\u00b4s,\u00a0wie\u00a0CD14\u00a0Expression \u00a0und\u00a0Hemmung \u00a0der\u00a0CD1a\u00a0Expression, \u00a0zu\u00a0\nsupprimieren. \u00a0\nIm\u00a0Unterschied \u00a0dazu\u00a0zeigte\u00a0iODN\u00a020958,\u00a0welches\u00a0nur\u00a0TLR7\u00a0inhibiert,\u00a0keine\u00a0Hemmung \u00a0der\u00a0\nR848\u2010Wirkung\u00a0auf\u00a0die\u00a0DC\u2010Differenzierung. \u00a0Es\u00a0l\u00e4sst\u00a0sich\u00a0daraus\u00a0schlie\u00dfen, \u00a0dass\u00a0die\u00a0DC\u2010\nDifferenzierung \u00a0durch\u00a0R848\u00a0\u00fcber\u00a0TLR8\u00a0vermittelt \u00a0wurde.\u00a0\nDie\u00a0Expression \u00a0von\u00a0HLA\u2010DR\u00a0wurde\u00a0nicht\u00a0signifikant \u00a0von\u00a0den\u00a0verschiedenen \u00a0iODN\u00b4s\u00a0\nbeeinflusst. \u00a0Man\u00a0kann\u00a0daher\u00a0annehmen, \u00a0dass\u00a0diese\u00a0Expression \u00a0nicht\u00a0ausschlie\u00dflich \u00a0von\u00a0TLR7\u00a0\noder\u00a0TLR8\u00a0gesteuert \u00a0wurde.\u00a0\u00a0\n\u00a0\n\u00a0\nA\u00a0\n\u00a0\n\u00a0\nB\u00a0\n\u00a0\n\u00a071 Ergebnisse\nC\u00a0\n\u00a0\n\u00a0\nD\u00a0\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.2.3.1:\u00a0Die\u00a0ver\u00e4nderte \u00a0Differenzierung \u00a0der\u00a0DC\u00b4s\u00a0mit\u00a0Hilfe\u00a0von\u00a0\nR848\u00a0ist\u00a0TLR8\u00a0vermittelt. \u00a0Graphische \u00a0Darstellung. \u00a0\nA\u00a0CD14\u2010Expression \u00a0(%),\u00a0B\u00a0CD1a\u2010Expression \u00a0(%),\u00a0C\u00a0HLA\u2010DR\u2010Expression \u00a0\n(%)\u00a0und\u00a0D\u00a0HLA\u2010DR\u2010Expression \u00a0(MFI)\u00a0der\u00a0MoDC\u00b4s\u00a0(CtrDC)\u00a0und\u00a0\nunterschiedlich \u00a0inhibierten \u00a0R848\u2010DC\u00b4s\u00a0nach\u00a05\u00a0Tagen\u00a0Stimulation \u00a0mit\u00a0\nGM\u2010CSF/IL\u20104,\u00a0iODN\u00a02088,\u00a0iODN\u00a020958,\u00a0iODN\u00a020959\u00a0mit\u00a0und\u00a0ohne\u00a0\nR848.\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a03.\u00a0\n\u00a0\u00a0\u00a0p<\u00a00,05\u00a0versus\u00a0R848\u2010DC\u00b4s\u00a0(two\u2010tailed\u00a0t\u2010test).\u00a0\n0100002000030000\n\u00a072 Ergebnisse\n3.3 R848\u2010DC\u00b4s\texprimieren \tgr\u00f6\u00dfere \tMengen\tan\tT\u2010Zell\t\nkostimulatorischen \tMolek\u00fclen \tund\tHLA\u2010DR\t\t\n\u00a0\nNach\u00a0Stimulation \u00a0der\u00a0Monozyten \u00a0f\u00fcr\u00a05\u00a0Tage\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0und\u00a0verschiedenen \u00a0\nKonzentrationen \u00a0Gardiquimod \u00a0bzw.\u00a0R848\u00a0wurden\u00a0die\u00a0Zellen\u00a0geerntet\u00a0und\u00a0mit\u00a0\nfluoreszenzmarkierten \u00a0Antik\u00f6rpern \u00a0gegen\u00a0verschiedene \u00a0Oberfl\u00e4chenmolek\u00fcle \u00a0angef\u00e4rbt \u00a0(PE\u00a0\nanti\u2010human\u00a0BDCA\u20101,\u00a0PE\u00a0anti\u2010human\u00a0BDCA\u20102,\u00a0PE\u00a0anti\u2010human\u00a0BDCA\u20104,\u00a0PE\u00a0anti\u2010human\u00a0CD\u00a040,\u00a0\nPE\u00a0anti\u2010human\u00a0CD83,\u00a0PE\u00a0anti\u2010human\u00a0CD86,\u00a0PE\u00a0anti\u2010human\u00a0CD25,\u00a0PE\u00a0anti\u2010human\u00a0CD123\u00a0und\u00a0\nPE\u00a0anti\u2010human\u00a0HLA\u2010DR).\u00a0\nDie\u00a0geernteten \u00a0Zellen\u00a0wurden\u00a0wie\u00a0in\u00a0den\u00a0vorherigen \u00a0Versuchen \u00a0zus\u00e4tzlich \u00a0mit\u00a0CD14\u00a0und\u00a0\nCD1a\u00a0angef\u00e4rbt, \u00a0um\u00a0die\u00a0unterschiedliche \u00a0Differenzierung \u00a0der\u00a0Monozyten \u00a0zu\u00a0\u00fcberpr\u00fcfen. \u00a0\n\u00a0\u00a0\n3.3.1  R848\u2010DC\u00b4s\texprimieren \tgr\u00f6\u00dfere\tMengen\t\nan\tT\u2010Zell\tkostimulatorischen \t\nMolek\u00fclen \tund\tHLA\u2010DR\tim\tVergleich \tzu\tkonventionellen \tMoDC\u00b4s\t\n\u00a0\nDie\u00a0Expression \u00a0der\u00a0kostimulatorischen \u00a0Molek\u00fcle \u00a0und\u00a0des\u00a0HLA\u2010DR\u00a0sind\u00a0von\u00a0gro\u00dfer\u00a0\nimmunologischer \u00a0Bedeutung, \u00a0da\u00a0man\u00a0durch\u00a0ihre\u00a0Pr\u00e4senz\u00a0eine\u00a0Aussage\u00a0\u00fcber\u00a0den\u00a0\nReifungsgrad \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0machen\u00a0kann.\u00a0So\u00a0exprimieren \u00a0unreife\u00a0DC\u00b4s\u00a0nur\u00a0geringe\u00a0Mengen\u00a0\nan\u00a0CD40,\u00a0CD83\u00a0und\u00a0CD86\u00a0auf\u00a0ihren\u00a0Oberfl\u00e4chen \u00a0(Abb.1.3.4.1), \u00a0w\u00e4hrend\u00a0reife\u00a0DC\u00b4s,\u00a0die\u00a0der\u00a0\nAntigenpr\u00e4sentation \u00a0f\u00e4hig\u00a0sind,\u00a0in\u00a0hohem\u00a0Ma\u00dfe\u00a0CD40,\u00a0CD83,\u00a0CD86\u00a0und\u00a0HLA\u2010DR\u00a0exprimieren. \u00a0\nSo\u00a0stellt\u00a0u.a.\u00a0CD86\u00a0ein\u00a0wichtiges \u00a0Molek\u00fcl\u00a0dar,\u00a0da\u00a0es\u00a0zum\u00a0sog.\u00a0B7\u2010Komplex\u00a0geh\u00f6rt\u00a0und\u00a0mit\u00a0\nCD28\u00a0auf\u00a0den\u00a0T\u2010Zellen\u00a0interagiert \u00a0und\u00a0somit\u00a0an\u00a0einer\u00a0Ausl\u00f6sung \u00a0von\u00a0T\u2010Zell\u2010Antworten \u00a0\nbeteiligt\u00a0ist.\u00a0Ein\u00a0weiteres\u00a0wichtiges \u00a0Molek\u00fcl\u00a0f\u00fcr\u00a0die\u00a0Interaktion \u00a0zwischen\u00a0APC\u00b4s\u00a0und\u00a0CD4+\u00a0T\u2010\nZellen\u00a0stellt\u00a0HLA\u2010DR\u00a0dar.\u00a0\n\u00a0\u00a0\u00a0\u00a073 Ergebnisse\nA\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0B\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nC\u00a0\n\u00a0\u00a0\n\u00a074 Ergebnisse\nAbb.\u00a03.3.1.1:\u00a0Die\u00a0Expression \u00a0von\u00a0CD86\u00a0und\u00a0HLA\u2010DR\u00a0der\u00a0R848\u2010DC\u00b4s\u00a0\nim\u00a0Vergleich \u00a0zu\u00a0der\u00a0Stimulation \u00a0mit\u00a0Gardiquimod. \u00a0R848\u2010DC\u00b4s\u00a0\nexprimieren \u00a0in\u00a0h\u00f6herem \u00a0Ma\u00dfe\u00a0kostimulatorische \u00a0Molek\u00fcle \u00a0als\u00a0\nGardiquimod \u2010DC\u00b4s\u00a0und\u00a0MoDC\u00b4s.\u00a0FACS\u2010Analyse\u00a0eines\u00a0Spenders \u00a0nach\u00a0\nMonozyten \u2010Separation \u00a0durch\u00a0den\u00a0AutoMACS\u2122 \u00a0Separator \u00a0und\u00a0\nanschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0\nohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0oder\u00a01\u00a0\u00b5g/ml\u00a0(3,19\u00a0\u00b5M)\u00a0Gardiquimod \u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nA\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s,\u00a0B\u00a0der\u00a01\u00a0\u00b5g/ml\u00a0(3,19\u00a0\u00b5M)\u00a0Gardiquimod \u2010DC\u00b4s\u00a0\nund\u00a0C\u00a0der\u00a03\u00a0\u00b5M\u00a0R848\u2010DC\u00b4s\u00a0mit\u00a0PE\u00a0anti\u2010human\u00a0CD86\u00a0und\u00a0PE\u00a0anti\u2010\nhuman\u00a0HLA\u2010DR.\u00a0\n\u00a0\n\u00a0\nDie\u00a0kostimulatorischen \u00a0Molek\u00fcle \u00a0CD40,\u00a0CD83\u00a0und\u00a0CD86\u00a0wurden\u00a0von\u00a0den\u00a0R848\u2010DC\u00b4s\u00a0in\u00a0\nsignifikant \u00a0h\u00f6heren\u00a0Mengen\u00a0auf\u00a0ihren\u00a0Oberfl\u00e4chen \u00a0exprimiert \u00a0als\u00a0bei\u00a0den\u00a0konventionellen \u00a0\nMoDC\u00b4s.\u00a0Ebenso\u00a0wurde\u00a0HLA\u2010DR\u00a0in\u00a0signifikant \u00a0gr\u00f6\u00dferen\u00a0Mengen\u00a0auf\u00a0den\u00a0Oberfl\u00e4chen \u00a0der\u00a0\nR848\u2010DC\u00b4s\u00a0pr\u00e4sentiert \u00a0als\u00a0bei\u00a0der\u00a0Kontrolle\u00a0(MoDC\u00b4s). \u00a0\nDie\u00a0Gardiquimod \u2010DC\u00b4s\u00a0exprimierten \u00a0auf\u00a0ihren\u00a0Oberfl\u00e4chen \u00a0nur\u00a0mittelm\u00e4\u00dfige \u00a0Mengen\u00a0an\u00a0\nCD40,\u00a0CD83,\u00a0CD86\u00a0und\u00a0HLA\u2010DR.\u00a0\n\u00a0\nAu\u00dferdem \u00a0wurden\u00a0die\u00a0Expressionen \u00a0von\u00a0BDCA\u20101,\u00a0BDCA\u20102,\u00a0BDCA\u20104\u00a0untersucht, \u00a0bei\u00a0denen\u00a0\nsich\u00a0aber\u00a0keine\u00a0Unterschiede \u00a0zwischen\u00a0den\u00a0vier\u00a0Gruppen\u00a0nachweisen \u00a0lie\u00df.\u00a0BDCA\u20102\u00a0und\u00a0\nBDCA\u20104\u00a0werden\u00a0vor\u00a0allem\u00a0von\u00a0pDC\u00b4s\u00a0exprimiert; \u00a0BDCA\u20101\u00a0vor\u00a0allem\u00a0von\u00a0mDC\u00b4s.\u00a0Diese\u00a0\nUntersuchungen \u00a0wurden\u00a0angeschlossen, \u00a0um\u00a0eine\u00a0eventuelle \u00a0Aussage\u00a0\u00fcber\u00a0die\u00a0\nDifferenzierungsrichtung \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0machen\u00a0zu\u00a0k\u00f6nnen,\u00a0was\u00a0aber\u00a0nicht\u00a0m\u00f6glich\u00a0war.\u00a0\nEbenso\u00a0wurde\u00a0die\u00a0Expression \u00a0von\u00a0CD25\u00a0(\u03b1\u2010Kette\u00a0des\u00a0IL\u20102\u00a0Rezeptors) \u00a0untersucht, \u00a0um\u00a0eine\u00a0\nAussage\u00a0\u00fcber\u00a0eine\u00a0m\u00f6gliche\u00a0Differenzierung \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0zu\u00a0regulatorischen \u00a0DC\u00b4s\u00a0zu\u00a0\nmachen;\u00a0es\u00a0lie\u00dfen\u00a0sich\u00a0aber\u00a0keine\u00a0signifikanten \u00a0Unterschiede \u00a0zwischen\u00a0den\u00a0vier\u00a0Gruppen\u00a0\nnachweisen. \u00a0\n\u00a0\u00a075 Ergebnisse\n\u00a0\nA\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0B\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a00,00200,00400,00600,00800,001000,001200,001400,00\nMoDC\u00b4s 0,1\u00b5g/ml\nGardiquimod1\u00b5g/ml\nGardiquimod3\u00b5M\u00a0R848\n0,00200,00400,00600,00800,001000,001200,001400,00\nMoDC\u00b4s 0,1\u00b5g/ml\nGardiquimod1\u00b5g/ml\nGardiquimod3\u00b5M\u00a0R848CD40\u00a0(MFI)\u00a0\nCD83\u00a0(MFI)\u00a0\u00a076 Ergebnisse\n\u00a0\nC\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0D\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a00,00500,001000,001500,002000,002500,003000,003500,004000,00\nMoDC\u00b4s 0,1\u00b5g/ml\nGardiquimod1\u00b5g/ml\nGardiquimod3\u00b5M\u00a0R848\n0,005000,0010000,0015000,0020000,0025000,0030000,00\nMoDC\u00b4s 0,1\u00b5g/ml\nGardiquimod1\u00b5g/ml\nGardiquimod3\u00b5M\u00a0R848CD86\u00a0(MFI)\u00a0\nHLA\u2010DR\u00a0(MFI)\u00a0\u00a077 Ergebnisse\n\u00a0\nE\u00a0\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.3.1.2:\u00a0Die\u00a0Expression \u00a0kostimulatorischer \u00a0Molek\u00fcle \u00a0und\u00a0HLA\u2010\nDR\u00a0der\u00a0R848\u2010DC\u00b4s\u00a0im\u00a0Vergleich \u00a0zu\u00a0der\u00a0Stimulation \u00a0mit\u00a0Gardiquimod. \u00a0\nR848\u00a0blockiert\u00a0nicht\u00a0die\u00a0Differenzierung \u00a0und\u00a0Reifung\u00a0der\u00a0DC\u00b4s.\u00a0Es\u00a0\nentsteht\u00a0eine\u00a0andere\u00a0Zellpopulation. \u00a0Graphische \u00a0Darstellung \u00a0der\u00a0\nz.T.\u00a0beispielhaft \u00a0dargestellten \u00a0FACS\u2010Analysen. \u00a0\nA\u00a0CD40\u2010Expression \u00a0(MFI),\u00a0B\u00a0CD83\u2010Expression \u00a0(MFI),\u00a0C\u00a0CD86\u2010\nExpression \u00a0(MFI),\u00a0D\u00a0HLA\u2010DR\u2010Expression \u00a0(MFI)\u00a0und\u00a0E\u00a0HLA\u2010DR\u2010\nExpression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0Stimulation \u00a0\nmit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0oder\u00a00,1\u00a0\u2013\u00a01\u00a0\u00b5g/ml\u00a0(0,319\u00a0\u2013\u00a0\n3,19\u00a0\u00b5M)\u00a0Gardiquimod \u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a06.\u00a0\n\u00a0\u00a0\u00a0p<\u00a00,05\u00a0versus\u00a0MoDC\u00b4s\u00a0(Kontroll\u2010DC\u00b4s)\u00a0(two\u2010tailed\u00a0t\u2010test).\u00a0\n\u00a0\n\u00a0\u00a00,0020,0040,0060,0080,00100,00120,00\nMoDC\u00b4s 0,1\u00b5g/ml\nGardiquimod1\u00b5g/ml\nGardiquimod3\u00b5M\u00a0R848HLA\u2010DR\u00a0(%)\u00a0\u00a078 Ergebnisse\n3.3.2  R848\u2010DC\u00b4s\texprimieren \tCD123\t\n\u00a0\nA\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.3.2.1:\u00a0R848\u2010DC\u00b4s\u00a0exprimieren \u00a0CD123.\u00a0FACS\u2010Analyse\u00a0eines\u00a0\nSpenders \u00a0nach\u00a0Monozyten \u2010Separation \u00a0durch\u00a0den\u00a0AutoMACS\u2122 \u00a0\nSeparator \u00a0und\u00a0anschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010\nCSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0oder\u00a01\u00a0\u00b5g/ml\u00a0(3,19\u00a0\u00b5M)\u00a0\nGardiquimod \u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nA\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s,\u00a0der\u00a01\u00a0\u00b5g/ml\u00a0Gardiquimod \u2010DC\u00b4s\u00a0und\u00a0der\u00a03\u00a0\u00b5M\u00a0\nR848\u2010DC\u00b4s\u00a0mit\u00a0PE\u00a0anti\u2010human\u00a0CD123.\u00a0\n\u00a0\n\u00a0Wie\u00a0schon\u00a0bei\u00a0den\u00a0vorangegangenen \u00a0Experimenten \u00a0unterschieden \u00a0sich\u00a0die\u00a0Gardiquimod \u2010\nDC\u00b4s\u00a0in\u00a0ihrem\u00a0Expressionsmuster \u00a0nicht\u00a0signifikant \u00a0von\u00a0dem\u00a0der\u00a0MoDC\u00b4s.\u00a0Anders\u00a0verhielten \u00a0\nsich\u00a0die\u00a0R848\u2010DC\u00b4s.\u00a0\nR848\u2010DC\u00b4s\u00a0exprimierten, \u00a0im\u00a0Gegensatz \u00a0zu\u00a0\nkonventionellen \u00a0MoDC\u00b4s\u00a0und\u00a0den\u00a0Gardiquimod \u2010\nDC\u00b4s,\u00a0in\u00a0hohem\u00a0Ma\u00dfe\u00a0die\u00a0\u03b1\u2010Kette\u00a0des\u00a0IL\u20103\u00a0Rezeptors \u00a0(CD123),\u00a0welche\u00a0eigentlich \u00a0ein\u00a0typischer\u00a0\nOberfl\u00e4chenmarker \u00a0der\u00a0pDC\u00b4s\u00a0ist.\u00a0\n\u00a0\u00a0\n\u00a079 Ergebnisse\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.3.1.2:\u00a0R848\u2010DC\u00b4s\u00a0exprimieren \u00a0CD123.\u00a0Graphische \u00a0Darstellung \u00a0\nder\u00a0z.T.\u00a0beispielhaft \u00a0dargestellten \u00a0FACS\u2010Analysen. \u00a0\nA\u00a0CD123\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0\nStimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0oder\u00a00,1\u00a0\u2013\u00a01\u00a0\n\u00b5g/ml\u00a0(0,319\u00a0\u2013\u00a03,19\u00a0\u00b5M)\u00a0Gardiquimod \u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a06.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a00,0010,0020,0030,0040,0050,0060,0070,0080,0090,00100,00\nMoDC\u00b4s 0,1\u00b5g/ml\nGardiquimod1\u00b5g/ml\nGardiquimod3\u00b5M\u00a0R848CD123\u00a0pos\u00a0(%)\u00a080 Ergebnisse\n3.4 Die\tExpression \tvon\tFOXP3\tund\tCD122\t\n\u00a0\n3.4.1  Expression \tvon\tFOXP3\t\n\u00a0\nAuch\u00a0bei\u00a0den\u00a0zwei\u00a0folgenden \u00a0Versuchsreihen \u00a0wurden\u00a0die\u00a0zuvor\u00a0separierten \u00a0Monozyten \u00a0mit\u00a0\nGM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0bzw.\u00a0bei\u00a0dem\u00a0Nachweis \u00a0der\u00a0CD122\u2010Expression \u00a0\nzus\u00e4tzlich \u00a0noch\u00a0die\u00a0nur\u00a0mit\u00a0R848\u00a0stimulierten \u00a0und\u00a0unstimulierten \u00a0Monozyten, \u00a0f\u00fcr\u00a05\u00a0Tage\u00a0\nkultiviert\u00a0und\u00a0anschlie\u00dfend \u00a0angef\u00e4rbt. \u00a0\nZus\u00e4tzlich \u00a0zu\u00a0den\u00a0Oberfl\u00e4chenmolek\u00fclen \u00a0CD14\u00a0und\u00a0CD1a\u00a0wurden\u00a0die\u00a0Zellen\u00a0noch\u00a0mit\u00a0dem\u00a0\nintrazellul\u00e4ren \u00a0Antik\u00f6rper \u00a0FOXP3\u00a0angef\u00e4rbt, \u00a0um\u00a0weitere\u00a0Charakteristika \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0zu\u00a0\nerfassen.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.4.1.1:\u00a0Die\u00a0FOXP3\u2010Expression \u00a0der\u00a0MoDC\u00b4s\u00a0und\u00a0der\u00a0R848\u2010DC\u00b4s\u00a0\nim\u00a0Vergleich. \u00a0R848\u00a0ver\u00e4ndert \u00a0nicht\u00a0die\u00a0intrazellul\u00e4re \u00a0FOXP3\u2010\nExpression. \u00a0Graphische \u00a0Darstellung. \u00a0\nFOXP3\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0\nStimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848.\u00a0\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a03.\u00a0\n\u00a00,00,20,40,60,81,01,21,41,6\nMoDC\u00b4s R848 \u2010DC\u00b4sFOXP3\u00a0pos\u00a0(%)\u00a081 Ergebnisse\n3.4.2  Expression \tvon\tCD122\t\n\u00a0\nMit\u00a0dieser\u00a0Analyse\u00a0sollte\u00a0untersucht \u00a0werden,\u00a0ob\u00a0es\u00a0sich\u00a0bei\u00a0den\u00a0von\u00a0R848\u2010DC\u00b4s\u00a0exprimierten \u00a0\nIL\u20102\u00a0Rezeptoren \u00a0um\u00a0komplette, \u00a0funktionsf\u00e4hige \u00a0Rezeptoren \u00a0handelte. \u00a0\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.4.2.1:\u00a0Die\u00a0CD122\u2010Expression \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0im\u00a0Vergleich. \u00a0\nR848\u00a0ver\u00e4ndert \u00a0nicht\u00a0die\u00a0CD122\u2010Expression. \u00a0Graphische \u00a0Darstellung. \u00a0\u00a0\nCD122\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0\nStimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0oder\u00a0nur\u00a0mit\u00a0\nR848\u00a0bzw.\u00a0ganz\u00a0ohne\u00a0Stimuli\u00a0(Monozyten). \u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a04.\u00a0\n\u00a0\n\u00a0\nBei\u00a0der\u00a0CD122\u2010Expression \u00a0(\u03b2\u2010Kette\u00a0des\u00a0IL\u20102\u00a0Rezeptors) \u00a0konnten\u00a0zwischen\u00a0den\u00a0MoDC\u00b4s,\u00a0den\u00a0\nR848\u2010DC\u00b4s\u00a0sowie\u00a0bei\u00a0nur\u00a0mit\u00a0R848\u00a0stimulierten \u00a0Monozyten \u00a0und\u00a0unstimulierten \u00a0Monozyten \u00a0\nkeine\u00a0signifikanten \u00a0Unterschiede \u00a0festgestellt \u00a0werden.\u00a0\n\u00a0\n\u00a00,02,04,06,08,010,012,014,016,018,0\nMoDC\u00b4s R848 \u2010DC\u00b4s R848 MonozytenCD122\u00a0pos\u00a0(%)\u00a082 Ergebnisse\n3.5 R848\u2010DC\u00b4s\tzeigen\tauch\tnach\tdem\tEntfernen \tdes\tStimulators \t\nR848\teinen\tstabilen\tPh\u00e4notyp \t\n\u00a0\nDas\u00a0dreimalige \u00a0Waschen\u00a0der\u00a0mit\u00a01000\u00a0IU/ml\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0\nstimulierten \u00a0Zellen\u00a0an\u00a0Tag\u00a03\u00a0hatte\u00a0den\u00a0Zweck,\u00a0den\u00a0TLR7/8\u2010Liganden\u00a0R848\u00a0aus\u00a0der\u00a0Umgebung \u00a0\nder\u00a0Zellen\u00a0zu\u00a0entfernen. \u00a0Nun\u00a0wurde\u00a0die\u00a0Stabilit\u00e4t\u00a0der\u00a0bereits\u00a0differenzierten \u00a0Monozyten \u00a0\nnach\u00a0weiteren\u00a03\u00a0Tagen\u00a0in\u00a0Kultur\u00a0anhand\u00a0der\u00a0Expressionsmusters \u00a0der\u00a0Oberfl\u00e4chenmolek\u00fcle \u00a0\n\u00fcberpr\u00fcft. \u00a0Dazu\u00a0wurden\u00a0die\u00a0Zellen\u00a0wieder\u00a0wie\u00a0oben\u00a0beschrieben \u00a0mit\u00a0Antik\u00f6rpern \u00a0gegen\u00a0\nCD14,\u00a0CD1a,\u00a0HLA\u2013DR\u00a0und\u00a0CD123\u00a0angef\u00e4rbt. \u00a0\n\u00a0\u00a0A\u00a0 B\u00a0\n\u00a0\u00a0 \u00a0\n\u00a0\nC\u00a0 D\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a083 Ergebnisse\nE\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.5.1:\u00a0Die\u00a0Expression \u00a0der\u00a0Oberfl\u00e4chenmolek\u00fcle \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0\nim\u00a0Vergleich. \u00a0Graphische \u00a0Darstellung \u00a0der\u00a0FACS\u2010Analyse\u00a0eines\u00a0\nSpenders \u00a0nach\u00a0Monozyten \u2010Separation \u00a0durch\u00a0den\u00a0AutoMACS\u2122 \u00a0\nSeparator \u00a0und\u00a0anschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010\nCSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0f\u00fcr\u00a03\u00a0Tage;\u00a0danach\u00a0dreimaliges \u00a0\nWaschen \u00a0der\u00a0Zellen\u00a0mit\u00a0DC\u2010Medium\u00a0und\u00a0anschlie\u00dfend \u00a0wieder\u00a03\u00a0\nTage\u00a0mit\u00a0bzw.\u00a0ohne\u00a0GM\u2010CSF\u00a0und\u00a0IL\u20104\u00a0in\u00a0Kultur\u00a0genommen. \u00a0\u00a0\nA\u00a0CD14\u2010Expression \u00a0(%),\u00a0B\u00a0CD1a\u2010Expression \u00a0(%),\u00a0C\u00a0CD123\u2010Expression \u00a0\n(%),\u00a0HLA\u2010DR\u2010Expression \u00a0(MHC\u2010II)\u00a0(%)\u00a0und\u00a0D\u00a0HLA\u2010DR\u2010Expression \u00a0(MHC\u2010\nII)\u00a0(MFI)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a06\u00a0Tagen.\u00a0\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a03.\u00a0\n\u00a0\n\u00a0\nAuch\u00a0nach\u00a0dem\u00a0Entfernen \u00a0des\u00a0R848\u00a0zeigten\u00a0die\u00a0Zellen,\u00a0was\u00a0die\u00a0Oberfl\u00e4chenexpression \u00a0\nbetraf,\u00a0einen\u00a0stabilen\u00a0Ph\u00e4notyp. \u00a0\nR848\u2010DC\u00b4s\u00a0exprimierten \u00a0weiterhin \u00a0gro\u00dfe\u00a0Mengen\u00a0an\u00a0CD14,\u00a0CD123\u00a0und\u00a0HLA\u2010DR\u00a0(MHC\u2010II)\u00a0und\u00a0\ngeringen\u00a0Mengen\u00a0an\u00a0CD1a.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a084 Ergebnisse\n3.6 R848\u2010DC\u00b4s\tinduzieren \teine\tbessere\tT\u2010Zell\u2010Proliferation \tals\t\nkonventionelle \tMoDC\u00b4s\t\n\u00a0\nUm\u00a0die\u00a0T\u2010Zell\u2010Proliferationsrate \u00a0unter\u00a0Einwirkung \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0im\u00a0Vergleich \u00a0zu\u00a0der\u00a0der\u00a0\nMoDC\u00b4s\u00a0zu\u00a0testen,\u00a0wurde\u00a0eine\u00a0MLR\u00a0angesetzt. \u00a0Dazu\u00a0wurden\u00a0zuerst\u00a0die\u00a0zuvor\u00a0frisch\u00a0\nseparierten \u00a0Monozyten \u00a0mit\u00a01000\u00a0IU/ml\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a03\u00a0Tage\u00a0\nkultiviert. \u00a0Dann\u00a0wurden\u00a0die\u00a0MoDC\u00b4s\u00a0und\u00a0die\u00a0R848\u2010DC\u00b4s\u00a0(Stimulatorzellen) \u00a0geerntet\u00a0und\u00a0mit\u00a0\nfrisch\u00a0isolierten, \u00a0allogenen \u00a0und\u00a0mit\u00a01\u00a0\u00b5M\u00a0CFDA\u2010SE\u00a0markierten \u00a0PBMC\u00b4s\u00a0(Responderzellen) \u00a0in\u00a0\nder\u00a0Ratio\u00a01+4\u00a0in\u00a0einer\u00a0MLR\u00a0f\u00fcr\u00a05\u00a0\u2013\u00a07\u00a0Tage\u00a0angesetzt. \u00a0Als\u00a0Positiv\u2010Kontrolle\u00a0dienten\u00a0durch\u00a00,5\u00a0\n\u00b5g/ml\u00a0anti\u2010CD3/anti\u2010CD28\u00a0aktivierte \u00a0Responderzellen \u00a0und\u00a0als\u00a0Negativ\u2010Kontrolle\u00a0dienten\u00a0\nunstimulierte \u00a0Responderzellen. \u00a0\nDie\u00a0gesamten \u00a0Zellen\u00a0der\u00a0jeweiligen \u00a0MLR\u00a0wurden\u00a0mit\u00a0fluoreszenzmarkierten \u00a0Antik\u00f6rpern \u00a0\ngegen\u00a0CD11b,\u00a0CD3\u00a0und\u00a0CD4\u00a0angef\u00e4rbt. \u00a0Die\u00a0CFSE\u2010F\u00e4rbung\u00a0wurde\u00a0im\u00a0FITC\u2010Kanal\u00a0detektiert. \u00a0\n\u00a0A\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a085 Ergebnisse\nB\u00a0\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.6.1:\u00a0FACS\u2010Analyse\u00a0der\u00a0T\u2010Zell\u2010Proliferation \u00a0eines\u00a0Spenders \u00a0\nnach\u00a0Monozyten \u2010Separation \u00a0durch\u00a0den\u00a0AutoMACS\u2122 \u00a0Separator \u00a0und\u00a0\nanschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0\nohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0\u00fcber\u00a03\u00a0Tage.\u00a0Ansetzen \u00a0der\u00a0MLR\u00a0mit\u00a0den\u00a0\nStimulatorzellen \u00a0und\u00a0frisch\u00a0isolierten, \u00a0mit\u00a01\u00a0\u00b5M\u00a0CFDA\u00a0SE\u00a0\nmarkierten, \u00a0allogenen \u00a0PBMC\u00b4s\u00a0(Responderzellen) \u00a0in\u00a0der\u00a0Ratio\u00a01\u00a0+\u00a04\u00a0\nf\u00fcr\u00a05\u00a0\u2013\u00a07\u00a0d.\u00a0\nA\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s\u00a0(Stimulatorzellen) \u00a0mit\u00a0den\u00a0markierten \u00a0\nResponderzellen \u00a0(Ratio\u00a01+4)\u00a0mit\u00a0APC\u00a0anti\u2010human\u00a0CD11b,\u00a0APC\u2010H7\u00a0\nanti\u2010human\u00a0CD4,\u00a0Pacific\u00a0Blue\u00a0anti\u2010human\u00a0CD3;\u00a0B\u00a0F\u00e4rbung\u00a0der\u00a03\u00a0\u00b5M\u00a0\nR848\u2010DC\u00b4s\u00a0(Stimulatorzellen) \u00a0mit\u00a0den\u00a0markierten \u00a0Responderzellen \u00a0\n(Ratio\u00a01+4)\u00a0s.o..\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a086 Ergebnisse\nUm\u00a0die\u00a0MLR\u00a0auszuwerten, \u00a0wurden\u00a0im\u00a0ersten\u00a0Schritt\u00a0grob\u00a0die\u00a0Lymphozyten \u00a0in\u00a0der\u00a0FSC/SSC\u2010\nDarstellung \u00a0ausgew\u00e4hlt \u00a0(Abb.\u00a03.6.1,\u00a0P1),\u00a0von\u00a0diesen\u00a0wurden\u00a0nur\u00a0die\u00a0CD11b\u00a0neg\u00a0Zellen\u00a0weiter\u00a0\ndargestellt, \u00a0da\u00a0CD11b\u00a0haupts\u00e4chlich \u00a0von\u00a0Granulozyten, \u00a0Monozyten, \u00a0einigen\u00a0NK\u2010Zellen\u00a0\nexprimiert \u00a0wird\u00a0(Abb.\u00a03.6.1,\u00a0CD11b\u00a0neg).\u00a0Ausgehend \u00a0von\u00a0diesen\u00a0Zellen\u00a0wurden\u00a0nun\u00a0die\u00a0CD3\u00a0\npos\u00a0T\u2010Zellen\u00a0ausgew\u00e4hlt \u00a0(Abb.\u00a03.6.1,\u00a0CD3\u00a0pos),\u00a0von\u00a0denen\u00a0wiederum \u00a0nochmals \u00a0die\u00a0CD3\u00a0pos\u00a0\nbzw.\u00a0CD4\u00a0pos\u00a0Zellen\u00a0auf\u00a0der\u00a0Ordinate\u00a0gegen\u00a0die\u00a0CFSE\u2010Fluoreszenz \u00a0auf\u00a0der\u00a0Abszisse\u00a0\ndargestellt \u00a0wurden\u00a0um\u00a0die\u00a0gesamte\u00a0T\u2010Zellproliferation \u00a0(Abb.\u00a03.6.1,\u00a0Quadrant \u00a0Q1\u20101)\u00a0bzw.\u00a0die\u00a0\nProliferation \u00a0der\u00a0CD4+\u00a0TH\u2010Zellen\u00a0(Abb.\u00a03.6.1,\u00a0Quadrant \u00a0Q1)\u00a0und\u00a0der\u00a0CD8+\u00a0T\u2010Zellen\u00a0(Abb.\u00a03.6.1,\u00a0\nQuadrant \u00a0Q3)\u00a0zu\u00a0bestimmen. \u00a0\n\u00a0\nMan\u00a0kann\u00a0deutlich\u00a0bei\u00a0den\u00a0FACS\u2010Analysen\u00a0erkennen, \u00a0dass\u00a0die\u00a0allogenen \u00a0T\u2010Zellen,\u00a0welche\u00a0mit\u00a0\nR848\u2010DC\u00b4s\u00a0stimuliert \u00a0wurden\u00a0eine\u00a0h\u00f6here\u00a0Gesamt\u2010T\u2010Zellproliferation \u00a0(CD3\u00a0pos\u00a0T\u2010Zellen)\u00a0im\u00a0\nVergleich \u00a0zu\u00a0den\u00a0CtrDC\u00a0(MoDC\u00b4s) \u00a0aufweisen \u00a0(Abb.\u00a03.6.1\u00a0Quadrant \u00a0Q1\u20101).\u00a0Des\u00a0Weiteren \u00a0\nkonnte\u00a0auch\u00a0eine\u00a0h\u00f6here\u00a0Proliferation \u00a0der\u00a0CD4+\u00a0TH\u2010Zellen\u00a0(Abb.\u00a03.6.1\u00a0Quadrant \u00a0Q1),\u00a0sowie\u00a0\nder\u00a0CD8+\u00a0T\u2010Zellen\u00a0(Abb.\u00a03.6.1\u00a0Quadrant \u00a0Q3)\u00a0festgestellt \u00a0werden.\u00a0\u00a0\n\u00a0\u00a0\u00a0\nA\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a087 Ergebnisse\nB\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0C\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.6.2:\u00a0R848\u2010DC\u00b4s\u00a0induzieren \u00a0eine\u00a0bessere\u00a0T\u2010Zell\u2010Proliferation \u00a0\nals\u00a0MoDC\u00b4s.\u00a0Graphische \u00a0Darstellung \u00a0der\u00a0z.T.\u00a0beispielhaft \u00a0\ndargestellten \u00a0FACS\u2010Analysen. \u00a0\nA\u00a0Relative\u00a0CD3\u2010\u00a0(%),\u00a0B\u00a0CD4\u2010\u00a0(%)\u00a0und\u00a0C\u00a0CD8\u2010Proliferation \u00a0(%)\u00a0der\u00a0\nResponderzellen \u00a0induziert\u00a0durch\u00a0CtrDC\u00a0(MoDC\u00b4s) \u00a0und\u00a0R848\u2010DC\u00b4s\u00a0\u00fcber\u00a0\n5\u00a0\u2013\u00a07\u00a0Tage.\u00a0\nAls\u00a0Negativ\u2010Kontrolle\u00a0dienten\u00a0unstimulierte \u00a0\nResponderzellen. \u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a05.\u00a0\n\u00a0\u00a0\u00a0p<\u00a00,05\u00a0versus\u00a0MoDC\u00b4s\u00a0(CtrDC\u00b4s)\u00a0(two\u2010tailed\u00a0t\u2010test).\u00a0\n\u00a0\n\u00a088 Ergebnisse\n3.7 R848\u2010DC\u00b4s\tproduzieren \tverschiedene \tZytokine \tmit\t\nimmunregulatorischen \tFunktionen \t\n\u00a0\nAm\u00a0Ende\u00a0der\u00a0Untersuchungen \u00a0wurde\u00a0die\u00a0Bestimmung \u00a0der\u00a0Zytokinproduktion \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0\ndurchgef\u00fchrt. \u00a0Es\u00a0sollte\u00a0untersucht \u00a0werden,\u00a0ob\u00a0die\u00a0R848\u2010DC\u00b4s\u00a0im\u00a0Vergleich \u00a0zu\u00a0den\u00a0\nkonventionellen \u00a0MoDC\u00b4s\u00a0nach\u00a0Restimulation \u00a0mit\u00a0LPS\u00a0(TLR4\u2010Ligand)\u00a0bzw.\u00a0CpG\u00a02006\u00a0(TLR9\u2010\nLigand,\u00a0B\u2010Typ)\u00a0ein\u00a0anderes\u00a0Zytokinprolfil \u00a0sezernieren. \u00a0\nUm\u00a0die\u00a0\u00dcberst\u00e4nde \u00a0zur\u00a0Zytokinbestimmung \u00a0mittels\u00a0CBA\u00a0zu\u00a0gewinnen, \u00a0wurden\u00a0Monozyten \u00a0\nf\u00fcr\u00a03\u00a0Tage\u00a0mit\u00a01000\u00a0IU/ml\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0stimuliert. \u00a0Anschlie\u00dfend \u00a0\nwurde\u00a0durch\u00a0dreimaliges \u00a0Waschen\u00a0der\u00a0TLR7/8\u2010Ligand\u00a0R848\u00a0aus\u00a0den\u00a0Vertiefungen \u00a0entfernt.\u00a0\nDie\u00a0schon\u00a0differenzierten \u00a0Zellen\u00a0wurden\u00a0nach\u00a012h\u00a0bzw.\u00a072h\u00a0Ruhen\u00a0mit\u00a02\u00a0\u00b5g/ml\u00a0LPS\u00a0\u00a0bzw.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n3\u00a0\u00b5g/ml\u00a0CpG\u00a02006\u00a0(TLR9\u2010Ligand,\u00a0B\u2010Typ)\u00a0f\u00fcr\u00a0jeweils\u00a024h\u00a0restimuliert. \u00a0Danach\u00a0wurden\u00a0die\u00a0\n\u00dcberst\u00e4nde \u00a0abgenommen \u00a0und\u00a0mittels\u00a0CBA\u00a0analysiert. \u00a0\n\u00a0\u00a0\nEin\u00a0exemplarisches \u00a0Beispiel\u00a0einer\u00a0CBA\u2010Analyse\u00a0ist\u00a0anschlie\u00dfend \u00a0dargestellt. \u00a0\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a03.7.1:\u00a0R848\u2010DC\u00b4s\u00a0produzieren \u00a0verschiedene \u00a0Zytokine\u00a0mit\u00a0\nimmunregulatorischen \u00a0Funktionen. \u00a0Beispielhafte \u00a0Darstellung \u00a0einer\u00a0\nCBA\u00a0FACS\u2010Analyse.\u00a0\n\u00a089 Ergebnisse\nNach\u00a0der\u00a0Monozyten \u2010Separation \u00a0durch\u00a0den\u00a0AutoMACS\u2122 \u00a0Separator \u00a0\nwurden\u00a0die\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0f\u00fcr\u00a03\u00a0\nTage\u00a0kultiviert. \u00a0Anschlie\u00dfend \u00a0erfolgte\u00a0dreimaliges \u00a0Waschen\u00a0der\u00a0Zellen\u00a0\nmit\u00a0DC\u2010Medium\u00a0und\u00a0dann\u00a0wurden\u00a0die\u00a0Zellen\u00a0nach\u00a012h\u00a0bzw.\u00a072h\u00a0\nRuhen\u00a0mit\u00a02\u00a0\u00b5g/ml\u00a0LPS\u00a0bzw.\u00a03\u00a0\u00b5g/ml\u00a0CpG\u00a02006\u00a0f\u00fcr\u00a0jeweils\u00a024h\u00a0\nrestimuliert. \u00a0\u00a0\n\u00a0\n\u00a0\nUm\u00a0etwaige\u00a0direkte\u00a0Beeinflussungen \u00a0von\u00a0R848\u00a0in\u00a0der\u00a0Kultur\u00a0auszuschlie\u00dfen, \u00a0wurde\u00a0R848\u00a0\ndurch\u00a0mehrmaliges \u00a0Waschen\u00a0entfernt\u00a0und\u00a0Ruhezeiten \u00a0von\u00a012h\u00a0und\u00a072h\u00a0vor\u00a0der\u00a0\nRestimulation \u00a0mit\u00a0LPS\u00a0bzw.\u00a0CpG\u00a02006\u00a0eingehalten. \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a012\u00a0h\u00a0Ruhen\u00a0\u00a0 72\u00a0h\u00a0Ruhen\u00a0\nA\u00a0\n\u00a0\u00a0 \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a090 Ergebnisse\nB\u00a0\n\u00a0\u00a0 \u00a0\n\u00a0\n\u00a0C\u00a0\n\u00a0\u00a0 \u00a0\n\u00a0\n\u00a0\nD\u00a0\n\u00a0\u00a0 \u00a0\n\u00a091 Ergebnisse\nE\u00a0\n\u00a0\u00a0 \u00a0\nAbb.\u00a03.7.2:\u00a0R848\u2010DC\u00b4s\u00a0produzieren \u00a0nach\u00a0Restimulation \u00a0mit\u00a0LPS\u00a0\nverschiedene \u00a0Zytokine\u00a0mit\u00a0immunregulatorischen \u00a0Funktionen. \u00a0\nGraphische \u00a0Darstellung \u00a0der\u00a0z.T.\u00a0beispielhaft \u00a0dargestellten \u00a0CBA\u2010\nAnalysen. \u00a0\u00a0\nA\u00a0IL\u201012p70\u2010Produktion \u00a0(pg/ml);\u00a0B\u00a0TNF\u2010\u03b1\u2010Produktion \u00a0(pg/ml);\u00a0C\u00a0IL\u201010\u2010\nProduktion \u00a0(pg/ml);\u00a0D\u00a0IL\u20106\u2010Produktion \u00a0(pg/ml)\u00a0und\u00a0E\u00a0Verh\u00e4ltnis \u00a0TNF\u2010\u03b1\u00a0\nzu\u00a0IL\u201010\u00a0nach\u00a012\u00a0bzw.\u00a072\u00a0h\u00a0Ruhen\u00a0und\u00a0folgender \u00a0Restimulation \u00a0der\u00a0\nCtrDC\u00a0(MoDC\u00b4s) \u00a0und\u00a0der\u00a0R848\u2010DC\u00b4s\u00a0mit\u00a02\u00a0\u00b5g/ml\u00a0LPS.\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=4.\u00a0\n\u00a0\u00a0\u00a0p<\u00a00,05\u00a0versus\u00a0CtrDC\u00b4s\u00a0(MoDC\u00b4s) \u00a0(friedman\u00a0test).\u00a0\n\u00a0\n\u00a0\nAuf\u00a0die\u00a0Darstellung \u00a0der\u00a0Daten\u00a0der\u00a0MoDC\u00b4s\u00a0und\u00a0der\u00a0R848\u2010DC\u00b4s\u00a0nach\u00a0der\u00a0Restimulation \u00a0mit\u00a0\nCpG\u00a02006\u00a0wurde\u00a0aus\u00a0\u00dcbersichtsgr\u00fcnden \u00a0verzichtet. \u00a0\nDie\u00a0Analysen\u00a0ergaben,\u00a0dass\u00a0R848\u2010DC\u00b4s,\u00a0im\u00a0Vergleich \u00a0zu\u00a0MoDC\u00b4s,\u00a0nach\u00a0Restimulation \u00a0mit\u00a0LPS\u00a0\noder\u00a0CpG\u00a02006\u00a0geringere \u00a0Mengen\u00a0der\u00a0proinflammatorischen \u00a0Zytokine\u00a0IL\u201012p70,\u00a0TNF\u2010\u03b1\u00a0und\u00a0\nIL\u20106\u00a0produzierten. \u00a0\nIm\u00a0Gegensatz \u00a0dazu\u00a0war\u00a0die\u00a0Produktion \u00a0von\u00a0immunsuppressivem \u00a0IL\u201010\u00a0bei\u00a0den\u00a0R848\u2010DC\u00b4s\u00a0\nnach\u00a0Restimulation \u00a0mit\u00a0LPS\u00a0bzw.\u00a0CpG\u00a02006\u00a0leicht\u00a0erh\u00f6ht.\u00a0\nBei\u00a0der\u00a0Produktion \u00a0von\u00a0IL\u20108\u00a0und\u00a0IL\u20101\u03b2\u00a0waren\u00a0keine\u00a0Unterschiede \u00a0zwischen\u00a0den\u00a0MoDC\u00b4s\u00a0und\u00a0\nden\u00a0R848\u2010DC\u00b4s\u00a0festzustellen. \u00a0\n\u00a092 Ergebnisse\nDie\u00a0Analyse\u00a0des\u00a0TNF\u2010\u03b1/IL\u201010\u00a0Verh\u00e4ltnisses \u00a0zeigte\u00a0eine\u00a0Verschiebung \u00a0der\u00a0Produktion \u00a0des\u00a0\nproinflammatorischen \u00a0TNF\u2010\u03b1\u00a0zugunsten \u00a0der\u00a0des\u00a0immunregulatorischen \u00a0IL\u201010\u00a0bei\u00a0den\u00a0R848\u2010\nDC\u00b4s\u00a0im\u00a0Vergleich \u00a0zu\u00a0den\u00a0konventionellen \u00a0MoDC\u00b4s\u00a0nach\u00a0der\u00a0Restimulation \u00a0mit\u00a0LPS\u00a0bzw.\u00a0CpG\u00a0\n2006.\u00a0\n\u00a0\u00a0\u00a093 Diskussion\n4 Diskussion \t\n\u00a0\nResiquimod \u00a0(R848)\u00a0als\u00a0synthetischer \u00a0TLR7/8\u2010Ligand\u00a0stellt\u00a0einen\u00a0neuartigen \u00a0Immunmodulator \u00a0\ndar,\u00a0dessen\u00a0Effekte\u00a0auf\u00a0die\u00a0in\u00a0vitro\u00a0generierten \u00a0MoDC\u00b4s\u00a0erst\u00a0teilweise\u00a0verstanden \u00a0sind.\u00a0\nEs\u00a0liegen\u00a0nur\u00a0wenige\u00a0Studien\u00a0dar\u00fcber\u00a0vor,\u00a0die\u00a0die\u00a0permanente \u00a0Stimulation \u00a0von\u00a0in\u00a0vitro\u00a0\ngenerierten \u00a0MoDC\u00b4s\u00a0mit\u00a0dem\u00a0synthetischen \u00a0TLR7/8\u2010Liganden\u00a0R848\u00a0untersucht \u00a0haben\u00a0(112,\u00a0\n117\u2010119).\u00a0\u00a0\nIm\u00a0Rahmen\u00a0dieser\u00a0Arbeit\u00a0wurden\u00a0mittels\u00a0FACS\u2010Analyse\u00a0die\u00a0Wirkungen \u00a0verschiedener \u00a0TLR7\u2010\u00a0\nund\u00a0TLR7/8\u2010Liganden\u00a0auf\u00a0die\u00a0Differenzierung \u00a0und\u00a0Reifung\u00a0der\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0\nDC\u00b4s\u00a0untersucht. \u00a0Des\u00a0Weiteren \u00a0wurden\u00a0unterschiedliche \u00a0inhibitorische \u00a0Oligonukleotide \u00a0\n(iODN\u00b4s)\u00a0eingesetzt, \u00a0um\u00a0den\u00a0Toll\u2010like\u00a0Rezeptor\u00a0zu\u00a0identifizieren, \u00a0durch\u00a0den\u00a0die\u00a0Modulation \u00a0\nder\u00a0MoDC\u00b4s\u00a0hervorgerufen \u00a0wird.\u00a0Zu\u00a0kl\u00e4ren\u00a0war\u00a0au\u00dferdem, \u00a0ob\u00a0die\u00a0permanente \u00a0Pr\u00e4senz\u00a0des\u00a0\nTLR7/8\u2010Liganden\u00a0R848\u00a0Einfluss\u00a0auf\u00a0die\u00a0Stabilit\u00e4t\u00a0der\u00a0neu\u00a0entstandenen \u00a0Zellpopulation \u00a0hat.\u00a0\nAnschlie\u00dfend \u00a0wurde\u00a0die\u00a0neu\u00a0entstandene \u00a0Zellpopulation \u00a0noch\u00a0auf\u00a0ihre\u00a0F\u00e4higkeit\u00a0hin\u00a0\nuntersucht, \u00a0nach\u00a0Restimulation \u00a0verschiedene \u00a0Zytokine\u00a0zu\u00a0produzieren \u00a0und\u00a0allogene\u00a0T\u2010Zellen\u00a0\nzur\u00a0Proliferation \u00a0anzuregen. \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a094 Diskussion\nAus\u00a0dem\u00a0Blut\u00a0verschiedener \u00a0Spender\u00a0wurden\u00a0Monozyten \u00a0separiert\u00a0und\u00a0anschlie\u00dfend, \u00a0in\u00a0\nAnwesenheit \u00a0von\u00a0verschiedenen \u00a0Konzentrationen \u00a0(3\u00a0\u00b5M,\u00a02,25\u00a0\u00b5M,\u00a01,5\u00a0\u00b5M,\u00a0750\u00a0nM\u00a0und\u00a0300\u00a0\nnM)\u00a0an\u00a0R848,\u00a0differenziert. \u00a0Die\u00a0neu\u00a0entstandenen \u00a0DC\u00b4s\u00a0wurden\u00a0mittels\u00a0FACS\u2010Analyse\u00a0auf\u00a0ihre\u00a0\nExpression \u00a0der\u00a0Oberfl\u00e4chenmolek\u00fcle \u00a0CD14\u00a0und\u00a0CD1a\u00a0hin\u00a0untersucht. \u00a0\u00a0\nCD14\u00a0gilt\u00a0als\u00a0Oberfl\u00e4chenmarker \u00a0f\u00fcr\u00a0Monozyten \u00a0und\u00a0es\u00a0dient\u00a0u.a.\u00a0als\u00a0LPS\u2010Rezeptor. \u00a0Das\u00a0\nOberfl\u00e4chenmolek\u00fcl \u00a0CD1a\u00a0findet\u00a0man\u00a0vor\u00a0allem\u00a0auf\u00a0DC\u00b4s.\u00a0\u00a0\nAb\u00a0einer\u00a0Stimulationskonzentration \u00a0von\u00a01,5\u00a0\u00b5M\u00a0R848\u00a0konnten\u00a0deutliche \u00a0Effekte\u00a0beobachtet \u00a0\nwerden.\u00a0Es\u00a0zeigte\u00a0sich,\u00a0dass\u00a0R848\u00a0dosisabh\u00e4ngig \u00a0eine\u00a0Hemmung \u00a0von\u00a0CD1a\u00a0und\u00a0eine\u00a0\nPersistenz \u00a0von\u00a0CD14\u00a0bewirkte. \u00a0So\u00a0kann\u00a0angenommen \u00a0werden,\u00a0dass\u00a0es\u00a0sich\u00a0bei\u00a0der\u00a0neu\u00a0\nentstanden \u00a0Zellpopulation \u00a0(im\u00a0Weiteren \u00a0R848\u2010DC\u00b4s\u00a0genannt)\u00a0nicht\u00a0mehr\u00a0um\u00a0konventionelle \u00a0\nMoDC\u00b4s\u00a0handelt,\u00a0sondern\u00a0um\u00a0eine\u00a0distinkte\u00a0dendritische \u00a0Zellpopulation, \u00a0die\u00a0ein\u00a0modifiziertes \u00a0\nOberfl\u00e4chenexpressionsmuster \u00a0aufweist.\u00a0\n\u00a0\u00a0\n4.1 Expression \tder\tT\u2010Zell\tkostimulatorischen \tMolek\u00fcle \tCD40,\tCD83,\t\nCD86,\tHLA\u2010DR\tund\tCD123\t\n\u00a0\nMittels\u00a0weiterer\u00a0FACS\u2010Analysen\u00a0wurden\u00a0die\u00a0R848\u2010DC\u00b4s\u00a0und\u00a0die\u00a0konventionellen \u00a0MoDC\u00b4s\u00a0zum\u00a0\nVergleich \u00a0auf\u00a0ihr\u00a0Oberfl\u00e4chenexpressionsmuster \u00a0untersucht. \u00a0\u00a0\nDas\u00a0Oberfl\u00e4chenmolek\u00fcl \u00a0HLA\u2010DR\u00a0dient\u00a0der\u00a0Antigenpr\u00e4sentation. \u00a0CD40\u00a0stellt\u00a0den\u00a0Rezeptor\u00a0f\u00fcr\u00a0\nden\u00a0CD40\u2010Liganden\u00a0der\u00a0T\u2010Zellen\u00a0dar\u00a0und\u00a0f\u00f6rdert\u00a0so\u00a0das\u00a0Wachstum \u00a0und\u00a0die\u00a0Differenzierung \u00a0\nvon\u00a0B\u2010Zellen\u00a0sowie\u00a0die\u00a0Zytokinproduktion \u00a0bei\u00a0Makrophagen \u00a0und\u00a0dendritischen \u00a0Zellen.\u00a0CD83\u00a0\nwird\u00a0von\u00a0DC\u00b4s\u00a0und\u00a0einigen\u00a0B\u2010Zellen\u00a0exprimiert \u00a0und\u00a0dient\u00a0als\u00a0Aktivierungsmarker \u00a0f\u00fcr\u00a0DC\u00b4s.\u00a0\nCD86\u00a0findet\u00a0man\u00a0prim\u00e4r\u00a0auf\u00a0der\u00a0Oberfl\u00e4che \u00a0von\u00a0Monozyten, \u00a0aktivierten \u00a0APC\u00b4s,\u00a0insbesondere \u00a0\nauf\u00a0DC\u00b4s\u00a0(83\u201084).\u00a0Au\u00dferdem \u00a0stellt\u00a0das\u00a0kostimulatorische \u00a0Molek\u00fcl\u00a0CD86\u00a0einen\u00a0Bestandteil \u00a0des\u00a0\nsog.\u00a0B7\u2010Komplexes \u00a0(CD80/86) \u00a0dar,\u00a0welches\u00a0mit\u00a0dem\u00a0CD28\u2010Molek\u00fcl\u00a0der\u00a0T\u2010Zellen\u00a0interagiert. \u00a0\nAus\u00a0diesem\u00a0Grund\u00a0wird\u00a0CD86\u00a0u.a.\u00a0als\u00a0wichtigstes \u00a0Molek\u00fcl\u00a0f\u00fcr\u00a0die\u00a0Ausl\u00f6sung \u00a0von\u00a0T\u2010Zell\u2010\nAntworten \u00a0angesehen \u00a0(76\u201077).\u00a0\u00a0\nDie\u00a0Reifungsmarker \u00a0HLA\u2010DR,\u00a0CD40\u00a0und\u00a0CD86\u00a0wurden\u00a0von\u00a0R848\u2010DC\u00b4s\u00a0in\u00a0h\u00f6herem\u00a0Ma\u00dfe\u00a0\nexprimiert, \u00a0was\u00a0f\u00fcr\u00a0einen\u00a0h\u00f6heren\u00a0Ausreifungsgrad \u00a0dieser\u00a0Zellpopulation \u00a0im\u00a0Vergleich \u00a0zu\u00a0\u00a095 Diskussion\nkonventionellen \u00a0MoDC\u00b4s\u00a0spricht.\u00a0Die\u00a0vermehrte \u00a0Expression \u00a0von\u00a0CD83,\u00a0das,\u00a0wie\u00a0bereits\u00a0\nerw\u00e4hnt,\u00a0als\u00a0Aktivierungsmarker \u00a0von\u00a0dendritischen \u00a0Zellen\u00a0gilt\u00a0(85),\u00a0spricht\u00a0f\u00fcr\u00a0einen\u00a0\nerh\u00f6hten \u00a0Aktivierungsgrad \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0im\u00a0Vergleich \u00a0zu\u00a0den\u00a0MoDC\u00b4s.\u00a0\nAuch\u00a0Assier\u00a0et\u00a0al.\u00a0untersuchten \u00a0die\u00a0Wirkung\u00a0von\u00a0R848\u00a0auf\u00a0MoDC\u00b4s\u00a0(112).\u00a0Sie\u00a0kamen\u00a0zu\u00a0dem\u00a0\nSchluss,\u00a0dass\u00a0R848\u00a0die\u00a0MoDC\u2010Differenzierung \u00a0und\u00a0\u2010Reifung\u00a0hemmt,\u00a0was\u00a0mit\u00a0unseren\u00a0\nUntersuchungsergebnissen \u00a0nicht\u00a0best\u00e4tigt\u00a0werden\u00a0konnte.\u00a0Vielmehr\u00a0handelt\u00a0es\u00a0sich\u00a0bei\u00a0den\u00a0\nR848\u2010DC\u00b4s\u00a0um\u00a0eine\u00a0distinkte\u00a0dendritische \u00a0Zellpopulation \u00a0aus\u00a0anders\u00a0differenzierten \u00a0Zellen\u00a0\n(modifiziertes \u00a0Oberfl\u00e4chenexpressionsmuster) \u00a0mit\u00a0einem\u00a0h\u00f6heren\u00a0Reifungs\u2010\u00a0und\u00a0\nAktivierungsgrad \u00a0als\u00a0der\u00a0der\u00a0MoDC\u00b4s.\u00a0\nEine\u00a0Arbeitsgruppe, \u00a0die\u00a0die\u00a0topische\u00a0Applikation \u00a0einer\u00a0Creme\u00a0mit\u00a0dem\u00a0Inhaltsstoff \u00a0R848\u00a0bei\u00a0\nMenschen \u00a0untersuchte, \u00a0berichtete \u00a0im\u00a0Jahr\u00a02003\u00a0von\u00a0einem\u00a0R\u00fcckgang \u00a0der\u00a0CD1a\u00a0\nexprimierenden \u00a0Zellen,\u00a0aber\u00a0einem\u00a0Anstieg\u00a0an\u00a0HLA\u2010DR\u00a0exprimierenden \u00a0Zellen\u00a0(120).\u00a0Dies\u00a0\nstimmt\u00a0mit\u00a0denen\u00a0im\u00a0Rahmen\u00a0dieser\u00a0Dissertation \u00a0durchgef\u00fchrten \u00a0in\u00a0vitro\u00a0Versuche \u00a0\u00fcberein.\u00a0\nDa\u00a0die\u00a0R848\u2010Stimulation \u00a0von\u00a0MoDC\u00b4s\u00a0auch\u00a0zu\u00a0einer\u00a0Reduktion \u00a0der\u00a0Endozytose \u00a0f\u00fchrte,\u00a0kann\u00a0\nangenommen \u00a0werden,\u00a0dass\u00a0diese\u00a0Ver\u00e4nderung \u00a0auch\u00a0die\u00a0Schl\u00fcsselfunktion \u00a0der\u00a0DC\u00b4s\u00a0(121)\u00a0\nver\u00e4ndert. \u00a0\nR848\u00a0induzierte \u00a0bei\u00a0den\u00a0R848\u2010DC\u00b4s\u00a0die\u00a0Expression \u00a0von\u00a0CD123\u00a0(\u03b1\u2010Kette\u00a0des\u00a0IL\u20103\u2010Rezeptors), \u00a0\ndie\u00a0auch\u00a0nach\u00a0dem\u00a0Entfernen \u00a0von\u00a0R848\u00a0stabil\u00a0blieb.\u00a0MoDC\u00b4s\u00a0exprimierten \u00a0nur\u00a0geringe\u00a0\nMengen\u00a0an\u00a0CD123.\u00a0\u00a0\nDas\u00a0Vorkommen \u00a0des\u00a0Molek\u00fcls\u00a0CD123\u00a0in\u00a0hohem\u00a0Ausma\u00df\u00a0ist\u00a0eigentlich \u00a0nur\u00a0den\u00a0pDC\u00b4s\u00a0\nvorbehalten. \u00a0So\u00a0kann\u00a0man\u00a0annehmen, \u00a0dass\u00a0R848\u2010DC\u00b4s\u00a0eine\u00a0distinkte\u00a0DC\u2010Population \u00a0\ndarstellen, \u00a0die\u00a0auch\u00a0Merkmale \u00a0der\u00a0pDC\u00b4s\u00a0aufweisen. \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a096 Diskussion\n4.2 TLR8\tals\tVermittler \tder\timmunmodulatorischen \tWirkung \tvon\tR848\t\nauf\tMoDC\u00b4s\t\n\u00a0\nUm\u00a0den\u00a0TLR\u00a0zu\u00a0identifizieren, \u00a0der\u00a0die\u00a0Modulation \u00a0der\u00a0Differenzierung \u00a0und\u00a0Reifung\u00a0bei\u00a0den\u00a0\nR848\u2010DC\u00b4s\u00a0hervorruft, \u00a0wurden\u00a0zuerst\u00a0weitere\u00a0Experimente \u00a0mit\u00a0spezifischen \u00a0TLR7\u2010Liganden\u00a0\nangeschlossen. \u00a0\nSo\u00a0wurden\u00a0MoDC\u00b4s\u00a0mit\u00a0verschiedenen \u00a0Gardiquimod \u2010Konzentrationen \u00a0(spezifischer \u00a0TLR7\u2010\nLigand)\u00a0stimuliert. \u00a0Es\u00a0zeigten\u00a0sich\u00a0keine\u00a0wesentlichen \u00a0Unterschiede \u00a0in\u00a0der\u00a0Differenzierung \u00a0\nund\u00a0Reifung\u00a0der\u00a0Zellen\u00a0im\u00a0Vergleich \u00a0zu\u00a0den\u00a0MoDC\u00b4s.\u00a0Die\u00a0Gardiquimod \u2010DC\u00b4s\u00a0exprimierten \u00a0auf\u00a0\nihren\u00a0Oberfl\u00e4chen \u00a0nur\u00a0mittelm\u00e4\u00dfige \u00a0Mengen\u00a0an\u00a0CD40,\u00a0CD83,\u00a0CD86\u00a0und\u00a0HLA\u2010DR.\u00a0Dies\u00a0f\u00fchrt\u00a0\nzu\u00a0dem\u00a0Schluss,\u00a0dass\u00a0der\u00a0R848\u2010Effekt\u00a0auf\u00a0die\u00a0Reifung\u00a0der\u00a0DC\u00b4s\u00a0nicht\u00a0durch\u00a0eine\u00a0TLR7/8\u00a0\nStimulation \u00a0hervorgerufen \u00a0wird,\u00a0sondern\u00a0dass\u00a0die\u00a0Stimulation \u00a0des\u00a0TLR8\u00a0eine\u00a0wesentliche \u00a0\nRolle\u00a0spielt.\u00a0\n\u00a0\nUm\u00a0den\u00a0Verdacht\u00a0zu\u00a0verifizieren, \u00a0wurden\u00a0anschlie\u00dfend \u00a0drei\u00a0verschiedene, \u00a0spezifische \u00a0\ninhibitorische \u00a0ODN\u00b4s\u00a0eingesetzt. \u00a0Es\u00a0wurde\u00a0ein\u00a0TLR7/8/9\u2010Inhibitor\u00a0(iODN\u00a02088),\u00a0ein\u00a0TLR\u00a07/8\u2010\nInhibitor\u00a0(iODN\u00a020959)und \u00a0ein\u00a0TLR7\u2010Inhibitor\u00a0(iODN\u00a020958)\u00a0verwendet. \u00a0\u00a0\nDie\u00a0R848\u2010Effekte\u00a0auf\u00a0die\u00a0CD1a\u00a0und\u00a0die\u00a0CD14\u00a0Expression \u00a0wurden\u00a0in\u00a0der\u00a0Gegenwart \u00a0der\u00a0TLR8\u00a0\ninhibierenden \u00a0iODN\u00a02088\u00a0und\u00a0iODN\u00a020959\u00a0antagonisiert. \u00a0Im\u00a0Gegensatz \u00a0dazu\u00a0wurden\u00a0die\u00a0\nR848\u2010Effekte\u00a0auf\u00a0die\u00a0MoDC\u2010Differenzierung \u00a0in\u00a0Gegenwart \u00a0von\u00a0iODN\u00a020958,\u00a0welches\u00a0nur\u00a0TLR7\u00a0\ninhibiert,\u00a0nicht\u00a0beeinflusst. \u00a0Es\u00a0konnte\u00a0also\u00a0bewiesen \u00a0werden,\u00a0dass\u00a0R848\u00a0die\u00a0Differenzierung \u00a0\nund\u00a0Reifung\u00a0der\u00a0MoDC\u00b4s\u00a0haupts\u00e4chlich \u00a0\u00fcber\u00a0TLR8\u00a0moduliert. \u00a0\u00a0\nDie\u00a0Differenzierung \u00a0und\u00a0Reifung\u00a0der\u00a0R848\u2010DC\u00b4s,\u00a0erkennbar \u00a0an\u00a0den\u00a0exprimierten \u00a0\nkostimulatorischen \u00a0Molek\u00fclen \u00a0und\u00a0am\u00a0exprimierten \u00a0HLA\u2010DR,\u00a0war\u00a0zum\u00a0Teil\u00a0aufgehoben \u00a0wenn\u00a0\neine\u00a0TLR8\u2010Stimulation \u00a0fehlte.\u00a0So\u00a0kann\u00a0man\u00a0annehmen, \u00a0dass\u00a0die\u00a0DC\u2010Reifung\u00a0vorrangig, \u00a0aber\u00a0\nnicht\u00a0ausschlie\u00dflich, \u00a0durch\u00a0TLR8\u00a0vermittelt \u00a0wurde.\u00a0\n\u00a0\nDes\u00a0Weiteren \u00a0konnte\u00a0nachgewiesen \u00a0werden,\u00a0dass\u00a0f\u00fcr\u00a0die\u00a0Entstehung \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0\nunbedingt \u00a0eine\u00a0Kostimulation \u00a0der\u00a0Monozyten \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0zus\u00e4tzlich \u00a0zu\u00a0R848\u00a0vorhanden \u00a0\nsein\u00a0muss.\u00a0Nur\u00a0R848\u00a0differenzierte \u00a0die\u00a0Monozyten \u00a0nicht\u00a0zu\u00a0DC\u00b4s\u00a0aus.\u00a0\u00a097 Diskussion\n\u00a0\nAu\u00dferdem \u00a0sollte\u00a0der\u00a0Einfluss\u00a0der\u00a0permanenten \u00a0Pr\u00e4senz\u00a0des\u00a0TLR7/8\u2010Liganden\u00a0R848\u00a0auf\u00a0die\u00a0\nStabilit\u00e4t\u00a0der\u00a0neu\u00a0entstandenen \u00a0Zellpopulation \u00a0untersucht \u00a0werden.\u00a0Dazu\u00a0wurden\u00a0die\u00a0mit\u00a0und\u00a0\nohne\u00a0R848\u00a0stimulierten \u00a0MoDC\u00b4s\u00a0am\u00a0dritten\u00a0Tag\u00a0der\u00a0Stimulation \u00a0dreimal\u00a0gewaschen. \u00a0Somit\u00a0\nwurde\u00a0R848\u00a0aus\u00a0der\u00a0Umgebung \u00a0der\u00a0Zellen\u00a0entfernt.\u00a0Anschlie\u00dfend \u00a0wurden\u00a0die\u00a0bereits\u00a0\ndifferenzierten \u00a0MoDC\u00b4s\u00a0nach\u00a0weiteren\u00a03\u00a0Tagen\u00a0Inkubation \u00a0geerntet\u00a0und\u00a0mittels\u00a0FACS\u2010\nAnalysen\u00a0auf\u00a0ihr\u00a0Oberfl\u00e4chenexpressionsmuster \u00a0untersucht. \u00a0\u00a0\nDie\u00a0R848\u2010DC\u00b4s\u00a0zeigten\u00a0auch\u00a0nach\u00a0l\u00e4ngerem \u00a0Entfernen \u00a0von\u00a0R848\u00a0einen\u00a0stabilen\u00a0Ph\u00e4notyp. \u00a0\nDiese\u00a0Erkenntnis \u00a0kann\u00a0in\u00a0zuk\u00fcnftigen \u00a0klinischen \u00a0Therapien \u00a0von\u00a0Nutzen\u00a0sein,\u00a0da\u00a0dadurch\u00a0die\u00a0\nBehandlungsintervalle \u00a0gegebenenfalls \u00a0verl\u00e4ngert \u00a0werden\u00a0k\u00f6nnten.\u00a0\n\u00a0\u00a0\n4.3 Induktion \tder\tallogenen \tT\u2010Zell\u2010Proliferation \tdurch\tR848\u2010DC\u00b4s\t\t\n\u00a0\nUm\u00a0die\u00a0funktionellen \u00a0Eigenschaften \u00a0und\u00a0die\u00a0F\u00e4higkeit\u00a0der\u00a0Proliferationsanregung \u00a0der\u00a0T\u2010\nZellen\u00a0durch\u00a0die\u00a0neu\u00a0enstandenen \u00a0R848\u2010DC\u00b4s\u00a0zu\u00a0erfassen,\u00a0wurden\u00a0MLR\u00b4s\u00a0angesetzt. \u00a0Dazu\u00a0\nwurden\u00a0die\u00a0mit\u00a0CFSE\u2010markierten \u00a0PBMC\u00b4s\u00a0(Responderzellen) \u00a0mit\u00a0den\u00a0allogenen \u00a0MoDC\u00b4s\u00a0bzw.\u00a0\nR848\u2010DC\u00b4s\u00a0(Stimulatorzellen) \u00a0in\u00a0einem\u00a0Stimulator \u2010Responder \u2010Verh\u00e4ltnis \u00a0von\u00a01:5\u00a0gemischt, \u00a0\nkultiviert\u00a0und\u00a0anschlie\u00dfend \u00a0die\u00a0T\u2010Zell\u2010Proliferation \u00a0mittels\u00a0FACS\u2010Analyse\u00a0ausgewertet. \u00a0\nDie\u00a0CD3+\u00a0T\u2010Zellen\u00a0zeigten\u00a0insgesamt \u00a0eine\u00a0st\u00e4rkere\u00a0Proliferation \u00a0im\u00a0Vergleich \u00a0zu\u00a0den\u00a0mit\u00a0\nMoDC\u00b4s\u00a0stimulierten \u00a0PBMC\u00b4s.\u00a0Nach\u00a0der\u00a0Stimulation \u00a0mit\u00a0den\u00a0R848\u2010DC\u00b4s\u00a0zeigten\u00a0vor\u00a0allem\u00a0die\u00a0\nCD4+\u00a0T\u2010Zellen\u00a0eine\u00a0st\u00e4rkere\u00a0Proliferation. \u00a0\nEs\u00a0existieren \u00a0CD4+\u00a0T\u2010Zellen,\u00a0die\u00a0auch\u00a0T\u2010Helferzellen \u00a0genannt\u00a0werden,\u00a0da\u00a0sie\u00a0wichtige\u00a0\nFunktionen \u00a0bei\u00a0der\u00a0T\u2010B\u2010Stimulation \u00a0erf\u00fcllen.\u00a0Diese\u00a0TH\u2010Zellen\u00a0produzieren \u00a0selbst\u00a0oder\u00a0\ninduzieren \u00a0die\u00a0Produktion \u00a0von\u00a0verschiedenen \u00a0Interleukinen, \u00a0die\u00a0wiederum \u00a0regulierende \u00a0\nWirkung\u00a0auf\u00a0andere\u00a0Lymphozyten \u00a0aus\u00fcben.\u00a0\u00a0\nDie\u00a0Ergebnisse \u00a0der\u00a0T\u2010Zellproliferationstests \u00a0best\u00e4tigen \u00a0die\u00a0Annahme, \u00a0dass\u00a0es\u00a0sich\u00a0bei\u00a0den\u00a0\nR848\u2010DC\u00b4s\u00a0um\u00a0eine\u00a0funktionell \u00a0reifere\u00a0Zellpopulation \u00a0mit\u00a0h\u00f6chstwahrscheinlich \u00a0auch\u00a0\nregulatorischen \u00a0Eigenschaften \u00a0handelt.\u00a0\u00a098 Diskussion\nDa\u00a0R848\u2010DC\u00b4s\u00a0konstant\u00a0eine\u00a0signifikant \u00a0h\u00f6here\u00a0T\u2010Zell\u2010Proliferation \u00a0induzierten, \u00a0ist\u00a0\nanzunehmen, \u00a0dass\u00a0R848\u00a0die\u00a0Differenzierung \u00a0von\u00a0funktionell \u00a0aktiven\u00a0DC\u00b4s\u00a0nicht\u00a0inhibiert\u00a0\nsondern\u00a0f\u00f6rdert.\u00a0Da\u00a0diese\u00a0Experimente \u00a0mit\u00a0einem\u00a0Gemisch\u00a0aus\u00a0naiven\u00a0und\u00a0Ged\u00e4chtnis \u00a0T\u2010\nZellen\u00a0durchgef\u00fchrt \u00a0wurden,\u00a0sollten\u00a0weitere\u00a0Versuche \u00a0folgen,\u00a0in\u00a0denen\u00a0naive\u00a0CD4+\u00a0TH\u2010Zellen\u00a0\nals\u00a0Responderzellen \u00a0eingesetzt \u00a0werden,\u00a0um\u00a0deren\u00a0Proliferation \u00a0unter\u00a0R848\u2010Wirkung\u00a0zu\u00a0\nerfassen,\u00a0da\u00a0die\u00a0Induktion \u00a0der\u00a0Proliferation \u00a0naiver\u00a0CD4+\u00a0TH\u2010Zellen\u00a0ein\u00a0Hauptmerkmal \u00a0\nfunktionell \u00a0aktiver\u00a0DC\u00b4s\u00a0ist.\u00a0Des\u00a0Weiteren \u00a0sollte\u00a0die\u00a0funktionelle \u00a0Polarisierung \u00a0mit\u00a0R848\u2010DC\u00b4s\u00a0\nstimulierten \u00a0CD4+\u00a0TH\u2010Zellen\u00a0\u00fcberpr\u00fcft \u00a0werden,\u00a0indem\u00a0man\u00a0deren\u00a0Zytokinproduktion \u00a0\nanalysiert. \u00a0\n\u00a0\u00a0\n4.4 Zytokinproduktion \tder\tR848\u2010DC\u00b4s\t\n\u00a0\nDie\u00a0R848\u2010DC\u00b4s\u00a0sezernierten \u00a0im\u00a0Vergleich \u00a0zu\u00a0MoDC\u00b4s,\u00a0nach\u00a0einer\u00a0Restimulation \u00a0mit\u00a0LPS\u00a0bzw.\u00a0\nCpG\u00a02006,\u00a0weniger\u00a0proinflammatorische \u00a0Zytokine\u00a0(IL\u201012p70,\u00a0TNF\u2010\u03b1\u00a0und\u00a0IL\u20106)\u00a0und\u00a0mehr\u00a0\nimmunsuppressives \u00a0IL\u201010.\u00a0\u00a0\nDie\u00a0reduzierte \u00a0Produktion \u00a0von\u00a0IL\u20106\u00a0kann\u00a0zu\u00a0einer\u00a0verringerten \u00a0Interaktion \u00a0des\u00a0angeborenen \u00a0\nImmunsystems \u00a0mit\u00a0dem\u00a0erworbenen \u00a0Immunsystem \u00a0f\u00fchren\u00a0(92).\u00a0\u00a0\nDurch\u00a0die\u00a0reduzierte \u00a0Produktion \u00a0von\u00a0IL\u201012p70\u00a0findet\u00a0keine\u00a0Differenzierung \u00a0von\u00a0TH1\u2010Zellen\u00a0aus\u00a0\nnaiven\u00a0T\u2010Zellen\u00a0statt\u00a0(68),\u00a0und\u00a0NK\u2010Zellen\u00a0und\u00a0CD8+\u2010CTL\u00a0weisen\u00a0eine\u00a0geringere \u00a0Aktivit\u00e4t\u00a0auf\u00a0als\u00a0\nbei\u00a0der\u00a0Interaktion \u00a0mit\u00a0konventionellen \u00a0MoDC\u00b4s.\u00a0\nDie\u00a0vermehrte \u00a0Produktion \u00a0von\u00a0IL\u201010\u00a0kann\u00a0zu\u00a0einer\u00a0vermehrten \u00a0Differenzierung \u00a0von\u00a0TH2\u2010Zellen\u00a0\naus\u00a0naiven\u00a0T\u2010Zellen,\u00a0einer\u00a0Verminderung \u00a0der\u00a0DC\u2010Reifung\u00a0durch\u00a0Hemmung \u00a0der\u00a0Translokation \u00a0\nvon\u00a0MHC\u2010II\u2010Peptid\u2010Komplexen \u00a0auf\u00a0die\u00a0Zelloberfl\u00e4che \u00a0(31,\u00a068)\u00a0und\u00a0zu\u00a0einer\u00a0gesteigerten \u00a0\nBildung\u00a0von\u00a0regulatorischen \u00a0T\u2010Zellen\u00a0f\u00fchren.\u00a0Au\u00dferdem \u00a0wird\u00a0die\u00a0Bildung\u00a0von\u00a0IL\u20106\u00a0sowie\u00a0TNF\u00a0\ngehemmt \u00a0und\u00a0somit\u00a0eine\u00a0T\u2010Zellaktivierung \u00a0direkt\u00a0unterdr\u00fcckt. \u00a0\nDie\u00a0Analyse\u00a0des\u00a0TNF\u2010\u03b1/IL\u201010\u00a0Verh\u00e4ltnisses \u00a0zeigt\u00a0eine\u00a0Verschiebung \u00a0der\u00a0Produktion \u00a0des\u00a0\nproinflammatorischen \u00a0TNF\u2010\u03b1\u00a0zugunsten \u00a0der\u00a0des\u00a0immunregulatorischen \u00a0IL\u201010\u00a0bei\u00a0den\u00a0R848\u2010\nDC\u00b4s\u00a0im\u00a0Vergleich \u00a0zu\u00a0den\u00a0konventionellen \u00a0MoDC\u00b4s\u00a0nach\u00a0der\u00a0Restimulation \u00a0mit\u00a0LPS\u00a0bzw.\u00a0CpG\u00a0\n2006.\u00a0\u00a099 Diskussion\nAus\u00a0diesem\u00a0Zytokinprofil \u00a0kann\u00a0geschlossen \u00a0werden,\u00a0dass\u00a0sich\u00a0die\u00a0R848\u2010DC\u00b4s\u00a0an\u00a0der\u00a0\nantiinflammatorischen \u00a0Regulation \u00a0der\u00a0Immunantwort \u00a0beteiligen \u00a0und\u00a0eine\u00a0Verlagerung \u00a0\ndessen\u00a0auf\u00a0eine\u00a0TH2\u2010Zell\u2010dominierte \u00a0Reaktion\u00a0bewirken, \u00a0was\u00a0den\u00a0Organismus \u00a0vor\u00a0einer\u00a0\n\u00fcbersteigerten \u00a0zellvermittelten \u00a0Immunreaktion \u00a0sch\u00fctzen\u00a0kann.\u00a0\nSomit\u00a0liegt\u00a0die\u00a0Annahme \u00a0nahe,\u00a0dass\u00a0es\u00a0sich\u00a0bei\u00a0den\u00a0R848\u2010DC\u00b4s\u00a0um\u00a0eine\u00a0distinkte\u00a0\nZellpopulation \u00a0dendritischer \u00a0Zellen\u00a0handelt,\u00a0die\u00a0einen\u00a0h\u00f6heren\u00a0Ausreifungsgrad \u00a0und\u00a0\nAktivierungsgrad \u00a0als\u00a0der\u00a0der\u00a0MoDC\u00b4s\u00a0aufweisen, \u00a0einige\u00a0Oberfl\u00e4chenmerkmale \u00a0mit\u00a0denen\u00a0der\u00a0\npDC\u00b4s\u00a0teilen\u00a0und\u00a0auch\u00a0regulatorische \u00a0Eigenschaften \u00a0besitzen.\u00a0\u00a0\nSo\u00a0f\u00fchrt\u00a0eine\u00a0TLR8\u2010Stimulation, \u00a0im\u00a0Gegensatz \u00a0zu\u00a0einer\u00a0TLR7\u2010Stimulation, \u00a0nicht\u00a0nur\u00a0\nquantitativ \u00a0bei\u00a0MoDC\u00b4s\u00a0zu\u00a0einer\u00a0ver\u00e4nderten \u00a0Zytokinproduktion \u00a0und\u00a0Expression \u00a0\nverschiedener \u00a0Oberfl\u00e4chenmolek\u00fcle, \u00a0sondern\u00a0hat\u00a0auch\u00a0qualitative \u00a0Auswirkungen \u00a0auf\u00a0deren\u00a0\nFunktion. \u00a0\n\u00a0\u00a0100 Zusammenfassung\n5 Zusammenfassung \t\n\u00a0\nDendritische \u00a0Zellen\u00a0stellen\u00a0eine\u00a0wichtige\u00a0Gruppe\u00a0von\u00a0APC\u00b4s\u00a0dar,\u00a0die\u00a0sowohl\u00a0das\u00a0angeborene \u00a0\nwie\u00a0auch\u00a0das\u00a0erworbene \u00a0Immunsystem \u00a0beeinflussen. \u00a0Synthetische \u00a0Imidazoquinolinderivate, \u00a0\nzu\u00a0denen\u00a0auch\u00a0R848\u00a0z\u00e4hlt,\u00a0werden\u00a0in\u00a0klinischen \u00a0Untersuchungen \u00a0auf\u00a0ihre\u00a0Wirksamkeit \u00a0hin\u00a0\ngetestet,\u00a0die\u00a0Immunantwort \u00a0zu\u00a0beeinflussen. \u00a0\nVon\u00a0R848\u00a0ist\u00a0bekannt,\u00a0dass\u00a0es\u00a0die\u00a0MoDC\u2010Differenzierung \u00a0und\u00a0\u2010Reifung\u00a0beeinflusst, \u00a0aber\u00a0die\u00a0\nRolle\u00a0der\u00a0vermittelnden \u00a0TLR\u00b4s\u00a0(TLR7\u00a0und\u00a0TLR8)\u00a0ist\u00a0noch\u00a0nicht\u00a0genauer\u00a0untersucht \u00a0worden.\u00a0\nUm\u00a0den\u00a0Einfluss\u00a0von\u00a0TLR7\u00a0und\u00a0TLR8\u00a0auf\u00a0die\u00a0Differenzierung \u00a0und\u00a0Reifung\u00a0konventioneller \u00a0\nMoDC\u00b4s\u00a0zu\u00a0untersuchen \u00a0wurden\u00a0MoDC\u00b4s\u00a0mit\u00a0dem\u00a0TLR7/8\u2010Liganden\u00a0R848,\u00a0mit\u00a0spezifischen \u00a0\nTLR7\u2010Liganden\u00a0(Gardiquimod \u00a0und\u00a0Loxoribine) \u00a0und\u00a0mit\u00a0veschiedenen \u00a0inhibitorischen \u00a0ODN\u00b4s\u00a0\n(iODN\u00a02088,\u00a0iODN\u00a020958\u00a0und\u00a0iODN\u00a020959)\u00a0behandelt. \u00a0\nIn\u00a0vitro\u00a0generierte \u00a0MoDC\u00b4s,\u00a0die\u00a0mit\u00a0dem\u00a0synthetischen \u00a0Imidazoquinolinderivat \u00a0R848\u00a0\nstimuliert \u00a0wurden,\u00a0zeigten\u00a0dosisabh\u00e4ngig \u00a0eine\u00a0modifizierte \u00a0DC\u2010Differenzierung. \u00a0Bei\u00a0den\u00a0\nspezifischen \u00a0TLR7\u2010Liganden\u00a0hingegen\u00a0konnten\u00a0keine\u00a0Wirkungen, \u00a0die\u00a0sich\u00a0in\u00a0der\u00a0analysierten \u00a0\nCD14\u2010\u00a0und\u00a0CD1a\u2010Expression \u00a0bemerkbar \u00a0machten, \u00a0nachgewiesen \u00a0werden.\u00a0\nDie\u00a0Kostimulation \u00a0mit\u00a0den\u00a0verschiedenen \u00a0iODN\u00b4s\u00a0best\u00e4tigte \u00a0die\u00a0Annahme, \u00a0dass\u00a0die\u00a0\nver\u00e4nderte \u00a0MoDC\u2010Differenzierung \u00a0und\u00a0\u2010Reifung\u00a0auf\u00a0einer\u00a0TLR8\u2010Aktivierung \u00a0beruht,\u00a0da\u00a0nur\u00a0\ndie\u00a0TLR8\u00a0inhibitorischen \u00a0iODN\u00b4s\u00a02088\u00a0und\u00a020959\u00a0die\u00a0R848\u2010Effekte\u00a0aufheben \u00a0konnten.\u00a0\nDes\u00a0Weiteren \u00a0exprimierten \u00a0R848\u2010DC\u00b4s\u00a0einen\u00a0h\u00f6heren\u00a0Anteil\u00a0der\u00a0T\u2010Zell\u00a0kostimulatorischen \u00a0\nMolek\u00fcle \u00a0CD40,\u00a0CD83,\u00a0CD86\u00a0und\u00a0HLA\u2010DR\u00a0im\u00a0Vergleich \u00a0zu\u00a0konventionellen \u00a0MoDC\u00b4s\u00a0und\u00a0mit\u00a0\nTLR7\u2010Liganden\u00a0stimulierten \u00a0MoDC\u00b4s.\u00a0\u00a0\nR848\u2010DC\u00b4s\u00a0f\u00fchrten\u00a0zu\u00a0einer\u00a0st\u00e4rkeren \u00a0allogenen \u00a0CD4+\u00a0und\u00a0CD8+\u00a0T\u2010Zellproliferation \u00a0im\u00a0\nVergleich \u00a0zu\u00a0konventionellen \u00a0MoDC\u00b4s.\u00a0\nR848\u2010DC\u00b4s\u00a0produzierten \u00a0nach\u00a0einer\u00a0weiteren\u00a0Stimulation \u00a0ein\u00a0immunregulatorisches \u00a0\nZytokinprofil. \u00a0\u00a0101 Zusammenfassung\nSo\u00a0stellen\u00a0R848\u2010DC\u00b4s\u00a0m\u00f6glicherweise \u00a0eine\u00a0distinkte\u00a0dendritische \u00a0Zellpopulation \u00a0dar,\u00a0die\u00a0auch\u00a0\nregulatorische \u00a0Funktionen \u00a0aus\u00fcben\u00a0k\u00f6nnen.\u00a0\nDie\u00a0selektive\u00a0Stimulation \u00a0von\u00a0MoDC\u00b4s\u00a0in\u00a0der\u00a0Gegenwart \u00a0von\u00a0GM\u2010CSF/IL\u20104\u00a0\u00fcber\u00a0TLR8\u00a0f\u00fchrt\u00a0zu\u00a0\neiner\u00a0Ver\u00e4nderung \u00a0der\u00a0Immunantwort \u00a0auf\u00a0zwei\u00a0Ebenen;\u00a0zum\u00a0einen\u00a0durch\u00a0die\u00a0Modifizierung \u00a0\nder\u00a0DC\u2010Differenzierung, \u00a0und\u00a0zum\u00a0anderen\u00a0durch\u00a0die\u00a0gesteigerte \u00a0Reifung\u00a0und\u00a0m\u00f6glicherweise \u00a0\ndie\u00a0Aus\u00fcbung \u00a0einer\u00a0regulatorischen \u00a0Funktion\u00a0dieser\u00a0Zellen.\u00a0\nDiese\u00a0Ergebnisse \u00a0liefern\u00a0neue\u00a0Erkenntnisse \u00a0\u00fcber\u00a0die\u00a0Rolle\u00a0des\u00a0TLR8\u00a0und\u00a0k\u00f6nnen\u00a0au\u00dferdem \u00a0\ndazu\u00a0beitragen \u00a0in\u00a0Zukunft\u00a0TLR\u2010gest\u00fctzte \u00a0Immuntherapien \u00a0zu\u00a0entwickeln. \u00a0\u00a0102 Summary\n6 Summary \t\n\u00a0\nDendritic\u00a0cells\u00a0represent \u00a0important \u00a0APC\u00b4s\u00a0modulating \u00a0the\u00a0innate\u00a0and\u00a0adaptive\u00a0immune\u00a0\nsystem.\u00a0Synthetic \u00a0imidazoquinoline \u00a0compounds, \u00a0like\u00a0R848,\u00a0undergoing \u00a0clinical\u00a0testing\u00a0to\u00a0\ninvestigate \u00a0their\u00a0efficacy\u00a0to\u00a0modify\u00a0the\u00a0immune\u00a0response. \u00a0\nR848\u00a0is\u00a0known\u00a0to\u00a0modulate \u00a0MoDC\u00a0differentiation \u00a0and\u00a0maturation, \u00a0but\u00a0the\u00a0role\u00a0of\u00a0TLR7\u00a0and\u00a0\nTLR8\u00a0is\u00a0not\u00a0yet\u00a0investigated. \u00a0\nIn\u00a0order\u00a0to\u00a0analyse\u00a0the\u00a0contribution \u00a0of\u00a0TLR7\u00a0and\u00a0TLR8\u00a0on\u00a0differentiation \u00a0and\u00a0maturation \u00a0of\u00a0\nconventional \u00a0moDC\u00b4s,\u00a0they\u00a0were\u00a0treated\u00a0with\u00a0the\u00a0TLR7/8\u00a0ligand\u00a0R848,\u00a0with\u00a0selective\u00a0TLR7\u00a0\nligands\u00a0(gardiquimod \u00a0and\u00a0loxoribine) \u00a0and\u00a0with\u00a0several\u00a0inhibitory \u00a0ODN\u00b4s\u00a0(iODN\u00a022088,\u00a0iODN\u00a0\n20958\u00a0and\u00a0iODN\u00a020959).\u00a0\nIn\u00a0vitro\u00a0generated \u00a0moDC\u00b4s\u00a0stimulated \u00a0with\u00a0the\u00a0synthetic\u00a0imidazoquinoline \u00a0compound \u00a0R848\u00a0\nlead\u00a0to\u00a0a\u00a0modified\u00a0DC\u00a0differentiation \u00a0in\u00a0a\u00a0dose\u2010dependent \u00a0manner.\u00a0In\u00a0contrast\u00a0selective\u00a0TLR7\u00a0\nligands\u00a0had\u00a0no\u00a0effect\u00a0on\u00a0moDC\u00a0differentiation \u00a0as\u00a0analysed\u00a0by\u00a0CD14\u00a0and\u00a0CD1a\u00a0expression. \u00a0\nCostimulation \u00a0with\u00a0several\u00a0iODN\u00b4s\u00a0confirmed \u00a0the\u00a0assumption \u00a0that\u00a0the\u00a0modified\u00a0moDC\u00a0\ndifferentiation \u00a0and\u00a0maturation \u00a0is\u00a0based\u00a0on\u00a0the\u00a0activation \u00a0of\u00a0TLR8,\u00a0because\u00a0R848\u00a0effects\u00a0were\u00a0\nonly\u00a0antagonized \u00a0in\u00a0the\u00a0presence\u00a0of\u00a0TLR8\u00a0iODN\u00b4s\u00a02088\u00a0and\u00a020959.\u00a0\u00a0\nDirect\u00a0comparison \u00a0of\u00a0R848\u2010DC\u00b4s\u00a0with\u00a0conventional \u00a0moDC\u00b4s\u00a0and\u00a0TLR7\u2010stimulated \u00a0DC\u00b4s\u00a0\nrevealed\u00a0significantly \u00a0higher\u00a0expression \u00a0of\u00a0T\u2010cell\u00a0costimulatory \u00a0molecules \u00a0CD40,\u00a0CD83,\u00a0CD86\u00a0\nand\u00a0HLA\u2010DR.\u00a0\u00a0\nAccordingly \u00a0R848\u2010DC\u00b4s\u00a0boosted\u00a0significantly \u00a0stronger\u00a0allogeneic \u00a0CD4+\u00a0and\u00a0CD8+\u00a0T\u2010cell\u00a0\nproliferation \u00a0in\u00a0comparison \u00a0to\u00a0conventional \u00a0moDC\u00b4s.\u00a0\u00a0\nIn\u00a0addition\u00a0R848\u2010DC\u00b4s\u00a0exhibited \u00a0after\u00a0restimulation \u00a0an\u00a0immunoregulatory \u00a0cytokine\u00a0profile.\u00a0\nR848\u2010DC\u00b4s\u00a0represent \u00a0possibly\u00a0a\u00a0distinct\u00a0dendritic\u00a0cell\u00a0population \u00a0which\u00a0can\u00a0exert\u00a0\nimmunoregulatory \u00a0functions. \u00a0\u00a0103 Summary\nThe\u00a0selective\u00a0stimulation \u00a0of\u00a0moDC\u00b4s\u00a0in\u00a0the\u00a0presence\u00a0of\u00a0GM\u2010CSF/IL\u20104\u00a0via\u00a0TLR8\u00a0with\u00a0R848\u00a0leads\u00a0\nto\u00a0an\u00a0alteration \u00a0of\u00a0the\u00a0immune\u00a0response\u00a0at\u00a0two\u00a0levels;\u00a0firstly,\u00a0by\u00a0modifying \u00a0DC\u00a0\ndifferentiation, \u00a0and\u00a0secondly, \u00a0by\u00a0increasing \u00a0DC\u00a0maturation \u00a0und\u00a0promoting \u00a0possibly\u00a0more\u00a0\nregulatory \u00a0function\u00a0of\u00a0these\u00a0cells.\u00a0\nThese\u00a0results\u00a0give\u00a0new\u00a0insights\u00a0into\u00a0the\u00a0distinct\u00a0function\u00a0of\u00a0TLR8\u00a0and\u00a0may\u00a0be\u00a0relevant\u00a0to\u00a0\ndevelop\u00a0TLR\u2010based\u00a0immune\u00a0therapies \u00a0in\u00a0the\u00a0future.\u00a0\u00a0104 Literaturverzeichnis\n7 Literaturverzeichnis \t\n\u00a0\n1. Dr.\u00a0Christian\u00a0Hahn\u00a0(2003).\u00a0Die\u00a0Rolle\u00a0von\u00a0IL\u20104\u00a0und\u00a0IL\u20103\u00a0in\u00a0Maus\u2010Modellen \u00a0f\u00fcr\u00a0\nallergische \u00a0Erkrankungen \u00a0\n2. Green,\u00a0D.\u00a0R.,\u00a0Reed,\u00a0J.,\u00a0C.\u00a0(1998).\u00a0Mitochondria \u00a0and\u00a0apoptosis. \u00a0Science\u00a0281:\u00a01309\u2010\n1312\u00a0\n3. Savill,\u00a0J.,\u00a0Fadok,\u00a0V.\u00a0(2000).\u00a0Corpse\u00a0clearance \u00a0defines\u00a0the\u00a0meaning\u00a0of\u00a0cell\u00a0death.\u00a0\nNature\u00a0407:\u00a0784\u2010788\u00a0\n4. Lodoen,\u00a0M.,\u00a0B.,\u00a0Lanier,\u00a0L.,\u00a0L.\u00a0(2005).\u00a0Viral\u00a0modulation \u00a0of\u00a0NK\u00a0cell\u00a0immunity. \u00a0Nat.\u00a0\nRev.\u00a0Microbiol. \u00a03:\u00a059\u201069\u00a0\n5. Dr.\u00a0Mathias\u00a0Krummen \u00a0(2006).\u00a0Synergistische \u00a0Aktivierung \u00a0von\u00a0dendritischen \u00a0\nZellen\u00a0durch\u00a0Kombination \u00a0von\u00a0TLR\u00a0Liganden\u00a0und\u00a0Untersuchung \u00a0von\u00a0Dextran\u2010\nbasierenden \u00a0Nanopartikeln \u00a0als\u00a0Carrier\u00a0in\u00a0der\u00a0Immuntherapie. \u00a0\n6. Akira,\u00a0S.,\u00a0Uematsu,S., \u00a0Takeuchi, \u00a0O.\u00a0(2006).\u00a0Pathogen \u00a0recognition \u00a0and\u00a0innate\u00a0\nimmunity. \u00a0Cell\u00a0124:783\u00a0\n7. McInturff, \u00a0J.\u00a0E.,\u00a0Modlin,R. \u00a0L.,\u00a0Kim,J.\u00a0(2005).\u00a0The\u00a0role\u00a0of\u00a0toll\u2010like\u00a0receptors \u00a0in\u00a0\nthe\u00a0pathogenesis \u00a0and\u00a0treatment \u00a0of\u00a0dermatological \u00a0disease.\u00a0J.\u00a0Invest.\u00a0Dermatol. \u00a0\n125:1\u00a0\n8. Kaisho,\u00a0T.,\u00a0Akira,\u00a0S.\u00a0(2006).\u00a0Toll\u2010like\u00a0receptor\u00a0function\u00a0and\u00a0signaling .\u00a0J.\u00a0Allergy\u00a0\nClin.\u00a0Immunol. \u00a0117:979\u00a0\n9. Takeda,\u00a0K.,\u00a0Akira,\u00a0S.\u00a0(2005).\u00a0Toll\u2010like\u00a0receptors \u00a0in\u00a0innate\u00a0immunity. \u00a0Int.\u00a0\nImmunol. \u00a017:1\u00a0\n10. Akira,\u00a0S.\u00a0(2000).\u00a0Toll\u2010like\u00a0receptors: \u00a0lessons\u00a0from\u00a0knockout \u00a0mice.\u00a0Biochem.\u00a0Soc.\u00a0\nTrans.\u00a028:551\u00a0\n11. Moussian, \u00a0B.,\u00a0Roth,\u00a0S.\u00a0(2005).\u00a0Dorsoventral \u00a0axis\u00a0formation \u00a0in\u00a0the\u00a0Drosophila \u00a0\nembryo\u2010shaping\u00a0and\u00a0transducing \u00a0a\u00a0morphogen \u00a0gradient.\u00a0Curr.\u00a0Biol.\u00a015:R887\u00a0\n12. Royet,\u00a0J.,\u00a0Reichhart, \u00a0J.\u00a0M.,\u00a0Hoffmann, \u00a0J.\u00a0A.\u00a0(2005).\u00a0Sensing\u00a0and\u00a0signaling\u00a0\nduring\u00a0infection\u00a0in\u00a0Drosophila. \u00a0Curr.\u00a0Opin.\u00a0Immunol. \u00a017:11\u00a0\n13. Beutler,\u00a0B.\u00a0(2004).\u00a0Inferences, \u00a0questions \u00a0and\u00a0possibilities \u00a0in\u00a0Toll\u2010like\u00a0receptor\u00a0\nsignalling. \u00a0Nature\u00a0430:257\u00a0\u00a0105 Literaturverzeichnis\n14. Kiyoshi,\u00a0T.,\u00a0Akira,\u00a0S.\u00a0(2005).\u00a0Toll\u2010like\u00a0receptors \u00a0in\u00a0innate\u00a0immunity. \u00a0Int.\u00a0Immunol. \u00a0\nVol.\u00a017,\u00a0No.\u00a01,\u00a0pp\u00a01\u201014\u00a0\n15. Poltorak,\u00a0A.,\u00a0Smirnova,I., \u00a0He,\u00a0X.,\u00a0Liu,\u00a0M.\u00a0Y.,\u00a0Van\u00a0Huffel,\u00a0C.,\u00a0McNally,O., \u00a0Birdwell,\u00a0\nD.,\u00a0Alejos,\u00a0E.,\u00a0Silva,\u00a0M.,\u00a0Du,\u00a0X.,\u00a0Thompson, \u00a0P.,\u00a0Chan,\u00a0E.\u00a0K.,\u00a0Ledesma, \u00a0J.,\u00a0Roe,\u00a0B.,\u00a0\nClifton,\u00a0S.,\u00a0Vogel,\u00a0S.\u00a0N.,\u00a0Beutler,\u00a0B.\u00a0(1998).\u00a0Genetic\u00a0and\u00a0physical\u00a0mapping\u00a0of\u00a0the\u00a0\nLps\u00a0locus:\u00a0identification \u00a0of\u00a0the\u00a0toll\u20104\u00a0receptor\u00a0as\u00a0a\u00a0candidate \u00a0gene\u00a0in\u00a0the\u00a0critical\u00a0\nregion.\u00a0Blood\u00a0Cells\u00a0Mol\u00a0Dis\u00a024:340\u00a0\n16. Netea,\u00a0M.\u00a0G.,\u00a0Ferwerda, \u00a0G.,\u00a0van\u00a0der\u00a0Graaf,\u00a0C.\u00a0A.,\u00a0Van\u00a0der\u00a0Meer,\u00a0J.\u00a0W.,\u00a0Kullberg,\u00a0B.\u00a0\nJ.\u00a0(2006).\u00a0Recognition \u00a0of\u00a0fungal\u00a0pathogens \u00a0by\u00a0toll\u2010like\u00a0receptors. \u00a0Curr.\u00a0Pharm.\u00a0\nDes.\u00a012:4195\u00a0\n17. Poltorak,\u00a0A.,\u00a0He,\u00a0X.,\u00a0Smirnova, \u00a0I.,\u00a0Liu,\u00a0M.\u00a0Y.,\u00a0Van\u00a0Huffel,\u00a0C.,\u00a0Du,\u00a0X.,\u00a0Birdwell,\u00a0D.,\u00a0\nAlejos,\u00a0E.,\u00a0Silva,\u00a0M.,\u00a0Galanos,\u00a0C.,\u00a0Freudenberg, \u00a0M.,\u00a0Ricciardi\u2010Castagnoli, \u00a0P.,\u00a0\nLayton,\u00a0B.,\u00a0Beutler,\u00a0B.\u00a0(1998).\u00a0Defective \u00a0LPS\u00a0signaling\u00a0in\u00a0C3H/HeJ\u00a0and\u00a0\nC57BL/10ScCr \u00a0mice:\u00a0mutations \u00a0in\u00a0Tlr4\u00a0gene.\u00a0Science\u00a0282:2085\u00a0\n18. Koedel,\u00a0U.,\u00a0Angele,\u00a0B.,\u00a0Rupprecht, \u00a0T.,\u00a0Wagner,\u00a0H.,\u00a0Roggenkamp, \u00a0A.,\u00a0Pfister,\u00a0H.\u00a0\nW.,\u00a0Kirschning, \u00a0C.\u00a0J.\u00a0(2003).\u00a0Toll\u2010Like\u00a0Receptor\u00a02\u00a0Participates \u00a0in\u00a0Mediation \u00a0of\u00a0\nImmune\u00a0Response \u00a0in\u00a0Experimental \u00a0Pneumococcal \u00a0Meningitis. \u00a0J.\u00a0Immunol. \u00a0\n170:438\u00a0\n19. Wang,\u00a0J.,\u00a0Shao,\u00a0Y.,\u00a0Bennett,\u00a0T.\u00a0A.,\u00a0Shankar,\u00a0R.\u00a0A.,\u00a0Wightman, \u00a0P.\u00a0D.,\u00a0Reddy,\u00a0L.\u00a0G.\u00a0\n(2006).\u00a0The\u00a0Functional \u00a0Effects\u00a0of\u00a0Physical\u00a0Interactions \u00a0among\u00a0Toll\u2010like\u00a0Receptors \u00a0\n7,\u00a08,\u00a0and\u00a09.\u00a0J.\u00a0Biol.\u00a0Chem.\u00a0281:37427\u00a0\n20. Kang,\u00a0S.\u00a0S.,\u00a0Kauls,\u00a0L.\u00a0S.,\u00a0Gaspari,\u00a0A.\u00a0A.\u00a0(2006).\u00a0Toll\u2010like\u00a0receptors: \u00a0applications \u00a0to\u00a0\ndermatologic \u00a0disease.\u00a0J.\u00a0Am.\u00a0Acad.\u00a0Dermatol. \u00a054:951\u00a0\n21. Dr.\u00a0Nicole\u00a0Fitzner\u00a0(2006).\u00a0Die\u00a0Expression \u00a0von\u00a0funktionellen \u00a0Toll\u2010like\u00a0Rezeptoren \u00a0\nauf\u00a0humanen \u00a0Hautendothelzellen \u00a0als\u00a0essentieller \u00a0Faktor\u00a0in\u00a0der\u00a0\nEntz\u00fcndungsreaktion. \u00a0\n22. Hemmi,\u00a0H.\u00a0et\u00a0al.\u00a0(2002).\u00a0Small\u00a0anti\u2010viral\u00a0compounds \u00a0activate\u00a0immune\u00a0cells\u00a0via\u00a0\nthe\u00a0TLR7\u00a0MyD88\u00a0signaling\u00a0pathway. \u00a0Nat.\u00a0Immunol. \u00a03\u00a0(2):\u00a0196\u2010200\u00a0\n23. Jurk,\u00a0M.\u00a0et\u00a0al.\u00a0(2002).\u00a0Human\u00a0TLR7\u00a0or\u00a0TLR8\u00a0independently \u00a0confer\u00a0responsiveness \u00a0\nto\u00a0the\u00a0antiviral\u00a0compound \u00a0R848.\u00a0Nat.\u00a0Immunol. \u00a03\u00a0(6):\u00a0499\u00a0\u00a0106 Literaturverzeichnis\n24. Caron,\u00a0G.et\u00a0al.\u00a0(2005).\u00a0Direct\u00a0stimulation \u00a0of\u00a0human\u00a0T\u00a0cells\u00a0via\u00a0TLR5\u00a0and\u00a0TLR7/8:\u00a0\nflagellin\u00a0and\u00a0R848\u00a0up\u2010regulate\u00a0proliferation \u00a0and\u00a0IFN\u2010gamma\u00a0production \u00a0by\u00a0\nmemory\u00a0CD4+\u00a0T\u00a0cells.\u00a0J.\u00a0Immunol .\u00a0175,\u00a01551\u00a0\n25. Lee,\u00a0J.\u00a0et\u00a0al.\u00a0(2002).\u00a0Molecular \u00a0basis\u00a0for\u00a0the\u00a0immunostimulatory \u00a0activity\u00a0of\u00a0\nguanine\u00a0nucleoside \u00a0analogs:\u00a0Activation \u00a0of\u00a0Toll\u2010like\u00a0receptor\u00a07.\u00a0Proc.\u00a0Natl.\u00a0Acad.\u00a0\nSci.\u00a0U\u00a0S\u00a0A.\u00a0100\u00a0(11):\u00a06646\u20106651\u00a0\n26. Landy,\u00a0M.\u00a0and\u00a0Baker,\u00a0P.\u00a0(1966).\u00a0J.\u00a0Immunol. ,\u00a097,\u00a0670\u00a0\n27. Skidmore, \u00a0B.\u00a0et\u00a0al.\u00a0(1975).\u00a0J.\u00a0Immunol .,\u00a0114,\u00a0770\u00a0\n28. Kawai,\u00a0T.,\u00a0Akira,\u00a0S.\u00a0(2005).\u00a0Pathogen \u00a0recognition \u00a0with\u00a0Toll\u2010like\u00a0receptors. \u00a0Curr.\u00a0\nOpin.\u00a0Immunol. \u00a017:338\u00a0\n29. Kawai,\u00a0T.,\u00a0Akira,\u00a0S.\u00a0(2006).\u00a0TLR\u00a0signaling. \u00a0Cell\u00a0Death\u00a0Differ\u00a013:816\u00a0\n30. Steinman, \u00a0R.\u00a0M.,\u00a0Cohn,\u00a0Z.\u00a0A.\u00a0(1973).\u00a0Identification \u00a0of\u00a0a\u00a0novel\u00a0cell\u00a0type\u00a0in\u00a0\nperipheral \u00a0lymphoid \u00a0organs\u00a0of\u00a0mice.\u00a0I.\u00a0Morphology, \u00a0quantitation, \u00a0tissue\u00a0\ndistribution. \u00a0J.\u00a0Exp.\u00a0Med.\u00a0137(5):\u00a01142\u201062\u00a0\n31. Banchereau, \u00a0J.,\u00a0Steinman, \u00a0R.\u00a0M.\u00a0(1998).\u00a0Dendritic\u00a0cells\u00a0and\u00a0the\u00a0control\u00a0of\u00a0\nimmunity. \u00a0Nature\u00a0392:\u00a0254\u2010252\u00a0\n32. Bell,\u00a0D.,\u00a0Young,\u00a0J.\u00a0W.,\u00a0Banchereau, \u00a0J.\u00a0(1999).\u00a0Dendritic\u00a0cells.\u00a0Adv.\u00a0Immunol\u00a072:\u00a0\n255\u2010324\u00a0\n33. Hart,\u00a0D.\u00a0N.\u00a0(1997).\u00a0Dendritic\u00a0cells:\u00a0unique\u00a0leukocyte \u00a0populations \u00a0which\u00a0control\u00a0\nthe\u00a0primary\u00a0immune\u00a0response. \u00a0Blood\u00a090:\u00a03245\u20103287\u00a0\n34. Steinman, \u00a0R.\u00a0M.\u00a0(1991).\u00a0The\u00a0dendritic\u00a0cell\u00a0system\u00a0and\u00a0its\u00a0role\u00a0in\u00a0immunogenicity. \u00a0\nAnnu.\u00a0Rev.\u00a0Immunol .\u00a09:\u00a0271\u2010296\u00a0\n35. Grouard,\u00a0G.,\u00a0Rissoan,\u00a0M.\u00a0C.,\u00a0Filgueira,\u00a0L.,\u00a0Durand,\u00a0I.,\u00a0Banchereau, \u00a0J.,\u00a0Liu,Y.\u00a0J.\u00a0\n(1997).\u00a0The\u00a0enigmatic \u00a0plasmacytoid \u00a0T\u00a0cells\u00a0develop\u00a0into\u00a0dendritic\u00a0cells\u00a0with\u00a0\ninterleukin \u00a0(IL)\u20103\u00a0and\u00a0CD40\u2010ligand.\u00a0J.\u00a0Exp.\u00a0Med .\u00a0185:\u00a01101\u20101111\u00a0\n36. Olweus,\u00a0J.,\u00a0BitMansour, \u00a0A.,\u00a0Warnke,\u00a0R.,\u00a0Thompson \u00a0P.\u00a0A.,\u00a0Carballido, \u00a0J.,\u00a0Picker,\u00a0L.\u00a0\nJ.,\u00a0Lund\u2010Johansen, \u00a0F.\u00a0(1997).\u00a0Dendritic\u00a0cell\u00a0ontogeny: \u00a0a\u00a0human\u00a0dendritic\u00a0cell\u00a0\nlineage\u00a0of\u00a0myeloid\u00a0origin.\u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A.\u00a094:\u00a0122551\u201012556\u00a0\u00a0\n37. O\u00b4Doherty, \u00a0U.,\u00a0Steinman, \u00a0R.\u00a0M.,\u00a0Peng,\u00a0M.,\u00a0Cameron, \u00a0P.\u00a0U.,\u00a0Gezelter,\u00a0S.,Kopeloff, \u00a0\nI.,\u00a0Swiggard, \u00a0W.\u00a0J.,\u00a0Pope,\u00a0M.,\u00a0Bhardwaj, \u00a0N.\u00a0(1993).\u00a0Dendritic\u00a0cells\u00a0freshly\u00a0isolated\u00a0\nfrom\u00a0human\u00a0blood\u00a0express\u00a0CD4\u00a0and\u00a0mature\u00a0into\u00a0typical\u00a0immunostimulatory \u00a0\u00a0107 Literaturverzeichnis\ndendritic\u00a0cells\u00a0after\u00a0culture\u00a0in\u00a0monocyte \u2010conditioned \u00a0medium .\u00a0J.\u00a0Exp.\u00a0Med .\u00a0178:\u00a0\n1067\u20101076\u00a0\n38. Strobl,\u00a0H.,\u00a0Scheinecker, \u00a0C.,\u00a0Riedl,\u00a0E.,\u00a0Csmarits, \u00a0B.,\u00a0Bello\u2010Fernandez, \u00a0C.,\u00a0Pickl,\u00a0W.\u00a0\nF.,\u00a0Majdic,\u00a0O.,\u00a0Knapp,\u00a0W.\u00a0(1998).\u00a0Identification \u00a0of\u00a0CD68+lin\u00a0peripheral \u00a0blood\u00a0cells\u00a0\nwith\u00a0dendritic\u00a0precursor \u00a0characteristics. \u00a0J.\u00a0Immunol .\u00a0161:\u00a0740\u2010748\u00a0\n39. Banchereau, \u00a0J.\u00a0et\u00a0al.\u00a0(2000).\u00a0Immunobiology \u00a0of\u00a0dendritic\u00a0cells.\u00a0Annu.\u00a0Rev.\u00a0\nImmunol .\u00a018:\u00a0767\u2010811\u00a0\n40. Palucka,\u00a0K.,\u00a0Banchereau, \u00a0J.\u00a0(1999).\u00a0Linking\u00a0innate\u00a0and\u00a0adaptive\u00a0immunity. \u00a0Nat.\u00a0\nMed.\u00a05:\u00a0868\u2010870\u00a0\n41. Siegal,\u00a0F.\u00a0P.,\u00a0Kadowaki, \u00a0N.,\u00a0Shodell,\u00a0M.,\u00a0Fitzgerald \u2010Bocarsly,\u00a0P.\u00a0A.,\u00a0Shah,\u00a0K.,\u00a0Ho,\u00a0S.,\u00a0\nAntonenko, \u00a0S.,\u00a0Liu,\u00a0Y.\u00a0J.\u00a0(1999).\u00a0The\u00a0nature\u00a0of\u00a0the\u00a0principal\u00a0type\u00a0I\u00a0interferon \u2010\nproducting \u00a0cells\u00a0in\u00a0human\u00a0blood.\u00a0Science\u00a0284:\u00a018835\u20101837\u00a0\n42. Cella,\u00a0M.,\u00a0Engering, \u00a0A.,\u00a0Pinet,\u00a0V.,\u00a0Pietres,\u00a0J.,\u00a0Lanzavecchia, \u00a0A.\u00a0(1997).\u00a0\nInflammatory \u00a0stimuli\u00a0induce\u00a0accumulation \u00a0of\u00a0MHC\u00a0class\u00a0II\u00a0complexes \u00a0on\u00a0\ndendritic\u00a0cells.\u00a0Nature\u00a0388:\u00a0782\u2010787\u00a0\n43. Shah,\u00a0P.\u00a0D.\u00a0(1987).\u00a0Dendritic\u00a0cells\u00a0but\u00a0not\u00a0macrophages \u00a0are\u00a0targets\u00a0for\u00a0immune\u00a0\nregulation \u00a0by\u00a0natural\u00a0killer\u00a0cells.\u00a0Cell\u00a0Immunol .\u00a0104:\u00a0440\u2010445\u00a0\n44. Geldhof,\u00a0A.\u00a0B.,\u00a0Moser,\u00a0M.,\u00a0Lespagnard, \u00a0L.,\u00a0Thielemanns, \u00a0K.,\u00a0De\u00a0Baetselier, \u00a0P.\u00a0\n(1998).\u00a0Interleukin \u201012\u2010activated \u00a0natural\u00a0killer\u00a0cells\u00a0recognize \u00a0B7\u00a0costimulatory \u00a0\nmolecules \u00a0on\u00a0tumor\u00a0cells\u00a0and\u00a0autologous \u00a0dendritic\u00a0cells.\u00a0Blood\u00a091:\u00a0196\u2010206\u00a0\n45. Dieu,\u00a0M.\u00a0C.,\u00a0Vanbervliet, \u00a0B.,\u00a0Vicari,\u00a0A.,\u00a0Bridon,\u00a0J.\u00a0M.,Oldham, \u00a0E.,\u00a0Ait\u2010Yahia,\u00a0S.,\u00a0\nBriere,\u00a0F.,\u00a0Zlotnik,\u00a0A.,\u00a0Lebecque, \u00a0S.,\u00a0Caux,\u00a0C.\u00a0(1998).\u00a0Selective\u00a0recruitment \u00a0of\u00a0\nimmature \u00a0and\u00a0mature\u00a0dendritic\u00a0cells\u00a0by\u00a0distinct\u00a0chemokines \u00a0expressed \u00a0in\u00a0\ndifferent\u00a0anatomic \u00a0sites .\u00a0J.\u00a0Exp.\u00a0Med.\u00a0188:\u00a0373\u2010386\u00a0\n46. Power,\u00a0C.\u00a0A.,\u00a0Church,\u00a0d.\u00a0J.,\u00a0Meyer,\u00a0A.,\u00a0Alouan,\u00a0S.,\u00a0Proudfoot, \u00a0A.\u00a0E.,\u00a0Clark\u2010Lewis,\u00a0\nI.,Sozzani, \u00a0S.,\u00a0Mantovani, \u00a0A.,\u00a0Wells,\u00a0T.\u00a0N.\u00a0(1997).\u00a0Cloning\u00a0and\u00a0characterization \u00a0of\u00a0\na\u00a0specific\u00a0receptor\u00a0for\u00a0the\u00a0novel\u00a0CC\u00a0chemokine \u00a0MIP\u20103\u03b1\u00a0from\u00a0lung\u00a0dendritic\u00a0cells.\u00a0\nJ.\u00a0Exp.\u00a0Med.\u00a0186:\u00a0825\u2010835\u00a0\n47. Greaves,\u00a0D.\u00a0R.,\u00a0Wang,\u00a0W.,\u00a0Dairaghi,\u00a0D.\u00a0J.,\u00a0Dieu,\u00a0M.\u00a0C.,\u00a0Saint\u2010Vis,\u00a0B.,\u00a0Franz\u2010Bacon,\u00a0\nK.,\u00a0Rossi,\u00a0D.,\u00a0Caux,\u00a0C.,\u00a0Mc\u2010Clanahan, \u00a0T.,\u00a0Gordon,\u00a0S.,\u00a0Zlotnik,\u00a0A.,\u00a0Schall,\u00a0T.\u00a0J.\u00a0(1997).\u00a0\nCCR6,\u00a0a\u00a0chemokine \u00a0receptor\u00a0that\u00a0interacts\u00a0with\u00a0macrophage \u00a0inflammarory \u00a0\u00a0108 Literaturverzeichnis\nprotein\u00a03\u03b1\u00a0and\u00a0is\u00a0highly\u00a0expressed \u00a0on\u00a0human\u00a0dendritic\u00a0cells.\u00a0J.\u00a0Exp.\u00a0Med .\u00a0186:\u00a0\n837\u2010844\u00a0\n48. Mommaas, \u00a0A.\u00a0M.,\u00a0Mulder,\u00a0A.\u00a0A.,\u00a0Jordens,\u00a0R.,\u00a0Out,\u00a0C.,\u00a0Tan,\u00a0M.\u00a0C.,\u00a0Cresswell, \u00a0P.,\u00a0\nKluin,\u00a0P\u00a0M.,\u00a0Koning,\u00a0F.\u00a0(1999).\u00a0Human\u00a0epidermal \u00a0Langerhans \u00a0cells\u00a0lack\u00a0functional \u00a0\nmannose\u00a0receptors \u00a0and\u00a0a\u00a0fully\u00a0developed \u00a0endosomal \u00a0/\u00a0lysosomal \u00a0compartment \u00a0\nfor\u00a0loading\u00a0of\u00a0HLA\u00a0class\u00a0II\u00a0molecules. \u00a0Eur.\u00a0J.\u00a0Immunol. \u00a029:\u00a0571\u2010580\u00a0\n49. Engering, \u00a0A.\u00a0J.,\u00a0Cella,\u00a0M.,\u00a0Fluitsma,\u00a0D.,\u00a0Brockhaus, \u00a0M.,\u00a0Hoefsmit, \u00a0E.\u00a0C.,\u00a0\nLanzavecchia, \u00a0A.,\u00a0Pieters,\u00a0J.\u00a0(1997).\u00a0The\u00a0mannose \u00a0receptor\u00a0functions \u00a0as\u00a0a\u00a0high\u00a0\ncapacity\u00a0and\u00a0broad\u00a0specificity \u00a0antigen\u00a0receptor\u00a0in\u00a0human\u00a0dendritic\u00a0cells.\u00a0Eur.\u00a0J.\u00a0\nImmunol. \u00a027:\u00a02417\u20102425\u00a0\n50. Jiang,\u00a0W.,\u00a0Swiggard, \u00a0W.\u00a0J.,\u00a0Heufler,\u00a0C.,\u00a0Peng,\u00a0M.,\u00a0Mirza,\u00a0A.,\u00a0Steinman, \u00a0R.\u00a0M.,\u00a0\nNussenzweig, \u00a0M.\u00a0C.\u00a0(1995).\u00a0The\u00a0receptor\u00a0DEC\u2010205\u00a0expressed \u00a0by\u00a0dendritic\u00a0cells\u00a0\nand\u00a0thymic\u00a0epithelial \u00a0cells\u00a0is\u00a0involved\u00a0in\u00a0antigen\u00a0processing. \u00a0Nature\u00a0375:\u00a0151\u2010155\u00a0\n51. Sallusto,\u00a0F.,\u00a0Cella,\u00a0M.,\u00a0Danieli,\u00a0C.,\u00a0Lanzavecchia, \u00a0A.\u00a0(1995).\u00a0Dendritic\u00a0cells\u00a0use\u00a0\nmacropinocytosis \u00a0and\u00a0the\u00a0mannose\u00a0receptor\u00a0to\u00a0concentrate \u00a0macromolecules \u00a0in\u00a0\nthe\u00a0major\u00a0histocompatibility \u00a0complex\u00a0class\u00a0II\u00a0compartment: \u00a0downregulation \u00a0by\u00a0\ncytokines \u00a0and\u00a0bacterial\u00a0products. \u00a0J.\u00a0Exp.\u00a0Med.\u00a0182:\u00a0389\u2010400\u00a0\n52. Tan,\u00a0M.\u00a0C.,\u00a0Mommaas, \u00a0A.\u00a0M.,\u00a0Drijfhout, \u00a0J.\u00a0W.,\u00a0Jordens,\u00a0R.,\u00a0Onderwater, \u00a0J.\u00a0J.,\u00a0\nVerwoerd, \u00a0D.,\u00a0Mulder,\u00a0A.\u00a0A.,\u00a0van\u00a0der\u00a0Heiden,\u00a0A.\u00a0N.,\u00a0Scheidegger, \u00a0D.,\u00a0Oomen,\u00a0L.\u00a0\nC.,\u00a0Ottenhoff, \u00a0T.\u00a0H.,\u00a0Tulp,\u00a0A.,\u00a0Neefjes,\u00a0J.\u00a0J.,\u00a0Koning,\u00a0F.\u00a0(1997).\u00a0Mannose \u00a0receptor\u2010\nmediated \u00a0uptake\u00a0of\u00a0antigen\u00a0strongly\u00a0enhances \u00a0HLA\u00a0class\u00a0II\u2010restricted \u00a0antigen\u00a0\npresentation \u00a0by\u00a0cultured\u00a0dendritic\u00a0cells.\u00a0Eur.\u00a0J.\u00a0Immunol. \u00a027:\u00a02426\u20102435\u00a0\n53. Reis\u00a0e\u00a0Sousa,\u00a0C.,\u00a0Stahl,\u00a0P.\u00a0D.,\u00a0Austyn,\u00a0J.\u00a0M.\u00a0(1993).\u00a0Phagocytosis \u00a0of\u00a0antigen\u00a0by\u00a0\nLangerhans \u00a0cells\u00a0in\u00a0vitro.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0178:\u00a0509\u2010519\u00a0\n54. Fanger,\u00a0N.\u00a0A.,\u00a0Wardwell, \u00a0K,\u00a0Shen,\u00a0L.,\u00a0Tedder,\u00a0T.\u00a0F.,\u00a0Guyre,\u00a0P.\u00a0M.\u00a0(1996).\u00a0Type\u00a0I\u00a0(CD\u00a0\n64)\u00a0and\u00a0type\u00a0II\u00a0(CD32)\u00a0Fc\u00a0\u03b3\u00a0receptor\u2010mediated \u00a0phagocytosis \u00a0by\u00a0human\u00a0blood\u00a0\ndendritic\u00a0cells.\u00a0J.\u00a0Immunol. \u00a0157:\u00a0541\u2010548\u00a0\n55. Inaba,\u00a0K.,\u00a0Inaba,\u00a0M.,\u00a0Naito,\u00a0M.,\u00a0Steinman, \u00a0R.\u00a0M.\u00a0(1993).\u00a0Dendritic\u00a0cell\u00a0progenitors \u00a0\nphagocytose \u00a0particulates, \u00a0including\u00a0bacillus\u00a0Calmette\u2010Guerin\u00a0organisms, \u00a0and\u00a0\nsensitize\u00a0mice\u00a0to\u00a0mycobacterial \u00a0antigens\u00a0in\u00a0vivo.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0178:\u00a0479\u2010488\u00a0\u00a0109 Literaturverzeichnis\n56. Rescigno, \u00a0M.,\u00a0Granucci, \u00a0F.,\u00a0Citterio,\u00a0S.,\u00a0Foti,\u00a0M.,\u00a0Ricciardi\u2010Castagnoli, \u00a0P.\u00a0(1999).\u00a0\nCoordinated \u00a0events\u00a0during\u00a0bacteria\u2010induced\u00a0DC\u00a0maturation .\u00a0Immunol. \u00a0Today\u00a020:\u00a0\n200\u2010203\u00a0\n57. Albert,\u00a0M.\u00a0L.,\u00a0Pearce,\u00a0S.\u00a0F.,\u00a0Francisco, \u00a0L.\u00a0M.,\u00a0Sauter,\u00a0B.,\u00a0Roy,\u00a0P.,\u00a0Silverstein, \u00a0R.\u00a0L.,\u00a0\nBhardwaj, \u00a0N.\u00a0(1998).\u00a0Immature \u00a0dendritic\u00a0cells\u00a0phagocytose \u00a0apoptotic \u00a0cells\u00a0via\u00a0\n\u03b1v\u03b25\u00a0and\u00a0CD36,\u00a0and\u00a0cross\u2010present\u00a0antigens\u00a0to\u00a0cytotoxic\u00a0T\u00a0lymphocytes. \u00a0J.\u00a0Exp.\u00a0\nMed.\u00a0188:\u00a01359\u20101368\u00a0\n58. Albert,\u00a0M.\u00a0L.,\u00a0Sauter,\u00a0B.,\u00a0Bhardwaj, \u00a0N.\u00a0(1998).\u00a0Dendritic\u00a0cells\u00a0aquire\u00a0antigen\u00a0from\u00a0\napoptotic \u00a0cells\u00a0and\u00a0induce\u00a0class\u00a0I\u2010restricted \u00a0CTLs.\u00a0Nature\u00a0392:\u00a086\u201089\u00a0\n59. Rubartelli, \u00a0A.,\u00a0Poggi,\u00a0A.,\u00a0Zocchi,\u00a0M.\u00a0R.\u00a0(1997).\u00a0The\u00a0selective\u00a0engulfment \u00a0of\u00a0\napoptotic \u00a0bodies\u00a0by\u00a0dendritic\u00a0cells\u00a0is\u00a0mediated \u00a0by\u00a0the\u00a0\u03b1\u00a0(v)\u00a0\u03b23\u00a0integrin\u00a0and\u00a0\nrequires\u00a0intracellular \u00a0and\u00a0extracellular \u00a0calcium.\u00a0Eur.\u00a0J.\u00a0Immunol. \u00a027:\u00a01893\u20101900\u00a0\n60. Winzler,\u00a0C.,\u00a0Rovere,\u00a0P.,\u00a0Rescigno, \u00a0M.,\u00a0Granucci, \u00a0F.,\u00a0Penna,\u00a0G.,\u00a0Adorini,\u00a0L.,\u00a0\nZimmermann, \u00a0V.\u00a0S.,\u00a0Davoust,\u00a0J.,\u00a0Ricciardi\u2010Castagnoli, \u00a0P.\u00a0(1997).\u00a0Maturation \u00a0\nstages\u00a0of\u00a0mouse\u00a0dendritic\u00a0cells\u00a0in\u00a0growth\u00a0factor\u2010dependent \u00a0long\u2010term\u00a0cultures.\u00a0\nJ.\u00a0Exp.\u00a0Med.\u00a0185:\u00a0317\u2010328\u00a0\n61. Zhou,\u00a0L.\u00a0J.,\u00a0Tedder,\u00a0T.\u00a0F.\u00a0(1995).\u00a0Human\u00a0blood\u00a0dendritic\u00a0cells\u00a0selectively \u00a0express\u00a0\nCD83,\u00a0a\u00a0member\u00a0of\u00a0the\u00a0immunoglobin \u00a0superfamily .\u00a0J.\u00a0Immunol. \u00a0154\u00a0(8):\u00a03821\u2010\n3835\u00a0\n62. Sallusto,\u00a0F.,\u00a0Lanzavecchia, \u00a0A.\u00a0(1994).\u00a0Efficient\u00a0presentation \u00a0of\u00a0soluble\u00a0antigen\u00a0by\u00a0\ncultured\u00a0human\u00a0dendritic\u00a0cells\u00a0is\u00a0maintained \u00a0by\u00a0granulocyte \u00a0/\u00a0macrophage \u00a0\ncolony\u2010stimulating \u00a0factor\u00a0plus\u00a0interleukin \u00a04\u00a0and\u00a0downregulated \u00a0by\u00a0tumor\u00a0\nnecrosis\u00a0factor\u00a0\u03b1.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0179:\u00a01109\u20101118\u00a0\n63. Inaba,\u00a0K.,\u00a0Turley,\u00a0S.,\u00a0Yamaide,\u00a0F.,\u00a0Lyoda,\u00a0T.,\u00a0Mahnke,\u00a0K.,\u00a0Inaba,\u00a0M.,\u00a0Pack,\u00a0M.,\u00a0\nSubklewe, \u00a0M.,\u00a0Sauter,\u00a0B,\u00a0Sheff,\u00a0D.,\u00a0Albert,\u00a0M.,\u00a0Bhardwaj, \u00a0N.,\u00a0Mellman, \u00a0I.,\u00a0\nSteinman, \u00a0R.\u00a0M.\u00a0(1998).\u00a0Efficient\u00a0presentation \u00a0of\u00a0phagocytosed \u00a0cellular\u00a0\nfragments \u00a0on\u00a0the\u00a0major\u00a0histocompartibility \u00a0complex\u00a0class\u00a0II\u00a0products\u00a0of\u00a0\ndendritic\u00a0cells.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0188:\u00a02163\u20102173\u00a0\n64. Inaba,\u00a0K.,\u00a0Pack,\u00a0M.,\u00a0Inaba,\u00a0M.,\u00a0Sakuta,\u00a0H.,\u00a0Isdell,\u00a0F.,\u00a0Steinman, \u00a0R.\u00a0M.\u00a0(1997).\u00a0High\u00a0\nlevels\u00a0of\u00a0a\u00a0major\u00a0histocompartibility \u00a0complex\u00a0II\u2010self\u00a0peptide\u00a0complex\u00a0on\u00a0\ndendritic\u00a0cells\u00a0from\u00a0the\u00a0T\u00a0cell\u00a0areas\u00a0of\u00a0lymph\u00a0nodes.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0186:\u00a0665\u2010672\u00a0\u00a0110 Literaturverzeichnis\n65. Kleijmeer, \u00a0M.\u00a0J.,\u00a0Ossevoort, \u00a0M.\u00a0A.,\u00a0van\u00a0Veen,\u00a0C.\u00a0J.,\u00a0van\u00a0Hellemond, \u00a0J.\u00a0J.,\u00a0Neefjes,\u00a0\nJ.\u00a0J.,\u00a0Kast,\u00a0W.\u00a0M.,\u00a0Melief,\u00a0C.\u00a0J.,\u00a0Geuze,\u00a0H.\u00a0J.\u00a0(1995).\u00a0MHC\u00a0class\u00a0II\u00a0compartments \u00a0\nand\u00a0the\u00a0kinetics\u00a0of\u00a0antigen\u00a0presentation \u00a0in\u00a0activated \u00a0mouse\u00a0spleen\u00a0dendritic\u00a0\ncells.\u00a0J.\u00a0Immunol. \u00a0154:\u00a05715\u20105724\u00a0\n66. Nijman,\u00a0H.\u00a0W.,\u00a0Kleijmeer, \u00a0M.\u00a0J.,\u00a0Ossevoort, \u00a0M.\u00a0A.,\u00a0Oortschot, \u00a0V.\u00a0M.,\u00a0Vierboom, \u00a0\nM.\u00a0P.,\u00a0van\u00a0de\u00a0Keur,\u00a0M.,\u00a0Kenemana, \u00a0P.,\u00a0Kast,\u00a0W.\u00a0M.,\u00a0Geuze,\u00a0H.\u00a0J.,\u00a0Melief,\u00a0C.\u00a0J.\u00a0\n(1995).\u00a0Antigen\u00a0capture\u00a0and\u00a0major\u00a0histocompartibility \u00a0class\u00a0II\u00a0compartments \u00a0of\u00a0\nfreshly\u00a0isolated\u00a0and\u00a0cultured\u00a0human\u00a0blood\u00a0dendritic\u00a0cells.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0182:\u00a0163\u2010\n174\u00a0\n67. Pierre,\u00a0P.,\u00a0Turley,\u00a0S.\u00a0J.,\u00a0Gatti,\u00a0E.,\u00a0Hull,\u00a0M.,\u00a0Meltzer,\u00a0J.,\u00a0Mirza,\u00a0A.,\u00a0Inaba,\u00a0K.,\u00a0\nSteinman, \u00a0R.\u00a0M.,\u00a0Mellman, \u00a0I.\u00a0(1997).\u00a0Developmental \u00a0regulation \u00a0of\u00a0MHC\u00a0class\u00a0II\u00a0\ntransport \u00a0in\u00a0mouse\u00a0dendritic\u00a0cells.\u00a0Nature\u00a0388:\u00a0787\u2010792\u00a0\n68. www.wikipedia.org \u00a0\n69. Sornasse, \u00a0T.,\u00a0Flamand,\u00a0V.,\u00a0De\u00a0Becker,\u00a0G.,\u00a0Bazin,\u00a0H.,\u00a0Tielemanns, \u00a0F.,\u00a0Thielemanns, \u00a0\nK.,\u00a0Urbian,\u00a0J.,\u00a0Leo,\u00a0O.,\u00a0moser,\u00a0M.\u00a0(1992).\u00a0Antigen\u2010pulsed\u00a0dendritic\u00a0cells\u00a0can\u00a0\nefficiently \u00a0induce\u00a0an\u00a0antibody\u00a0response\u00a0in\u00a0vivo.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0175:\u00a015\u201021\u00a0\n70. Inaba,\u00a0K.,\u00a0Young,\u00a0J.\u00a0W.,\u00a0Steinman, \u00a0R.\u00a0M.\u00a0(1987).\u00a0Direct\u00a0activation \u00a0of\u00a0\nCD8+cytotoxic\u00a0T\u00a0lymphocytes \u00a0by\u00a0dendritic\u00a0cells.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0166:\u00a0182\u2010194\u00a0\n71. Macatonia, \u00a0S.\u00a0E.,\u00a0Taylor,\u00a0P.\u00a0M.,\u00a0Knight,\u00a0S.\u00a0C.,\u00a0Askona,\u00a0B.\u00a0A.\u00a0(1989).\u00a0Primary\u00a0\nstimulation \u00a0by\u00a0dendritic\u00a0cells\u00a0induces\u00a0antiviral\u00a0proliferative \u00a0and\u00a0cytotoxic\u00a0T\u00a0cell\u00a0\nresponses \u00a0in\u00a0vitro.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0169:\u00a01255\u20101264\u00a0\n72. Nair,\u00a0S.,\u00a0Zhou,\u00a0F.,\u00a0Reddy,\u00a0R.,\u00a0Huang,\u00a0L.,\u00a0Rouse,\u00a0B.\u00a0T.\u00a0(1992).\u00a0Soluble\u00a0proteins\u00a0\ndelivered \u00a0to\u00a0dendritic\u00a0cells\u00a0via\u00a0pH\u2010sensitive\u00a0liposomes \u00a0induce\u00a0primary\u00a0cytotoxic\u00a0T\u00a0\nlymphocyte \u00a0responses \u00a0in\u00a0vitro.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0175:\u00a0609\u2010612\u00a0\n73. Mehta\u2010Damani,\u00a0A.,\u00a0Markowitz, \u00a0A.\u00a0S.,\u00a0Engleman, \u00a0E.\u00a0G.\u00a0(1994).\u00a0Generation \u00a0of\u00a0\nantigen\u2010specific\u00a0CD8+\u00a0CTLs\u00a0from\u00a0naive\u00a0precursors. \u00a0J.\u00a0Immunol .\u00a0153:\u00a0996\u20101003\u00a0\n74. Kayser,F.\u00a0H.,\u00a0Bienz,\u00a0K.\u00a0A.,\u00a0Eckert,\u00a0J.,\u00a0Zinkernagel, \u00a0R.\u00a0M.\u00a0(1998).\u00a0Medizinische \u00a0\nMikrobiologie. \u00a0Georg\u00a0Thieme\u00a0Verlag\u00a0\n75. Rescigno, \u00a0M.\u00a0C.,\u00a0Winzler,\u00a0D.,\u00a0Delia,\u00a0D.,\u00a0Mutini,\u00a0C.,\u00a0Lutz,\u00a0M.,\u00a0Ricciardi\u2010Castagnoli, \u00a0\nP.\u00a0(1997).\u00a0Dendritic\u00a0cell\u00a0maturation \u00a0is\u00a0required\u00a0for\u00a0initiation\u00a0of\u00a0the\u00a0immune\u00a0\nresponse. \u00a0J.\u00a0Leukoc.\u00a0Biol.\u00a061\u00a0(4):\u00a0415\u2010421\u00a0\u00a0111 Literaturverzeichnis\n76. Caux,\u00a0C.,\u00a0Vanbervliet, \u00a0B.,\u00a0Masacrier, \u00a0C.,\u00a0Azuma,\u00a0M.,\u00a0Okumura, \u00a0K.,\u00a0Lanier,\u00a0L.\u00a0L.,\u00a0\nBanchereau, \u00a0J.\u00a0(1994).\u00a0B70/B7\u20102\u00a0is\u00a0identical\u00a0to\u00a0CD86\u00a0and\u00a0is\u00a0the\u00a0major\u00a0functional \u00a0\nligand\u00a0for\u00a0CD28\u00a0expressed \u00a0on\u00a0human\u00a0dendritic\u00a0cells.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0180:\u00a01841\u20101847\u00a0\n77. Inaba,\u00a0K.,\u00a0Witmer\u2010Pack,\u00a0M.,\u00a0Inaba,\u00a0M.,\u00a0Hathcock, \u00a0K.\u00a0S.,\u00a0Sakuta,\u00a0H.,\u00a0Azuma,\u00a0M.,\u00a0\nYagita,\u00a0H.,\u00a0Okumura, \u00a0K.,\u00a0Linsley\u00a0P.\u00a0S.,\u00a0Ikehara,\u00a0S.,\u00a0Murramatsu, \u00a0S.,\u00a0Hodes,\u00a0R.\u00a0J.,\u00a0\nSteinman, \u00a0R.\u00a0M.\u00a0(1994).\u00a0The\u00a0tissue\u00a0distribution \u00a0of\u00a0the\u00a0B7\u20102\u00a0costimulator \u00a0in\u00a0mice:\u00a0\nabundant \u00a0expression \u00a0on\u00a0dendritic\u00a0cells\u00a0in\u00a0situ\u00a0and\u00a0during\u00a0maturation \u00a0in\u00a0vitro.\u00a0J.\u00a0\nExp.\u00a0Med.\u00a0180:\u00a01849\u20101860\u00a0\n78. Ridge,\u00a0J.\u00a0P.,\u00a0Di\u00a0Rosa,\u00a0F.,\u00a0Matzinger, \u00a0P.\u00a0(1998).\u00a0A\u00a0conditioned \u00a0dendritic\u00a0cell\u00a0can\u00a0be\u00a0\na\u00a0temporal\u00a0bridge\u00a0between\u00a0a\u00a0CD4+\u00a0T\u2010helper\u00a0and\u00a0a\u00a0t\u2010killer\u00a0cell.\u00a0Nature\u00a0393:\u00a0474\u2010\n48\u00a0\n79. Bennett,\u00a0S.\u00a0R.,\u00a0Carbone,\u00a0F.\u00a0R.,\u00a0Karamalis, \u00a0F.,\u00a0Flavell,\u00a0R.\u00a0A.,\u00a0Miller,\u00a0J.\u00a0F.,\u00a0Heath,\u00a0W.\u00a0\nR.\u00a0(1998).\u00a0Help\u00a0for\u00a0cytotoxic\u2010T\u2010cell\u00a0responses \u00a0is\u00a0mediated \u00a0by\u00a0CD40\u00a0signalling. \u00a0\nNature\u00a0393:\u00a0478\u2010480\u00a0\n80. Schoenberger, \u00a0S.\u00a0P.,\u00a0Toes,\u00a0R.\u00a0E.,\u00a0van\u00a0der\u00a0Voort,\u00a0E.\u00a0I.,\u00a0Offringa,\u00a0R.,\u00a0Melief,\u00a0C.\u00a0J.\u00a0\n(1998).\u00a0T\u2010cell\u00a0help\u00a0for\u00a0cytotoxic\u00a0T\u00a0lymphocytes \u00a0is\u00a0mediated \u00a0by\u00a0CD40\u2010CD40\u2010L\u00a0\ninteractions. \u00a0Nature\u00a0393:\u00a0480\u2010483\u00a0\n81. Caux,\u00a0C.,\u00a0Massacrier, \u00a0C.,\u00a0Vanbervliet, \u00a0B.,\u00a0Dubois,\u00a0B.,\u00a0Van\u00a0Kotten,\u00a0C.,\u00a0Durand,\u00a0I.,\u00a0\nBanchereau, \u00a0J.\u00a0(1994).\u00a0Activation \u00a0of\u00a0human\u00a0dendritic\u00a0cells\u00a0through\u00a0CD40\u00a0cross\u2010\nlinking.\u00a0J.\u00a0Exp.\u00a0Med.\u00a0180:\u00a01263\u20101272\u00a0\n82. Barclay,\u00a0N.A.,\u00a0Brown,\u00a0M.\u00a0H.,\u00a0Birkeland, \u00a0M.L.\u00a0et\u00a0al.,\u00a0ed.\u00a0(1997).\u00a0The\u00a0Leucocyte \u00a0\nAntigen\u00a0Facts\u00a0Book.\u00a0San\u00a0Diego,\u00a0CA:\u00a0Academic \u00a0Press\u00a0(Biology). \u00a0\n83. Schlossman, \u00a0S.\u00a0F.,\u00a0Boumsell, \u00a0L.,\u00a0Gilks,\u00a0W.,\u00a0et\u00a0al.\u00a0(1995).\u00a0Leucocyte \u00a0typing\u00a0V:\u00a0White\u00a0\ncell\u00a0differentiation \u00a0antigens.\u00a0New\u00a0York:\u00a0Oxford\u00a0University \u00a0Press .\u00a0\n84. Azuma,\u00a0M.,\u00a0Ito,\u00a0D.,\u00a0Yagita,\u00a0H.,\u00a0et\u00a0al.\u00a0(1993).\u00a0B70\u00a0antigen\u00a0is\u00a0a\u00a0second\u00a0ligand\u00a0for\u00a0\nCTLA\u20104\u00a0and\u00a0CD28.\u00a0Nature\u00a0366\u00a0(6450) :\u00a076\u201079\u00a0\n85. Dzionek,\u00a0A.,\u00a0et\u00a0al.\u00a0(2000).\u00a0BDCA\u20102,\u00a0BDCA\u20103,\u00a0BDCA\u20104:\u00a0Three\u00a0markers\u00a0for\u00a0distinct\u00a0\nsubsets\u00a0of\u00a0dendritic\u00a0cells\u00a0in\u00a0human\u00a0peripheral \u00a0blood.\u00a0J.\u00a0Immunol. \u00a0165.\u00a06035\u20106046\u00a0\n86. Grabbe,\u00a0S.,\u00a0et\u00a0al.\u00a0(2000).\u00a0Dendritic\u00a0cells:\u00a0multi\u2010lineal\u00a0and\u00a0multi\u2010functional. \u00a0\nImmunol. \u00a0Today\u00a021:431\u2010433\u00a0\n87. Shevach,\u00a0E.\u00a0M.\u00a0(2001).\u00a0Certified\u00a0professionals: \u00a0CD4+\u00a0CD25+\u00a0suppressor \u00a0T\u2010cells.\u00a0J.\u00a0\nExp.\u00a0Med.\u00a0193:\u00a0F41\u2010F46\u00a0\u00a0112 Literaturverzeichnis\n88. Kishimoto,T., \u00a0von\u00a0dem\u00a0Borne,\u00a0A.\u00a0E.\u00a0G.,\u00a0Goyert,\u00a0S.\u00a0M.,\u00a0et\u00a0al.\u00a0(1997).\u00a0Leucocyte \u00a0\ntyping\u00a0VI:\u00a0White\u00a0cell\u00a0differentiation \u00a0antigens.\u00a0London:\u00a0Garland\u00a0Publishing. \u00a0\n89. Hori,\u00a0S.,\u00a0et\u00a0al.\u00a0(2003).\u00a0Science\u00a0299:\u00a01057\u00a0\n90. Dinarello, \u00a0C.A.\u00a0(2005).Blocking \u00a0IL\u20101\u00a0in\u00a0systemic\u00a0inflammation. \u00a0J.\u00a0Exp.\u00a0Med.\u00a0201:\u00a0\n1355\u20101359\u00a0\n91. Rivest\u00a0S.\u00a0et\u00a0al.\u00a0(2000).How \u00a0the\u00a0blood\u00a0talks\u00a0to\u00a0the\u00a0brain\u00a0parenchyma \u00a0and\u00a0the\u00a0\nparaventricular \u00a0nucleus\u00a0of\u00a0the\u00a0hypothalamus \u00a0during\u00a0systemic\u00a0inflammatory \u00a0and\u00a0\ninfectious \u00a0stimuli.\u00a0Proc.\u00a0Soc.\u00a0Exp.\u00a0Biol.\u00a0Med.\u00a0223\u00a0(1):\u00a022\u201038\u00a0\u00a0\n92. Jones,\u00a0S.A.\u00a0(2005).\u00a0Directing\u00a0tranition\u00a0from\u00a0innate\u00a0to\u00a0acquired\u00a0immunity: \u00a0\nDefining\u00a0a\u00a0role\u00a0for\u00a0IL\u20106.\u00a0J.\u00a0Immunol. \u00a0175:3463\u20103468\u00a0\n93. Heinrich,\u00a0P.C.\u00a0et\u00a0al.\u00a0(2003).Principles \u00a0of\u00a0Interleukin \u00a0(IL)\u20106\u2010type\u00a0signaling\u00a0and\u00a0its\u00a0\nregulation. \u00a0Biochem.\u00a0J.\u00a0374:\u00a01\u201020\u00a0\n94. Fischer,\u00a0C.\u00a0P.\u00a0(2006).\u00a0Interleukin \u20106\u00a0in\u00a0acute\u00a0exercise\u00a0and\u00a0training:\u00a0what\u00a0is\u00a0the\u00a0\nbiological \u00a0relevance? \u00a0Exerc.\u00a0Immunol. \u00a0Rev.\u00a012:\u00a06\u201033\u00a0\n95. Brat,\u00a0D.\u00a0J.,\u00a0Bellail,\u00a0A.\u00a0C.,\u00a0Van\u00a0Meir,\u00a0E.\u00a0G.\u00a0(2005).\u00a0The\u00a0role\u00a0of\u00a0interleukin \u20108\u00a0and\u00a0its\u00a0\nreceptors \u00a0in\u00a0gliomangenesis \u00a0and\u00a0tumoral\u00a0angiogenesis. \u00a0Neuro\u2010oncology .\u00a07\u00a0(2):\u00a0\n122\u2010133\u00a0\n96. Gr\u00fctz,\u00a0G.\u00a0(2005).\u00a0New\u00a0sights\u00a0into\u00a0the\u00a0molecular \u00a0mechanism \u00a0of\u00a0interleukin \u201010\u2010\nmediated \u00a0immunosuppression. \u00a0J.\u00a0Leuk.\u00a0Biol.\u00a077:\u00a03\u201015\u00a0\n97. Segal,\u00a0B.\u00a0M.,\u00a0Klinman,\u00a0D.\u00a0M.,\u00a0Shevach,\u00a0E.,\u00a0M.\u00a0(1997).\u00a0Microbial \u00a0products\u00a0induce\u00a0\nautoimmune \u00a0disease\u00a0by\u00a0an\u00a0IL\u201012\u2010dependent \u00a0pathway .\u00a0J.\u00a0Immunol. \u00a0158\u00a0(11):\u00a0\n5087\u20135090 \u00a0\n98. Hehlgans, \u00a0T.,\u00a0Pfeffer,\u00a0K.\u00a0(2005).\u00a0The\u00a0intriguing \u00a0biology\u00a0of\u00a0the\u00a0tumour\u00a0necrosis\u00a0\nfactor\u00a0/\u00a0tumor\u00a0necrosis\u00a0factor\u00a0receptor\u00a0superfamily: \u00a0players,\u00a0rules\u00a0and\u00a0the\u00a0\ngames.\u00a0Immunol. 115:\u00a01\u201020\u00a0\u00a0\n99. Schwartz, \u00a0R.,\u00a0Dameshek, \u00a0W.\u00a0(1959).\u00a0Drug\u00a0\u2013\u00a0induced\u00a0immunological \u00a0tolerance. \u00a0\nNature\u00a0183:\u00a01682\u20101683\u00a0\n100. Schwartz, \u00a0R.,\u00a0Dameshek, \u00a0W.\u00a0(1960).\u00a0The\u00a0effects\u00a0of\u00a06\u2010mercaptopurine \u00a0on\u00a0\nhomograft \u00a0reactions. \u00a0J.\u00a0Clin.\u00a0Invest.\u00a039:\u00a0952\u2010958\u00a0\n101. Hackstein, \u00a0H.,\u00a0Taner,\u00a0T.,\u00a0Logar,\u00a0A.\u00a0J.,\u00a0Thompson, \u00a0A.\u00a0W.\u00a0(2002).\u00a0Rapamycin \u00a0inhibits\u00a0\nmacropinocytosis \u00a0and\u00a0mannose\u00a0receptor\u2010mediated \u00a0endocytosis \u00a0by\u00a0bone\u2010\nmarrow\u00a0derived\u00a0dendritic\u00a0cells.\u00a0Blood\u00a0100:\u00a01084\u20101087\u00a0\u00a0113 Literaturverzeichnis\n102. Hackstein, \u00a0H.,\u00a0Taner,\u00a0Zahorchak, \u00a0A.\u00a0F.,\u00a0Morelli,\u00a0A.\u00a0E.,\u00a0Logar,\u00a0A.\u00a0J.,\u00a0Gessner,\u00a0A.,\u00a0\nThompson, \u00a0A.\u00a0W.\u00a0(2003).\u00a0Rapamycin \u00a0inhibits\u00a0IL\u20104\u2010induced\u00a0dendritic\u00a0cell\u00a0\nmaturation \u00a0in\u00a0vitro\u00a0and\u00a0dendritic\u00a0cell\u00a0mobilization \u00a0and\u00a0function\u00a0in\u00a0vivo.\u00a0Blood\u00a0\n101:\u00a04457\u20104463\u00a0\n103. Turnquist, \u00a0H.\u00a0R.,\u00a0Cardinal,\u00a0J.,\u00a0Macedo,\u00a0C.,\u00a0Rosborough, \u00a0B.\u00a0R.,\u00a0Sumpter,\u00a0T.\u00a0L.,\u00a0\nGeller,\u00a0D.\u00a0A.,\u00a0Metes,\u00a0D.,\u00a0Thompson, \u00a0A.\u00a0W.\u00a0(2010).\u00a0mTOR\u00a0and\u00a0GSK\u20103\u00a0shape\u00a0the\u00a0\nCD4+\u00a0T\u2010cell\u00a0stimulatory \u00a0and\u00a0differentiation \u00a0capacity\u00a0of\u00a0myeloid\u00a0DCs\u00a0after\u00a0\nexposure\u00a0to\u00a0LPS.\u00a0Blood\u00a0115:\u00a04758\u20104769\u00a0\n104. Hackstein, \u00a0H.,\u00a0Morelli,\u00a0A.\u00a0E.,\u00a0Larregina, \u00a0A.\u00a0T.,\u00a0Ganster,\u00a0R.\u00a0W.,\u00a0Papworth, \u00a0G.\u00a0D.,\u00a0\nLogar,\u00a0A.\u00a0J.,\u00a0Watkins,\u00a0S.\u00a0C.,\u00a0Falo,\u00a0L.\u00a0D.,\u00a0Thompson, \u00a0A.\u00a0W.\u00a0(2001).\u00a0Aspirin\u00a0inhibits\u00a0in\u00a0\nvitro\u00a0maturation \u00a0and\u00a0in\u00a0vivo\u00a0immunostimulatory \u00a0function\u00a0of\u00a0murine\u00a0myeloid\u00a0\ndendritic\u00a0cells.\u00a0J.\u00a0Immunol. \u00a0166:\u00a07053\u20107062\u00a0\n105. Buckland, \u00a0M.,\u00a0Jago,\u00a0C.,\u00a0Fazekesova, \u00a0H.,\u00a0George,\u00a0A.,\u00a0Lechler,\u00a0R.,\u00a0Lombardi, \u00a0G.\u00a0\n(2006).\u00a0Aspirin\u00a0modified\u00a0dendritic\u00a0cells\u00a0are\u00a0potent\u00a0inducers\u00a0of\u00a0allo\u2010specific\u00a0\nregulatory \u00a0T\u2010cells.\u00a0Int.\u00a0Immunopharmacol. \u00a06:\u00a01895\u20101901\u00a0\n106. Hackstein, \u00a0H.,\u00a0Thompson, \u00a0A.\u00a0W.\u00a0(2004).\u00a0Dendritic\u00a0cells\u00a0emerging \u00a0\npharmacological \u00a0targets\u00a0of\u00a0immunosuppressive \u00a0drugs.\u00a0Nat.\u00a0Rev.\u00a0Immunol .\u00a04:\u00a024\u2010\n34\u00a0\n107. Turnquist, \u00a0H.\u00a0R.,\u00a0Fischer,\u00a0R.\u00a0T.,\u00a0Thompson, \u00a0A.\u00a0W.\u00a0(2010).\u00a0Pharmacological \u00a0\nmodification \u00a0of\u00a0dendritic\u00a0cells\u00a0to\u00a0promote\u00a0their\u00a0tolerogenicity \u00a0in\u00a0transplantation. \u00a0\nMethods\u00a0Mol.\u00a0Biol.\u00a0595:\u00a0135\u2010148\u00a0\n108. Schon,\u00a0M.\u00a0P.,\u00a0Schon,\u00a0M.\u00a0(2008).\u00a0TLR7\u00a0and\u00a0TLR8\u00a0as\u00a0targets\u00a0in\u00a0cancer\u00a0therapy.\u00a0\nOncogene \u00a027:\u00a0190\u2010199\u00a0\n109. Miller,\u00a0R.\u00a0L.,\u00a0Meng,\u00a0T.\u00a0C.,\u00a0Tomai,\u00a0M.\u00a0A.\u00a0(2008).\u00a0The\u00a0antiviral\u00a0activity\u00a0of\u00a0Toll\u2010like\u00a0\nreceptor\u00a07\u00a0and\u00a07/8\u00a0agonists.\u00a0Drug\u00a0News\u00a0Perspect\u00a021:69\u201087\u00a0\n110. Tomai,\u00a0M.\u00a0A.,\u00a0Miller,\u00a0R.\u00a0L.,\u00a0Lipson,\u00a0K.\u00a0E.,\u00a0Kieper,\u00a0W.\u00a0C.,\u00a0Zarraga,\u00a0I.\u00a0E.,\u00a0Vasilakos, \u00a0J.\u00a0\nP.\u00a0(2007).\u00a0Resiquimod \u00a0and\u00a0other\u00a0immune\u00a0response\u00a0modifiers \u00a0as\u00a0vaccine\u00a0\nadjuvants. \u00a0Expert\u00a0Rev.\u00a06:\u00a0835\u2010847\u00a0\n111. Szeimies,\u00a0R.\u00a0M.,\u00a0Bichel,\u00a0J.,\u00a0Ortonne,\u00a0J.\u00a0P.,\u00a0Stockfleth, \u00a0E.,\u00a0Lee,\u00a0J.,\u00a0Meng,\u00a0T.\u00a0C.\u00a0\n(2008).\u00a0A\u00a0phase\u00a0II\u00a0dose\u2010ranging\u00a0study\u00a0of\u00a0topical\u00a0resiquimod \u00a0to\u00a0treat\u00a0actinic\u00a0\nkeratosis. \u00a0Br.\u00a0J.\u00a0Dermatol. \u00a0159:\u00a0205\u2010210\u00a0\u00a0114 Literaturverzeichnis\n112. Assier,\u00a0E.,\u00a0Marin\u2010Esteban,\u00a0V.,\u00a0Haziot,\u00a0A.,\u00a0Maggi,\u00a0E.,\u00a0Charron,\u00a0D.,\u00a0Mooney,\u00a0N.\u00a0\n(2007).\u00a0TLR7/8\u00a0agonists\u00a0impair\u00a0monocyte \u2010derived\u00a0dendritic\u00a0cell\u00a0differentiation \u00a0\nand\u00a0maturation. \u00a0J.\u00a0Leuk.\u00a0Biol.\u00a081:\u00a0221\u2010228\u00a0\n113. Larange,\u00a0A.,\u00a0Antonios, \u00a0D.,\u00a0Pallardy,\u00a0M.,\u00a0Kerdine\u2010Romer,\u00a0S.\u00a0(2009).\u00a0TLR\u00a07\u00a0and\u00a0TLR8\u00a0\nagonists\u00a0trigger\u00a0different\u00a0signaling\u00a0pathways \u00a0for\u00a0human\u00a0dendritic\u00a0cell\u00a0\nmaturation. \u00a0J.\u00a0Leukoc.\u00a0Biol.\u00a085:\u00a0673\u2010683\u00a0\n114. Lombardi, \u00a0V.,\u00a0Van\u00a0Overtvelt, \u00a0L.,\u00a0Horiot,\u00a0S.,\u00a0Miongeon, \u00a0P.\u00a0(2009).\u00a0Human\u00a0dendritic\u00a0\ncells\u00a0stimulated \u00a0via\u00a0TLR7\u00a0and/or\u00a0ZTLR8\u00a0induce\u00a0the\u00a0sequential \u00a0production \u00a0of\u00a0IL\u2010\n10,\u00a0IFN\u2010gamma\u00a0and\u00a0IL\u201017\u00a0by\u00a0na\u00efve\u00a0CD4+\u00a0T\u00a0cells.\u00a0J.\u00a0Immunol. \u00a0182:\u00a03372\u20103379\u00a0\n115. Gorden,\u00a0K.\u00a0B.,\u00a0Gorski,\u00a0K.\u00a0S.,\u00a0Gibson,\u00a0S.\u00a0J.,\u00a0Kedl,\u00a0R.\u00a0M.,\u00a0Kieper,\u00a0W.\u00a0C.,\u00a0Qiu,\u00a0X.,\u00a0\nTomai,\u00a0M.\u00a0A.,\u00a0Alkan,\u00a0S.\u00a0S.,\u00a0Vasilakos, \u00a0J.\u00a0P.\u00a0(2005).\u00a0Synthetic \u00a0TLR\u00a0agonists\u00a0reveal\u00a0\nfunctional \u00a0differences \u00a0between\u00a0human\u00a0TLR7\u00a0and\u00a0TLR8.\u00a0J.\u00a0Immunol. \u00a0174:\u00a01259\u2010\n1268\u00a0\n116. mit\u00a0freundlicher \u00a0Genehmigung \u00a0von\u00a0Frau\u00a0Dr.\u00a0Nelli\u00a0Baal\u00a0(2007),\u00a0Zellul\u00e4re\u00a0\nInteraktionen \u00a0w\u00e4hrend\u00a0der\u00a0plazentaren \u00a0Vaskularisation: \u00a0Modell\u00a0der\u00a0plazentaren \u00a0\nVaskulogenese \u00a0unter\u00a0besonderer \u00a0Ber\u00fccksichtigung \u00a0der\u00a0Rolle\u00a0des\u00a0Trophoblasten) \u00a0\n117. Ahonen,\u00a0C.\u00a0L.,\u00a0Gibson,\u00a0S.\u00a0J.,\u00a0Smith,\u00a0R.\u00a0M.,\u00a0Pederson, \u00a0L.\u00a0K.,\u00a0Lindh,\u00a0J.\u00a0M.,\u00a0Tomai,\u00a0M.\u00a0\nA.,\u00a0Vasilakos, \u00a0J.\u00a0P.\u00a0(1999).\u00a0Dendritic\u00a0cell\u00a0maturation \u00a0and\u00a0subsequent \u00a0enhanced \u00a0T\u2010\ncell\u00a0stimulation \u00a0induced\u00a0with\u00a0the\u00a0novel\u00a0synthetic\u00a0immune\u00a0response\u00a0modifier\u00a0R\u2010\n848.\u00a0Cell.\u00a0Immunol. \u00a0197:\u00a062\u201072\u00a0\n118. Gautier,\u00a0G.,\u00a0Humbert, \u00a0M.,\u00a0Deauvieau, \u00a0F.,\u00a0Scuiller,\u00a0M.,\u00a0Hiscott,\u00a0J.,Bates,\u00a0E.\u00a0E.,\u00a0\nTrinchieri, \u00a0G.,\u00a0Caux,\u00a0C.,\u00a0Garrone,\u00a0P.\u00a0(2005).\u00a0A\u00a0type\u00a0I\u00a0interferone \u00a0autocrine \u2010\nparacrine \u00a0loop\u00a0is\u00a0involved\u00a0in\u00a0Toll\u2010like\u00a0receptor\u2010induced\u00a0interleukin \u201012p70\u00a0\nsecretion \u00a0by\u00a0dendritic\u00a0cells.\u00a0J.\u00a0Exp.\u00a0Med .\u00a0201:\u00a01435\u20101446\u00a0\n119. Fogel,\u00a0M.,\u00a0Long,\u00a0J.\u00a0A.,\u00a0Thompson, \u00a0P.\u00a0J.,\u00a0Upham,\u00a0J.\u00a0W.\u00a0(2002).\u00a0Dendritic\u00a0cell\u00a0\nmaturation \u00a0and\u00a0IL\u201012\u00a0synthesis\u00a0induced\u00a0by\u00a0the\u00a0synthetic\u00a0immune\u2010resonse\u00a0\nmodifier\u00a0S\u201028463.\u00a0J.\u00a0Leukoc.\u00a0Biol.\u00a072:\u00a0932\u2010938\u00a0\n120. Sauder,\u00a0D.\u00a0N.,\u00a0Smith,\u00a0M.\u00a0H.,\u00a0Senta\u2010McMillian, \u00a0T.,\u00a0Sorta,\u00a0I.,\u00a0Meng,\u00a0T.\u00a0C.\u00a0(2003).\u00a0\nRandomized, \u00a0single\u2010blind,\u00a0placebo\u2010controlled \u00a0study\u00a0of\u00a0topical\u00a0application \u00a0of\u00a0the\u00a0\nimmune\u00a0response\u00a0modulator \u00a0resiquimod \u00a0in\u00a0healthy\u00a0adults.\u00a0Antimicrob. \u00a0Agents\u00a0\nChemother. \u00a017:\u00a03846\u20103852\u00a0\u00a0115 Literaturverzeichnis\n121. Trinchieri, \u00a0G.,\u00a0Scott,\u00a0P.\u00a0(1995).\u00a0Interleukin \u201012:\u00a0a\u00a0proinflammatory \u00a0cytokine\u00a0with\u00a0\nimmunoregulatory \u00a0functions. \u00a0Res.\u00a0Immunol. \u00a0146:\u00a0423\u2010431\u00a0\u00a0116 Abbildungsverzeichnis\n8 Abbildungsverzeichnis \t\n\u00a0\nAbb.\u00a01.1.1:\u00a0\u00a0\nMechanismen \u00a0des\u00a0angeborenen \u00a0und\u00a0erworbenen \u00a0Immunsystems. \u00a0\n\u00a0Abb.\u00a01.2.3.1 :\u00a0\u00a0\n\u00dcbersicht \u00a0exogener \u00a0TLR\u2010Liganden\u00a0im\u00a0humanen \u00a0und\u00a0murinen\u00a0System.\u00a0Dargestellt \u00a0sind\u00a0zur\u00a0\nVerdeutlichung \u00a0der\u00a0Vielfalt\u00a0der\u00a0Pathogenerkennung \u00a0verschiedene \u00a0exogene\u00a0TLR\u2010Liganden. \u00a0\n\u00a0Abb.\u00a01.2.3.1.1: \u00a0\u00a0\nStrukturformel \u00a0von\u00a0R848.\u00a0\n\u00a0\nAbb.\u00a01.2.3.2.1: \u00a0\u00a0\nStrukturformel \u00a0vom\u00a0Gardiquimod. \u00a0\n\u00a0\nAbb.\u00a01.2.3.3.1: \u00a0\u00a0\nStrukturformel \u00a0von\u00a0Loxoribine. \u00a0\n\u00a0Abb.\u00a01.2.3.5.1: \u00a0\u00a0\nHaupts\u00e4chliche\n\u00a0Angriffspunkte \u00a0und\u00a0deren\u00a0Auswirkungen \u00a0hervorgerufen \u00a0durch\u00a0die\u00a0\nverschiedenen \u00a0CpG\u00a0ODN\u00b4s.\u00a0\n\u00a0Abb.\u00a01.2.3.5.2: \u00a0\u00a0\nDie\u00a0unterschiedlichen \u00a0Basensequenzen \u00a0der\u00a0drei\u00a0CpG\u00a0ODN\u00a0Klassen.\u00a0Basen\u00a0in\u00a0Gro\u00dfbuchstaben \u00a0\ndargestellt \u00a0bezeichnen \u00a0Phosphodiester \u00a0und\u00a0Basen\u00a0in\u00a0Kleinbuchstaben \u00a0sind\u00a0Phosphorothioate \u00a0\n(Nuklease \u00a0resistent). \u00a0\n\u00a0\n\u00a0\u00a0117 Abbildungsverzeichnis\nAbb.\u00a01.2.3.6.1: \u00a0\u00a0\nDie\u00a0unterschiedlichen \u00a0Basensequenzen \u00a0der\u00a0verwendeten \u00a0iODN\u00b4s.\u00a0\n\u00a0Abb.\u00a01.2.4.1:\u00a0\u00a0\nSchematische \u00a0Darstellung \u00a0der\u00a0TLR\u2010Signalwege. \u00a0Es\u00a0werden\u00a0der\u00a0MyD88\u2010abh\u00e4ngige \u00a0und\u00a0der\u00a0\nMyD88\u2010unabh\u00e4ngige \u00a0Signalweg \u00a0unterschieden. \u00a0Beide\u00a0aktivieren \u00a0die\u00a0Transkriptionsfaktoren \u00a0\nNF\u2010\u03baB\u00a0sowie\u00a0verschiedene \u00a0Interferon \u2010regulierende \u00a0Faktoren\u00a0(IRF3,\u00a0IRF5,\u00a0IRF7)\u00a0und\u00a0induzieren \u00a0\nso\u00a0die\u00a0Freisetzung \u00a0verschiedener \u00a0Zytokine,\u00a0sowie\u00a0die\u00a0Bildung\u00a0von\n\u00a0Adh\u00e4sionsmolek\u00fclen. \u00a0\n\u00a0\nAbb.\u00a01.3.1:\u00a0\u00a0\nDendritische \u00a0Zellen.\u00a0\n\u00a0Abb.\u00a01.3.1.1:\u00a0\u00a0\nVerschiedene \u00a0Urspr\u00fcnge \u00a0der\u00a0dendritischen \u00a0Zellen\u00a0(DC\u00b4s).\u00a0\n\u00a0\nAbb.\u00a01.3.4.1:\u00a0\u00a0\nReifung\u00a0der\u00a0dendritischen \u00a0Zellen.\u00a0\n\u00a0Abb.\u00a01.3.7.1:\u00a0\u00a0\nDie\u00a0Plastizit\u00e4t \u00a0der\u00a0dendritischen \u00a0Zellen.\u00a0\n\u00a0Abb.\u00a01.4.1.1:\u00a0\u00a0\nT\u2010Zell\u2010Differenzierung. \u00a0\n\u00a0\nAbb.\u00a01.4.2.1:\u00a0\u00a0\nT\u2010Zell\u2010Aktivierung \u00a0durch\u00a0reife\u00a0DC\u00b4s.\u00a0\n\u00a0Abb.\u00a02.2.5.1:\u00a0\u00a0\nSchematische \u00a0Darstellung \u00a0der\u00a0FACS\u2010Messung. \u00a0Die\u00a0fluoreszenzmarkierten \u00a0Zellen\n\u00a0werden\u00a0mit\u00a0\ndem\u00a0Probenstrom \u00a0in\u00a0die\u00a0Messzelle \u00a0geleitet.\u00a0Der\u00a0H\u00fcllstrom \u00a0beschleunigt \u00a0die\u00a0Zellen\u00a0und\u00a0f\u00fchrt\u00a0\nsie\u00a0einzeln\u00a0hintereinander \u00a0in\u00a0die\u00a0Mitte\u00a0des\u00a0Probenflusses \u00a0zur\u00a0Messkapillare \u00a0\n(hydrodynamische \u00a0Fokussierung). \u00a0Wenn\u00a0die\u00a0Zelle\u00a0die\u00a0Lichtquelle \u00a0passiert,\u00a0wird\u00a0ein\u00a0\u00a0118 Abbildungsverzeichnis\nFluorochrom \u00a0angeregt\u00a0und\u00a0als\u00a0Emissionslicht \u00a0zum\u00a0Photomultiplier \u00a0geleitet.\u00a0Das\u00a0Lichtsignal \u00a0\nwird\u00a0verst\u00e4rkt\u00a0und\u00a0in\u00a0ein\u00a0elektrisches \u00a0Signal\u00a0umgewandelt. \u00a0Der\u00a0Computer \u00a0berechnet \u00a0\nangehende \u00a0Signale\u00a0und\u00a0zeigt\u00a0diese\u00a0digital\u00a0an\u00a0(Histogramm, \u00a0Dot\u00a0Plot).\u00a0\n\u00a0\nAbbildung \u00a02.2.6.1:\u00a0\u00a0\nSchematische \u00a0Darstellung \u00a0des\u00a0CFDA\u2010SE\u2010Labeling\u00a0und\u00a0der\u00a0Verteilung \u00a0des\u00a0CFSE\u00a0auf\u00a0die\u00a0\nTochterzellen. \u00a0A\u00a0Im\u00a0ersten\u00a0Labelingschritt \u00a0diffundiert \u00a0CFDA\u2010SE\u00a0durch\u00a0die\u00a0Zellmembran, \u00a0\ndanach\u00a0wird\u00a0es\u00a0durch\u00a0Esterasen \u00a0gespalten \u00a0und\u00a0das\u00a0fluoreszierende \u00a0CFSE\u00a0kann\u00a0nicht\u00a0mehr\u00a0\nzur\u00fcckdiffundieren. \u00a0B\u00a0Bei\u00a0einer\u00a0Zellteilung \u00a0wird\u00a0das\u00a0intrazellul\u00e4r \u00a0vorhandene \u00a0CFSE\u00a0\ngleichm\u00e4\u00dfig \u00a0auf\u00a0die\u00a0Tochterzellen \u00a0verteilt.\u00a0Die\u00a0dadurch\u00a0bedingte\u00a0niedrigere \u00a0Fluoreszenz \u00a0der\u00a0\nproliferierten \u00a0Zellen\u00a0l\u00e4sst\u00a0sich\u00a0am\u00a0Durchflusszytometer \u00a0messen.\u00a0\n\u00a0Abb.\u00a02.2.8.1:\u00a0\u00a0\nAls\u00a0Beispiel\u00a0abgebildet \u00a0ist\u00a0eine\u00a0Probenmessung \u00a0mit\u00a0den\u00a06\u00a0im\u00a0Kit\u00a0enthaltenen \u00a0Beads .\u00a0\nGemessen \u00a0wurden\u00a0die\u00a0Fluoreszenz \u2010Intensit\u00e4ten \u00a0mit\u00a0dem\u00a0FL3\u2010Detektor\u00a0(Abszisse). \u00a0Die\u00a0\nquantitative \u00a0Konzentration \u00a0der\u00a0einzelnen \u00a0Zytokine\u00a0ist\u00a0auf\u00a0der\u00a0Ordinate\u00a0dargestellt. \u00a0\n\u00a0Abb.\u00a03.1.1:\u00a0\u00a0\nR848\u00a0ver\u00e4ndert \u00a0dosisabh\u00e4ngig \u00a0die\u00a0Differenzierung \u00a0der\u00a0aus\u00a0Monozyten \u00a0expandierten \u00a0\ndendritischen \u00a0Zellen\u00a0(DC`s).\u00a0FACS\u2010Analyse\u00a0\neines\u00a0Spenders \u00a0nach\u00a0Monozyten \u2010Separation \u00a0durch\u00a0\nden\u00a0AutoMACS\u2122 \u00a0Separator \u00a0und\u00a0anschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0\nund\u00a0ohne\u00a03\u00a0\u00b5M\u00a0\u2013\u00a0300\u00a0nM\u00a0R848\u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nA\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s\u00a0mit\u00a0FITC\u00a0anti\u2010human\u00a0CD14\u00a0und\u00a0APC\u00a0anti\u2010human\u00a0CD1a;\u00a0B\u00a0F\u00e4rbung\u00a0der\u00a0\n3\u00a0\u00b5M\u00a0R848\u2010DC\u00b4s\u00a0s.o.;\u00a0C\u00a0F\u00e4rbung\u00a0der\u00a0750\u00a0nM\u00a0R848\u2010DC\u00b4s\u00a0s.o.;\u00a0D\u00a0F\u00e4rbung\u00a0der\u00a0300\u00a0nM\u00a0R848\u2010\nDC\u00b4s\u00a0s.o..\u00a0Die\u00a0entsprechenden \u00a0Isotypkontrollen \u00a0wurden\u00a0mitgef\u00fchrt. \u00a0\u00a0\n\u00a0Abb.\u00a03.1.2:\u00a0\u00a0\nR848\u00a0ver\u00e4ndert \u00a0dosisabh\u00e4ngig \u00a0die\u00a0Differenzierung \u00a0der\u00a0aus\u00a0Monozyten \u00a0expandierten \u00a0\ndendritischen \u00a0Zellen\u00a0(DC`s).\u00a0Graphische \u00a0Darstellung \u00a0der\u00a0z.T.\u00a0beispielhaft \u00a0dargestellten \u00a0FACS\u2010\nAnalysen. \u00a0\u00a0\nA\u00a0CD14\u2010Expression \u00a0(%)\u00a0und\u00a0B\u00a0\nCD1a\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0\nStimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0\u2013\u00a0300\u00a0nM\u00a0R848.\u00a0\u00a0\u00a0119 Abbildungsverzeichnis\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a04.\u00a0\n\u00a0\u00a0\u00a0p<\u00a00,05\u00a0versus\u00a0MoDC\u00b4s\u00a0(Kontroll\u2010DC\u00b4s)\u00a0(two\u2010tailed\u00a0t\u2010test).\u00a0\n\u00a0Abb.\u00a03.2.1.1:\u00a0\u00a0\nGardiquimod \u00a0und\u00a0R848\u00a0im\u00a0Vergleich. \u00a0Gardiquimod \u00a0als\u00a0spezifischer \u00a0TLR7\u2010Ligand\u00a0ver\u00e4ndert \u00a0im\u00a0\nGegensatz \u00a0zu\u00a0R848\u00a0die\u00a0Differenzierung \u00a0der\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0dendritischen \u00a0Zellen\u00a0\n(MoDC`s) \u00a0nicht.\u00a0FACS\u2010Analyse\u00a0\neines\u00a0Spenders \u00a0nach\u00a0Monozyten \u2010Separation \u00a0durch\u00a0den\u00a0\nAutoMACS\u2122 \u00a0Separator \u00a0und\u00a0anschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0\nohne\u00a00,1\u00a0\u2013\u00a01\u00a0\u00b5g/ml\u00a0(0,319\u00a0\u2013\u00a03,19\u00a0\u00b5M)\u00a0Gardiquimod \u00a0bzw.\u00a03\u00a0\u00b5M\u00a0R848\u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nA\u00a0Isotypkontrolle \u00a0der\u00a0MoDC\u00b4s;\u00a0B\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s\u00a0mit\u00a0FITC\u00a0anti\u2010human\u00a0CD14,\u00a0APC\u00a0anti\u2010\nhuman\u00a0CD1a,\u00a0PE\u00a0anti\u2010human\u00a0HLA\u2010DR;\u00a0C\u00a0F\u00e4rbung\u00a0der\u00a00,1\u00a0\u00b5g/ml\u00a0(0,319\u00a0\u00b5M)\u00a0Gardiquimod \u2010DC\u00b4s\u00a0\ns.o.;\u00a0Isotypkontrolle \u00a00,1\u00a0\u00b5g/ml\u00a0(0,319\u00a0\u00b5M)\u00a0Gardiquimod \u2010DC\u00b4s\u00a0siehe\u00a0MoDC\u00b4s;\u00a0D\u00a0F\u00e4rbung\u00a0der\u00a01\u00a0\n\u00b5g/ml\u00a0(3,19\u00a0\u00b5M)\u00a0Gardiquimod \u2010DC\u00b4s\u00a0s.o.;\u00a0Isotypkontrolle \u00a0der\u00a01\u00a0\u00b5g/ml\u00a0(3,19\u00a0\u00b5M)\u00a0Gardiquimod \u2010\nDC\u00b4s\u00a0siehe\u00a0MoDC\u00b4s;\u00a0E\u00a0Isotypkontrolle \u00a0der\u00a03\u00a0\u00b5M\u00a0R848\u2010DC\u00b4s;\u00a0F\u00a0F\u00e4rbung\u00a0der\u00a03\u00a0\u00b5M\u00a0R848\u2010DC\u00b4s\u00a0\ns.o..\u00a0\u00a0\n\u00a0Abb.\u00a03.2.1.2:\u00a0\u00a0\nGardiquimod \u00a0und\u00a0R848\u00a0im\u00a0Vergleich. \u00a0Gardiquimod \u00a0als\u00a0spezifischer \u00a0TLR7\u2010Ligand\u00a0ver\u00e4ndert \u00a0im\u00a0\nGegensatz \u00a0zu\u00a0R848\u00a0die\u00a0Differenzierung \u00a0der\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0dendritischen \u00a0Zellen\u00a0\n(DC`s)\u00a0nicht.\u00a0Graphische \u00a0Darstellung \u00a0der\u00a0beispielhaft \u00a0dargestellten \u00a0FACS\u2010Analysen. \u00a0\nA\u00a0CD14\u2010Expression \u00a0(%),\u00a0B\n\u00a0CD1a\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0\nStimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0und\u00a00,1\u00a0\u2013\u00a01\u00a0\u00b5g/ml\u00a0(0,319\u00a0\u2013\u00a03,19\u00a0\u00b5M)\u00a0Gardiquimod \u00a0oder\u00a03\u00b5M\u00a0\nR848.\u00a0\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a06.\u00a0\n\u00a0Abb.\u00a03.2.2.1:\u00a0\u00a0\nLoxoribine \u00a0hat\u00a0keinen\u00a0Effekt\u00a0auf\u00a0die\u00a0Differenzierung \u00a0der\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0\ndendritischen \u00a0Zellen\u00a0(MoDC`s). \u00a0Als\u00a0Beispiel\u00a0eine\u00a0FACS\u2010Analyse\u00a0eines\u00a0Spenders \u00a0nach\u00a0\nMonozyten \u2010Separation \u00a0durch\u00a0den\u00a0AutoMACS\u2122 \u00a0Separator \u00a0und\u00a0anschlie\u00dfender \u00a0Stimulation \u00a0\nder\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a0500\u00a0\u00b5M\u00a0Loxoribine \u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nA\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s\u00a0mit\u00a0FITC\u00a0anti\u2010human\u00a0CD14\u00a0und\u00a0APC\u00a0anti\u2010human\u00a0CD1a;\u00a0B\u00a0F\u00e4rbung\u00a0der\u00a0\nmit\u00a0500\u00a0\u00b5M\u00a0Loxoribine \u00a0stimulierten \u00a0MoDC\u00b4s\u00a0s.o..\u00a0\u00a0\u00a0120 Abbildungsverzeichnis\nAbb.\u00a03.2.2.2:\u00a0\u00a0\nLoxoribine \u00a0hat\u00a0keinen\u00a0Effekt\u00a0auf\u00a0die\u00a0Differenzierung \u00a0der\u00a0aus\u00a0Monozyten \u00a0generierten \u00a0\ndendritischen \u00a0Zellen\u00a0(MoDC`s). \u00a0Graphische \u00a0Darstellung \u00a0der\u00a0z.T.\u00a0beispielhaft \u00a0dargestellten \u00a0\nFACS\u2010Analysen. \u00a0\nA\u00a0CD14\u2010Expression \u00a0(%)\u00a0und\u00a0B\u00a0CD1a\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0\nStimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a01\u00a0mM\u00a0\u2013\u00a0100\u00a0\u00b5M\u00a0Loxoribine \u00a0bzw.\u00a0der\u00a0\nentsprechenden, \u00a0als\u00a0neg.\u00a0Kontrolle\u00a0dienenden, \u00a0Mengen\u00a0DMSO\u00a0(L\u00f6sungsmittel). \u00a0\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a03.\u00a0\n\u00a0\nAbb.\u00a03.2.3.1:\u00a0\u00a0\nDie\u00a0ver\u00e4nderte \u00a0Differenzierung \u00a0der\u00a0DC\u00b4s\u00a0mit\u00a0Hilfe\u00a0von\u00a0R848\u00a0ist\u00a0TLR8\u00a0vermittelt. \u00a0Graphische \u00a0\nDarstellung. \u00a0\nA\u00a0CD14\u2010Expression \u00a0(%),\u00a0B\u00a0CD1a\u2010Expression \u00a0(%),\u00a0C\u00a0HLA\u2010DR\u2010Expression \u00a0(%)\u00a0und\u00a0D\u00a0HLA\u2010DR\u2010\nExpression \u00a0(MFI)\u00a0der\u00a0MoDC\u00b4s\u00a0(CtrDC)\u00a0und\u00a0unterschiedlich \u00a0inhibierten \u00a0R848\u2010DC\u00b4s\u00a0nach\u00a05\u00a0\nTagen\u00a0Stimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104,\u00a0iODN\u00a02088,\u00a0iODN\u00a020958,\u00a0iODN\u00a020959\u00a0mit\u00a0und\u00a0ohne\u00a0\nR848.\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a03.\u00a0\n\u00a0\u00a0\u00a0p<\u00a00,05\u00a0versus\u00a0R848\u2010DC\u00b4s\u00a0(two\u2010tailed\u00a0t\u2010test).\u00a0\n\u00a0\nAbb.\u00a03.3.1.1:\u00a0\u00a0\nDie\u00a0Expression \u00a0von\u00a0CD86\u00a0und\u00a0HLA\u2010DR\u00a0der\u00a0R848\u2010DC\u00b4s\u00a0im\u00a0Vergleich \u00a0zu\u00a0der\u00a0Stimulation \u00a0mit\u00a0\nGardiquimod. \u00a0R848\u2010DC\u00b4s\u00a0exprimieren \u00a0in\u00a0h\u00f6herem\u00a0Ma\u00dfe\u00a0costimulatorische \u00a0Molek\u00fcle \u00a0als\u00a0\nGardiquimod \u2010DC\u00b4s\u00a0und\u00a0MoDC\u00b4s.\u00a0FACS\u2010Analyse\u00a0eines\u00a0Spenders \u00a0nach\u00a0Monozyten \u2010Separation \u00a0\ndurch\u00a0den\u00a0AutoMACS\u2122 \u00a0Separator \u00a0und\u00a0anschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u2010\n4\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0oder\u00a01\u00a0\u00b5g/ml\u00a0(3,19\u00a0\u00b5M)\u00a0Gardiquimod \u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nA\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s,\u00a0B\u00a0der\u00a01\u00a0\u00b5g/ml\u00a0(3,19\u00a0\u00b5M)\u00a0Gardiquimod \u2010DC\u00b4s\u00a0und\u00a0C\u00a0der\u00a03\u00a0\u00b5M\u00a0R848\u2010\nDC\u00b4s\u00a0mit\u00a0PE\u00a0anti\u2010human\u00a0CD86\u00a0und\u00a0PE\u00a0anti\u2010human\u00a0HLA\u2010DR.\u00a0\n\u00a0\nAbb.\u00a03.3.1.2:\u00a0\u00a0\nDie\u00a0Expression \u00a0kostimulatorischer \u00a0Molek\u00fcle \u00a0und\u00a0HLA\u2010DR\u00a0der\u00a0R848\u2010DC\u00b4s\u00a0im\u00a0Vergleich \u00a0zu\u00a0der\u00a0\nStimulation \u00a0mit\u00a0Gardiquimod. \u00a0R848\u00a0blockiert\u00a0nicht\u00a0die\u00a0Differenzierung \u00a0und\u00a0Reifung\u00a0der\u00a0DC\u00b4s.\u00a0\u00a0121 Abbildungsverzeichnis\nEs\u00a0entsteht\u00a0eine\u00a0andere\u00a0Zellpopulation. \u00a0Graphische \u00a0Darstellung \u00a0der\u00a0z.T.\u00a0beispielhaft \u00a0\ndargestellten \u00a0FACS\u2010Analysen. \u00a0\nA\u00a0CD40\u2010Expression \u00a0(MFI),\u00a0B\u00a0CD83\u2010Expression \u00a0(MFI),\u00a0C\u00a0CD86\u2010Expression \u00a0(MFI),\u00a0D\u00a0HLA\u2010DR\u2010\nExpression \u00a0(MFI)\u00a0und\u00a0E\u00a0HLA\u2010DR\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0\nStimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0oder\u00a00,1\u00a0\u2013\u00a01\u00a0\u00b5g/ml\u00a0(0,319\u00a0\u2013\u00a03,19\u00a0\u00b5M)\u00a0\nGardiquimod \u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a06.\u00a0\n\u00a0\u00a0\u00a0p<\u00a00,05\u00a0versus\u00a0MoDC\u00b4s\u00a0(Kontroll\u2010DC\u00b4s)\u00a0(two\u2010tailed\u00a0t\u2010test).\u00a0\n\u00a0\nAbb.\u00a03.3.2.1:\u00a0\u00a0\nR848\u2010DC\u00b4s\u00a0exprimieren \u00a0CD123.\u00a0FACS\u2010Analyse\u00a0eines\u00a0Spenders \u00a0nach\u00a0Monozyten \u2010Separation \u00a0\ndurch\u00a0den\u00a0AutoMACS\u2122 \u00a0Separator \u00a0und\u00a0anschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0\u00a0\nGM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0oder\u00a01\u00a0\u00b5g/ml\u00a0(3,19\u00a0\u00b5M)\u00a0Gardiquimod \u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nA\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s,\u00a0der\u00a01\u00a0\u00b5g/ml\u00a0Gardiquimod \u2010DC\u00b4s\u00a0und\u00a0der\u00a03\u00a0\u00b5M\u00a0R848\u2010DC\u00b4s\u00a0mit\u00a0PE\u00a0anti\u2010\nhuman\u00a0CD123.\u00a0\n\u00a0Abb.\u00a03.3.2.2:\u00a0\u00a0\nR848\n\u2010DC\u00b4s\u00a0exprimieren \u00a0CD123.\u00a0Graphische \u00a0Darstellung \u00a0der\u00a0z.T.\u00a0beispielhaft \u00a0dargestellten \u00a0\nFACS\u2010Analysen. \u00a0\nA\u00a0CD123\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0Stimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0\nmit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0oder\u00a00,1\u00a0\u2013\u00a01\u00a0\u00b5g/ml\u00a0(0,319\u00a0\u2013\u00a03,19\u00a0\u00b5M)\u00a0Gardiquimod \u00a0\u00fcber\u00a05\u00a0Tage.\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a06.\u00a0\n\u00a0\nAbb.\u00a03.4.1.1:\u00a0\u00a0\nDie\u00a0FOXP3\u2010Expression \u00a0der\u00a0MoDC\u00b4s\u00a0und\u00a0der\u00a0R848\u2010DC\u00b4s\u00a0im\u00a0Vergleich. \u00a0R848\u00a0ver\u00e4ndert \u00a0nicht\u00a0die\u00a0\nintrazellul\u00e4re \u00a0FOXP3\u2010Expression \u00a0.\u00a0Graphische \u00a0Darstellung. \u00a0\nFOXP3\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0Stimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0\nmit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848.\u00a0\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a03.\u00a0\n\u00a0\u00a0\u00a0\u00a0122 Abbildungsverzeichnis\nAbb.\u00a03.4.2.1:\u00a0\u00a0\nDie\u00a0CD122\u2010Expression \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0im\u00a0Vergleich. \u00a0R848\u00a0ver\u00e4ndert \u00a0nicht\u00a0die\u00a0CD122\u2010\nExpression. \u00a0Graphische \u00a0Darstellung. \u00a0\u00a0\nCD122\u2010Expression \u00a0(%)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a05\u00a0Tagen\u00a0Stimulation \u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0\nmit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0oder\u00a0nur\u00a0mit\u00a0R848\u00a0bzw.\u00a0ganz\u00a0ohne\u00a0Stimuli\u00a0(Monozyten). \u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a04.\u00a0\n\u00a0Abb.\u00a03.5.1:\u00a0\u00a0\nDie\u00a0Expression \u00a0der\u00a0Oberfl\u00e4chenmolek\u00fcle \u00a0der\u00a0R848\u2010DC\u00b4s\u00a0im\u00a0Vergleich. \u00a0Graphische \u00a0Darstellung \u00a0\nder\u00a0FACS\u2010Analyse\u00a0eines\u00a0Spenders \u00a0nach\u00a0Monozyten \u2010Separation \u00a0durch\u00a0den\u00a0AutoMACS\u2122 \u00a0\nSeparator \u00a0und\u00a0anschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0\nR848\u00a0f\u00fcr\u00a03\u00a0Tage;\u00a0danach\u00a0\ndreimaliges \u00a0Waschen\u00a0der\u00a0Zellen\u00a0mit\u00a0DC\u2010Medium\u00a0und\u00a0anschlie\u00dfend \u00a0\nwieder\u00a03\u00a0Tage\u00a0mit\u00a0bzw.\u00a0ohne\u00a0GM\u2010CSF\u00a0und\u00a0IL\u20104\u00a0in\u00a0Kultur\u00a0genommen. \u00a0\u00a0\nA\u00a0CD14\u2010Expression \u00a0(%),\u00a0B\u00a0CD1a\u2010Expression \u00a0(%),\u00a0C\u00a0CD123\u2010Expression \u00a0(%),\u00a0HLA\u2010DR\u2010Expression \u00a0\n(MHC\u2010II)\u00a0(%)\u00a0und\u00a0D\u00a0HLA\u2010DR\u2010Expression \u00a0(MHC\u00a0II)\u00a0(MFI)\u00a0der\u00a0isolierten \u00a0Monozyten \u00a0nach\u00a06\u00a0\nTagen.\u00a0\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a03.\u00a0\n\u00a0Abb.\u00a03.6.1:\u00a0\u00a0\nFACS\u2010Analyse\u00a0der\u00a0T\u2010Zell\u2010Proliferation \u00a0eines\u00a0Spenders \u00a0nach\u00a0Monozyten \u2010Separation \u00a0durch\u00a0den\u00a0\nAutoMACS\u2122 \u00a0Separator \u00a0und\u00a0anschlie\u00dfender \u00a0Stimulation \u00a0der\u00a0Zellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0\nohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0\u00fcber\u00a03\u00a0Tage.\u00a0Ansetzen \u00a0\nder\u00a0MLR\u00a0mit\u00a0den\u00a0Stimulatorzellen \u00a0und\u00a0frisch\u00a0\nisolierten, \u00a0mit\u00a01\u00a0\u00b5M\u00a0CFDA\u00a0SE\u00a0markierten, \u00a0allogenen \u00a0PBMC\u00b4s\u00a0(Responderzellen) \u00a0in\u00a0der\u00a0Ratio\u00a01\u00a0\n+\u00a04\u00a0f\u00fcr\u00a05\u00a0\u2013\u00a07\u00a0d.\u00a0\nA\u00a0F\u00e4rbung\u00a0der\u00a0MoDC\u00b4s\u00a0(Stimulatorzellen) \u00a0mit\u00a0den\u00a0markierten \u00a0Responderzellen \u00a0(Ratio\u00a01+4)\u00a0\nmit\u00a0APC\u00a0anti\u2010human\u00a0CD11b,\u00a0APC\u2010H7\u00a0anti\u2010human\u00a0CD4,\u00a0Pacific\u00a0Blue\u00a0anti\u2010human\u00a0CD3;\u00a0B\u00a0\nF\u00e4rbung\u00a0der\u00a03\u00a0\u00b5M\u00a0R848\u2010DC\u00b4s\u00a0(Stimulatorzellen) \u00a0mit\u00a0den\u00a0markierten \u00a0Responderzellen \u00a0(Ratio\u00a0\n1+4)\u00a0s.o..\u00a0\n\u00a0\nAbb.\u00a03.6.2:\u00a0\u00a0\nR848\u2010DC\u00b4s\u00a0induzieren \u00a0eine\u00a0bessere\u00a0T\u2010Zell\u2010Proliferation \u00a0als\u00a0MoDC\u00b4s.\u00a0Graphische \u00a0Darstellung \u00a0\nder\u00a0z.T.\u00a0beispielhaft \u00a0dargestellten \u00a0FACS\u2010Analysen. \u00a0\u00a0123 Abbildungsverzeichnis\nA\u00a0Relative\u00a0CD3\u2010\u00a0(%),\u00a0B\u00a0CD4\u2010\u00a0(%)\u00a0und\u00a0C\u00a0CD8\u2010Proliferation \u00a0(%)\u00a0der\u00a0Responderzellen \u00a0induziert\u00a0\ndurch\u00a0CtrDC\u00a0(MoDC\u00b4s) \u00a0und\u00a0R848\u2010DC\u00b4s\u00a0\u00fcber\u00a05\u00a0\u2013\u00a07\u00a0Tage.\u00a0Als\u00a0Negativ\u2010Kontrolle\u00a0dienten\u00a0\nunstimulierte \u00a0Responderzellen. \u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=\u00a05.\u00a0\n\u00a0\u00a0\u00a0p<\u00a00,05\u00a0versus\u00a0MoDC\u00b4s\u00a0(CtrDC\u00b4s)\u00a0(two\u2010tailed\u00a0t\u2010test).\u00a0\n\u00a0Abb.\u00a03.7.1:\u00a0\u00a0\nR848\u2010DC\u00b4s\u00a0produzieren \u00a0verschiedene \u00a0Zytokine\u00a0mit\u00a0immunregulatorischen \u00a0\nFunktionen. \u00a0Beispielhafte \u00a0Darstellung \u00a0einer\u00a0CBA\u00a0FACS\u2010Analyse.\u00a0\nNach\u00a0der\u00a0Monozyten \u2010Separation \u00a0durch\u00a0den\u00a0AutoMACS\u2122 \u00a0Separator \u00a0wurden\u00a0die\u00a0\nZellen\u00a0mit\u00a0GM\u2010CSF/IL\u20104\u00a0mit\u00a0und\u00a0ohne\u00a03\u00a0\u00b5M\u00a0R848\u00a0f\u00fcr\u00a03\u00a0Tage\u00a0kultiviert. \u00a0\nAnschlie\u00dfend \u00a0erfolgte\u00a0dreimaliges \u00a0Waschen\u00a0der\u00a0Zellen\u00a0mit\u00a0DC\n\u2010Medium\u00a0und\u00a0dann\u00a0\nwurden\u00a0die\u00a0Zellen\u00a0nach\u00a012h\u00a0bzw.\u00a072h\u00a0Ruhen\u00a0mit\u00a02\u00a0\u00b5g/ml\u00a0LPS\u00a0bzw.\u00a03\u00a0\u00b5g/ml\u00a0CpG\u00a0\n2006\u00a0f\u00fcr\u00a0jeweils\u00a024h\u00a0restimuliert. \u00a0\u00a0\n\u00a0\nAbb.\u00a03.7.2:\u00a0\u00a0\nR848\u2010DC\u00b4s\u00a0produzieren \u00a0nach\u00a0Restimulation \u00a0mit\u00a0LPS\u00a0verschiedene \u00a0Zytokine\u00a0mit\u00a0\nimmunregulatorischen \u00a0Funktionen. \u00a0Graphische \u00a0Darstellung \u00a0der\u00a0beispielhaft \u00a0dargestellten \u00a0\nCBA\u2010Analysen. \u00a0\u00a0\nA\u00a0IL\u201012p70\u2010Produktion \u00a0(pg/ml);\u00a0B\u00a0TNF\u2010\u03b1\u2010Produktion \u00a0(pg/ml);\u00a0C\u00a0IL\u201010\u2010Produktion \u00a0(pg/ml);\u00a0D\u00a0\nIL\u20106\u2010Produktion \u00a0(pg/ml)\u00a0und\u00a0E\u00a0Verh\u00e4ltnis \u00a0TNF\u2010\u03b1\u00a0zu\u00a0IL\u201010\u00a0nach\u00a012\u00a0bzw.\u00a072\u00a0h\u00a0Ruhen\u00a0und\u00a0\nfolgender \u00a0Restimulation \u00a0der\u00a0CtrDC\u00a0(MoDC\u00b4s) \u00a0und\u00a0der\u00a0R848\u2010DC\u00b4s\u00a0mit\u00a02\u00a0\u00b5g/ml\u00a0LPS.\u00a0\nMittelwerte \u00a0\u00b1\u00a0stat.\u00a0Standardfehler; \u00a0Anzahl\u00a0der\u00a0Stimulationen \u00a0n\u00a0=4.\u00a0\n\u00a0\u00a0\u00a0p<\u00a00,05\u00a0versus\u00a0CtrDC\u00b4s\u00a0(MoDC\u00b4s) \u00a0(friedman\u00a0test).\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0124 Abk\u00fcrzungsverzeichnis\n9 Abk\u00fcrzungsverzeichnis \t\n\u00a0\nAbb.\u00a0 Abbildung \u00a0\nAK\u00a0 Antik\u00f6rper \u00a0\nAP\u00a0 Adaptorprotein \u00a0\nAPC\u00a0 Allophycocyanin \u00a0\nAPC\u00a0 antigen\u00a0presenting \u00a0cell\u00a0\nBDCA\u00a0 blood\u00a0dendritic\u00a0cell\u00a0antigen\u00a0\nBSA\u00a0 bovine\u00a0serum\u00a0albumin\u00a0\nbzw.\u00a0 beziehungsweise \u00a0\nca.\u00a0 circa\u00a0\nCa2+\u00a0Calcium\u00a0\nCBA\u00a0 cytometric \u00a0bead\u00a0array\u00a0\nCCL\u00a0 CC\u00a0motif\u00a0receptor\u00a0ligand\u00a0\nCCR\u00a0 CC\u00a0motif\u00a0receptor\u00a0\u00a0\nCD\u00a0 cluster\u00a0of\u00a0differentiation \u00a0\nCFDA\u2010SE\u00a0 Carboxyfluoreszeindiazetat \u2010Succinimidylester \u00a0\nCFSE\u00a0 Carboxyfluoreszein \u2010Succinimidylester \u00a0\nCO2\u00a0 Kohlendioxid \u00a0\nCOX2\u00a0 Cyclooxygenase \u00a02\u00a0\nCpG\u00a0 Cytosin\u2010phosphatidyl \u2010Guanosin \u00a0\u00a0125 Abk\u00fcrzungsverzeichnis\nCSF\u00a0 colony\u00a0stimulating \u00a0factor\u00a0\nCTL\u00a0 cytotoxic\u00a0T\u00a0lymphocyte \u00a0\nDAG\u00a0 Diacylglycerol \u00a0\nDC\u00a0 dendritic\u00a0cell\u00a0\nDMSO\u00a0 Dimethylsulfoxid \u00a0\nDNA\u00a0 Desoxyribonukleins\u00e4ure \u00a0\nds\u00a0 double\u00a0stranded\u00a0\nEDTA\u00a0 Ethylendiamintetraacetat \u00a0\nELISA\u00a0 enzyme\u2010linked\u2010immunosorbent \u00a0assay\u00a0\nER\u00a0 endoplasmatisches \u00a0Retikulum \u00a0\nFACS\u00a0 fluorescent \u2010activating \u00a0cell\u00a0sorting\u00a0\nFCS\u00a0 fetal\u00a0calf\u00a0serum\u00a0\nFcy\u2010Rezeptor\u00a0 niedrig\u00a0affiner\u00a0Rezeptor\u00a0f\u00fcr\u00a0das\u00a0Fc\u2010Fragment \u00a0des\u00a0IgG\u00a0\nFITC\u00a0 Fluoresceinisothiocyanat \u00a0\nFL\u00a0 Fluoreszenz \u00a0Kanal\u00a0\nFOXP3\u00a0 Forkhead \u00a0box\u00a0protein\u00a0P3\u00a0\nFSC\u00a0 forward\u00a0scatter\u00a0\ng\u00a0 Gramm\u00a0\ng\u00a0 Gravidit\u00e4t \u00a0\nGM\u2010CSF\u00a0 granulocyte \u2010macrophage \u00a0colony\u00a0stimulating \u00a0factor\u00a0\nh\u00a0 Stunde\u00a0\nHEPES\u00a0 2\u2010(N\u2010Hydroxyethylpiperazin) \u20102\u00b4\u2010Ethansulfons\u00e4ure \u00a0\u00a0126 Abk\u00fcrzungsverzeichnis\nHIV\u00a0 humanes\u00a0Immundefizienz \u00a0Virus\u00a0\nHLA\u00a0 human\u00a0leucocyte \u00a0antigen\u00a0\nICAM\u00a0 intrazellul\u00e4res \u00a0Adh\u00e4sionsmolek\u00fcl \u00a0\niDC\u00b4s\u00a0 gewebsst\u00e4ndige \u00a0unreife\u00a0dendritische \u00a0Zellen\u00a0\nIFN\u00a0 Interferon \u00a0\nIg\u00a0 Immunglobulin \u00a0\nIL\u00a0 Interleukin \u00a0\niODN\u00b4s\u00a0 inhibitorische \u00a0synthethische \u00a0Oligonucleotide \u00a0\nIP3\u00a0 Inositoltriphosphat \u00a0\nIRAK\u00a0 Interleukin \u20101\u00a0rezeptor\u00a0associated \u00a0kinase\u00a0\nIRF\u00a0 IFN\u2010regulatory \u00a0factor\u00a0\nJAK\u00a0 Janus\u2010aktivierte \u00a0Kinase\u00a0\nl\u00a0 Liter\u00a0\nLC\u00b4s\u00a0 Langerhanszellen \u00a0\nLPS\u00a0 Lipopolysaccharid \u00a0\nLRR\u00b4s\u00a0 Leucin\u2010reiche\u00a0Abschnitte \u00a0\nLTA\u00a0 Lipoteichons\u00e4ure \u00a0\nM\u00a0 Molar\u00a0(mol/l)\u00a0\nm\u00a0 Meter\u00a0\nm\u00a0 Milli\u00a0(10\u20103)\u00a0\nMACS\u00a0 magnetic \u00a0activating \u00a0cell\u00a0sorting\u00a0\nMAP\u2010Kinase\u00a0 Mitogen\u2010aktivierte \u00a0Proteinkinase \u00a0\u00a0127 Abk\u00fcrzungsverzeichnis\nM\u2010CSF\u00a0 macrophage \u00a0colony\u00a0stimulating \u00a0factor\u00a0\nMDA5\u00a0 melanoma \u00a0differentiation \u2010associated \u00a0gene\u00a05\u00a0\nmDC\u00b4s\u00a0 myeloide \u00a0dendritische \u00a0Zellen\u00a0\nMFI\u00a0 mittlere\u00a0Fluoreszenzintensit\u00e4t \u00a0\nMHC\u00a0 major\u00a0histocompatibility \u00a0complex\u00a0\nMIIC\u00b4s\u00a0 MHC\u2010II\u2010rich\u2010compartiments \u00a0\nMIP\u00a0 Makrophagen \u00a0inflammatorisches \u00a0Protein\u00a0\nmin\u00a0 Minute\u00a0\nMLR\u00a0 mixed\u00a0Lymphocyte \u2010reaction\u00a0\nMoDC\u00b4s\u00a0 monocyte \u00a0derived\u00a0dendritic\u00a0cells\u00a0\nmRNA\u00a0 messenger \u00a0RNA\u00a0\nMyD88\u00a0 myeloid\u00a0differentiation \u00a0primary\u2010response\u00a0protein\u00a088\u00a0\n\u00b5\u00a0 Mikro\u00a0(10\u20106)\u00a0\nn\u00a0 Nano\u00a0(10\u20109)\u00a0\nNF\u2010\u03baB\u00a0 Nukle\u00e4rer \u00a0Faktor\u2010\u03baB\u00a0\nNK\u2010Zellen\u00a0 nat\u00fcrliche \u00a0Killerzellen \u00a0\nNLR\u00b4s\u00a0 Nod\u2010like\u00a0receptors \u00a0\nODN\u00b4s\u00a0 synthethische \u00a0Oligodesoxynucleotide \u00a0\np\u00a0 Piko\u00a0(10\u201012)\u00a0\nPAMP\u00b4s\u00a0 pathogen \u2010associated \u00a0molecular \u00a0patterns\u00a0\u00a0\nPam3Cys\u00a0 synthetisches \u00a0tripalmitoyliertes \u00a0Lipopeptid \u00a0\nPBMC\u00b4s\u00a0 peripheral \u00a0blood\u00a0mononuclear \u00a0cells\u00a0\u00a0128 Abk\u00fcrzungsverzeichnis\nPBS\u00a0 phosphate \u00a0buffered\u00a0saline\u00a0\npDC\u00b4s\u00a0 plasmacytiod \u00a0dendritic\u00a0cells\u00a0\nPE\u00a0 Phycoerythrin \u00a0\nPGE 2\u00a0 Prostaglandin \u00a0E2\u00a0\nPIP 2\u00a0 Phosphatidylinositoldiphosphat \u00a0\nPKC\u00a0 Proteinkinase \u00a0C\u00a0\nPLC\u00a0 Phospholipase \u00a0C\u00a0\nPRR\u00b4s\u00a0 pattern\u00a0recognition \u00a0receptors \u00a0\nrh\u00a0GM\u2010CSF\u00a0 rekombinantes \u00a0humanes\u00a0GM\u2010CSF\u00a0\nRIP\u00a0 Rezeptorinteragierendes \u00a0Protein\u00a0\nRLH\u00b4s\u00a0 RIG\u2010like\u00a0helicases\u00a0\nRNA\u00a0 Ribonukleins\u00e4ure \u00a0\nrpm\u00a0 rounds\u00a0per\u00a0minute\u00a0\nRPMI\u00a0 Roswell\u00a0Park\u00a0Memorial \u00a0Institute\u2010Medium\u00a0\nRT\u00a0 Raumtemperatur \u00a0\nsIL\u20106R\u00a0 l\u00f6slicher\u00a0Interleukin \u20106\u2010Rezeptor\u00a0\nss\u00a0 single\u00a0stranded\u00a0\nSSC\u00a0 side\u00a0scatter\u00a0\nSTAT\u00a0 signal\u00a0transducer \u00a0and\u00a0activator\u00a0of\u00a0transcription \u00a0\nTBK\u00a0 TANK\u2010bindende \u00a0Kinase\u00a0\nTCR\u00a0 T\u00a0cell\u00a0receptor\u00a0\nTGF\u00a0 transforming \u00a0growth\u00a0factor\u00a0\u00a0129 Abk\u00fcrzungsverzeichnis\nTH1\u2010Zellen\u00a0 T\u2010Helferzelle \u00a01\u00a0\nTH2\u2010Zellen\u00a0 T\u2010Helferzelle \u00a02\u00a0\nTIR\u00a0 Toll\u2010/IL\u20101\u00a0receptor\u00a0domain\u00a0\nTIRAP\u00a0 Toll\u2010/IL\u20101\u00a0receptor\u00a0(TIR)\u2010domain\u00a0containing \u00a0adaptor\u00a0\n\u00a0 protein\u00a0\nTLR\u00b4s\u00a0 Toll\u2010like\u00a0receptors \u00a0\nTNF\u00a0 tumor\u2010necrosis\u00a0factor\u00a0\nTRAF\u00a0 tumor\u2010necrosis\u00a0factor\u2010associated \u2010factor\u00a0\nTRAM\u00a0 TRIF\u2010related\u00a0adaptor\u00a0molecule\u00a0\nTRIF\u00a0 TIR\u2010domain\u2010containing \u00a0adaptor\u00a0inducing\u00a0IFN\u2010\u03b2\u00a0\ntRNA\u00a0 transfer\u00a0RNA\u00a0\nu.a.\u00a0 unter\u00a0anderem\u00a0\nz.B.\u00a0 zum\u00a0Beispiel\u00a0\nz.T.\u00a0 zum\u00a0Teil\u00a0\n\u00b0C\u00a0 Grad\u00a0Celsius\u00a0\n%\u00a0 Prozent\u00a0\n%\u00a0(v/v)\u00a0 Volumenprozent \u00a0pro\u00a0Volumen\u00a0\n%\u00a0(w/v)\u00a0 Gewichtsprozent \u00a0pro\u00a0Volumen\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0130 Danksagung\n10 Danksagung \t\n\u00a0\nAn\u00a0dieser\u00a0Stelle\u00a0m\u00f6chte\u00a0ich\u00a0allen\u00a0danken,\u00a0die\u00a0zum\u00a0Gelingen\u00a0dieser\u00a0Arbeit\u00a0beigetragen \u00a0\nhaben.\u00a0\n\u00a0\n\u00a0\nAls\u00a0erstes\u00a0m\u00f6chte\u00a0ich\u00a0mich\u00a0bei\u00a0Herrn\u00a0Prof.\u00a0Dr.\u00a0Gregor\u00a0Bein\u00a0und\u00a0Herrn\u00a0Prof.\u00a0Dr.\u00a0Holger\u00a0\nHackstein \u00a0f\u00fcr\u00a0die\u00a0Bereitstellung \u00a0des\u00a0interessanten \u00a0Themas\u00a0und\u00a0der\u00a0Schaffung \u00a0optimaler \u00a0\nBedingungen \u00a0zur\u00a0Anfertigung \u00a0dieser\u00a0Arbeit\u00a0bedanken. \u00a0\n\u00a0\nGanz\u00a0herzlich\u00a0danke\u00a0ich\u00a0Herrn\u00a0Prof.\u00a0Dr.\u00a0Holger\u00a0Hackstein \u00a0f\u00fcr\u00a0die\u00a0vielen\u00a0fachlichen \u00a0\nAnregungen, \u00a0die\u00a0stete\u00a0Diskussionsbereitschaft \u00a0und\u00a0die\u00a0umfassende \u00a0Betreuung \u00a0und\u00a0\nF\u00f6rderung \u00a0meiner\u00a0Arbeit.\u00a0\n\u00a0\nHerrn\u00a0Prof.\u00a0Dr.\u00a0Tillmann\u00a0R\u00fcmenapf \u00a0m\u00f6chte\u00a0ich\u00a0f\u00fcr\u00a0die\u00a0Vertretung \u00a0der\u00a0Arbeit\u00a0am\u00a0\nFachbereich \u00a0Veterin\u00e4rmedizin \u00a0der\u00a0Justus\u2010Liebig\u2010Universit\u00e4t \u00a0Gie\u00dfen\u00a0sowie\u00a0f\u00fcr\u00a0seine\u00a0\nfreundliche \u00a0Unterst\u00fctzung \u00a0und\u00a0stete\u00a0Gespr\u00e4chsbereitschaft \u00a0danken.\u00a0\n\u00a0\nVielen\u00a0Dank\u00a0auch\u00a0an\u00a0Frau\u00a0Angelika\u00a0Nockher,\u00a0Frau\u00a0Gaby\u00a0Haley,\u00a0Frau\u00a0Dr.\u00a0Nelli\u00a0Baal\u00a0und\u00a0Frau\u00a0\nChristina\u00a0Lang,\u00a0die\u00a0mich\u00a0nicht\u00a0nur\u00a0fachkundig \u00a0in\u00a0die\u00a0Methoden \u00a0eingef\u00fchrt \u00a0haben,\u00a0sondern\u00a0\nmir\u00a0auch\u00a0bei\u00a0allen\u00a0Problemen \u00a0mit\u00a0Rat,\u00a0Tat\u00a0und\u00a0Fachwissen \u00a0zur\u00a0Seite\u00a0standen.\u00a0\n\u00a0\nAu\u00dferdem \u00a0vielen\u00a0Dank\u00a0meinen\u00a0Zimmergenossinen \u00a0Frau\u00a0Dr.\u00a0Sabrina\u00a0Immecke, \u00a0Frau\u00a0Juliane\u00a0\nBechtel\u00a0und\u00a0Frau\u00a0Dr.\u00a0Natalia\u00a0Soriano\u2010Sarabia\u00a0f\u00fcr\u00a0die\u00a0immerw\u00e4hrende \u00a0Diskussionsbereitschaft \u00a0\nund\u00a0Hilfe.\u00a0\n\u00a0\nVon\u00a0Herzen\u00a0danke\u00a0ich\u00a0meinen\u00a0Eltern\u00a0f\u00fcr\u00a0all\u00a0die\u00a0Unterst\u00fctzung \u00a0vor\u00a0und\u00a0w\u00e4hrend\u00a0der\u00a0\nErstellung \u00a0meiner\u00a0Dissertation. \u00a0\n\u00a0\nBesonderen \u00a0Dank\u00a0an\u00a0meinen\u00a0Mann\u00a0Andreas,\u00a0der\u00a0mir\u00a0stets\u00a0mit\u00a0Verst\u00e4ndnis \u00a0und\u00a0Geduld\u00a0zur\u00a0\nSeite\u00a0stand\u00a0und\u00a0ein\u00a0dickes\u00a0Dankesch\u00f6n \u00a0an\u00a0unseren\u00a0Sohn\u00a0Luis,\u00a0der\u00a0abends\u00a0immer\u00a0so\u00a0sch\u00f6n\u00a0\ngeschlafen \u00a0hat,\u00a0und\u00a0mir\u00a0so\u00a0erm\u00f6glichte \u00a0die\u00a0Dissertation \u00a0fertigzustellen. \u00a0\u00a0131 Publikationen\n11 Publikationen \t\n\u00a0\n\u00a0Immecke, \u00a0S.\u00a0N.,\u00a0Wilhelm,\u00a0J.,\u00a0Bechtel,\u00a0J.,\u00a0Knoche,\u00a0A.,\u00a0Bein,\u00a0G.,\u00a0Hackstein, \u00a0H.\u00a0(2011).\u00a0\u00a0\nThe\u00a0cyclophilin \u2010binding\u00a0agent\u00a0Sanglifehrin \u00a0A\u00a0is\u00a0a\u00a0novel\u00a0dendritic\u00a0cell\u00a0chemokine \u00a0and\u00a0\nmigration \u00a0inhibitor.\u00a0PLoS\u00a0One.\u00a06(3):\u00a0e\u00a018406\u00a0\n\u00a0\n\u00a0\nDie\u00a0Ergebnisse \u00a0dieser\u00a0Dissertation \u00a0wurden\u00a0ver\u00f6ffentlicht: \u00a0\nHackstein, \u00a0H.,\u00a0Knoche,\u00a0A.,\u00a0Nockher,\u00a0A.,\u00a0Poeling,\u00a0J.,\u00a0Kubin,\n\u00a0T.,\u00a0Jurk,\u00a0M.,\u00a0Vollmer,\u00a0J.,\u00a0Bein,\u00a0G.\u00a0\n(2011).\u00a0\u00a0\nThe\u00a0TLR7/8\u00a0ligand\u00a0resiquimod \u00a0targets\u00a0monocyte \u2010derived\u00a0dendritic\u00a0cell\u00a0differentiation \u00a0via\u00a0\nTLR8\u00a0and\u00a0augments \u00a0functional \u00a0dendritic\u00a0cell\u00a0generation. \u00a0Cell\u00a0Immunol. \u00a0Vol.\u00a0271:\u00a0401\u2010412\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0132 Erkl\u00e4rung\n\u00a0\nIch\u00a0erkl\u00e4re:\u00a0Ich\u00a0habe\u00a0die\u00a0vorgelegte \u00a0Dissertation \u00a0selbstst\u00e4ndig \u00a0und\u00a0ohne\u00a0unerlaubte \u00a0\nfremde\u00a0Hilfe\u00a0und\u00a0nur\u00a0mit\u00a0den\u00a0Hilfen\u00a0angefertigt, \u00a0die\u00a0ich\u00a0in\u00a0der\u00a0Dissertation \u00a0angegeben \u00a0\nhabe.\u00a0Alle\u00a0Textstellen, \u00a0die\u00a0w\u00f6rtlich\u00a0oder\u00a0sinngem\u00e4\u00df \u00a0aus\u00a0ver\u00f6ffentlichten \u00a0oder\u00a0nicht\u00a0\nver\u00f6ffentlichten \u00a0Schriften\u00a0entnommen \u00a0sind,\u00a0und\u00a0alle\u00a0Angaben, \u00a0die\u00a0auf\u00a0m\u00fcndlichen \u00a0\nAusk\u00fcnften \u00a0beruhen,\u00a0sind\u00a0als\u00a0solche\u00a0kenntlich\u00a0gemacht. \u00a0\u00a0\nBei\u00a0den\u00a0von\u00a0mir\u00a0durchgef\u00fchrten \u00a0und\u00a0in\u00a0der\u00a0Dissertation \u00a0erw\u00e4hnten \u00a0Untersuchungen \u00a0habe\u00a0\nich\u00a0die\u00a0Grunds\u00e4tze \u00a0guter\u00a0wissenschaftlicher \u00a0Praxis,\u00a0wie\u00a0sie\u00a0in\u00a0der\u00a0\u201eSatzung\u00a0der\u00a0Justus\u2010Liebig\u2010\nUniversit\u00e4t \u00a0Gie\u00dfen\u00a0zur\u00a0Sicherung \u00a0guter\u00a0wissenschaftlicher \u00a0Praxis\u201c\u00a0niedergelegt \u00a0sind,\u00a0\neingehalten. \u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nAngela\u00a0Knoche\u00a0Angela Knoche    Exp. Immunmodulation durch synth. TLR7- u. 7/8-Liganden\nVVB9 7 8 3 8 3 5 9 5 8 8 9 0VVB LAUFERSWEILER VERLAG\nSTAUFENBERGRING 15\nD-35396 GIESSEN\nTel: 0641-5599888 Fax: -5599890\nredaktion@doktorverlag.de\nwww.doktorverlag.deVVB LAUFERSWEILER VERLAG\u00e9dition scientifique\nISBN: 978-3-8359-5889-0Angela KnocheExperimentelle Immunmodulation durch den \nEinsatz synthetischer Toll-like Rezeptor7- und \n7/8-Liganden\nVVB LAUFERSWEILER VERLAG\u00e9dition scientifiqueINAUGURAL-DISSERTATION \nzur Erlangung des Grades eines Dr. med. vet. \nbeim Fachbereich Veterin\u00e4rmedizin \nder Justus-Liebig-Universit\u00e4t Gie\u00dfen\n \n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}